{"f0efc7104651baf03c3bb08565dd1d907cbeb976": [["IntroductIonMicrobial agents that most commonly lead to childhood infections are viruses.", [["infections", "DISEASE", 66, 76], ["IntroductIonMicrobial agents", "TREATMENT", 0, 28], ["childhood infections", "PROBLEM", 56, 76], ["viruses", "PROBLEM", 81, 88], ["infections", "OBSERVATION", 66, 76]]], ["In developed countries, infants and preschool children have viral infection 6-10 times in a year, and school-age children and adolescents have 3-5 times in a year.", [["viral infection", "DISEASE", 60, 75], ["infants", "ORGANISM", 24, 31], ["children", "ORGANISM", 46, 54], ["children", "ORGANISM", 113, 121], ["adolescents", "ORGANISM", 126, 137], ["infants", "SPECIES", 24, 31], ["children", "SPECIES", 46, 54], ["children", "SPECIES", 113, 121], ["adolescents", "SPECIES", 126, 137], ["viral infection", "PROBLEM", 60, 75], ["infection", "OBSERVATION", 66, 75]]], ["1 In a study published by American Centers for Disease Control and Prevention in 2015, pathogens were detected in 80% of 2,254 pneumonia cases in patients aged between a day and 17 years, 66% of these pathogens were viruses.", [["pneumonia", "DISEASE", 127, 136], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["a study", "TEST", 5, 12], ["Disease Control", "TREATMENT", 47, 62], ["pathogens", "PROBLEM", 87, 96], ["pneumonia cases", "PROBLEM", 127, 142], ["these pathogens", "PROBLEM", 195, 210], ["pneumonia", "OBSERVATION", 127, 136]]], ["2, 3 Viruses may cause several clinical conditions that require hospitalization in a PICU such as bronchiolitis, pneumonia, chronic lung diseases, and more severe manifestations such as myocarditis, encephalitis, and sepsis.", [["lung", "ANATOMY", 132, 136], ["bronchiolitis", "DISEASE", 98, 111], ["pneumonia", "DISEASE", 113, 122], ["chronic lung diseases", "DISEASE", 124, 145], ["myocarditis", "DISEASE", 186, 197], ["encephalitis", "DISEASE", 199, 211], ["sepsis", "DISEASE", 217, 223], ["lung", "ORGAN", 132, 136], ["several clinical conditions", "PROBLEM", 23, 50], ["bronchiolitis", "PROBLEM", 98, 111], ["pneumonia", "PROBLEM", 113, 122], ["chronic lung diseases", "PROBLEM", 124, 145], ["more severe manifestations", "PROBLEM", 151, 177], ["myocarditis", "PROBLEM", 186, 197], ["encephalitis", "PROBLEM", 199, 211], ["sepsis", "PROBLEM", 217, 223], ["bronchiolitis", "OBSERVATION", 98, 111], ["pneumonia", "OBSERVATION", 113, 122], ["chronic", "OBSERVATION_MODIFIER", 124, 131], ["lung", "ANATOMY", 132, 136], ["diseases", "OBSERVATION", 137, 145], ["more severe", "OBSERVATION_MODIFIER", 151, 162], ["myocarditis", "OBSERVATION", 186, 197], ["encephalitis", "OBSERVATION", 199, 211], ["sepsis", "OBSERVATION", 217, 223]]], ["Besides the known agents, recently new generation viruses including human metapneumovirus (HMPV), coronavirus, and bocavirus have also been lead to cause these manifestations.", [["human metapneumovirus (HMPV), coronavirus", "DISEASE", 68, 109], ["human metapneumovirus", "ORGANISM", 68, 89], ["HMPV", "ORGANISM", 91, 95], ["coronavirus", "ORGANISM", 98, 109], ["bocavirus", "GENE_OR_GENE_PRODUCT", 115, 124], ["human", "SPECIES", 68, 73], ["metapneumovirus", "SPECIES", 74, 89], ["coronavirus", "SPECIES", 98, 109], ["human metapneumovirus", "SPECIES", 68, 89], ["HMPV", "SPECIES", 91, 95], ["recently new generation viruses", "PROBLEM", 26, 57], ["human metapneumovirus (HMPV)", "PROBLEM", 68, 96], ["coronavirus", "PROBLEM", 98, 109], ["bocavirus", "PROBLEM", 115, 124], ["these manifestations", "PROBLEM", 154, 174], ["new", "OBSERVATION_MODIFIER", 35, 38], ["generation viruses", "OBSERVATION", 39, 57]]], ["4, 5 In this study, it is aimed to bring out the clinical characteristics of patients who had viral infections requiring PICU admission during winter season in Turkey.Statistical AnalysisInitially descriptive properties of variables (mean, median, number, and percentage) were found.", [["viral infections", "DISEASE", 94, 110], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["this study", "TEST", 8, 18], ["viral infections", "PROBLEM", 94, 110], ["infections", "OBSERVATION", 100, 110]]], ["Numerical variables were checked for normal distribution.", [["Numerical variables", "TEST", 0, 19]]], ["Student t test was used for normally distributed numerical variables.", [["Student t test", "TEST", 0, 14], ["normally distributed numerical variables", "PROBLEM", 28, 68]]], ["Mann-Whitney U test was used for variables with no normal distribution when two groups were compared.", [["Whitney U test", "TEST", 5, 19], ["distribution", "OBSERVATION_MODIFIER", 58, 70]]], ["In comparison with the numerical values of multiple groups, ANOVA was used for variables with normal distribution and Kruskal Vallis test was used for variables with no normal distribution.", [["Kruskal Vallis test", "TEST", 118, 137], ["no", "UNCERTAINTY", 166, 168], ["normal", "OBSERVATION", 169, 175], ["distribution", "OBSERVATION_MODIFIER", 176, 188]]], ["Comparison of categorical variables was carried out by chi-square test and Fisher Exact test.", [["categorical variables", "TEST", 14, 35], ["chi-square test", "TEST", 55, 70], ["Fisher Exact test", "TEST", 75, 92]]], ["The most effective presenting finding on mortality was revealed with regression analysis.", [["regression analysis", "TEST", 69, 88]]], ["Multivariate regression analysis was performed for determining mortality risk factor.", [["Multivariate regression analysis", "TEST", 0, 32], ["mortality risk factor", "PROBLEM", 63, 84]]], ["Critical pH and pCO 2 value were found with the ROC curve.", [["Critical pH", "TEST", 0, 11], ["pCO 2 value", "TEST", 16, 27], ["the ROC curve", "TEST", 44, 57]]], ["ROC analysis was performed to evaluate the relationship between blood pH and mortality.", [["blood", "ANATOMY", 64, 69], ["blood", "ORGANISM_SUBSTANCE", 64, 69], ["ROC analysis", "TEST", 0, 12], ["blood pH", "TEST", 64, 72]]], ["The p-value <0.05 was considered as significant.", [["The p-value", "TEST", 0, 11], ["significant", "OBSERVATION_MODIFIER", 36, 47]]], ["The results were evaluated using the Statistical Package for Social Sciences -SPSS 17 (Chicago, USA) program.resultsData of 302 patients with severe viral infections were followed in PICU of 16 centers in Turkey.", [["viral infections", "DISEASE", 149, 165], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["severe viral infections", "PROBLEM", 142, 165], ["severe", "OBSERVATION_MODIFIER", 142, 148], ["viral", "OBSERVATION_MODIFIER", 149, 154], ["infections", "OBSERVATION", 155, 165]]], ["Out of 302 patients, 113 (37%) were girls and 189 (63%) were boys.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["girls", "SPECIES", 36, 41], ["boys", "SPECIES", 61, 65], ["girls", "TEST", 36, 41]]], ["Mortality rate was 7.6% (23/302).", [["Mortality rate", "TEST", 0, 14]]], ["The mean PRISM score was 37.2\u00b113.2 in patients who died and 11.1\u00b110.3 in patients discharged (p <0.001).", [["patients", "ORGANISM", 38, 46], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 73, 81], ["The mean PRISM score", "TEST", 0, 20]]], ["Median age of patients was 12 months.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["Forty-seven percent of patients were under one year of age and 53% of patients were over one year of age.", [["patients", "ORGANISM", 23, 31], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 70, 78]]], ["Mortality rate was 9.2% and 6.3% in each age groups, respectively (p = 0.34).", [["Mortality rate", "TEST", 0, 14]]], ["It was seen that 45.7% of the patients were admitted to the emergency department, 24.2% were admitted to the inpatient service of the same hospital, and 23.3% of the patients were accepted from the inpatient or emergency services of other hospitals.", [["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 166, 174]]], ["The mean duration of symptoms before admission to the hospital was 3.9\u00b12.8 days.", [["symptoms", "PROBLEM", 21, 29]]], ["Duration of stay in PICU was between one day and 116 days, hospital duration was between two days and 120 days.resultsSymptoms were cough in 78.1%, fever in 62.5%, nasal discharge in 45.6%, gastrointestinal symptoms in 20.8%, neurological symptoms (seizures, changes in consciousness) in 17.5%, and rash in 4.6% of all patients.", [["nasal", "ANATOMY", 164, 169], ["gastrointestinal", "ANATOMY", 190, 206], ["neurological", "ANATOMY", 226, 238], ["cough", "DISEASE", 132, 137], ["fever", "DISEASE", 148, 153], ["gastrointestinal symptoms", "DISEASE", 190, 215], ["neurological symptoms", "DISEASE", 226, 247], ["seizures", "DISEASE", 249, 257], ["rash", "DISEASE", 299, 303], ["nasal", "ORGANISM_SUBDIVISION", 164, 169], ["gastrointestinal", "ORGAN", 190, 206], ["patients", "ORGANISM", 319, 327], ["patients", "SPECIES", 319, 327], ["Symptoms", "PROBLEM", 118, 126], ["cough", "PROBLEM", 132, 137], ["fever", "PROBLEM", 148, 153], ["nasal discharge", "TEST", 164, 179], ["gastrointestinal symptoms", "PROBLEM", 190, 215], ["neurological symptoms", "PROBLEM", 226, 247], ["seizures", "PROBLEM", 249, 257], ["changes in consciousness", "PROBLEM", 259, 283], ["rash", "PROBLEM", 299, 303], ["gastrointestinal", "ANATOMY", 190, 206]]], ["Hypoxia was found in 49%, tachypnea in 43%, fever in 40%, tachycardia in 34%, and hypotension in 7% of patients.", [["Hypoxia", "DISEASE", 0, 7], ["tachypnea", "DISEASE", 26, 35], ["fever", "DISEASE", 44, 49], ["tachycardia", "DISEASE", 58, 69], ["hypotension", "DISEASE", 82, 93], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["Hypoxia", "PROBLEM", 0, 7], ["tachypnea", "PROBLEM", 26, 35], ["fever", "PROBLEM", 44, 49], ["tachycardia", "PROBLEM", 58, 69], ["hypotension", "PROBLEM", 82, 93], ["hypotension", "OBSERVATION", 82, 93]]], ["Physical examinations revealed respiratory findings in 86%, prolonged capillary filling in 32%, neurological findings in 14%, and gastrointestinal system findings in 10% of all patients.resultsIndication of PICU admission was respiratory dysfunction in 71.5%, circulatory dysfunction in 10.2%, neurologic dysfunction in 7.6%, and MODS in 10.5% of patients.", [["respiratory", "ANATOMY", 31, 42], ["capillary", "ANATOMY", 70, 79], ["neurological", "ANATOMY", 96, 108], ["gastrointestinal system", "ANATOMY", 130, 153], ["respiratory", "ANATOMY", 226, 237], ["circulatory", "ANATOMY", 260, 271], ["neurologic", "ANATOMY", 294, 304], ["respiratory dysfunction", "DISEASE", 226, 249], ["circulatory dysfunction", "DISEASE", 260, 283], ["neurologic dysfunction", "DISEASE", 294, 316], ["MODS", "DISEASE", 330, 334], ["capillary", "TISSUE", 70, 79], ["gastrointestinal", "ORGAN", 130, 146], ["patients", "ORGANISM", 177, 185], ["patients", "ORGANISM", 347, 355], ["patients", "SPECIES", 177, 185], ["patients", "SPECIES", 347, 355], ["Physical examinations", "TEST", 0, 21], ["respiratory findings", "TEST", 31, 51], ["prolonged capillary filling", "TEST", 60, 87], ["neurological findings", "TEST", 96, 117], ["respiratory dysfunction", "PROBLEM", 226, 249], ["circulatory dysfunction", "PROBLEM", 260, 283], ["neurologic dysfunction", "PROBLEM", 294, 316], ["MODS", "TEST", 330, 334], ["respiratory", "ANATOMY", 31, 42], ["capillary filling", "OBSERVATION", 70, 87], ["gastrointestinal system", "ANATOMY", 130, 153], ["MODS", "OBSERVATION", 330, 334]]], ["At the time of admission and in follow-up, respiratory failure was observed in 91.3%, cardiovascular failure in 22.1%, hematological failure in 15.2%, renal failure in 10.2%, and hepatic failure in 9.9% of patients.", [["respiratory", "ANATOMY", 43, 54], ["cardiovascular", "ANATOMY", 86, 100], ["hematological", "ANATOMY", 119, 132], ["renal", "ANATOMY", 151, 156], ["hepatic", "ANATOMY", 179, 186], ["respiratory failure", "DISEASE", 43, 62], ["cardiovascular failure", "DISEASE", 86, 108], ["hematological failure", "DISEASE", 119, 140], ["renal failure", "DISEASE", 151, 164], ["hepatic failure", "DISEASE", 179, 194], ["renal", "ORGAN", 151, 156], ["hepatic", "ORGAN", 179, 186], ["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["respiratory failure", "PROBLEM", 43, 62], ["cardiovascular failure", "PROBLEM", 86, 108], ["hematological failure", "PROBLEM", 119, 140], ["renal failure", "PROBLEM", 151, 164], ["hepatic failure", "PROBLEM", 179, 194], ["respiratory", "ANATOMY", 43, 54], ["failure", "OBSERVATION", 55, 62], ["cardiovascular", "ANATOMY", 86, 100], ["failure", "OBSERVATION", 101, 108], ["failure", "OBSERVATION", 133, 140], ["renal", "ANATOMY", 151, 156], ["failure", "OBSERVATION", 157, 164], ["hepatic", "ANATOMY", 179, 186], ["failure", "OBSERVATION", 187, 194]]], ["In regression analysis, MODS was found as a predictor for mortality [odds ratio: 20.5(95%), confidence interval (CI): 5.8-72.1; p = 0.00].resultsAnemia was found in 45.4%, leukocytosis in 17.8%, leukopenia in 14.2%, thrombocytosis in 19.8%, thrombocytopenia in 14.9%, prolonged INR in 26.6%, and electrolyte imbalance in 74.8% of patients.", [["MODS", "DISEASE", 24, 28], ["resultsAnemia", "DISEASE", 138, 151], ["leukocytosis", "DISEASE", 172, 184], ["leukopenia", "DISEASE", 195, 205], ["thrombocytosis", "DISEASE", 216, 230], ["thrombocytopenia", "DISEASE", 241, 257], ["patients", "ORGANISM", 330, 338], ["patients", "SPECIES", 330, 338], ["regression analysis", "TEST", 3, 22], ["MODS", "PROBLEM", 24, 28], ["ratio", "TEST", 74, 79], ["CI", "TEST", 113, 115], ["resultsAnemia", "TEST", 138, 151], ["leukocytosis", "TEST", 172, 184], ["leukopenia", "TEST", 195, 205], ["thrombocytosis", "TEST", 216, 230], ["thrombocytopenia", "PROBLEM", 241, 257], ["prolonged INR", "TEST", 268, 281], ["electrolyte imbalance", "PROBLEM", 296, 317], ["thrombocytosis", "OBSERVATION", 216, 230], ["thrombocytopenia", "OBSERVATION", 241, 257]]], ["Acidosis was found in 55.2%, alkalosis in 5.9%, high PCO 2 in 37.7%, and elevated lactate in 56.9% of patients.", [["Acidosis", "DISEASE", 0, 8], ["alkalosis", "DISEASE", 29, 38], ["PCO", "DISEASE", 53, 56], ["lactate", "CHEMICAL", 82, 89], ["lactate", "CHEMICAL", 82, 89], ["lactate", "SIMPLE_CHEMICAL", 82, 89], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["Acidosis", "TEST", 0, 8], ["alkalosis", "TEST", 29, 38], ["high PCO", "TEST", 48, 56], ["elevated lactate", "PROBLEM", 73, 89]]], ["The mean lactate value was 6.3\u00b16.1 in patients who died and 2.7\u00b12.5 in patients who were discharged (p <0.001).", [["lactate", "CHEMICAL", 9, 16], ["lactate", "CHEMICAL", 9, 16], ["lactate", "SIMPLE_CHEMICAL", 9, 16], ["patients", "ORGANISM", 38, 46], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 71, 79], ["The mean lactate value", "TEST", 0, 22]]], ["In regression analysis, acidosis was found to be a predictor for mortality (odds ratio 2.5(95%) CI, 1.2-4.8; p = 0.007).", [["acidosis", "DISEASE", 24, 32], ["regression analysis", "TEST", 3, 22], ["acidosis", "PROBLEM", 24, 32], ["mortality", "TEST", 65, 74], ["odds ratio", "TEST", 76, 86], ["CI", "TEST", 96, 98], ["p", "TEST", 109, 110], ["acidosis", "OBSERVATION", 24, 32]]], ["It was found that pH \u22647.10 negatively affected survival (specificity 97.9% and sensitivity 26.3%).", [["pH", "TEST", 18, 20], ["specificity", "TEST", 57, 68], ["sensitivity", "TEST", 79, 90]]], ["PCO 2 \u226560 mm Hg was also shown to have negative effect on survival (specificity 78.1% and sensitivity 68.4%).", [["Hg", "CHEMICAL", 13, 15], ["PCO", "TEST", 0, 3], ["mm Hg", "TEST", 10, 15], ["survival", "TEST", 58, 66], ["specificity", "TEST", 68, 79], ["sensitivity", "TEST", 90, 101]]], ["Clinical and laboratory findings at the time of admission of patients associated with mortality are shown in Table 1 and age-related discriminating factors are shown in Table 2 .resultsAnterior-posterior chest radiograph revealed positive findings in 86% of patients (infiltration in 74%, atelectasis in 9%, pleural effusion in 5%, and pneumothorax in 4%).", [["chest", "ANATOMY", 204, 209], ["pleural effusion", "ANATOMY", 308, 324], ["atelectasis", "DISEASE", 289, 300], ["pleural effusion", "DISEASE", 308, 324], ["pneumothorax", "DISEASE", 336, 348], ["patients", "ORGANISM", 61, 69], ["patients", "ORGANISM", 258, 266], ["pleural", "ORGAN", 308, 315], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 258, 266], ["posterior chest radiograph", "TEST", 194, 220], ["infiltration", "TEST", 268, 280], ["atelectasis", "PROBLEM", 289, 300], ["pleural effusion", "PROBLEM", 308, 324], ["pneumothorax", "PROBLEM", 336, 348], ["posterior", "ANATOMY_MODIFIER", 194, 203], ["chest", "ANATOMY", 204, 209], ["positive", "OBSERVATION", 230, 238], ["infiltration", "OBSERVATION", 268, 280], ["atelectasis", "OBSERVATION", 289, 300], ["pleural", "ANATOMY", 308, 315], ["effusion", "OBSERVATION", 316, 324], ["pneumothorax", "OBSERVATION", 336, 348]]], ["No statistically significant difference was found between the patients who died and discharged in terms of chest radiograph findings.", [["chest", "ANATOMY", 107, 112], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["chest radiograph findings", "TEST", 107, 132], ["statistically", "OBSERVATION_MODIFIER", 3, 16], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["difference", "OBSERVATION", 29, 39], ["chest", "ANATOMY", 107, 112]]], ["Out of all, 53.3% patients had underlying disease [neurologic in 17.8%, respiratory in 16.5%, cardiovascular in 12.5%, immunological in 6.2%, hematological-oncological in 5.9%, renal in 2.3%, and others (metabolic disease, chromosomal anomalies) 9.5%].", [["neurologic", "ANATOMY", 51, 61], ["respiratory", "ANATOMY", 72, 83], ["cardiovascular", "ANATOMY", 94, 108], ["hematological", "ANATOMY", 142, 155], ["renal", "ANATOMY", 177, 182], ["chromosomal", "ANATOMY", 223, 234], ["metabolic disease", "DISEASE", 204, 221], ["chromosomal anomalies", "DISEASE", 223, 244], ["patients", "ORGANISM", 18, 26], ["renal", "ORGAN", 177, 182], ["chromosomal", "CELLULAR_COMPONENT", 223, 234], ["patients", "SPECIES", 18, 26], ["underlying disease", "PROBLEM", 31, 49], ["neurologic", "TEST", 51, 61], ["respiratory", "TEST", 72, 83], ["cardiovascular", "TEST", 94, 108], ["immunological", "TEST", 119, 132], ["hematological", "TEST", 142, 155], ["renal", "TEST", 177, 182], ["others (metabolic disease", "PROBLEM", 196, 221], ["chromosomal anomalies)", "PROBLEM", 223, 245], ["disease", "OBSERVATION", 42, 49], ["renal", "ANATOMY", 177, 182]]], ["Sixty percent of patients who died had underlying disease.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["underlying disease", "PROBLEM", 39, 57], ["disease", "OBSERVATION", 50, 57]]], ["This rate was 52% in discharged patients (p >0.05).resultsThe total number of viruses detected in nasal swabs of patients hospitalized in PICU, number of viruses when multiple reproductions were included and excluded in the patients who died, mortality rates when the viruses were evaluated in themselves are shown in Table 3 .", [["nasal swabs", "ANATOMY", 98, 109], ["patients", "ORGANISM", 32, 40], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 98, 109], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 224, 232], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 224, 232], ["This rate", "TEST", 0, 9], ["viruses", "PROBLEM", 78, 85], ["the viruses", "PROBLEM", 264, 275], ["total", "OBSERVATION_MODIFIER", 62, 67], ["number", "OBSERVATION_MODIFIER", 68, 74], ["viruses", "OBSERVATION", 78, 85], ["nasal", "ANATOMY", 98, 103]]], ["Multiple viruses were detected in 13% of all patients.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["Multiple viruses", "PROBLEM", 0, 16], ["viruses", "OBSERVATION", 9, 16]]], ["Multiple viruses isolated was in 17.3% of the patients who died and in 13.2% of the discharged patients (p >0.05).", [["patients", "ORGANISM", 46, 54], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 95, 103], ["Multiple viruses", "PROBLEM", 0, 16], ["viruses", "OBSERVATION", 9, 16]]], ["For patients detected with a single-virus infection, there was statistically no difference between the species of the virus, between patients who survived, and patients who died (p = 0.195).", [["infection", "DISEASE", 42, 51], ["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 133, 141], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 133, 141], ["patients", "SPECIES", 160, 168], ["a single-virus infection", "PROBLEM", 27, 51], ["the virus", "PROBLEM", 114, 123], ["infection", "OBSERVATION", 42, 51]]], ["When the viruses were evaluated among themselves and patients with multiple viruses were excluded, 37% of patients with coronavirus were found to have died (Table 3) .resultsMedian age of patients with influenza was 41 (11-75) months and median age of patients with the viruses other than influenza was 10 (3.5-28) months (p <0.001).", [["coronavirus", "DISEASE", 120, 131], ["influenza", "DISEASE", 202, 211], ["influenza", "DISEASE", 289, 298], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 106, 114], ["coronavirus", "ORGANISM", 120, 131], ["patients", "ORGANISM", 188, 196], ["patients", "ORGANISM", 252, 260], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 106, 114], ["patients", "SPECIES", 188, 196], ["patients", "SPECIES", 252, 260], ["the viruses", "PROBLEM", 5, 16], ["multiple viruses", "PROBLEM", 67, 83], ["coronavirus", "PROBLEM", 120, 131], ["influenza", "PROBLEM", 202, 211], ["the viruses", "PROBLEM", 266, 277], ["influenza", "PROBLEM", 289, 298], ["viruses", "OBSERVATION", 9, 16], ["viruses", "OBSERVATION", 76, 83], ["viruses", "OBSERVATION", 270, 277]]], ["The median PRISM score was 22 (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) and median PELOD score was 11 (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) in patients with influenza.", [["influenza", "DISEASE", 263, 272], ["10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20", "SIMPLE_CHEMICAL", 187, 239], ["patients", "ORGANISM", 249, 257], ["patients", "SPECIES", 249, 257], ["The median PRISM score", "TEST", 0, 22], ["median PELOD score", "TEST", 132, 150], ["influenza", "PROBLEM", 263, 272], ["influenza", "OBSERVATION", 263, 272]]], ["The median PRISM score was 9 (3-17) and median PELOD score was 10 (1-15) in patients with the viruses other than influenza (p <0.005).", [["influenza", "DISEASE", 113, 122], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["The median PRISM score", "TEST", 0, 22], ["median PELOD score", "TEST", 40, 58], ["the viruses", "PROBLEM", 90, 101], ["influenza", "PROBLEM", 113, 122], ["viruses", "OBSERVATION", 94, 101]]], ["The relationships between the indication of PICU admission, organ failures at the time of admission or revealed at follow-up, and species of viruses isolated are shown in Table 4 .", [["organ", "ANATOMY", 60, 65], ["organ", "ORGAN", 60, 65], ["organ failures", "PROBLEM", 60, 74], ["viruses", "PROBLEM", 141, 148]]], ["Among all, 60.2% of patients received antiviral therapy, 94.3% antibiotic therapy, 15.8% antifungal therapy.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["antiviral therapy", "TREATMENT", 38, 55], ["antibiotic therapy", "TREATMENT", 63, 81], ["antifungal therapy", "TREATMENT", 89, 107], ["antifungal therapy", "OBSERVATION", 89, 107]]], ["47.4% of patients who died, and 61.6% of the patients discharged received antiviral therapy (p = 0.22).", [["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 45, 53], ["antiviral therapy", "TREATMENT", 74, 91]]], ["The median duration of stay on MV was 4 (2-5) days, median duration of stay in PICU was 7 (4-15), and median duration of hospital was 15 (10-27) days in patients who received antiviral therapy.", [["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["MV", "SPECIES", 31, 33], ["MV", "TEST", 31, 33], ["antiviral therapy", "TREATMENT", 175, 192], ["antiviral therapy", "OBSERVATION", 175, 192]]], ["The median duration of stay on MV was 3 (2-5) days, median duration of stay in PICU was 7 (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) , and median duration of hospital was 15 days in the patients who did not receive antiviral therapy (p >0.05).", [["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 191, 199], ["MV", "SPECIES", 31, 33], ["MV", "TEST", 31, 33], ["antiviral therapy", "TREATMENT", 220, 237]]], ["It was found that virus species did not affect mortality between patients who received and did not receive antiviral therapy (Table 5) .", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["virus species", "PROBLEM", 18, 31], ["antiviral therapy", "TREATMENT", 107, 124], ["virus", "OBSERVATION", 18, 23]]], ["Of all, 92.3% of patients required respiratory support treatments.", [["respiratory", "ANATOMY", 35, 46], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["respiratory support treatments", "TREATMENT", 35, 65], ["respiratory support", "OBSERVATION", 35, 54]]], ["Renal replacement therapy was performed in 6.6%, plasma exchange in 5.2%, and ECMO in 1.9% of patients.dIscussIonViral respiratory tract infections are the most common infections worldwide.", [["Renal", "ANATOMY", 0, 5], ["plasma", "ANATOMY", 49, 55], ["respiratory tract infections", "DISEASE", 119, 147], ["infections", "DISEASE", 168, 178], ["Renal", "ORGAN", 0, 5], ["plasma", "ORGANISM_SUBSTANCE", 49, 55], ["patients", "ORGANISM", 94, 102], ["IonViral respiratory tract", "ORGANISM", 110, 136], ["patients", "SPECIES", 94, 102], ["Renal replacement therapy", "TREATMENT", 0, 25], ["plasma exchange", "TEST", 49, 64], ["ECMO", "TREATMENT", 78, 82], ["IonViral respiratory tract infections", "PROBLEM", 110, 147], ["replacement therapy", "OBSERVATION", 6, 25], ["respiratory tract", "ANATOMY", 119, 136], ["most common", "OBSERVATION_MODIFIER", 156, 167], ["infections", "OBSERVATION", 168, 178]]], ["They are the most important cause of mortality in all age groups, particularly in children.", [["children", "ORGANISM", 82, 90], ["children", "SPECIES", 82, 90]]], ["7 This retrospective observational study was conducted in order to analyze the course of seasonal viral infections of respiratory tract in patients hospitalized in PICUs of 16 centers representing the whole country.", [["respiratory tract", "ANATOMY", 118, 135], ["viral infections", "DISEASE", 98, 114], ["respiratory tract", "DISEASE", 118, 135], ["respiratory tract", "ORGANISM_SUBDIVISION", 118, 135], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["This retrospective observational study", "TEST", 2, 40], ["seasonal viral infections of respiratory tract", "PROBLEM", 89, 135], ["respiratory tract", "ANATOMY", 118, 135]]], ["There are a bunch of studies in literature investigating the relationship between viruses and morbidity, comparison of single-multiple viruses or relationship between diseases and viruses.", [["single-multiple viruses", "PROBLEM", 119, 142], ["diseases", "PROBLEM", 167, 175], ["viruses", "PROBLEM", 180, 187], ["viruses", "OBSERVATION", 82, 89], ["viruses", "OBSERVATION", 135, 142], ["viruses", "OBSERVATION", 180, 187]]], ["[8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Current study is multi-directional and has comprehensively analyzed all these issues in a very large population requiring PICU.", [["[8] [9] [10] [11] [12] [13] [14] [15] [16] [17", "SIMPLE_CHEMICAL", 0, 46], ["Current study", "TEST", 53, 66], ["very", "OBSERVATION_MODIFIER", 143, 147], ["large", "OBSERVATION_MODIFIER", 148, 153], ["population", "OBSERVATION", 154, 164]]], ["Viral respiratory tract infections constitute significant proportion of patients admitted to PICUs in winter, and these patients require advanced intensive care support with high mortality and morbidity rates.", [["respiratory tract", "ANATOMY", 6, 23], ["Viral respiratory tract infections", "DISEASE", 0, 34], ["Viral respiratory tract", "ORGANISM", 0, 23], ["patients", "ORGANISM", 72, 80], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 120, 128], ["Viral respiratory tract infections", "PROBLEM", 0, 34], ["advanced intensive care support", "TREATMENT", 137, 168], ["morbidity rates", "PROBLEM", 193, 208], ["respiratory tract", "ANATOMY", 6, 23]]], ["In line with this, our study group shows a very high mortality rate as 7.6%, which supports the justification of this multicenter survey.", [["our study group", "TEST", 19, 34], ["a very high mortality rate", "PROBLEM", 41, 67]]], ["Although respiratory tract viruses commonly cause lower respiratory tract infections, presentation with extrapulmonary clinical manifestations are also likely in children under one year of age.", [["respiratory tract", "ANATOMY", 9, 26], ["lower respiratory tract", "ANATOMY", 50, 73], ["extrapulmonary", "ANATOMY", 104, 118], ["respiratory tract viruses", "DISEASE", 9, 34], ["lower respiratory tract infections", "DISEASE", 50, 84], ["respiratory tract viruses", "ORGANISM", 9, 34], ["tract", "ORGANISM_SUBDIVISION", 68, 73], ["children", "ORGANISM", 162, 170], ["children", "SPECIES", 162, 170], ["respiratory tract viruses", "PROBLEM", 9, 34], ["lower respiratory tract infections", "PROBLEM", 50, 84], ["extrapulmonary clinical manifestations", "PROBLEM", 104, 142], ["respiratory tract", "ANATOMY", 9, 26], ["lower", "ANATOMY_MODIFIER", 50, 55], ["respiratory tract", "ANATOMY", 56, 73], ["infections", "OBSERVATION", 74, 84], ["extrapulmonary", "ANATOMY", 104, 118]]], ["8, 19 Similarly, the most common cause of hospitalization was respiratory symptoms in our study.", [["respiratory", "ANATOMY", 62, 73], ["respiratory symptoms", "DISEASE", 62, 82], ["respiratory symptoms", "PROBLEM", 62, 82], ["our study", "TEST", 86, 95]]], ["Fever, neurological symptoms, circulatory disorders, and shock were more common indications for hospitalization in patients under one year compared to older children (Table 2 ).", [["neurological", "ANATOMY", 7, 19], ["circulatory", "ANATOMY", 30, 41], ["Fever", "DISEASE", 0, 5], ["neurological symptoms", "DISEASE", 7, 28], ["circulatory disorders", "DISEASE", 30, 51], ["shock", "DISEASE", 57, 62], ["patients", "ORGANISM", 115, 123], ["children", "ORGANISM", 157, 165], ["patients", "SPECIES", 115, 123], ["children", "SPECIES", 157, 165], ["Fever", "PROBLEM", 0, 5], ["neurological symptoms", "PROBLEM", 7, 28], ["circulatory disorders", "PROBLEM", 30, 51], ["shock", "PROBLEM", 57, 62], ["circulatory disorders", "OBSERVATION", 30, 51]]], ["In patients over one year of age presenting with respiratory symptoms, hypoxia as well as a need for MV were more common.", [["respiratory", "ANATOMY", 49, 60], ["respiratory symptoms", "DISEASE", 49, 69], ["hypoxia", "DISEASE", 71, 78], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["MV", "SPECIES", 101, 103], ["respiratory symptoms", "PROBLEM", 49, 69], ["hypoxia", "PROBLEM", 71, 78], ["MV", "TREATMENT", 101, 103], ["respiratory", "ANATOMY", 49, 60], ["hypoxia", "OBSERVATION", 71, 78]]], ["We attributed this situation to RSV, which was more frequently observed in this age group.", [["RSV", "DISEASE", 32, 35], ["RSV", "ORGANISM", 32, 35], ["RSV", "SPECIES", 32, 35], ["RSV", "PROBLEM", 32, 35], ["RSV", "OBSERVATION", 32, 35]]], ["In the literature, RSV is more prevalent in infancy for PICU admission though influenza and bocavirus that was more common in our patients less than one year of age.", [["RSV", "DISEASE", 19, 22], ["influenza and bocavirus", "DISEASE", 78, 101], ["RSV", "ORGANISM", 19, 22], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["RSV", "SPECIES", 19, 22], ["RSV", "PROBLEM", 19, 22], ["influenza", "PROBLEM", 78, 87], ["bocavirus", "PROBLEM", 92, 101], ["RSV", "OBSERVATION", 19, 22], ["more prevalent", "OBSERVATION_MODIFIER", 26, 40]]], ["1, 9, 10 We statistically evaluated all initial symptoms (clinical, laboratory, and radiological) and virus species through four parameters (duration of stay on mechanical ventilation (MV), duration of stay in PICU, duration of hospitalization, and mortality).", [["MV", "SPECIES", 185, 187], ["all initial symptoms", "PROBLEM", 36, 56], ["virus species", "PROBLEM", 102, 115], ["mechanical ventilation", "TREATMENT", 161, 183]]], ["Accordingly, we assessed relationship among presenting symptoms, virus species, and severity of disease.", [["presenting symptoms", "PROBLEM", 44, 63], ["virus species", "PROBLEM", 65, 78], ["disease", "PROBLEM", 96, 103], ["disease", "OBSERVATION", 96, 103]]], ["It was observed that presenting symptoms that have an effect on mortality were neurologic symptoms, hypotension, tachycardia, and hypoxia.", [["neurologic", "ANATOMY", 79, 89], ["neurologic symptoms", "DISEASE", 79, 98], ["hypotension", "DISEASE", 100, 111], ["tachycardia", "DISEASE", 113, 124], ["hypoxia", "DISEASE", 130, 137], ["presenting symptoms", "PROBLEM", 21, 40], ["neurologic symptoms", "PROBLEM", 79, 98], ["hypotension", "PROBLEM", 100, 111], ["tachycardia", "PROBLEM", 113, 124], ["hypoxia", "PROBLEM", 130, 137], ["tachycardia", "OBSERVATION", 113, 124], ["hypoxia", "OBSERVATION", 130, 137]]], ["It was also found that liver and renal function test abnormalities, higher lactate values were related with death.", [["liver", "ANATOMY", 23, 28], ["renal", "ANATOMY", 33, 38], ["lactate", "CHEMICAL", 75, 82], ["death", "DISEASE", 108, 113], ["lactate", "CHEMICAL", 75, 82], ["liver", "ORGAN", 23, 28], ["renal", "ORGAN", 33, 38], ["lactate", "SIMPLE_CHEMICAL", 75, 82], ["liver and renal function test abnormalities", "PROBLEM", 23, 66], ["higher lactate values", "PROBLEM", 68, 89], ["death", "PROBLEM", 108, 113], ["liver", "ANATOMY", 23, 28], ["renal", "ANATOMY", 33, 38]]], ["Eighty-seven percent of mortalities are presented with acidosis ( Table 1 ).", [["acidosis", "DISEASE", 55, 63], ["acidosis", "PROBLEM", 55, 63], ["mortalities", "OBSERVATION", 24, 35], ["acidosis", "OBSERVATION", 55, 63]]], ["The critical pH value related with mortality and critical PCO 2 was \u22647.10 and \u226560 mm Hg, respectively.", [["Hg", "CHEMICAL", 85, 87], ["The critical pH value", "TEST", 0, 21], ["critical PCO", "TEST", 49, 61], ["pH value", "OBSERVATION_MODIFIER", 13, 21]]], ["In regression analysis, acidosis alone was found to increase mortality by 2.5 folds.", [["acidosis", "DISEASE", 24, 32], ["regression analysis", "TEST", 3, 22], ["acidosis", "PROBLEM", 24, 32], ["acidosis", "OBSERVATION", 24, 32]]], ["In the light of these findings, it can be predicted that patients with neurological symptoms, tachycardia, hypotension, low levels of pulse sO 2 , acidosis, and impaired liver or renal function at the time of admission will have a higher morbidity and mortality.dIscussIonKumar et al. showed that organ failure in patients hospitalized in ICU with H1N1 infection increased mortality.", [["neurological", "ANATOMY", 71, 83], ["liver", "ANATOMY", 170, 175], ["renal", "ANATOMY", 179, 184], ["organ", "ANATOMY", 297, 302], ["neurological symptoms", "DISEASE", 71, 92], ["tachycardia", "DISEASE", 94, 105], ["hypotension", "DISEASE", 107, 118], ["acidosis", "DISEASE", 147, 155], ["impaired liver or renal function", "DISEASE", 161, 193], ["organ failure", "DISEASE", 297, 310], ["H1N1 infection", "DISEASE", 348, 362], ["patients", "ORGANISM", 57, 65], ["liver", "ORGAN", 170, 175], ["renal", "ORGAN", 179, 184], ["organ", "ORGAN", 297, 302], ["patients", "ORGANISM", 314, 322], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 314, 322], ["neurological symptoms", "PROBLEM", 71, 92], ["tachycardia", "PROBLEM", 94, 105], ["hypotension", "PROBLEM", 107, 118], ["low levels of pulse", "PROBLEM", 120, 139], ["acidosis", "PROBLEM", 147, 155], ["impaired liver", "PROBLEM", 161, 175], ["renal function", "PROBLEM", 179, 193], ["a higher morbidity", "PROBLEM", 229, 247], ["organ failure", "PROBLEM", 297, 310], ["H1N1 infection increased mortality", "PROBLEM", 348, 382], ["impaired", "OBSERVATION", 161, 169], ["liver", "ANATOMY", 170, 175], ["renal", "ANATOMY", 179, 184], ["organ", "ANATOMY", 297, 302], ["failure", "OBSERVATION", 303, 310], ["H1N1", "OBSERVATION_MODIFIER", 348, 352], ["infection", "OBSERVATION", 353, 362]]], ["11 Also, Kendirli et al. demonstrated the correlation between organ failures and mortality in the patients who presented with H1N1 infection.", [["organ", "ANATOMY", 62, 67], ["organ failures", "DISEASE", 62, 76], ["H1N1 infection", "DISEASE", 126, 140], ["organ", "ORGAN", 62, 67], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["organ failures", "PROBLEM", 62, 76], ["H1N1 infection", "PROBLEM", 126, 140], ["failures", "OBSERVATION", 68, 76], ["H1N1", "OBSERVATION_MODIFIER", 126, 130], ["infection", "OBSERVATION", 131, 140]]], ["12 Similarly, in our study, mortality rates were higher and in regression analysis, we demonstrated that initial presentation with MODS increased mortality by 20-folds.dIscussIonIn a study, it was shown that RSV was the most common agent in patients who needed intensive care.", [["MODS", "DISEASE", 131, 135], ["RSV", "DISEASE", 208, 211], ["RSV", "ORGANISM", 208, 211], ["patients", "ORGANISM", 241, 249], ["patients", "SPECIES", 241, 249], ["RSV", "SPECIES", 208, 211], ["our study", "TEST", 17, 26], ["mortality rates", "TEST", 28, 43], ["MODS increased mortality", "PROBLEM", 131, 155], ["a study", "TEST", 181, 188], ["RSV", "PROBLEM", 208, 211], ["intensive care", "TREATMENT", 261, 275], ["increased", "OBSERVATION_MODIFIER", 136, 145], ["RSV", "OBSERVATION", 208, 211]]], ["20 This is definitely compatible with our findings.dIscussIonSpaeder and Fackler reported that virus species did not affect durations of stay in PICU and hospital, as well as development of MODS and mortality.", [["MODS", "DISEASE", 190, 194], ["virus species", "PROBLEM", 95, 108], ["MODS", "PROBLEM", 190, 194], ["definitely compatible with", "UNCERTAINTY", 11, 37], ["MODS", "OBSERVATION", 190, 194]]], ["21 In our study, we also investigated virus species organ failure relationship and emerging indications for PICU admission.", [["organ", "ANATOMY", 52, 57], ["organ failure", "DISEASE", 52, 65], ["organ", "ORGAN", 52, 57], ["our study", "TEST", 6, 15], ["virus species organ failure", "PROBLEM", 38, 65]]], ["We demonstrated that there was no correlation between virus species and diagnosis of admission to PICU or type of organ failure developed (Table 4 ).", [["organ", "ANATOMY", 114, 119], ["organ failure", "DISEASE", 114, 127], ["organ", "ORGAN", 114, 119], ["virus species", "PROBLEM", 54, 67], ["organ failure", "PROBLEM", 114, 127], ["organ", "ANATOMY", 114, 119], ["failure", "OBSERVATION", 120, 127]]], ["However, 63% of the patients who died in 2017 winter season had RSV, parainfluenza or influenza.", [["RSV", "DISEASE", 64, 67], ["parainfluenza", "DISEASE", 69, 82], ["influenza", "DISEASE", 86, 95], ["patients", "ORGANISM", 20, 28], ["RSV", "ORGANISM", 64, 67], ["parainfluenza", "ORGANISM", 69, 82], ["patients", "SPECIES", 20, 28], ["parainfluenza", "SPECIES", 69, 82], ["RSV", "SPECIES", 64, 67], ["RSV", "PROBLEM", 64, 67], ["parainfluenza", "PROBLEM", 69, 82], ["influenza", "PROBLEM", 86, 95], ["parainfluenza", "OBSERVATION", 69, 82], ["influenza", "OBSERVATION", 86, 95]]], ["Secondary bacterial agent was observed in about half of the patients who died.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["Secondary bacterial agent", "PROBLEM", 0, 25], ["bacterial agent", "OBSERVATION", 10, 25]]], ["It is not easy to blame viral agents to be the leading causes of mortality because of the frequent accompaniment of secondary bacterial agents.", [["viral agents", "TREATMENT", 24, 36], ["secondary bacterial agents", "TREATMENT", 116, 142], ["secondary bacterial agents", "OBSERVATION", 116, 142]]], ["Similar to the literature, we found that secondary bacterial infections negatively affected mortality.", [["bacterial infections", "DISEASE", 51, 71], ["secondary bacterial infections", "PROBLEM", 41, 71], ["secondary", "OBSERVATION_MODIFIER", 41, 50], ["bacterial", "OBSERVATION_MODIFIER", 51, 60], ["infections", "OBSERVATION", 61, 71]]], ["15, 22, 23 In the present study, multiple viruses were detected in 13% of the patients.", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["the present study", "TEST", 14, 31], ["multiple viruses", "PROBLEM", 33, 49], ["multiple", "OBSERVATION_MODIFIER", 33, 41], ["viruses", "OBSERVATION", 42, 49]]], ["Although there are also contrary opinions, [24] [25] [26] detection of multiple viruses does not affect mortality and duration of stay in PICU.", [["multiple viruses", "PROBLEM", 71, 87], ["multiple", "OBSERVATION_MODIFIER", 71, 79], ["viruses", "OBSERVATION", 80, 87]]], ["22, 27, 28 Similarly, we showed that multiple viruses did not affect mortality.dIscussIonWhen multiple virus isolated patients were excluded, coronavirus revealed to be the most lethal virus as three out of eight patients with coronavirus died (Table 3 ).", [["coronavirus", "DISEASE", 142, 153], ["coronavirus", "DISEASE", 227, 238], ["patients", "ORGANISM", 118, 126], ["coronavirus", "ORGANISM", 142, 153], ["patients", "ORGANISM", 213, 221], ["coronavirus", "ORGANISM", 227, 238], ["patients", "SPECIES", 118, 126], ["patients", "SPECIES", 213, 221], ["multiple viruses", "PROBLEM", 37, 53], ["multiple virus isolated patients", "PROBLEM", 94, 126], ["coronavirus", "PROBLEM", 142, 153], ["the most lethal virus", "PROBLEM", 169, 190], ["coronavirus", "PROBLEM", 227, 238], ["multiple", "OBSERVATION_MODIFIER", 37, 45], ["viruses", "OBSERVATION", 46, 53]]], ["Coronavirus is known as the primary agent of upper respiratory tract infection and common cold.", [["upper respiratory tract", "ANATOMY", 45, 68], ["respiratory tract infection", "DISEASE", 51, 78], ["upper respiratory", "ORGANISM_SUBDIVISION", 45, 62], ["tract", "ORGANISM_SUBDIVISION", 63, 68], ["Coronavirus", "PROBLEM", 0, 11], ["upper respiratory tract infection", "PROBLEM", 45, 78], ["common cold", "PROBLEM", 83, 94], ["upper", "ANATOMY_MODIFIER", 45, 50], ["respiratory tract", "ANATOMY", 51, 68], ["infection", "OBSERVATION", 69, 78]]], ["29 Coronavirus had been defined as the causal agent of SARS (Severe Acute Respiratory Syndrome), which more severely progresses in adults, while the disease lasts shorter and shows milder progression in children.", [["SARS", "DISEASE", 55, 59], ["Acute Respiratory Syndrome", "DISEASE", 68, 94], ["children", "ORGANISM", 203, 211], ["children", "SPECIES", 203, 211], ["Coronavirus", "PROBLEM", 3, 14], ["SARS (Severe Acute Respiratory Syndrome", "PROBLEM", 55, 94], ["the disease", "PROBLEM", 145, 156], ["milder progression in children", "PROBLEM", 181, 211], ["Severe", "OBSERVATION_MODIFIER", 61, 67], ["Acute", "OBSERVATION_MODIFIER", 68, 73], ["Respiratory Syndrome", "OBSERVATION", 74, 94], ["severely", "OBSERVATION_MODIFIER", 108, 116], ["disease", "OBSERVATION", 149, 156], ["milder", "OBSERVATION_MODIFIER", 181, 187], ["progression", "OBSERVATION_MODIFIER", 188, 199]]], ["30 Unlike the literature, coronavirus presented severe symptoms with organ failures in our group of patients (Table 4 ).", [["organ", "ANATOMY", 69, 74], ["coronavirus", "DISEASE", 26, 37], ["organ failures", "DISEASE", 69, 83], ["coronavirus", "ORGANISM", 26, 37], ["organ", "ORGAN", 69, 74], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["coronavirus", "PROBLEM", 26, 37], ["severe symptoms", "PROBLEM", 48, 63], ["organ failures", "PROBLEM", 69, 83], ["severe", "OBSERVATION_MODIFIER", 48, 54]]], ["Lower respiratory tract infections caused by coronavirus types out of SARS are rare and some studies found the incidence of pneumonia and bronchitis as <5%.", [["respiratory tract", "ANATOMY", 6, 23], ["respiratory tract infections", "DISEASE", 6, 34], ["SARS", "DISEASE", 70, 74], ["pneumonia", "DISEASE", 124, 133], ["bronchitis", "DISEASE", 138, 148], ["Lower respiratory tract", "ORGANISM_SUBDIVISION", 0, 23], ["Lower respiratory tract infections", "PROBLEM", 0, 34], ["coronavirus types", "PROBLEM", 45, 62], ["SARS", "PROBLEM", 70, 74], ["some studies", "TEST", 88, 100], ["pneumonia", "PROBLEM", 124, 133], ["bronchitis", "PROBLEM", 138, 148], ["respiratory tract", "ANATOMY", 6, 23], ["infections", "OBSERVATION", 24, 34], ["coronavirus", "OBSERVATION", 45, 56], ["pneumonia", "OBSERVATION", 124, 133], ["bronchitis", "OBSERVATION", 138, 148]]], ["[31] [32] [33] [34] [35] [36] Therefore, in our study, the incidence of coronavirus was low that is consistent with the literature, but unlike that coronavirus caused lower respiratory tract infections and emerged as the most lethal viral agent (Table 3) .", [["lower respiratory tract", "ANATOMY", 167, 190], ["coronavirus", "DISEASE", 72, 83], ["coronavirus", "DISEASE", 148, 159], ["respiratory tract infections", "DISEASE", 173, 201], ["[31] [32] [33] [34] [35] [36]", "SIMPLE_CHEMICAL", 0, 29], ["coronavirus", "ORGANISM", 72, 83], ["tract", "ORGANISM_SUBDIVISION", 185, 190], ["our study", "TEST", 44, 53], ["coronavirus", "PROBLEM", 72, 83], ["coronavirus", "PROBLEM", 148, 159], ["lower respiratory tract infections", "PROBLEM", 167, 201], ["the most lethal viral agent", "TREATMENT", 217, 244], ["coronavirus", "OBSERVATION", 72, 83], ["consistent with", "UNCERTAINTY", 100, 115], ["coronavirus", "OBSERVATION", 148, 159], ["lower", "ANATOMY_MODIFIER", 167, 172], ["respiratory tract", "ANATOMY", 173, 190], ["infections", "OBSERVATION", 191, 201]]], ["However, 36% of the patients with coronavirus had secondary bacterial infections; so, coronavirus is not solely responsible for mortality.", [["coronavirus", "DISEASE", 34, 45], ["bacterial infections", "DISEASE", 60, 80], ["coronavirus", "DISEASE", 86, 97], ["patients", "ORGANISM", 20, 28], ["coronavirus", "ORGANISM", 34, 45], ["coronavirus", "ORGANISM", 86, 97], ["patients", "SPECIES", 20, 28], ["coronavirus", "SPECIES", 34, 45], ["coronavirus", "PROBLEM", 34, 45], ["secondary bacterial infections", "PROBLEM", 50, 80], ["coronavirus", "PROBLEM", 86, 97], ["bacterial infections", "OBSERVATION", 60, 80]]], ["Although secondary infections were found in only 16% of all patients, we found that 94% of the patients who presented with viral infections received antibiotics.dIscussIonSixty-two percent of the patients received antiviral treatment (oseltamivir) because antiviral therapy was started before nasal swab results in patients with severe infection findings.", [["nasal swab", "ANATOMY", 293, 303], ["infections", "DISEASE", 19, 29], ["viral infections", "DISEASE", 123, 139], ["oseltamivir", "CHEMICAL", 235, 246], ["infection", "DISEASE", 336, 345], ["oseltamivir", "CHEMICAL", 235, 246], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 95, 103], ["patients", "ORGANISM", 196, 204], ["oseltamivir", "SIMPLE_CHEMICAL", 235, 246], ["patients", "ORGANISM", 315, 323], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 196, 204], ["patients", "SPECIES", 315, 323], ["secondary infections", "PROBLEM", 9, 29], ["viral infections", "PROBLEM", 123, 139], ["antibiotics.dIscussIonSixty", "TREATMENT", 149, 176], ["antiviral treatment", "TREATMENT", 214, 233], ["oseltamivir", "TREATMENT", 235, 246], ["antiviral therapy", "TREATMENT", 256, 273], ["nasal swab", "TEST", 293, 303], ["severe infection findings", "PROBLEM", 329, 354], ["secondary", "OBSERVATION_MODIFIER", 9, 18], ["infections", "OBSERVATION", 19, 29], ["viral", "OBSERVATION_MODIFIER", 123, 128], ["infections", "OBSERVATION", 129, 139], ["severe", "OBSERVATION_MODIFIER", 329, 335], ["infection", "OBSERVATION", 336, 345]]], ["We found that antiviral therapy did not affect mortality (Table 5) including the influenza subgroup.", [["influenza", "DISEASE", 81, 90], ["antiviral therapy", "TREATMENT", 14, 31], ["the influenza subgroup", "PROBLEM", 77, 99], ["antiviral therapy", "OBSERVATION", 14, 31]]], ["Though, there are studies in literature showing that oseltamivir initiated in the early period was effective.", [["oseltamivir", "CHEMICAL", 53, 64], ["oseltamivir", "CHEMICAL", 53, 64], ["oseltamivir", "SIMPLE_CHEMICAL", 53, 64], ["studies", "TEST", 18, 25], ["oseltamivir", "TREATMENT", 53, 64], ["oseltamivir", "OBSERVATION", 53, 64]]], ["[37] [38] [39] However, weakness of our study is that the data we gathered is not capable of differentiating the initiation timing for antiviral therapy.", [["weakness", "PROBLEM", 24, 32], ["our study", "TEST", 36, 45], ["antiviral therapy", "TREATMENT", 135, 152]]], ["Further studies are needed for this issue.", [["Further studies", "TEST", 0, 15]]], ["Influenza is already known as the only agent that benefits from oseltamivir.", [["Influenza", "DISEASE", 0, 9], ["oseltamivir", "CHEMICAL", 64, 75], ["oseltamivir", "CHEMICAL", 64, 75], ["oseltamivir", "SIMPLE_CHEMICAL", 64, 75], ["Influenza", "PROBLEM", 0, 9], ["oseltamivir", "TREATMENT", 64, 75]]], ["When we separately evaluated the influenza subgroup, we found the median patient age as 41 months and higher PRISM and PELOD scores compared with rest of the viral agents.", [["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["higher PRISM and PELOD scores", "PROBLEM", 102, 131], ["the viral agents", "TREATMENT", 154, 170], ["viral agents", "OBSERVATION", 158, 170]]], ["Influenza was more common in older children and progressed more severely.", [["Influenza", "DISEASE", 0, 9], ["children", "ORGANISM", 35, 43], ["children", "SPECIES", 35, 43], ["Influenza", "PROBLEM", 0, 9]]], ["Therefore, oseltamivir can be preferred in children especially over one year of age and who presented with more severe symptoms because they are more likely to have influenza.dIscussIonConsistent with the literature, comorbidities were common in the present study.", [["oseltamivir", "CHEMICAL", 11, 22], ["oseltamivir", "CHEMICAL", 11, 22], ["oseltamivir", "SIMPLE_CHEMICAL", 11, 22], ["children", "ORGANISM", 43, 51], ["children", "SPECIES", 43, 51], ["oseltamivir", "TREATMENT", 11, 22], ["more severe symptoms", "PROBLEM", 107, 127], ["comorbidities", "PROBLEM", 217, 230], ["the present study", "TEST", 246, 263]]], ["9, [12] [13] [14] 20 Although 60% of the patients who died had an underlying disease, a statistical correlation is lacking as described in the literature.", [["[12] [13] [14] 20", "SIMPLE_CHEMICAL", 3, 20], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["an underlying disease", "PROBLEM", 63, 84], ["disease", "OBSERVATION", 77, 84]]], ["9, 12 In our study, it was found that mechanical respiratory support was administered to the majority of the patients and renal replacement therapy was applied in the group, which had organ failure and progression.", [["renal", "ANATOMY", 122, 127], ["organ", "ANATOMY", 184, 189], ["organ failure", "DISEASE", 184, 197], ["patients", "ORGANISM", 109, 117], ["renal", "ORGAN", 122, 127], ["organ", "ORGAN", 184, 189], ["patients", "SPECIES", 109, 117], ["our study", "TEST", 9, 18], ["mechanical respiratory support", "TREATMENT", 38, 68], ["renal replacement therapy", "TREATMENT", 122, 147], ["organ failure", "PROBLEM", 184, 197], ["respiratory support", "OBSERVATION", 49, 68], ["renal", "ANATOMY", 122, 127], ["replacement", "OBSERVATION", 128, 139], ["organ", "ANATOMY", 184, 189], ["failure", "OBSERVATION", 190, 197], ["progression", "OBSERVATION_MODIFIER", 202, 213]]], ["As expected, we found that PRISM and PELOD scores were higher in patients who died.conclusIonWe found that tachycardia, hypotension, hypoxia, acidosis, impaired liver or renal tests, and MODS at the time of admission are the factors associated with mortality and predictors of a severely progressing disease.", [["liver", "ANATOMY", 161, 166], ["renal", "ANATOMY", 170, 175], ["tachycardia", "DISEASE", 107, 118], ["hypotension", "DISEASE", 120, 131], ["hypoxia", "DISEASE", 133, 140], ["acidosis", "DISEASE", 142, 150], ["impaired liver or renal tests", "DISEASE", 152, 181], ["MODS", "DISEASE", 187, 191], ["patients", "ORGANISM", 65, 73], ["liver", "ORGAN", 161, 166], ["renal", "ORGAN", 170, 175], ["patients", "SPECIES", 65, 73], ["PRISM and PELOD scores", "PROBLEM", 27, 49], ["tachycardia", "PROBLEM", 107, 118], ["hypotension", "PROBLEM", 120, 131], ["hypoxia", "PROBLEM", 133, 140], ["acidosis", "PROBLEM", 142, 150], ["impaired liver or renal tests", "PROBLEM", 152, 181], ["MODS", "PROBLEM", 187, 191], ["a severely progressing disease", "PROBLEM", 277, 307], ["higher", "OBSERVATION_MODIFIER", 55, 61], ["tachycardia", "OBSERVATION", 107, 118], ["hypotension", "OBSERVATION", 120, 131], ["hypoxia", "OBSERVATION_MODIFIER", 133, 140], ["acidosis", "OBSERVATION", 142, 150], ["impaired", "OBSERVATION_MODIFIER", 152, 160], ["liver", "ANATOMY", 161, 166], ["renal", "ANATOMY", 170, 175], ["MODS", "OBSERVATION", 187, 191], ["severely", "OBSERVATION_MODIFIER", 279, 287], ["progressing", "OBSERVATION_MODIFIER", 288, 299], ["disease", "OBSERVATION", 300, 307]]], ["It was found that acidosis increased mortality by 2.5-folds and MODS by 20-folds.", [["acidosis", "DISEASE", 18, 26], ["MODS", "DISEASE", 64, 68], ["acidosis increased mortality", "PROBLEM", 18, 46], ["MODS", "TEST", 64, 68], ["acidosis", "OBSERVATION_MODIFIER", 18, 26], ["increased", "OBSERVATION_MODIFIER", 27, 36], ["mortality", "OBSERVATION_MODIFIER", 37, 46], ["MODS", "OBSERVATION", 64, 68]]], ["Respiratory symptoms were common and besides respiratory symptoms, incidence of circulatory disorders and shock findings were also high in patients less than one year of age.", [["Respiratory", "ANATOMY", 0, 11], ["respiratory", "ANATOMY", 45, 56], ["circulatory", "ANATOMY", 80, 91], ["Respiratory symptoms", "DISEASE", 0, 20], ["respiratory symptoms", "DISEASE", 45, 65], ["circulatory disorders", "DISEASE", 80, 101], ["shock", "DISEASE", 106, 111], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["Respiratory symptoms", "PROBLEM", 0, 20], ["respiratory symptoms", "PROBLEM", 45, 65], ["circulatory disorders", "PROBLEM", 80, 101], ["shock findings", "PROBLEM", 106, 120], ["circulatory disorders", "OBSERVATION", 80, 101], ["shock", "OBSERVATION", 106, 111], ["high", "OBSERVATION_MODIFIER", 131, 135]]], ["Fever, tachycardia, neurologic symptoms, the incidence of anemia, leukocytosis, thrombocytopenia, impaired renal tests, and electrolyte imbalance were high in patients less than one year of age.", [["neurologic", "ANATOMY", 20, 30], ["renal", "ANATOMY", 107, 112], ["Fever", "DISEASE", 0, 5], ["tachycardia", "DISEASE", 7, 18], ["neurologic symptoms", "DISEASE", 20, 39], ["anemia", "DISEASE", 58, 64], ["leukocytosis", "DISEASE", 66, 78], ["thrombocytopenia", "DISEASE", 80, 96], ["impaired renal tests", "DISEASE", 98, 118], ["renal", "ORGAN", 107, 112], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["Fever", "PROBLEM", 0, 5], ["tachycardia", "PROBLEM", 7, 18], ["neurologic symptoms", "PROBLEM", 20, 39], ["anemia", "PROBLEM", 58, 64], ["leukocytosis", "PROBLEM", 66, 78], ["thrombocytopenia", "PROBLEM", 80, 96], ["impaired renal tests", "PROBLEM", 98, 118], ["electrolyte imbalance", "PROBLEM", 124, 145], ["anemia", "OBSERVATION", 58, 64], ["leukocytosis", "OBSERVATION", 66, 78], ["thrombocytopenia", "OBSERVATION", 80, 96], ["renal", "ANATOMY", 107, 112], ["electrolyte imbalance", "OBSERVATION", 124, 145], ["high", "OBSERVATION_MODIFIER", 151, 155]]], ["Consequently, acidosis and MODS at the time of admission or a patient less than one year of age with symptoms mentioned above should alert clinicians for a possible poor prognosis.", [["acidosis", "DISEASE", 14, 22], ["MODS", "DISEASE", 27, 31], ["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69], ["acidosis", "PROBLEM", 14, 22], ["MODS", "PROBLEM", 27, 31], ["symptoms", "PROBLEM", 101, 109], ["acidosis", "OBSERVATION", 14, 22], ["MODS", "OBSERVATION", 27, 31]]], ["Although we could not show the relationship of virus type with severity and mortality, RSV, parainfluenza, and influenza were the commonly isolated viruses in the patients who died.", [["RSV", "DISEASE", 87, 90], ["parainfluenza", "DISEASE", 92, 105], ["influenza", "DISEASE", 111, 120], ["RSV", "ORGANISM", 87, 90], ["parainfluenza", "ORGANISM", 92, 105], ["patients", "ORGANISM", 163, 171], ["RSV", "SPECIES", 87, 90], ["parainfluenza", "SPECIES", 92, 105], ["patients", "SPECIES", 163, 171], ["RSV", "SPECIES", 87, 90], ["severity", "PROBLEM", 63, 71], ["mortality", "PROBLEM", 76, 85], ["RSV", "PROBLEM", 87, 90], ["parainfluenza", "PROBLEM", 92, 105], ["influenza", "PROBLEM", 111, 120], ["virus", "OBSERVATION", 47, 52], ["parainfluenza", "OBSERVATION", 92, 105]]], ["Coronavirus was found as the most lethal virus.", [["Coronavirus", "PROBLEM", 0, 11], ["the most lethal virus", "PROBLEM", 25, 46]]], ["Although coronavirus is known as the primary agent of upper respiratory tract infection and common cold, this result of our study can be attributed to the incidence of secondary bacterial infections being high in the patients with coronavirus detected.", [["upper respiratory tract", "ANATOMY", 54, 77], ["respiratory tract infection", "DISEASE", 60, 87], ["bacterial infections", "DISEASE", 178, 198], ["coronavirus", "DISEASE", 231, 242], ["coronavirus", "ORGANISM", 9, 20], ["upper respiratory tract", "ORGANISM_SUBDIVISION", 54, 77], ["patients", "ORGANISM", 217, 225], ["coronavirus", "ORGANISM", 231, 242], ["coronavirus", "SPECIES", 9, 20], ["patients", "SPECIES", 217, 225], ["coronavirus", "PROBLEM", 9, 20], ["upper respiratory tract infection", "PROBLEM", 54, 87], ["common cold", "PROBLEM", 92, 103], ["our study", "TEST", 120, 129], ["secondary bacterial infections", "PROBLEM", 168, 198], ["coronavirus", "PROBLEM", 231, 242], ["coronavirus", "OBSERVATION", 9, 20], ["upper", "ANATOMY_MODIFIER", 54, 59], ["respiratory tract", "ANATOMY", 60, 77], ["infection", "OBSERVATION", 78, 87], ["secondary", "OBSERVATION_MODIFIER", 168, 177], ["bacterial", "OBSERVATION_MODIFIER", 178, 187], ["infections", "OBSERVATION", 188, 198], ["high", "OBSERVATION_MODIFIER", 205, 209], ["coronavirus", "OBSERVATION", 231, 242]]], ["With this context, further studies are needed to investigate the relationship between coronavirus and mortality.conclusIonIn our study, we could not demonstrate effects of oseltamivir on mortality, duration of hospitalization, and stay in the PICU including influenza subgroup but there are studies reporting that oseltamivir initiated within first 48 hours is beneficial.", [["coronavirus", "DISEASE", 86, 97], ["oseltamivir", "CHEMICAL", 172, 183], ["influenza", "DISEASE", 258, 267], ["oseltamivir", "CHEMICAL", 314, 325], ["oseltamivir", "CHEMICAL", 172, 183], ["oseltamivir", "CHEMICAL", 314, 325], ["coronavirus", "ORGANISM", 86, 97], ["oseltamivir", "SIMPLE_CHEMICAL", 172, 183], ["oseltamivir", "SIMPLE_CHEMICAL", 314, 325], ["further studies", "TEST", 19, 34], ["coronavirus", "PROBLEM", 86, 97], ["our study", "TEST", 125, 134], ["oseltamivir", "TREATMENT", 172, 183], ["influenza subgroup", "PROBLEM", 258, 276], ["oseltamivir", "TREATMENT", 314, 325]]], ["Therefore, oseltamivir can be preferred in children who present with more severe symptoms because they are more likely to have influenza.", [["oseltamivir", "CHEMICAL", 11, 22], ["influenza", "DISEASE", 127, 136], ["oseltamivir", "CHEMICAL", 11, 22], ["oseltamivir", "SIMPLE_CHEMICAL", 11, 22], ["children", "ORGANISM", 43, 51], ["children", "SPECIES", 43, 51], ["oseltamivir", "TREATMENT", 11, 22], ["more severe symptoms", "PROBLEM", 69, 89], ["influenza", "PROBLEM", 127, 136], ["influenza", "OBSERVATION", 127, 136]]]], "5fe3dfe659e2183311054393985386371430fd8e": [["Study background (a) The canine distemper virus epidemic in the Serengeti National ParkIn 1993-1994, a CDV epidemic unexpectedly caused the death of an estimated 30% of the lion population in the Serengeti National Park (NP) (Roelke-Parker et al. 1996) and increased mortality and morbidity among infected juvenile spotted hyenas (Haas et al. 1996) .", [["canine distemper virus", "DISEASE", 25, 47], ["CDV", "DISEASE", 103, 106], ["death", "DISEASE", 140, 145], ["canine distemper virus", "ORGANISM", 25, 47], ["CDV", "ORGANISM", 103, 106], ["canine distemper virus", "SPECIES", 25, 47], ["canine distemper virus", "SPECIES", 25, 47], ["CDV", "SPECIES", 103, 106], ["Study background", "TEST", 0, 16], ["The canine distemper virus epidemic", "PROBLEM", 21, 56], ["a CDV epidemic", "PROBLEM", 101, 115], ["increased mortality", "PROBLEM", 257, 276], ["infected juvenile spotted hyenas", "PROBLEM", 297, 329], ["distemper virus", "OBSERVATION", 32, 47], ["increased", "OBSERVATION_MODIFIER", 257, 266], ["mortality", "OBSERVATION_MODIFIER", 267, 276], ["infected", "OBSERVATION_MODIFIER", 297, 305], ["juvenile", "OBSERVATION_MODIFIER", 306, 314]]], ["Clinical disease was also observed in a few bat-eared foxes Otocyon megalotis, silver-backed jackalsStudy background (a) The canine distemper virus epidemic in the Serengeti National ParkCanis mesomelas and golden jackals Canis aureus in the park (Roelke-Parker et al. 1996) .Study background (a) The canine distemper virus epidemic in the Serengeti National ParkThis epidemic was assumed to be caused by the 'spill-over' of a virulent CDV genotype from the domestic dog population outside the Serengeti NP (Roelke-Parker et al. 1996) , and the spread of the epidemic within the lion population was posited to require repeated introduction of the virus in terms of jackal-or spotted hyena-to-lion transmission (Craft et al. 2008; Craft et al. 2009 ).The assumed 'spill-over' of virulent CDV from domestic dogs is inconsistent with genetic evidence demonstrating that lions and spotted hyenas (i.e. non-canid species)Study background (a) The canine distemper virus epidemic in the Serengeti National Parkduring the 1993/1994 epidemic were infected with a distinct CDV strain from those that infected canids (domestic dogs and bat-eared fox) (Nikolin et al. 2017) .", [["silver", "CHEMICAL", 79, 85], ["canine distemper virus", "DISEASE", 125, 147], ["canine distemper virus", "DISEASE", 301, 323], ["CDV", "DISEASE", 787, 790], ["canine distemper virus", "DISEASE", 941, 963], ["infected canids", "DISEASE", 1090, 1105], ["silver", "CHEMICAL", 79, 85], ["foxes", "ORGANISM", 54, 59], ["Otocyon megalotis", "ORGANISM", 60, 77], ["silver", "SIMPLE_CHEMICAL", 79, 85], ["jackals", "ORGANISM", 93, 100], ["canine distemper virus", "ORGANISM", 125, 147], ["golden jackals Canis aureus", "ORGANISM", 207, 234], ["canine distemper virus", "ORGANISM", 301, 323], ["CDV", "ORGANISM", 436, 439], ["dog", "ORGANISM", 467, 470], ["lion", "ORGANISM", 579, 583], ["lion", "ORGANISM", 692, 696], ["CDV", "ORGANISM", 787, 790], ["dogs", "ORGANISM", 805, 809], ["spotted hyenas", "ORGANISM", 877, 891], ["canine distemper virus", "ORGANISM", 941, 963], ["CDV", "ORGANISM", 1063, 1066], ["canids", "ORGANISM", 1099, 1105], ["dogs", "ORGANISM", 1116, 1120], ["Otocyon megalotis", "SPECIES", 60, 77], ["canine distemper virus", "SPECIES", 125, 147], ["golden jackals", "SPECIES", 207, 221], ["Canis aureus", "SPECIES", 222, 234], ["canine distemper virus", "SPECIES", 301, 323], ["dog", "SPECIES", 467, 470], ["dogs", "SPECIES", 805, 809], ["canine distemper virus", "SPECIES", 941, 963], ["dogs", "SPECIES", 1116, 1120], ["bat-eared", "SPECIES", 1125, 1134], ["Otocyon megalotis", "SPECIES", 60, 77], ["canine distemper virus", "SPECIES", 125, 147], ["ParkCanis mesomelas", "SPECIES", 183, 202], ["golden jackals", "SPECIES", 207, 221], ["Canis aureus", "SPECIES", 222, 234], ["canine distemper virus", "SPECIES", 301, 323], ["CDV", "SPECIES", 436, 439], ["CDV", "SPECIES", 787, 790], ["canine distemper virus", "SPECIES", 941, 963], ["CDV", "SPECIES", 1063, 1066], ["bat-eared fox", "SPECIES", 1125, 1138], ["Clinical disease", "PROBLEM", 0, 16], ["Study background", "TEST", 100, 116], ["The canine distemper virus epidemic", "PROBLEM", 121, 156], ["golden jackals Canis aureus", "PROBLEM", 207, 234], ["Study background", "TEST", 276, 292], ["The canine distemper virus epidemic", "PROBLEM", 297, 332], ["a virulent CDV genotype", "PROBLEM", 425, 448], ["the virus", "TREATMENT", 643, 652], ["jackal", "TEST", 665, 671], ["spotted hyena", "TEST", 675, 688], ["virulent CDV", "PROBLEM", 778, 790], ["domestic dogs", "PROBLEM", 796, 809], ["lions and spotted hyenas", "PROBLEM", 867, 891], ["Study background", "TEST", 916, 932], ["The canine distemper virus epidemic", "PROBLEM", 937, 972], ["a distinct CDV strain", "PROBLEM", 1052, 1073], ["distemper virus", "OBSERVATION", 132, 147], ["golden jackals", "ANATOMY", 207, 221], ["Canis aureus", "OBSERVATION", 222, 234], ["distemper virus", "OBSERVATION", 308, 323], ["spill", "OBSERVATION_MODIFIER", 763, 768], ["domestic dogs", "OBSERVATION", 796, 809], ["lions", "OBSERVATION", 867, 872], ["distemper virus", "OBSERVATION", 948, 963], ["distinct", "OBSERVATION_MODIFIER", 1054, 1062], ["CDV strain", "OBSERVATION", 1063, 1073], ["infected", "OBSERVATION_MODIFIER", 1090, 1098]]], ["The frequent reintroduction of CDV from hyenas to lions is unlikely because the vast majority of the widely ranging adult population in the Serengeti NP of approximately 7200 hyenas (Hofer & East 1995) showed no symptoms and hence were not shedding virus (Nikolin et al. 2017) .", [["CDV", "ORGANISM", 31, 34], ["Serengeti NP", "ORGANISM", 140, 152], ["CDV", "SPECIES", 31, 34], ["CDV", "TREATMENT", 31, 34], ["symptoms", "PROBLEM", 212, 220], ["shedding virus", "PROBLEM", 240, 254], ["frequent", "OBSERVATION_MODIFIER", 4, 12], ["reintroduction", "OBSERVATION_MODIFIER", 13, 27], ["widely", "OBSERVATION_MODIFIER", 101, 107], ["ranging", "OBSERVATION_MODIFIER", 108, 115], ["adult", "OBSERVATION_MODIFIER", 116, 121], ["population", "OBSERVATION_MODIFIER", 122, 132], ["no", "UNCERTAINTY", 209, 211]]], ["Cubs < 12 months restricted in range to clan communal dens were the main hyena age category that shed virus.Study background (a) The canine distemper virus epidemic in the Serengeti National ParkDuring the 1993/1994 epidemic all 'Serengeti' strains from lions and spotted hyenas encoded a rare amino acid combination at two sites under positive selection in the region of the CDV-H protein that binds to SLAM (CD 150) host cell receptors, plus one novel substitution in the CDV-V protein, which suppresses host cytokines and affects the outcome of infection.", [["cell", "ANATOMY", 423, 427], ["canine distemper virus", "DISEASE", 133, 155], ["amino acid", "CHEMICAL", 294, 304], ["infection", "DISEASE", 548, 557], ["amino acid", "CHEMICAL", 294, 304], ["canine distemper virus", "ORGANISM", 133, 155], ["lions", "ORGANISM", 254, 259], ["amino acid", "AMINO_ACID", 294, 304], ["CDV-H", "GENE_OR_GENE_PRODUCT", 376, 381], ["SLAM (CD 150) host cell receptors", "GENE_OR_GENE_PRODUCT", 404, 437], ["CDV-V", "GENE_OR_GENE_PRODUCT", 474, 479], ["CDV-H protein", "PROTEIN", 376, 389], ["SLAM", "PROTEIN", 404, 408], ["CD 150) host cell receptors", "PROTEIN", 410, 437], ["CDV-V protein", "PROTEIN", 474, 487], ["cytokines", "PROTEIN", 511, 520], ["canine distemper virus", "SPECIES", 133, 155], ["canine distemper virus", "SPECIES", 133, 155], ["CDV-H", "SPECIES", 376, 381], ["Cubs", "TEST", 0, 4], ["Study background", "TEST", 108, 124], ["The canine distemper virus epidemic", "PROBLEM", 129, 164], ["spotted hyenas", "PROBLEM", 264, 278], ["a rare amino acid combination", "TREATMENT", 287, 316], ["positive selection", "TREATMENT", 336, 354], ["host cell receptors", "TREATMENT", 418, 437], ["the CDV", "TEST", 470, 477], ["infection", "PROBLEM", 548, 557], ["distemper virus", "OBSERVATION", 140, 155], ["positive selection", "OBSERVATION", 336, 354], ["host cytokines", "OBSERVATION", 506, 520], ["infection", "OBSERVATION", 548, 557]]], ["All 'Serengeti' strains from wild canids and a local domestic dog did not encode this rare amino acid combination in the CDV-H protein or the novel substitution in the CDV-V protein.Study background (a) The canine distemper virus epidemic in the Serengeti National ParkRather, 'Serengeti' canid strains encoded amino acid combinations in the CDV-H protein typical for strains from domestic dogs and wild carnivores worldwide, and in the CDV-V protein the same amino acid described in all other CDV strains for which genetic information is available (Nikolin et al. 2017 ).(b) Ecology of spotted hyenas in the Serengeti National ParkIn the Serengeti NP, hyenas live in fission-fusion societies (clans) that defend a territory.(b) Ecology of spotted hyenas in the Serengeti National ParkThey mainly feed on migratory ungulates, whose seasonal movements cause large Marescot fluctuations in food abundance within spotted hyena clan territories (Hofer & East 1993a; .", [["amino acid", "CHEMICAL", 91, 101], ["canine distemper virus", "DISEASE", 207, 229], ["amino acid", "CHEMICAL", 311, 321], ["amino acid", "CHEMICAL", 460, 470], ["amino acid", "CHEMICAL", 91, 101], ["amino acid", "CHEMICAL", 311, 321], ["amino acid", "CHEMICAL", 460, 470], ["Serengeti' strains", "ORGANISM", 5, 23], ["wild canids", "ORGANISM", 29, 40], ["dog", "ORGANISM", 62, 65], ["amino acid", "AMINO_ACID", 91, 101], ["CDV-H", "GENE_OR_GENE_PRODUCT", 121, 126], ["CDV-V", "GENE_OR_GENE_PRODUCT", 168, 173], ["canine distemper virus", "ORGANISM", 207, 229], ["Serengeti' canid strains", "ORGANISM", 278, 302], ["amino acid", "AMINO_ACID", 311, 321], ["CDV-H", "GENE_OR_GENE_PRODUCT", 342, 347], ["domestic dogs", "ORGANISM", 381, 394], ["CDV-V", "GENE_OR_GENE_PRODUCT", 437, 442], ["amino acid", "AMINO_ACID", 460, 470], ["CDV strains", "ORGANISM", 494, 505], ["CDV-H protein", "PROTEIN", 121, 134], ["CDV-V protein", "PROTEIN", 168, 181], ["CDV-H protein", "PROTEIN", 342, 355], ["CDV-V protein", "PROTEIN", 437, 450], ["dog", "SPECIES", 62, 65], ["canine distemper virus", "SPECIES", 207, 229], ["dogs", "SPECIES", 390, 394], ["CDV-H", "SPECIES", 121, 126], ["CDV-V", "SPECIES", 168, 173], ["canine distemper virus", "SPECIES", 207, 229], ["CDV-H", "SPECIES", 342, 347], ["CDV-V", "SPECIES", 437, 442], ["CDV", "SPECIES", 494, 497], ["All 'Serengeti' strains", "PROBLEM", 0, 23], ["wild canids", "PROBLEM", 29, 40], ["this rare amino acid", "TREATMENT", 81, 101], ["the CDV", "TEST", 117, 124], ["the novel substitution", "PROBLEM", 138, 160], ["the CDV", "TEST", 164, 171], ["Study background", "TEST", 182, 198], ["The canine distemper virus", "PROBLEM", 203, 229], ["'Serengeti' canid strains", "TREATMENT", 277, 302], ["amino acid combinations", "TREATMENT", 311, 334], ["the CDV", "TEST", 338, 345], ["strains", "PROBLEM", 368, 375], ["domestic dogs", "TREATMENT", 381, 394], ["the CDV", "TEST", 433, 440], ["amino acid", "TREATMENT", 460, 470], ["all other CDV strains", "PROBLEM", 484, 505], ["spotted hyenas", "PROBLEM", 587, 601], ["spotted hyenas", "PROBLEM", 740, 754], ["large Marescot fluctuations", "PROBLEM", 857, 884], ["distemper virus", "OBSERVATION", 214, 229], ["fusion societies", "OBSERVATION", 676, 692], ["spotted hyenas", "OBSERVATION", 740, 754], ["migratory ungulates", "OBSERVATION", 805, 824], ["large", "OBSERVATION_MODIFIER", 857, 862], ["Marescot fluctuations", "OBSERVATION", 863, 884]]], ["This presents lactating females with the problem of fulfilling the increased nutritional demands of lactation during periods when prey abundance in the clan territory is not sufficient to feed all clan members (East et al. 2015; Hofer et al. 2016) .(b) Ecology of spotted hyenas in the Serengeti National ParkFemales breed throughout the year, producing litters contain one or two cubs (rare litters of three cubs never survive) (Hofer & East 2008) , hence mothers always encounter periods when migratory prey are absent from their territories when lactating.(b) Ecology of spotted hyenas in the Serengeti National ParkWhen migratory ungulates are abundant in a clan's territory, all mothers feed locally and nurse their offspring daily but when absent, they undertake 'commuting' round-trips of approximately 80 to 140 km between the communal den and foraging areas.", [["spotted hyenas", "PROBLEM", 264, 278], ["spotted hyenas", "PROBLEM", 574, 588], ["increased", "OBSERVATION_MODIFIER", 67, 76], ["nutritional demands", "OBSERVATION", 77, 96], ["spotted hyenas", "OBSERVATION", 574, 588]]], ["When their mothers commute, dependent cubs may fast for up to 9 days (Hofer & East 1993b) .", [["mothers", "ORGANISM", 11, 18]]], ["Marescot Overview of our methods:Supplementary information on the methodsStep Procedure Established methods Document(s)FieldworkStep 1a Identifying, aging and sexing individuals in the field Frank, Glickman & Licht 1991 Hofer & East 1993a Main text: Study design and data collection Appendix: 2.(a)FieldworkStep 1b Monitoring clinical signs of CDV Haas et al. 1996 Main text: Study design and data collection Appendix: 2.(a)FieldworkStepLabworkStep 2a Serological analyses Developped in this study Appendix: 2.(b)LabworkStep 2b RT-PCR screening Hall 1999 Nikolin et al. 2017 Data preparationLabworkStep 3a Creating encounter histories Developped in this study Main text: Definition of demographic, social and infection states:LabworkStep 3b Assigning demographic states Developped in this study Main text: Definition of demographic, social and infection states,Demographic statesStep 3c Assessing standardized social status and assigning social states East et al. 2003 Goymann et al. 2001 East et al. 2003 East et al. 2009 Main text: Definition of demographic, social and infection states, Social statesDemographic statesStep 3d(a) Data collectionWe recorded the identity of all hyenas within a radius of about 100 m of communal dens for approximately three hours at dawn and dusk .", [["preparationLabworkStep 3a", "CHEMICAL", 580, 605], ["infection", "DISEASE", 709, 718], ["infection", "DISEASE", 844, 853], ["infection", "DISEASE", 1072, 1081], ["CDV", "ORGANISM", 344, 347], ["CDV", "SPECIES", 344, 347], ["Monitoring clinical signs", "TEST", 315, 340], ["CDV", "PROBLEM", 344, 347], ["a Serological analyses", "TEST", 450, 472], ["this study", "TEST", 487, 497], ["LabworkStep", "TEST", 513, 524], ["this study", "TEST", 649, 659], ["this study", "TEST", 784, 794], ["infection", "OBSERVATION", 709, 718], ["infection", "OBSERVATION", 844, 853], ["infection", "OBSERVATION", 1072, 1081], ["all", "OBSERVATION_MODIFIER", 1175, 1178], ["hyenas", "OBSERVATION", 1179, 1185]]], ["We excluded observations of individuals encountered in locations other than at or close to communal dens and birth dens to avoid heterogeneity in the sampling frame.", [["individuals", "PROBLEM", 28, 39], ["heterogeneity in the sampling frame", "PROBLEM", 129, 164], ["heterogeneity", "OBSERVATION", 129, 142]]], ["Animals were well habituated to the presence of observers in vehicles, which enabled detailed observations of social interactions and clinical signs indicative of CDV, even in very young individuals.(a) Data collectionAs part of our health monitoring of study clans, we recorded the start and end of clinical signs consistent with (but not exclusive to) clinical signs of CDV infection (blue sheen on eyes, respiratory distress, ataxia, poor limb coordination, bloody faeces and listlessness) and of secondary infections know to typically occur in spotted hyenas infected with CDV (nasal and or ocular discharge) (Haas et al. 1996) .", [["eyes", "ANATOMY", 401, 405], ["respiratory", "ANATOMY", 407, 418], ["limb", "ANATOMY", 442, 446], ["bloody faeces", "ANATOMY", 461, 474], ["nasal", "ANATOMY", 582, 587], ["ocular", "ANATOMY", 595, 601], ["CDV", "DISEASE", 163, 166], ["CDV infection", "DISEASE", 372, 385], ["respiratory distress", "DISEASE", 407, 427], ["ataxia", "DISEASE", 429, 435], ["listlessness", "DISEASE", 479, 491], ["infections", "DISEASE", 510, 520], ["CDV (nasal and or ocular discharge", "DISEASE", 577, 611], ["Animals", "ORGANISM", 0, 7], ["CDV", "ORGANISM", 163, 166], ["CDV", "ORGANISM", 372, 375], ["eyes", "ORGAN", 401, 405], ["limb", "ORGANISM_SUBDIVISION", 442, 446], ["CDV", "ORGANISM", 577, 580], ["nasal", "ORGAN", 582, 587], ["CDV", "SPECIES", 163, 166], ["CDV", "SPECIES", 372, 375], ["CDV", "SPECIES", 577, 580], ["clinical signs", "TEST", 134, 148], ["CDV", "PROBLEM", 163, 166], ["clinical signs", "TEST", 300, 314], ["CDV infection", "PROBLEM", 372, 385], ["blue sheen on eyes", "PROBLEM", 387, 405], ["respiratory distress", "PROBLEM", 407, 427], ["ataxia", "PROBLEM", 429, 435], ["poor limb coordination", "PROBLEM", 437, 459], ["bloody faeces", "PROBLEM", 461, 474], ["listlessness", "PROBLEM", 479, 491], ["secondary infections", "PROBLEM", 500, 520], ["CDV (nasal", "TREATMENT", 577, 587], ["CDV infection", "OBSERVATION", 372, 385], ["respiratory", "ANATOMY", 407, 418], ["infections", "OBSERVATION", 510, 520]]], ["Some spotted hyenas suspected to have contracted CDV showed several signs.", [["CDV", "DISEASE", 49, 52], ["CDV", "ORGANISM", 49, 52], ["CDV", "SPECIES", 49, 52], ["Some spotted hyenas", "PROBLEM", 0, 19], ["contracted CDV", "PROBLEM", 38, 52], ["several", "OBSERVATION_MODIFIER", 60, 67], ["signs", "OBSERVATION", 68, 73]]], ["Individuals with such signs were particularly closely monitored to record their potential date of death or disappearance.(a) Data collectionWe screened for the presence of CDV by RT-PCR, in faecal (n = 61) and saliva samples (n = 2) collected non-invasively, and blood (n = 27), or tissue (n = 16) samples collected from known hyenas that died from natural causes, were hit by vehicles on roads or were immobilized mostly for the removal of wire snares set by bushmeat hunters (Hofer, East & Campbell 1993 ).(b) Laboratory analysesGenetic analysis for assessing relatedness: Microsatellite DNA profiling was used to confirm the identity of the mother and sire of cubs born in study clans using the methods fully detailed elsewhere Wilhelm et al. 2003; East et al. 2009 ).", [["faecal", "ANATOMY", 190, 196], ["saliva samples", "ANATOMY", 210, 224], ["blood", "ANATOMY", 263, 268], ["tissue", "ANATOMY", 282, 288], ["samples", "ANATOMY", 298, 305], ["death", "DISEASE", 98, 103], ["CDV", "ORGANISM", 172, 175], ["faecal", "ORGANISM_SUBSTANCE", 190, 196], ["blood", "ORGANISM_SUBSTANCE", 263, 268], ["tissue", "TISSUE", 282, 288], ["hyenas", "ORGANISM", 327, 333], ["DNA", "CELLULAR_COMPONENT", 590, 593], ["CDV", "SPECIES", 172, 175], ["such signs", "PROBLEM", 17, 27], ["death", "PROBLEM", 98, 103], ["CDV", "PROBLEM", 172, 175], ["RT", "TEST", 179, 181], ["PCR", "TEST", 182, 185], ["saliva samples", "TEST", 210, 224], ["blood", "TEST", 263, 268], ["tissue (n = 16) samples", "TEST", 282, 305], ["known hyenas", "PROBLEM", 321, 333], ["the removal of wire snares", "TREATMENT", 426, 452], ["Laboratory analyses", "TEST", 512, 531], ["Genetic analysis", "TEST", 531, 547], ["Microsatellite DNA profiling", "PROBLEM", 575, 603], ["tissue", "ANATOMY", 282, 288]]], ["Table S2 we summarize and provide sample sizes for all combinations of states used in the female and male capture-markrecapture (CMR) data sets.", [["sample sizes", "TREATMENT", 34, 46]]], ["Marescot To verify that we fulfilled these assumptions, we conducted a preliminary assessment of the GOF of the most parameterized model to the data, by calculating chi-square values in contingency tables using the software U-CARE 2.3.2 (Choquet et al. 2009 ).RT-PCRThe validation of our model was first done with the test '3G.SM'.", [["SM", "PROTEIN", 327, 329], ["a preliminary assessment", "TEST", 69, 93], ["our model", "TEST", 284, 293], ["the test '", "TEST", 314, 324]]], ["This overall composite test is based on the conjunction of several null hypotheses depicting the main assumptions stated above.", [["This overall composite test", "TEST", 0, 27]]], ["We did not find any significant departure from those assumptions, meaning that the fully parameterized model adequately fitted the data (\u03c7 2 = 75.69, df=143 p-value = 0.7 for females and \u03c7 2 = 31.3, df = 37, p-value = 0.7 for males).RT-PCRWe then performed more specific tests.", [["the data", "TEST", 127, 135], ["df", "TEST", 150, 152], ["p-value", "TEST", 157, 164], ["females", "TEST", 175, 182], ["df", "TEST", 199, 201], ["p-value", "TEST", 208, 215], ["specific tests", "TEST", 262, 276]]], ["The test '3G.SR' is aimed at detecting a potential lack-of-fit due to heterogeneity in individual detection or the presence of individuals that temporarily move beyond the core study area.", [["The test '", "TEST", 0, 10], ["heterogeneity", "PROBLEM", 70, 83], ["individual detection", "TEST", 87, 107], ["heterogeneity", "OBSERVATION", 70, 83]]], ["If the presence of such transient individuals on the study site is overlooked, survival will be underestimated (Choquet et al. 2009 ).", [["such transient individuals", "PROBLEM", 19, 45], ["the study site", "TEST", 49, 63]]], ["The null hypothesis states that \"there is no difference in the probability of being later re-detected between \"new\" and \"old\" individuals detected simultaneously.\"", [["null", "OBSERVATION", 4, 8], ["no", "UNCERTAINTY", 42, 44]]], ["This test was not significant for both females (\u03c7 2 = 13.7, df = 32, p-value = 0.99) and males (\u03c7 2 = 31.3, df = 37, p-value = 0.7), showing that our estimations are not biased by potential heterogeneity in individual detection or temporal absence from the study area.RT-PCRThe test 'M.ITEC' for 'trap-dependence' is aimed at detecting a potential lack-of-fit due to the monitoring design resulting in some individuals responding positively or negatively to the capturing/detection method (e.g.. when some individuals are attracted to baited camera traps or afraid of flashing cameras.).", [["This test", "TEST", 0, 9], ["df", "TEST", 60, 62], ["p-value", "TEST", 69, 76], ["males", "TEST", 89, 94], ["df", "TEST", 108, 110], ["p-value", "TEST", 117, 124], ["our estimations", "TEST", 146, 161], ["the study area", "TEST", 253, 267], ["the monitoring design", "TEST", 367, 388], ["heterogeneity", "OBSERVATION", 190, 203]]], ["It tests the null hypothesis that \"there is no difference in the probabilities of being re-encountered in the different states at the occasion i+1 between the animals in the same state at occasion i whether encountered or not encountered at this date, conditional on presence at both occasions\" (Choquet et al. 2009 ).", [["no", "UNCERTAINTY", 44, 46]]], ["Here we could not run this test because a great majority of females and males were re-detected the year following their first detection, resulting in insufficient variation in the re-detection probability to run this test.RT-PCRHowever, our close observations of thousands of hyenas at communal dens during the past thirty years do not suggest in any way that some clan members would have avoided the vicinity of communal dens owing to the presence of the research vehicle.", [["this test", "TEST", 22, 31], ["their first detection", "TEST", 114, 135], ["this test", "TEST", 212, 221], ["communal dens", "PROBLEM", 413, 426], ["insufficient variation", "OBSERVATION", 150, 172]]], ["This test is based on the null hypothesis that 'there is no difference in the expected state of next reencounter among individuals previously encountered in the different states\" (Pradel, Wintrebert & Gimenez 2003 , Choquet et al. 2009 ).", [["This test", "TEST", 0, 9], ["no", "UNCERTAINTY", 57, 59]]], ["In our case, a non-significant test would confirm that the state transition of an individual detected at a given occasion does not depend on its state at the previous occasion.RT-PCRThis test was not significant for both females (\u03c7 2 =165.5, df = 172, p-value = 0.62) and males (\u03c7 2 = 26.8, df = 28, p-value = 0.53), showing that there was no effect of past state.RT-PCRTrue and apparent survival probability: In the CMR modelling context, the estimated survival probability is not always the \"true\" survival because mortality cannot be distinguished, but the \"apparent\" survival, which combines both the effect of mortality and emigration (Schaub et al. 2004 ).", [["a non-significant test", "TEST", 13, 35], ["RT-PCRThis test", "TEST", 176, 191], ["df", "TEST", 242, 244], ["p-value", "TEST", 252, 259], ["males", "TEST", 272, 277], ["df", "TEST", 291, 293], ["p-value", "TEST", 300, 307], ["the estimated survival probability", "PROBLEM", 440, 474]]], ["In the female analysis, we estimated the true survival of adults since females were philopatric whereas in the male analysis the survival of adults was likely underestimated because immigrant males can re-disperse (H\u00f6ner et al. 2007 [ ] ) 1 ( \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u03c0 \u2212 = Is (1) with \u03c0 being the probability of being in a given initial demographic, social and infection state.RT-PCRThe entries in I s correspond to the probabilities (from left to right) of being in a combination of states described in order in the section above (2.d) A similar matrix was constructed for males with 18 states corresponding to the initial state probabilities as cubs, pre-breeders, or breeders in each social and infection state.", [["infection", "DISEASE", 385, 394], ["infection", "DISEASE", 722, 731], ["adults", "ORGANISM", 58, 64], ["adults", "ORGANISM", 141, 147], ["matrix", "CELLULAR_COMPONENT", 571, 577], ["\u03c0", "PROTEIN", 309, 310], ["pre-breeders", "PROBLEM", 677, 689], ["infection state", "PROBLEM", 722, 737], ["infection", "OBSERVATION", 385, 394], ["left", "ANATOMY_MODIFIER", 464, 468], ["right", "ANATOMY_MODIFIER", 472, 477], ["infection", "OBSERVATION", 722, 731]]], ["As the social and infection processes occurring in males were modeled similarly as for females, we only show here how we modelled male demographic transitions and survival probabilities.The transitions between the demographic states of males can be represented by the matrixDemo males that considers the transitions of males, to different demographic states, that is to the pre-breeder (PB) and breeder (B) states, as defined in the main text and summarized in Table S2 .", [["infection", "DISEASE", 18, 27], ["the social and infection processes", "PROBLEM", 3, 37], ["infection", "OBSERVATION", 18, 27]]], ["Table S3 (Table S3) .Assignment of infection states:The partial observation matrix PO below represents cases where individuals are detected but their infection state is unknown.", [["infection", "DISEASE", 35, 44], ["infection", "DISEASE", 150, 159], ["infection", "PROBLEM", 35, 44], ["The partial observation matrix PO", "TREATMENT", 52, 85], ["their infection state", "PROBLEM", 144, 165], ["infection", "OBSERVATION", 35, 44], ["infection", "OBSERVATION", 150, 159]]], ["This is characterized by the last column, whose elements 1-\u03b4 denote the probability of failing to assign an infection state to an individual that has been detected.", [["infection", "DISEASE", 108, 117], ["elements 1-\u03b4", "DNA", 48, 60], ["an infection state", "PROBLEM", 105, 123], ["last column", "OBSERVATION_MODIFIER", 29, 40], ["infection", "OBSERVATION", 108, 117]]], ["Each element of the matrix is multiplied by a diagonal matrix of 1, Diag(1) of dimension 8 by 8 for females and of dimension 6 by 6 for males.", [["matrix", "CELLULAR_COMPONENT", 20, 26], ["Diag", "TEST", 68, 72], ["matrix", "ANATOMY_MODIFIER", 20, 26]]], ["Such an extension of the PO matrix represents the partial observation of infection states across the demographic and social states:Table S3The final matrices Final females and Final males (for the biological process) represent the transition probabilities of surviving females and males, respectively, to successive demographic states given their specific social and infection states as formulated in Infection/Social.", [["infection", "DISEASE", 73, 82], ["infection", "DISEASE", 367, 376], ["the PO matrix", "TREATMENT", 21, 34], ["infection", "PROBLEM", 73, 82], ["PO matrix", "OBSERVATION_MODIFIER", 25, 34], ["partial", "OBSERVATION_MODIFIER", 50, 57], ["infection", "OBSERVATION", 73, 82], ["infection", "OBSERVATION", 367, 376], ["Infection", "OBSERVATION", 401, 410]]], ["Diag(1) is a diagonal matrix of 1, with similar dimension as Infection/Social.", [["Infection", "OBSERVATION", 61, 70]]], ["Both matrices are the products of the survival and the demographic matrices of females and males, respectively i.e. Final females = Survival x Demo, and Final males = Survival males x Demo males, ) The probability of observing the illustrated encounter history is equivalent to the following formulation:Table S3where the indexed number 1 represents the first sampling occasion (i.e. the first detection occasion), 2 the second and 3 the third, ,\u03d5 the annual survival probability, r, the probability of staying in the same social state, (1r being its complement), \u03b2, the infection probability (i.e. the probability of transition: susceptible \u2192 infected, with 1-\u03b2 being its complement), \u03c8 the transition probability to the B state (with the upper index SA\u2192B denoting the specific transition from subadult to breeder, i.e, breeding probability of primiparous females); with 1-\u03c8 being the complement), p the detection probability (1-p being its complement, i.e. the probability that an individual is not detected) and \u03b4 the assignment probability of an individual into an infection state (susceptible, infected or recovered) conditional on its detection (1-\u03b4 being its complement, i.e., the probability that an individual has its infection state not assigned, i.e. that it is 'unknown').", [["infection", "DISEASE", 571, 580], ["infection", "DISEASE", 1069, 1078], ["infection", "DISEASE", 1227, 1236], ["\u03b2", "PROTEIN", 564, 565], ["the infection probability", "PROBLEM", 567, 592], ["the transition probability", "PROBLEM", 688, 714], ["an infection state", "PROBLEM", 1066, 1084], ["matrices", "OBSERVATION_MODIFIER", 5, 13], ["infection", "OBSERVATION", 571, 580], ["upper", "ANATOMY_MODIFIER", 740, 745], ["infection", "OBSERVATION", 1069, 1078], ["infection", "OBSERVATION", 1227, 1236]]], ["The expected effects of social status on both the infection and the survival probabilities, based on previous studies, are presented in Table S4 .Transition probabilities among demographic and social states and initial state probabilitiesAmong females, we tested whether demographic or social states, or the interaction between both terms, influenced the breeding transition probability, expecting NB more likely to breed than BTransition probabilities among demographic and social states and initial state probabilitiesand SA, and high-ranking females more likely to breed than low-ranking ones.", [["infection", "DISEASE", 50, 59], ["NB", "CANCER", 398, 400], ["the infection", "PROBLEM", 46, 59], ["the survival probabilities", "PROBLEM", 64, 90], ["previous studies", "TEST", 101, 117], ["infection", "OBSERVATION", 50, 59]]], ["We did not test for effects of infection states on demographic or social transitions to avoid over-parameterizing the models.Transition probabilities among demographic and social states and initial state probabilitiesFor both females and males we modeled initial state probabilities, as preliminary model runs suggested that including this parameter substantially improved model ranking.", [["infection", "DISEASE", 31, 40], ["infection", "PROBLEM", 31, 40], ["preliminary model runs", "TEST", 287, 309], ["infection", "OBSERVATION", 31, 40]]], ["We tested effects of demographic, social and infection states and two-way interactions between these states. for Pre-breeder males), social (H and L for high and low-ranking individuals respectively) andTransition probabilities among demographic and social states and initial state probabilitiesinfection states (S for susceptible, I for infected and R for Recovered) and are explained Table S2 .", [["infection", "DISEASE", 45, 54], ["infection", "PROBLEM", 45, 54], ["infection", "OBSERVATION", 45, 54]]], ["Between 6 and 12 months, high-ranking cubs have higher contact rates with clan members than low-ranking ones (as their mothers provide them with intense behavioral support (East, Hofer & Wickler 1993; East et al. 2009 ).Transition probabilities among demographic and social states and initial state probabilitiesThus, high-ranking cubs should globally be more exposed to CDV than low-ranking cubs, between 0 and 12 months.Transition probabilities among demographic and social states and initial state probabilitiesHigh-ranking cubs have a higher survival rate than low-ranking ones in the absence of CDV infection (Hofer & East 1993b; .", [["CDV infection", "DISEASE", 600, 613], ["mothers", "ORGANISM", 119, 126], ["CDV", "ORGANISM", 371, 374], ["CDV", "ORGANISM", 600, 603], ["CDV", "SPECIES", 371, 374], ["CDV", "SPECIES", 600, 603], ["high-ranking cubs", "TREATMENT", 318, 335], ["CDV", "PROBLEM", 371, 374], ["a higher survival rate", "PROBLEM", 537, 559], ["CDV infection", "PROBLEM", 600, 613], ["high", "OBSERVATION_MODIFIER", 318, 322], ["infection", "OBSERVATION", 604, 613]]], ["Thus, if high-ranking cubs are more exposed than low-ranking ones, all else being equal, the survival rate of high-ranking infected cubs should be reduced, and thus is, for simplicity, expected not to differ too much from that of low-ranking infected cubs.", [["high-ranking cubs", "PROBLEM", 9, 26], ["the survival rate", "TEST", 89, 106], ["high-ranking infected cubs", "PROBLEM", 110, 136], ["low-ranking infected cubs", "PROBLEM", 230, 255], ["reduced", "OBSERVATION_MODIFIER", 147, 154], ["infected cubs", "OBSERVATION", 242, 255]]], ["As high-ranking cubs are more often nursed than low-ranking cubs (Hofer & East 1993b; and receive more milk during their development (Hofer et al. 2016) , they should have a higher opportunity to allocate body resources to immune processes.", [["milk", "ANATOMY", 103, 107], ["body", "ANATOMY", 205, 209], ["milk", "ORGANISM_SUBSTANCE", 103, 107], ["body", "ORGANISM_SUBDIVISION", 205, 209]]], ["Therefore, the outcome of infection should be less severe for high-ranking cubs than for low-ranking ones, both in terms of \u03b2 Exposure to CDV should be higher for highranking than low-ranking subadults because the former receive more behavioral support from their mothers and thus have higher contact rates with conspecifics (East, Hofer & Wickler 1993; East et al. 2009 and see East et al. 2001 for data on contact rates).Transition probabilities among demographic and social states and initial state probabilitiesIn the absence of CDV infection, high-ranking subadults have higher survival rates than lowranking ones (Hofer & East 1993b; .", [["infection", "DISEASE", 26, 35], ["CDV infection", "DISEASE", 533, 546], ["CDV", "ORGANISM", 138, 141], ["CDV", "ORGANISM", 533, 536], ["subadults", "ORGANISM", 561, 570], ["CDV", "SPECIES", 138, 141], ["CDV", "SPECIES", 533, 536], ["infection", "PROBLEM", 26, 35], ["CDV", "TREATMENT", 138, 141], ["CDV infection", "PROBLEM", 533, 546], ["infection", "OBSERVATION", 26, 35], ["absence of", "UNCERTAINTY", 522, 532], ["CDV", "OBSERVATION_MODIFIER", 533, 536], ["infection", "OBSERVATION", 537, 546], ["high", "OBSERVATION_MODIFIER", 548, 552]]], ["Thus, if high-ranking subadults are more exposed than low-ranking ones, all else being equal, the survival rate of high-ranking infected subadults should be depressed to a level equivalent to that of low-ranking infected subadults.Transition probabilities among demographic and social states and initial state probabilitiesAs high-ranking subadults are more often nursed than low-ranking cubs (Hofer & East 1993b; , and receive more milk during their development (Hofer et al. 2016 (East, Hofer & Wickler 1993; East et al. 2009 and see for data on contact rates).Transition probabilities among demographic and social states and initial state probabilitiesIn the absence of CDV infection, high-ranking pre-breeders have higher survival rates than lowranking ones (Hofer & East 1993b; .", [["milk", "ANATOMY", 433, 437], ["depressed", "DISEASE", 157, 166], ["CDV infection", "DISEASE", 673, 686], ["subadults", "ORGANISM", 22, 31], ["subadults", "ORGANISM", 137, 146], ["subadults", "ORGANISM", 221, 230], ["milk", "ORGANISM_SUBSTANCE", 433, 437], ["CDV", "ORGANISM", 673, 676], ["CDV", "SPECIES", 673, 676], ["the survival rate", "TEST", 94, 111], ["CDV infection", "PROBLEM", 673, 686], ["absence of", "UNCERTAINTY", 662, 672], ["CDV", "OBSERVATION_MODIFIER", 673, 676], ["infection", "OBSERVATION", 677, 686], ["high", "OBSERVATION_MODIFIER", 688, 692]]], ["Thus, if high-ranking pre-breeders are more exposed than low-ranking ones, all else being equal, the survival rate of high-ranking infected pre-breeders should be depressed to a level equivalent to that of low-ranking infected pre-breeders.", [["depressed", "DISEASE", 163, 172], ["the survival rate", "TEST", 97, 114], ["high-ranking infected pre-breeders", "PROBLEM", 118, 152], ["low-ranking infected pre-breeders", "PROBLEM", 206, 239]]], ["High-ranking and low-ranking breeders should have similar opportunities to allocate body resources to immune processes.", [["body", "ANATOMY", 84, 88], ["body", "ORGANISM_SUBDIVISION", 84, 88]]], ["High-ranking males, have priority of access to food within their territory (in comparison to low-ranking males), but are more often present than low-ranking ones in their home territories thus probably experience more variation in prey abundance within territories than low-ranking makes, which spend more time feeding on the migratory herds (East & Hofer 1991(a) Social and breeding transition probabilities in females and malesFemales: High-ranking females were less likely than low-ranking ones to stay in their social status category, irrespective of their demographic or infection state ( Table 2 ).", [["infection", "DISEASE", 576, 585], ["infection state", "PROBLEM", 576, 591], ["ranking males", "OBSERVATION", 5, 18], ["territory", "OBSERVATION_MODIFIER", 65, 74], ["infection", "OBSERVATION", 576, 585]]], ["The breeding probability of females depended on an interaction between demographic and social states: Nonbreeders had the highest breeding probability, followed by breeders and then subadults and in all these demographic states, high-ranking females had a higher breeding probability than lowranking ones ( Table 2 ).", [["the highest breeding probability", "PROBLEM", 118, 150], ["a higher breeding probability", "PROBLEM", 254, 283], ["highest", "OBSERVATION_MODIFIER", 122, 129]]], ["It indicates that at the first detection occasion, there was a predominance of cubs as compared to other demographic states and a pre-dominance of highranking females as compared to low-ranking females.Males:The transition probability of staying in the same social status category for adult males was modeled as a constant as any other effects produced a model with non-identifiable parameters (see Table 2 for the value).", [["a predominance of cubs", "PROBLEM", 61, 83], ["highranking females", "PROBLEM", 147, 166], ["predominance", "OBSERVATION_MODIFIER", 63, 75], ["cubs", "OBSERVATION", 79, 83], ["highranking females", "OBSERVATION", 147, 166]]], ["The initial state probabilities depended on an interaction between (ii) The assignment probabilities of S, I and R infection states were best predicted by a model including the effect of infection states (susceptible: \u03b4 S : 0.85 \u00b1 0.07; infected: \u03b4 I : 0.14 \u00b1 0.01; recovered: \u03b4 R : 0.15 \u00b1 0.02).Males(i) The detection probabilities of males, as for females, accounted for effects of social states, irrespective of their demographic or infection state.", [["infection", "DISEASE", 115, 124], ["infection", "DISEASE", 187, 196], ["infection", "DISEASE", 436, 445], ["(ii)", "CHEMICAL", 67, 71], ["S, I and R infection", "PROBLEM", 104, 124], ["infection states", "PROBLEM", 187, 203], ["infection state", "PROBLEM", 436, 451], ["infection", "OBSERVATION", 115, 124], ["infection", "OBSERVATION", 187, 196], ["infection", "OBSERVATION", 436, 445]]], ["Overall, as for females and as expected, detection probabilities were very high.", [["detection probabilities", "TEST", 41, 64]]], ["There was a higher detection of high-ranking males (p H = 0.99, with S.E. < 0.01) than low-ranking ones (p L = 0.86 \u00b1 0.01), probably because high-ranking male breeders are more tolerated and thus more often present at communal dens than low-ranking ones (East & Hofer 1991) .Males(ii) The assignment probabilities of S, I and R infection states for males depended, as for females, on infection states (susceptible: \u03b4 S : 0.37 \u00b1 0.04; infected: \u03b4 I : 0.05 < 0.01; recovered: \u03b4 R : 0.09 \u00b1 0.01).", [["infection", "DISEASE", 329, 338], ["infection", "DISEASE", 385, 394], ["S.E.", "TEST", 69, 73], ["S, I and R infection", "PROBLEM", 318, 338], ["infection states", "PROBLEM", 385, 401], ["high", "OBSERVATION_MODIFIER", 32, 36], ["infection", "OBSERVATION", 329, 338]]]], "PMC6694993": [["IntroductionDue to the increasing number of multi-drug-resistant microbial pathogens and the inclusion of emerging infectious diseases such as severe acute respiratory syndrome and avian influenza, the treatment of microbial infections still remains a challenging job with the available antimicrobials and remains a worldwide problem for clinical management.1 Development of newer molecules with less expense and minimum toxicity for the management of infections due to multi-drug-resistant (MDR) microbial pathogens should represent the vital sphere of antimicrobial research today.", [["infectious diseases", "DISEASE", 115, 134], ["acute respiratory syndrome", "DISEASE", 150, 176], ["avian influenza", "DISEASE", 181, 196], ["microbial infections", "DISEASE", 215, 235], ["toxicity", "DISEASE", 421, 429], ["infections", "DISEASE", 452, 462], ["avian influenza", "SPECIES", 181, 196], ["multi-drug-resistant microbial pathogens", "PROBLEM", 44, 84], ["emerging infectious diseases", "PROBLEM", 106, 134], ["severe acute respiratory syndrome", "PROBLEM", 143, 176], ["avian influenza", "PROBLEM", 181, 196], ["microbial infections", "PROBLEM", 215, 235], ["the available antimicrobials", "TREATMENT", 273, 301], ["clinical management", "TREATMENT", 338, 357], ["newer molecules", "PROBLEM", 375, 390], ["minimum toxicity", "PROBLEM", 413, 429], ["the management", "TREATMENT", 434, 448], ["infections", "PROBLEM", 452, 462], ["multi-drug-resistant (MDR) microbial pathogens", "PROBLEM", 470, 516], ["increasing", "OBSERVATION_MODIFIER", 23, 33], ["number", "OBSERVATION_MODIFIER", 34, 40], ["multi-drug", "OBSERVATION_MODIFIER", 44, 54], ["resistant microbial pathogens", "OBSERVATION", 55, 84], ["infectious", "OBSERVATION", 115, 125], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["acute", "OBSERVATION_MODIFIER", 150, 155], ["respiratory syndrome", "OBSERVATION", 156, 176], ["newer molecules", "OBSERVATION_MODIFIER", 375, 390], ["less expense", "OBSERVATION_MODIFIER", 396, 408], ["infections", "OBSERVATION", 452, 462]]], ["A literature survey revealed that azo molecules are popular for versatile uses such as antiseptics,2 antimicrobial,3 antidiabetics,4 antineoplastics,5 transmissible spongiform encephalopathy,6 antiulcerative,7 antoxidant,8 analgesic,9 antiinflammatory,10 antiviral,11 antitubercular10 and antitumour12 activities.IntroductionA literature survey also revealed that azo-bearing ligands have a modified therapeutic effect when combined with transition metal ions.13, 14 The complexes of transition metals have significant biological functions including antibacterial, antifungal and anticancer activities.15 Cobalt, copper, nickel and zinc are the potentially used metal ions that form low-molecular-weight complexes, which are found to be effective against various diseases.", [["anticancer", "ANATOMY", 580, 590], ["azo", "CHEMICAL", 34, 37], ["transmissible spongiform encephalopathy", "DISEASE", 151, 190], ["Cobalt", "CHEMICAL", 605, 611], ["copper", "CHEMICAL", 613, 619], ["nickel", "CHEMICAL", 621, 627], ["zinc", "CHEMICAL", 632, 636], ["azo", "CHEMICAL", 34, 37], ["transition metal", "CHEMICAL", 438, 454], ["Cobalt", "CHEMICAL", 605, 611], ["copper", "CHEMICAL", 613, 619], ["nickel", "CHEMICAL", 621, 627], ["zinc", "CHEMICAL", 632, 636], ["azo molecules", "SIMPLE_CHEMICAL", 34, 47], ["antitubercular10", "SIMPLE_CHEMICAL", 268, 284], ["antitumour12", "SIMPLE_CHEMICAL", 289, 301], ["metal ions", "SIMPLE_CHEMICAL", 449, 459], ["anticancer", "CANCER", 580, 590], ["Cobalt", "SIMPLE_CHEMICAL", 605, 611], ["copper", "SIMPLE_CHEMICAL", 613, 619], ["nickel", "SIMPLE_CHEMICAL", 621, 627], ["zinc", "SIMPLE_CHEMICAL", 632, 636], ["metal ions", "SIMPLE_CHEMICAL", 662, 672], ["A literature survey", "TEST", 0, 19], ["azo molecules", "PROBLEM", 34, 47], ["antiseptics", "TREATMENT", 87, 98], ["3 antidiabetics", "TREATMENT", 115, 130], ["4 antineoplastics", "TREATMENT", 131, 148], ["5 transmissible spongiform encephalopathy", "PROBLEM", 149, 190], ["antoxidant", "TREATMENT", 210, 220], ["8 analgesic", "TREATMENT", 221, 232], ["9 antiinflammatory", "TREATMENT", 233, 251], ["antiviral", "TREATMENT", 255, 264], ["antitumour12 activities", "TREATMENT", 289, 312], ["IntroductionA literature survey", "TEST", 313, 344], ["azo-bearing ligands", "PROBLEM", 364, 383], ["transition metal ions", "TREATMENT", 438, 459], ["transition metals", "PROBLEM", 484, 501], ["antibacterial", "TREATMENT", 550, 563], ["antifungal and anticancer activities", "TREATMENT", 565, 601], ["Cobalt, copper, nickel and zinc", "TREATMENT", 605, 636], ["metal ions", "TREATMENT", 662, 672], ["various diseases", "PROBLEM", 755, 771], ["azo molecules", "OBSERVATION", 34, 47], ["spongiform encephalopathy", "OBSERVATION", 165, 190], ["significant", "OBSERVATION_MODIFIER", 507, 518], ["biological functions", "OBSERVATION", 519, 539], ["antibacterial", "OBSERVATION_MODIFIER", 550, 563]]], ["Literature support even suggests that metal complexes are more active than their ligands because the metal complexes serve as a vehicle for activation of the ligands as principal cytotoxic species.16, 17IntroductionThe biological aspects of metallic ligands depend upon the ease of cleaving the bond between the metal ion and the ligand.", [["metal ion", "SIMPLE_CHEMICAL", 312, 321], ["Literature support", "TREATMENT", 0, 18], ["principal cytotoxic species", "PROBLEM", 169, 196], ["metallic ligands", "PROBLEM", 241, 257], ["cytotoxic species", "OBSERVATION", 179, 196], ["metallic ligands", "OBSERVATION", 241, 257], ["ligand", "ANATOMY", 330, 336]]], ["It is well known that the metals present in complexes generally accelerate the drug action and the efficacy of therapeutic agents and that the pharmacological efficiencies of drug-based metal complexes depend upon the nature of the metal ion and the ligands.18 The present work is the continuation of our previously reported work to obtain some novel complexes where the 4-chlorophenyl and 4-methoxyphenyl substituted 4-hydroxycumarin azo-analogues are conjugated with different transitional metals with an intention to produce target molecules possessing good antimicrobial properties.3, 19Synthesis of ligands (3a\u20133b) ::: Materials and MethodsThe synthetic procedures yielding the ligands (E)-3-((4-chlorophenyl) diazenyl)-4-hydroxy-2H-chromen-2-one (HL1): (3a) and (E)-3-((4-methoxyphenyl) diazenyl)-4-hydroxy-2H-chromen-2-one (HL2): (3b) were carried out as described previously.3Synthesis procedure of metal complexes (4a\u20134h)20bib20bibr ::: Materials and MethodsA mixture of 25 mL was prepared with the appropriate metal chloride (Cu(II), Ni(II), Co(II) and Zn(II) of 10 mmol in ethanol and water, 1:1).", [["4-chlorophenyl", "CHEMICAL", 371, 385], ["4-methoxyphenyl", "CHEMICAL", 390, 405], ["4-hydroxycumarin azo", "CHEMICAL", 418, 438], ["E)-3-((4-chlorophenyl) diazenyl)-4-hydroxy-2H-chromen-2-one", "CHEMICAL", 692, 751], ["HL1", "CHEMICAL", 753, 756], ["4-methoxyphenyl) diazenyl)-4-hydroxy-2H-chromen-2-one", "CHEMICAL", 776, 829], ["HL2", "CHEMICAL", 831, 834], ["metal chloride", "CHEMICAL", 1020, 1034], ["Cu(II", "CHEMICAL", 1036, 1041], ["Ni", "CHEMICAL", 1044, 1046], ["Co(II", "CHEMICAL", 1052, 1057], ["Zn", "CHEMICAL", 1063, 1065], ["ethanol", "CHEMICAL", 1084, 1091], ["4-chlorophenyl", "CHEMICAL", 371, 385], ["4-methoxyphenyl", "CHEMICAL", 390, 405], ["4-hydroxycumarin azo", "CHEMICAL", 418, 438], ["(E)-3-((4-chlorophenyl) diazenyl)-4-hydroxy-2H-chromen-2-one", "CHEMICAL", 691, 751], ["HL1", "CHEMICAL", 753, 756], ["(E)-3-((4-methoxyphenyl) diazenyl)-4-hydroxy-2H-chromen-2-one", "CHEMICAL", 768, 829], ["HL2", "CHEMICAL", 831, 834], ["metal chloride", "CHEMICAL", 1020, 1034], ["Cu(II)", "CHEMICAL", 1036, 1042], ["Ni(II)", "CHEMICAL", 1044, 1050], ["Co(II)", "CHEMICAL", 1052, 1058], ["Zn(II)", "CHEMICAL", 1063, 1069], ["ethanol", "CHEMICAL", 1084, 1091], ["metal ion", "SIMPLE_CHEMICAL", 232, 241], ["4-chlorophenyl", "SIMPLE_CHEMICAL", 371, 385], ["4-methoxyphenyl substituted 4-hydroxycumarin azo-analogues", "SIMPLE_CHEMICAL", 390, 448], ["(E)-3-((4-chlorophenyl) diazenyl)-4-hydroxy-2H-chromen-2-one", "SIMPLE_CHEMICAL", 691, 751], ["HL1): (3a)", "SIMPLE_CHEMICAL", 753, 763], ["(E)-3-((4-methoxyphenyl) diazenyl)-4-hydroxy-2H-chromen-2-one", "SIMPLE_CHEMICAL", 768, 829], ["HL2): (3b)", "SIMPLE_CHEMICAL", 831, 841], ["metal complexes", "SIMPLE_CHEMICAL", 907, 922], ["4a\u20134h", "SIMPLE_CHEMICAL", 924, 929], ["metal chloride", "SIMPLE_CHEMICAL", 1020, 1034], ["Cu(II)", "SIMPLE_CHEMICAL", 1036, 1042], ["Ni(II)", "SIMPLE_CHEMICAL", 1044, 1050], ["Co(II)", "SIMPLE_CHEMICAL", 1052, 1058], ["Zn(II)", "SIMPLE_CHEMICAL", 1063, 1069], ["ethanol", "SIMPLE_CHEMICAL", 1084, 1091], ["water", "SIMPLE_CHEMICAL", 1096, 1101], ["therapeutic agents", "TREATMENT", 111, 129], ["drug-based metal complexes", "TREATMENT", 175, 201], ["chlorophenyl and 4-methoxyphenyl substituted", "TREATMENT", 373, 417], ["hydroxycumarin azo-analogues", "TREATMENT", 420, 448], ["different transitional metals", "TREATMENT", 469, 498], ["chlorophenyl) diazenyl", "TREATMENT", 701, 723], ["methoxyphenyl) diazenyl)", "TREATMENT", 778, 802], ["Synthesis procedure of metal complexes (4a\u20134h)", "TREATMENT", 884, 930], ["MethodsA mixture", "TREATMENT", 960, 976], ["the appropriate metal chloride (Cu(II), Ni(II), Co(II)", "TREATMENT", 1004, 1058], ["Zn(II)", "TREATMENT", 1063, 1069], ["metal complexes", "OBSERVATION", 186, 201], ["ligands", "ANATOMY", 250, 257], ["antimicrobial properties", "OBSERVATION", 561, 585]]], ["The above mixture was added to the solution of azo compound 3a\u20133b (0.40 g, 10 mmol) in ethanol and water in equal proportions to obtain 50 mL of solution.", [["azo compound 3a\u20133b", "CHEMICAL", 47, 65], ["ethanol", "CHEMICAL", 87, 94], ["azo", "CHEMICAL", 47, 50], ["ethanol", "CHEMICAL", 87, 94], ["azo compound 3a\u20133b", "SIMPLE_CHEMICAL", 47, 65], ["ethanol", "SIMPLE_CHEMICAL", 87, 94], ["water", "SIMPLE_CHEMICAL", 99, 104], ["The above mixture", "TREATMENT", 0, 17], ["the solution of azo compound 3a\u20133b", "TREATMENT", 31, 65], ["ethanol", "TREATMENT", 87, 94]]], ["The resulting solution was refluxed for 30 min at a controlled temperature not more than 78 \u00b0C. The precipitated complexes were separated by filtration using Whatman filter paper.", [["The resulting solution", "TREATMENT", 0, 22], ["Whatman filter paper", "TREATMENT", 158, 178]]], ["Separated precipitates were washed with 1:1 ethanol-water.", [["ethanol", "CHEMICAL", 44, 51], ["ethanol", "CHEMICAL", 44, 51], ["ethanol", "SIMPLE_CHEMICAL", 44, 51]]], ["Finally, obtained products were re-crystallized from diethyl ether and air dried.(E)-3-((4-chlorophenyl)diazenyl)-4-hydroxy-2H-chromen-2-one (HL1), (3a) ::: Spectral characterization ::: Materials and MethodsOff yellow-coloured powder; yield 91%; Rf: 0.7; m.p.: 235\u201340 \u00b0C; UV\u2013Vis (\u03bb max, DMSO): 409 nm; IR (KBr, \u03bd, cm\u22121): 3445(O\u2014H str.), 1619 (C000000000000000000000000000000000000111111111111000000000000111111111111000000000000000000000000000000000000C str.), 1500 (\u2013NN\u2013), 1726 (CO str.), 1298 (C\u2014O str.), 828 (1, 4 disubst.", [["diethyl ether", "CHEMICAL", 53, 66], ["E)-3-((4-chlorophenyl)diazenyl)-4-hydroxy-2H-chromen-2-one", "CHEMICAL", 82, 140], ["diethyl ether", "CHEMICAL", 53, 66], ["(E)-3-((4-chlorophenyl)diazenyl)-4-hydroxy-2H-chromen-2-one", "CHEMICAL", 81, 140], ["HL1", "CHEMICAL", 142, 145], ["DMSO", "CHEMICAL", 288, 292], ["CO", "CHEMICAL", 481, 483], ["diethyl ether", "SIMPLE_CHEMICAL", 53, 66], ["(E)-3-((4-chlorophenyl)diazenyl)-4-hydroxy-2H-chromen-2-one", "SIMPLE_CHEMICAL", 81, 140], ["HL1", "SIMPLE_CHEMICAL", 142, 145], ["(3a) ::", "SIMPLE_CHEMICAL", 148, 155], ["diethyl ether", "TREATMENT", 53, 66], ["chlorophenyl)diazenyl)", "TREATMENT", 91, 113], ["Methods", "TEST", 201, 208], ["yield", "TEST", 236, 241], ["Rf", "TEST", 247, 249], ["m.p.", "TEST", 256, 260], ["\u00b0C", "TEST", 269, 271], ["UV", "TEST", 273, 275], ["DMSO", "TEST", 288, 292], ["nm", "TEST", 299, 301], ["IR", "TEST", 303, 305], ["KBr", "TEST", 307, 310], ["CO str.", "TEST", 481, 488], ["C\u2014O str.", "TEST", 497, 505]]], ["Ar.); 1H NMR (DMSO-d6, \u03b4 ppm, 400 MHz): 16.86 (s, 1H, 4-enolic OH), 7.65 (m, coumarin H-7), 7.45 (m, coumarin H-6), 7.47 (d, coumarin H-8), 7.90 (d, coumarin H-5), 7.21\u20137.39 (m, 4H, Ar\u2014H); LC-MS (RT, % area); 2.291, 60.04 m/z; 301.2 (M+1); Analysis for C15H9ClN2O3: Calcd: C, 59.91; H, 3.02; N, 9.32; Found: C, 59.93; H, 3.04; N, 9.36%.(E)-3-((4-methoxyphenyl)diazenyl)-4-hydroxy-2H-chromen-2-one (HL2), (3b) ::: Spectral characterization ::: Materials and MethodsBrick red-coloured powder; yield 93%; Rf: 0.8; m.p.: 205\u201310 \u00b0C; UV\u2013Vis (\u03bb max, DMSO): 413 nm; IR (KBr, \u03bd, cm\u22121): 3479 (O\u2014H str.), 2929 (CH2 str.), 1603 (CC str.), 1745 (\u2013CO str.), 1505 (\u2013NN\u2013), 1487, 1113 (C\u2014O\u2014CH3 str), 1246 (C\u2014O str.), 758 (1, 2 disubst.", [["E)-3-((4-methoxyphenyl)diazenyl)-4-hydroxy-2H-chromen-2-one", "CHEMICAL", 337, 396], ["1H", "CHEMICAL", 6, 8], ["DMSO", "CHEMICAL", 14, 18], ["1H", "CHEMICAL", 50, 52], ["OH", "CHEMICAL", 63, 65], ["coumarin H-7", "CHEMICAL", 77, 89], ["coumarin H-6", "CHEMICAL", 101, 113], ["coumarin H-8", "CHEMICAL", 125, 137], ["coumarin", "CHEMICAL", 149, 157], ["C15H9ClN2O3", "CHEMICAL", 253, 264], ["H", "CHEMICAL", 283, 284], ["H", "CHEMICAL", 318, 319], ["(E)-3-((4-methoxyphenyl)diazenyl)-4-hydroxy-2H-chromen-2-one", "CHEMICAL", 336, 396], ["HL2", "CHEMICAL", 398, 401], ["DMSO", "CHEMICAL", 543, 547], ["CH3", "CHEMICAL", 673, 676], ["1H", "SIMPLE_CHEMICAL", 6, 8], ["4-enolic OH", "SIMPLE_CHEMICAL", 54, 65], ["coumarin H-7", "SIMPLE_CHEMICAL", 77, 89], ["coumarin H-6", "SIMPLE_CHEMICAL", 101, 113], ["coumarin H-8", "SIMPLE_CHEMICAL", 125, 137], ["coumarin H-5", "SIMPLE_CHEMICAL", 149, 161], ["Calcd: C", "SIMPLE_CHEMICAL", 266, 274], ["(E)-3-((4-methoxyphenyl)diazenyl)-4-hydroxy-2H-chromen-2-one", "SIMPLE_CHEMICAL", 336, 396], ["HL2", "SIMPLE_CHEMICAL", 398, 401], ["(3b) ::", "SIMPLE_CHEMICAL", 404, 411], ["DMSO", "TEST", 14, 18], ["coumarin H", "TEST", 77, 87], ["coumarin H", "TEST", 101, 111], ["coumarin H", "TEST", 125, 135], ["Ar\u2014H", "TEST", 182, 186], ["LC", "TEST", 189, 191], ["MS", "TEST", 192, 194], ["RT", "TEST", 196, 198], ["z", "TEST", 224, 225], ["Analysis", "TEST", 240, 248], ["Calcd", "TEST", 266, 271], ["C", "TEST", 273, 274], ["H", "TEST", 283, 284], ["N", "TEST", 292, 293], ["C", "TEST", 308, 309], ["H", "TEST", 318, 319], ["N", "TEST", 327, 328], ["methoxyphenyl)diazenyl", "TREATMENT", 346, 368], ["Materials", "TEST", 443, 452], ["MethodsBrick", "TEST", 457, 469], ["yield", "TEST", 491, 496], ["Rf", "TEST", 502, 504], ["m.p.", "TEST", 511, 515], ["\u00b0C", "TEST", 524, 526], ["UV", "TEST", 528, 530], ["DMSO", "TEST", 543, 547], ["nm", "TEST", 554, 556], ["IR", "TEST", 558, 560], ["KBr", "TEST", 562, 565], ["\u03bd", "TEST", 567, 568], ["str.", "TEST", 587, 591], ["CH2 str.", "TEST", 600, 608], ["CC str.", "TEST", 617, 624], ["\u2013CO str.", "TEST", 633, 641], ["C\u2014O", "TEST", 669, 672], ["C", "TEST", 689, 690], ["O str.", "TEST", 691, 697], ["LC", "ANATOMY", 189, 191]]], ["Ar.); 1H NMR (DMSO-d6, \u03b4 ppm, 400 MHz): 16.81 (s, 1H, 4-enolic OH), 7.65 (m, coumarin H-7), 7.46 (m, coumarin H-6), 8.09 (d, coumarin H-5), 7.57 (d, coumarin H-8), 6.94\u20137.34 (d, 4H, Ar\u2014H), 3.83 (s, 3H, Ar\u2014OCH3); LC-MS (RT, % area); 2.291, 60.04 m/z; 297.0 (M+1); Analysis for C16H12N2O4: Calcd: C, 64.86; H, 4.08; N, 9.46; Found: C, 64.91; H, 4.11; N, 9.43%.Nickel complex of (E)-3-((4-chlorophenyl)diazenyl)-4-hydroxy-2H-chromen-2-one (HL1), (4b) ::: Spectral characterization ::: Materials and MethodsLight green-coloured powder; yield 37%; Rf: 0.8; m.p.: 245\u201350 \u00b0C; UV\u2013Vis (\u03bb max, DMSO): 440 nm; IR (KBr, \u03bd, cm\u22121): 1625 (CC str.), 1529 (\u2013NN\u2013), 1723 (CO str.), 1299 (C\u2014O str.), 829 (1, 4 disubst.", [["Nickel", "CHEMICAL", 358, 364], ["(E)-3-((4-chlorophenyl)diazenyl)-4-hydroxy-2H-chromen-2-one", "CHEMICAL", 376, 435], ["1H", "CHEMICAL", 6, 8], ["DMSO", "CHEMICAL", 14, 18], ["1H", "CHEMICAL", 50, 52], ["OH", "CHEMICAL", 63, 65], ["coumarin H-7", "CHEMICAL", 77, 89], ["coumarin H-6", "CHEMICAL", 101, 113], ["8.09 (d, coumarin H-5), 7.57 (d, coumarin H-8", "CHEMICAL", 116, 161], ["Ar\u2014H", "CHEMICAL", 182, 186], ["3H", "CHEMICAL", 198, 200], ["Ar\u2014OCH3", "CHEMICAL", 202, 209], ["C16H12N2O4", "CHEMICAL", 276, 286], ["C", "CHEMICAL", 295, 296], ["H", "CHEMICAL", 305, 306], ["N", "CHEMICAL", 314, 315], ["H", "CHEMICAL", 340, 341], ["Nickel", "CHEMICAL", 358, 364], ["(E)-3-((4-chlorophenyl)diazenyl)-4-hydroxy-2H-chromen-2-one", "CHEMICAL", 376, 435], ["HL1", "CHEMICAL", 437, 440], ["DMSO", "CHEMICAL", 584, 588], ["CO", "CHEMICAL", 653, 655], ["1H", "SIMPLE_CHEMICAL", 6, 8], ["4-enolic OH", "SIMPLE_CHEMICAL", 54, 65], ["coumarin H-7", "SIMPLE_CHEMICAL", 77, 89], ["coumarin H-6", "SIMPLE_CHEMICAL", 101, 113], ["coumarin H-5", "SIMPLE_CHEMICAL", 125, 137], ["coumarin H-8", "SIMPLE_CHEMICAL", 149, 161], ["Ar\u2014H", "SIMPLE_CHEMICAL", 182, 186], ["Calcd: C", "SIMPLE_CHEMICAL", 288, 296], ["Nickel", "SIMPLE_CHEMICAL", 358, 364], ["(E)-3-((4-chlorophenyl)diazenyl)-4-hydroxy-2H-chromen-2-one", "SIMPLE_CHEMICAL", 376, 435], ["HL1", "SIMPLE_CHEMICAL", 437, 440], ["(4b) ::", "SIMPLE_CHEMICAL", 443, 450], ["DMSO", "TEST", 14, 18], ["coumarin H", "TEST", 77, 87], ["coumarin H", "TEST", 101, 111], ["coumarin H", "TEST", 125, 135], ["coumarin H", "TEST", 149, 159], ["Ar\u2014H", "TEST", 182, 186], ["3H", "TEST", 198, 200], ["Ar\u2014OCH3", "TEST", 202, 209], ["LC", "TEST", 212, 214], ["MS", "TEST", 215, 217], ["RT", "TEST", 219, 221], ["Analysis", "TEST", 263, 271], ["Calcd", "TEST", 288, 293], ["C", "TEST", 295, 296], ["H", "TEST", 305, 306], ["N", "TEST", 314, 315], ["C", "TEST", 330, 331], ["H", "TEST", 340, 341], ["N", "TEST", 349, 350], ["Nickel complex of (E)", "TREATMENT", 358, 379], ["chlorophenyl)diazenyl)", "TREATMENT", 386, 408], ["Materials", "TEST", 482, 491], ["yield", "TEST", 532, 537], ["Rf", "TEST", 543, 545], ["m.p.", "TEST", 552, 556], ["\u00b0C", "TEST", 565, 567], ["UV", "TEST", 569, 571], ["DMSO", "TEST", 584, 588], ["IR", "TEST", 599, 601], ["KBr", "TEST", 603, 606], ["CC str.", "TEST", 624, 631], ["CO str.", "TEST", 653, 660], ["C", "TEST", 669, 670], ["O str.", "TEST", 671, 677]]], ["Ar.), 446 (Ni\u2014N), 535 (Ni\u2014O); 1H NMR (DMSO-d6, \u03b4 ppm, 400 MHz): 7.71 (m, coumarin H-7), 7.36 (m, coumarin H-6), 7.38 (d, coumarin H-8), 8.11 (d, coumarin H-5), 7.26\u20137.33 {m, 8H, (C6H4)2; LC-MS (RT, % area); 1.147, 63.31 m/z; 654.01 (M+1); Analysis for C32H24ClN4NiO6: Calcd: C, 58.70; H, 3.69; N, 8.56; Ni, 8.56 Found: C, 58.68; H, 3.72; N, 8.58; Ni, 8.54%.Cobalt complex of (E)-3-((4-methoxyphenyl)diazenyl)-4-hydroxy-2H-chromen-2-one (HL2), (4e) ::: Spectral characterization ::: Materials and MethodsBrown-coloured powder; yield 43%; Rf: 0.7; m.p.: 245\u201350 \u00b0C; UV\u2013Vis (\u03bb max, DMSO): 450 nm; IR (KBr, \u03bd, cm\u22121): 3012 (Ar H), 2939 (CH2 str.), 1619 (CC str.), 1725 (\u2013CO str.), 1525 (\u2013NN\u2013), 1488, 1115 (C\u2014O\u2014CH3 str), 1248 (C\u2014O str.), 759 (1, 2 disubst Ar.), 449 (Co\u2014N), 538 (Co\u2014O); 1H NMR (DMSO-d6, \u03b4 ppm, 400 MHz): 7.64 (m, coumarin H-7), 7.41 (m, coumarin H-6), 8.07 (d, coumarin H-5), 7.49 (d, coumarin H-8), 6.91\u20137.23 {m, 8H, (C6H4)2}, 3.82 {s, 6H, (OCH3)2}; LC-MS (RT, % area); 1.871, 51.04 m/z; 651.0 (M + 1); Analysis for C33H27CoN4O7: Calcd: C, 60.93; H, 4.18; N, 8.61; Co, 9.06 Found: C, 60.94; H, 4.15; N, 8.65, Co, 9.09%.Antimicrobial activity ::: Materials and MethodsThe above newly synthesized 4-HC azo-analogues and their metal complexes were investigated over different freshly sub cultured microbial strains, viz.", [["Cobalt", "CHEMICAL", 357, 363], ["(E)-3-((4-methoxyphenyl)diazenyl)-4-hydroxy-2H-chromen-2-one", "CHEMICAL", 375, 435], ["4-HC azo", "CHEMICAL", 1205, 1213], ["(Ni\u2014N), 535", "CHEMICAL", 10, 21], ["Ni\u2014O", "CHEMICAL", 23, 27], ["1H", "CHEMICAL", 30, 32], ["DMSO", "CHEMICAL", 38, 42], ["coumarin H-7", "CHEMICAL", 73, 85], ["(m, coumarin H-6", "CHEMICAL", 93, 109], ["7.38 (d, coumarin H-8), 8.11 (d, coumarin H-5)", "CHEMICAL", 112, 158], ["8H", "CHEMICAL", 174, 176], ["(C6H4)2", "CHEMICAL", 178, 185], ["C32H24ClN4NiO6", "CHEMICAL", 252, 266], ["Calcd", "CHEMICAL", 268, 273], ["C", "CHEMICAL", 275, 276], ["H", "CHEMICAL", 285, 286], ["N", "CHEMICAL", 294, 295], ["Ni", "CHEMICAL", 303, 305], ["C", "CHEMICAL", 319, 320], ["H", "CHEMICAL", 329, 330], ["N", "CHEMICAL", 338, 339], ["Ni", "CHEMICAL", 347, 349], ["Cobalt", "CHEMICAL", 357, 363], ["(E)-3-((4-methoxyphenyl)diazenyl)-4-hydroxy-2H-chromen-2-one", "CHEMICAL", 375, 435], ["HL2", "CHEMICAL", 437, 440], ["DMSO", "CHEMICAL", 578, 582], ["CH3", "CHEMICAL", 704, 707], ["O", "CHEMICAL", 722, 723], ["Co\u2014O", "CHEMICAL", 772, 776], ["1H", "CHEMICAL", 779, 781], ["DMSO", "CHEMICAL", 787, 791], ["coumarin H-7", "CHEMICAL", 822, 834], ["(m, coumarin H-6", "CHEMICAL", 842, 858], ["8.07 (d, coumarin H-5), 7.49 (d, coumarin H-8", "CHEMICAL", 861, 906], ["{m", "CHEMICAL", 919, 921], ["8H", "CHEMICAL", 923, 925], ["(C6H4)2}, 3.82 {s, 6H, (OCH3)2", "CHEMICAL", 927, 957], ["C33H27CoN4O7", "CHEMICAL", 1026, 1038], ["C", "CHEMICAL", 1047, 1048], ["H", "CHEMICAL", 1057, 1058], ["N", "CHEMICAL", 1066, 1067], ["Co", "CHEMICAL", 1075, 1077], ["C", "CHEMICAL", 1091, 1092], ["H", "CHEMICAL", 1101, 1102], ["N", "CHEMICAL", 1110, 1111], ["Co", "CHEMICAL", 1119, 1121], ["4-HC azo", "CHEMICAL", 1205, 1213], ["coumarin H-7", "SIMPLE_CHEMICAL", 73, 85], ["coumarin H-6", "SIMPLE_CHEMICAL", 97, 109], ["coumarin H-8", "SIMPLE_CHEMICAL", 121, 133], ["coumarin H-5", "SIMPLE_CHEMICAL", 145, 157], ["C6H4)2", "SIMPLE_CHEMICAL", 179, 185], ["C32H24ClN4NiO6", "SIMPLE_CHEMICAL", 252, 266], ["Calcd: C", "SIMPLE_CHEMICAL", 268, 276], ["C", "SIMPLE_CHEMICAL", 319, 320], ["Cobalt", "SIMPLE_CHEMICAL", 357, 363], ["(E)-3-((4-methoxyphenyl)diazenyl)-4-hydroxy-2H-chromen-2-one", "SIMPLE_CHEMICAL", 375, 435], ["HL2", "SIMPLE_CHEMICAL", 437, 440], ["(4e) ::", "SIMPLE_CHEMICAL", 443, 450], ["coumarin H-7", "SIMPLE_CHEMICAL", 822, 834], ["coumarin H-6)", "SIMPLE_CHEMICAL", 846, 859], ["coumarin H-5", "SIMPLE_CHEMICAL", 870, 882], ["coumarin H-8", "SIMPLE_CHEMICAL", 894, 906], ["(C6H4)2}", "SIMPLE_CHEMICAL", 927, 935], ["Calcd: C", "SIMPLE_CHEMICAL", 1040, 1048], ["C", "SIMPLE_CHEMICAL", 1091, 1092], ["4-HC azo-analogues", "SIMPLE_CHEMICAL", 1205, 1223], ["NMR", "TEST", 33, 36], ["DMSO", "TEST", 38, 42], ["coumarin H", "TEST", 73, 83], ["coumarin H", "TEST", 97, 107], ["coumarin H", "TEST", 121, 131], ["coumarin H", "TEST", 145, 155], ["LC", "TEST", 187, 189], ["MS", "TEST", 190, 192], ["RT", "TEST", 194, 196], ["z", "TEST", 222, 223], ["Analysis", "TEST", 239, 247], ["C32H24Cl", "TEST", 252, 260], ["Calcd", "TEST", 268, 273], ["C", "TEST", 275, 276], ["H", "TEST", 285, 286], ["N", "TEST", 294, 295], ["Ni", "TEST", 303, 305], ["C", "TEST", 319, 320], ["H", "TEST", 329, 330], ["N", "TEST", 338, 339], ["Ni", "TEST", 347, 349], ["Cobalt complex", "TEST", 357, 371], ["Materials", "TEST", 482, 491], ["Methods", "TEST", 496, 503], ["Rf", "TEST", 537, 539], ["m.p.", "TEST", 546, 550], ["\u00b0C", "TEST", 559, 561], ["UV", "TEST", 563, 565], ["max", "TEST", 573, 576], ["DMSO", "TEST", 578, 582], ["nm", "TEST", 589, 591], ["IR", "TEST", 593, 595], ["KBr", "TEST", 597, 600], ["\u03bd", "TEST", 602, 603], ["cm", "TEST", 605, 607], ["\u2212", "TEST", 607, 608], ["CH2 str.", "TEST", 631, 639], ["CC str.", "TEST", 648, 655], ["C\u2014O", "TEST", 700, 703], ["str", "TEST", 708, 711], ["C", "TEST", 720, 721], ["str.", "TEST", 724, 728], ["Ar.", "TEST", 749, 752], ["Co\u2014N", "TEST", 760, 764], ["Co\u2014O", "TEST", 772, 776], ["NMR", "TEST", 782, 785], ["DMSO", "TEST", 787, 791], ["ppm", "TEST", 798, 801], ["MHz", "TEST", 807, 810], ["coumarin H", "TEST", 822, 832], ["coumarin H", "TEST", 846, 856], ["coumarin H", "TEST", 870, 880], ["coumarin H", "TEST", 894, 904], ["{s", "TEST", 942, 944], ["OCH3", "TEST", 951, 955], ["LC", "TEST", 960, 962], ["MS", "TEST", 963, 965], ["RT", "TEST", 967, 969], ["m/z", "TEST", 993, 996], ["Analysis", "TEST", 1013, 1021], ["C33H27CoN4O7", "TEST", 1026, 1038], ["Calcd", "TEST", 1040, 1045], ["C", "TEST", 1047, 1048], ["H", "TEST", 1057, 1058], ["N", "TEST", 1066, 1067], ["Co", "TEST", 1075, 1077], ["C", "TEST", 1091, 1092], ["H", "TEST", 1101, 1102], ["N", "TEST", 1110, 1111], ["Co", "TEST", 1119, 1121], ["Methods", "TREATMENT", 1170, 1177], ["HC azo-analogues", "TREATMENT", 1207, 1223], ["their metal complexes", "TREATMENT", 1228, 1249], ["different freshly sub cultured microbial strains", "TREATMENT", 1273, 1321], ["microbial strains", "OBSERVATION", 1304, 1321]]], ["Escherichia coli (MTCC 614), Klebsiella pneumonia (MTCC 109) and Candida albicans (MTCC 3017), that were procured from the Institute of Microbial Technology and Gene bank (IMTECH), Chandigarh, India.", [["Klebsiella pneumonia", "DISEASE", 29, 49], ["Candida albicans", "DISEASE", 65, 81], ["Escherichia coli", "ORGANISM", 0, 16], ["MTCC 614)", "ORGANISM", 18, 27], ["Klebsiella pneumonia", "ORGANISM", 29, 49], ["MTCC 109", "ORGANISM", 51, 59], ["Candida albicans", "ORGANISM", 65, 81], ["MTCC 3017", "CELL", 83, 92], ["Escherichia coli", "SPECIES", 0, 16], ["Klebsiella pneumonia", "SPECIES", 29, 49], ["Candida albicans", "SPECIES", 65, 81], ["Escherichia coli", "SPECIES", 0, 16], ["Klebsiella pneumonia (MTCC 109)", "SPECIES", 29, 60], ["Candida albicans", "SPECIES", 65, 81], ["Escherichia coli", "PROBLEM", 0, 16], ["Klebsiella pneumonia", "PROBLEM", 29, 49], ["Candida albicans", "PROBLEM", 65, 81], ["Klebsiella", "OBSERVATION_MODIFIER", 29, 39], ["pneumonia", "OBSERVATION", 40, 49]]], ["Staphylococcus aureus and Cryptococcus neoformans were obtained from the University Department of Pharmaceutical Sciences, Utkal University.", [["Staphylococcus aureus", "DISEASE", 0, 21], ["Staphylococcus aureus", "ORGANISM", 0, 21], ["Cryptococcus neoformans", "ORGANISM", 26, 49], ["Staphylococcus aureus", "SPECIES", 0, 21], ["Cryptococcus neoformans", "SPECIES", 26, 49], ["Staphylococcus aureus", "SPECIES", 0, 21], ["Cryptococcus neoformans", "SPECIES", 26, 49], ["Staphylococcus aureus", "PROBLEM", 0, 21], ["Cryptococcus neoformans", "PROBLEM", 26, 49], ["aureus", "OBSERVATION", 15, 21], ["Cryptococcus neoformans", "OBSERVATION", 26, 49]]], ["Ampicillin and fluconazole were used as reference antibiotics.Antimicrobial activity ::: Materials and MethodsThe antimicrobial diffusion test was performed using a cell suspension of approximately 1.5 \u00d7 106 CFU mL\u22121 employing a McFarland turbidity standard No. 0.5.", [["cell", "ANATOMY", 165, 169], ["Ampicillin", "CHEMICAL", 0, 10], ["fluconazole", "CHEMICAL", 15, 26], ["Ampicillin", "CHEMICAL", 0, 10], ["fluconazole", "CHEMICAL", 15, 26], ["Ampicillin", "SIMPLE_CHEMICAL", 0, 10], ["fluconazole", "SIMPLE_CHEMICAL", 15, 26], ["cell", "CELL", 165, 169], ["Ampicillin", "TREATMENT", 0, 10], ["fluconazole", "TREATMENT", 15, 26], ["reference antibiotics", "TREATMENT", 40, 61], ["The antimicrobial diffusion test", "TEST", 110, 142], ["a cell suspension", "TEST", 163, 180], ["a McFarland turbidity", "TEST", 227, 248]]], ["The antimicrobial activities of the novel 4-HC analogues (3a\u20133b) and the reported complexes (4a\u20134g) were determined by the agar well diffusion method using sterile molten nutrient agar (antibacterial activity) preparations of the compounds and Sabouraud dextrose agar (antifungal activity) preparations of compound 4d and their respective complexes.9Minimum inhibitory concentration (MIC) ::: Materials and MethodsA 1 mg mL\u22121 stock solution of each of the synthesized compounds and reference antibiotic was prepared using DMF.", [["4-HC", "CHEMICAL", 42, 46], ["dextrose", "CHEMICAL", 254, 262], ["DMF", "CHEMICAL", 522, 525], ["4-HC", "CHEMICAL", 42, 46], ["DMF", "CHEMICAL", 522, 525], ["4-HC analogues", "SIMPLE_CHEMICAL", 42, 56], ["3a\u20133b", "SIMPLE_CHEMICAL", 58, 63], ["4a\u20134g", "SIMPLE_CHEMICAL", 93, 98], ["DMF", "SIMPLE_CHEMICAL", 522, 525], ["sterile molten nutrient agar (antibacterial activity)", "TREATMENT", 156, 209], ["the compounds", "TREATMENT", 226, 239], ["Sabouraud dextrose agar", "TREATMENT", 244, 267], ["antifungal activity)", "TREATMENT", 269, 289], ["Materials", "TREATMENT", 393, 402], ["MethodsA", "TREATMENT", 407, 415], ["the synthesized compounds", "TREATMENT", 452, 477], ["reference antibiotic", "TREATMENT", 482, 502]]], ["Further, five different concentrations (500\u201331.25 \u03bcg mL\u22121) were prepared by the serial dilution method.", [["the serial dilution method", "TREATMENT", 76, 102]]], ["The different concentrations for the respective compounds were loaded into the wells and incubated at 37 \u00b0C for 18\u201324 h.", [["the respective compounds", "TREATMENT", 33, 57], ["different", "OBSERVATION_MODIFIER", 4, 13], ["concentrations", "OBSERVATION_MODIFIER", 14, 28]]], ["After incubation, the MIC was determined.9Acute toxicity study ::: Materials and MethodsThe experiment was carried under the guideline of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) and approved by the Institutional Animal Ethical Committee (IAEC), School of Pharmaceutical Sciences.", [["toxicity", "DISEASE", 48, 56], ["the MIC", "TREATMENT", 18, 25], ["Acute toxicity study", "PROBLEM", 42, 62], ["Methods", "TREATMENT", 81, 88], ["toxicity", "OBSERVATION", 48, 56]]], ["The said synthesized compounds were subjected to an acute oral toxicity study to establish their safety dose.", [["oral", "ANATOMY", 58, 62], ["toxicity", "DISEASE", 63, 71], ["oral", "ORGANISM_SUBDIVISION", 58, 62], ["an acute oral toxicity study", "PROBLEM", 49, 77], ["acute", "OBSERVATION_MODIFIER", 52, 57]]], ["Healthy young female Wister rats that were 8\u201312 weeks of age were selected.", [["Wister rats", "ORGANISM", 21, 32], ["rats", "SPECIES", 28, 32]]], ["OECD guideline No. 420 (2000) for the acute oral toxicity fixed dose procedure of the test compounds (3a\u20133b and 4a\u20134h) was followed.", [["oral", "ANATOMY", 44, 48], ["toxicity", "DISEASE", 49, 57], ["oral", "ORGANISM_SUBDIVISION", 44, 48], ["the acute oral toxicity fixed dose procedure", "TREATMENT", 34, 78], ["the test compounds", "TEST", 82, 100]]], ["To conduct the sighting study, a single animal was provided with suspensions of the synthesized compounds having a specific dose, viz.", [["the sighting study", "TEST", 11, 29]]], ["5 mg, 50 mg, 300 mg and 2000 mg/kg body weight, with the aid of an intubation canula.", [["body", "ANATOMY", 35, 39], ["body", "ORGANISM_SUBDIVISION", 35, 39], ["an intubation canula", "TREATMENT", 64, 84]]], ["In the main study, another 4 animals were administered 2000 mg/kg.", [["animals", "ORGANISM", 29, 36]]], ["The animals were observed for a period of 14 days.", [["animals", "ORGANISM", 4, 11]]], ["However, the acute toxic symptoms and the behavioural changes produced by the test compounds were observed continuously at an interval of 4 h up to 24 h.Statistical analysis ::: Materials and MethodsThe observed data on the zone of inhibitions were subjected to a one way analysis of variance.", [["the acute toxic symptoms", "PROBLEM", 9, 33], ["the behavioural changes", "PROBLEM", 38, 61], ["the test compounds", "TEST", 74, 92], ["Methods", "TREATMENT", 192, 199], ["acute", "OBSERVATION_MODIFIER", 13, 18], ["toxic", "OBSERVATION_MODIFIER", 19, 24]]], ["The mean zone of inhibition for each compound on each strain was compared with the reference antibiotic through a Dunnett Post Hoc test (https://www.statstodo.com/SSizAOV_Pgm.php).", [["a Dunnett Post Hoc test", "TEST", 112, 135], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["zone", "OBSERVATION_MODIFIER", 9, 13]]], ["The research hypothesis was \u2018the zone of inhibition for the test compound was higher than the reference antibiotics\u2019 against the hypothesis of no difference (null hypotheses), which states that there is no significant difference between the zone of inhibition of the test compound and the reference antibiotics.Sample size determination ::: Materials and MethodsA minimum sample size of five was calculated taking the probability of type 1 error (d) = 0.05, Power (1-\u03b2) = 0.8, Number of groups = 13 within group SD = 2.", [["the test compound", "TEST", 56, 73], ["the reference antibiotics", "TREATMENT", 90, 115], ["the test compound", "TEST", 263, 280], ["the reference antibiotics", "TREATMENT", 285, 310], ["MethodsA minimum sample size", "TEST", 355, 383], ["Power", "TEST", 458, 463], ["no", "UNCERTAINTY", 203, 205], ["significant", "OBSERVATION_MODIFIER", 206, 217], ["difference", "OBSERVATION_MODIFIER", 218, 228], ["size", "OBSERVATION_MODIFIER", 379, 383]]], ["However, a sample size of six has been taken in the study for each compound against each strain.ResultsThe metal complexes of 3-aryl-azo-4-hydroxy coumarin analogues were synthesized by refluxing different hydro alcoholic solutions of metal chlorides with 3-(4-chloro phenyl/4-methoxy phenyl)-azo-4-hydroxy coumarin analogues (Scheme 1) and finally re-crystallized from diethyl ether.", [["3-aryl-azo-4-hydroxy coumarin", "CHEMICAL", 126, 155], ["metal chlorides", "CHEMICAL", 235, 250], ["3-(4-chloro phenyl/4-methoxy phenyl)-azo-4-hydroxy coumarin", "CHEMICAL", 256, 315], ["diethyl ether", "CHEMICAL", 370, 383], ["3-aryl-azo-4-hydroxy coumarin", "CHEMICAL", 126, 155], ["metal chlorides", "CHEMICAL", 235, 250], ["3-(4-chloro phenyl/4-methoxy phenyl)-azo-4-hydroxy coumarin", "CHEMICAL", 256, 315], ["diethyl ether", "CHEMICAL", 370, 383], ["3-aryl-azo-4-hydroxy coumarin analogues", "SIMPLE_CHEMICAL", 126, 165], ["metal chlorides", "SIMPLE_CHEMICAL", 235, 250], ["3-(4-chloro phenyl/4-methoxy phenyl)-azo-4-hydroxy coumarin analogues", "SIMPLE_CHEMICAL", 256, 325], ["diethyl ether", "SIMPLE_CHEMICAL", 370, 383], ["a sample size", "TEST", 9, 22], ["the study", "TEST", 48, 57], ["each strain", "PROBLEM", 84, 95], ["The metal complexes", "TEST", 103, 122], ["azo", "TEST", 133, 136], ["hydroxy coumarin analogues", "TREATMENT", 139, 165], ["refluxing different hydro alcoholic solutions", "TREATMENT", 186, 231], ["metal chlorides", "TREATMENT", 235, 250], ["chloro phenyl/4-methoxy phenyl)", "TREATMENT", 261, 292], ["azo", "TREATMENT", 293, 296], ["hydroxy coumarin analogues", "TREATMENT", 299, 325], ["size", "OBSERVATION_MODIFIER", 18, 22]]], ["The structures of the prepared compounds are confirmed by different instrumental methods of analysis.", [["analysis", "TEST", 92, 100]]], ["The physical characteristics of the synthesized compounds are reported in Table 1.", [["the synthesized compounds", "PROBLEM", 32, 57]]], ["The FT/IR spectra of synthesized ligands 3a and 3b showed strong vibration bands at 3479\u20133445 cm\u22121, 1619\u20131603 cm\u22121, 1726\u20131745 cm\u22121, 1298\u20131246 cm\u22121 and 1529\u20131505 cm\u22121 due to presence of functional groups such as OH str., CC str., CO str., C\u2014O str. and NN str., respectively.", [["CC", "CHEMICAL", 220, 222], ["OH", "CHEMICAL", 211, 213], ["CO", "CHEMICAL", 229, 231], ["O", "CHEMICAL", 240, 241], ["OH str.", "SIMPLE_CHEMICAL", 211, 218], ["C\u2014O str", "GENE_OR_GENE_PRODUCT", 238, 245], ["The FT/IR spectra of synthesized ligands 3a", "TEST", 0, 43], ["strong vibration bands", "PROBLEM", 58, 80], ["str", "PROBLEM", 242, 245], ["strong", "OBSERVATION_MODIFIER", 58, 64], ["vibration bands", "OBSERVATION", 65, 80]]], ["The strong vibration bands of compound 3a at 1726, 1619 and 1298 cm\u22121 may be due to presence of a lactone carbonyl of CO str., CC str. and C\u2014O str., respectively, and are illustrated in Figure 1.", [["compound 3a", "CHEMICAL", 30, 41], ["lactone carbonyl", "CHEMICAL", 98, 114], ["CC", "CHEMICAL", 127, 129], ["lactone", "CHEMICAL", 98, 105], ["carbonyl", "CHEMICAL", 106, 114], ["CO", "CHEMICAL", 118, 120], ["lactone carbonyl", "SIMPLE_CHEMICAL", 98, 114], ["CO str.", "SIMPLE_CHEMICAL", 118, 125], ["CC str", "GENE_OR_GENE_PRODUCT", 127, 133], ["The strong vibration bands", "TEST", 0, 26], ["a lactone carbonyl of CO str.", "TREATMENT", 96, 125], ["strong", "OBSERVATION_MODIFIER", 4, 10], ["vibration", "OBSERVATION_MODIFIER", 11, 20], ["bands", "OBSERVATION_MODIFIER", 21, 26], ["compound 3a", "OBSERVATION_MODIFIER", 30, 41]]], ["The frequencies of all the complexes (4a\u20134h) assigned at 1629\u20131613 cm\u22121, 1729\u20131721 cm\u22121, 1296\u20131248 cm\u22121 and 1529\u20131524 cm\u22121 correspond to CC str., CO str., C\u2014O str. and NN str., respectively.", [["CC", "CHEMICAL", 137, 139], ["CO", "CHEMICAL", 146, 148], ["C\u2014O str", "GENE_OR_GENE_PRODUCT", 155, 162], ["str", "PROBLEM", 159, 162]]], ["The IR spectral bands of all metal complexes appearing at 451\u2013441 and 538\u2013531 cm\u22121 are assigned to (M\u2212N) and (M\u2212O), respectively.", [["all metal complexes", "TEST", 25, 44], ["spectral", "OBSERVATION_MODIFIER", 7, 15], ["bands", "OBSERVATION_MODIFIER", 16, 21], ["all", "OBSERVATION_MODIFIER", 25, 28], ["metal complexes", "OBSERVATION", 29, 44]]], ["The 1H NMR spectra of the ligands showed a broad singlet at \u03b4 16.81\u201316.86 ppm towards the presence of the enolic OH group of 4-hydroxy coumarin.", [["enolic OH", "CHEMICAL", 106, 115], ["4-hydroxy coumarin", "CHEMICAL", 125, 143], ["1H", "CHEMICAL", 4, 6], ["enolic OH", "CHEMICAL", 106, 115], ["4-hydroxy coumarin", "CHEMICAL", 125, 143], ["1H", "SIMPLE_CHEMICAL", 4, 6], ["enolic OH", "SIMPLE_CHEMICAL", 106, 115], ["4-hydroxy coumarin", "SIMPLE_CHEMICAL", 125, 143], ["The 1H NMR spectra of the ligands", "TEST", 0, 33], ["a broad singlet", "PROBLEM", 41, 56], ["hydroxy coumarin", "TREATMENT", 127, 143], ["broad", "OBSERVATION_MODIFIER", 43, 48]]], ["The 1H NMR spectrum of compound 3b showed a sharp singlet at \u03b4 3.83 ppm corresponding to the proton of \u2013OCH3 (Figure 2).", [["1H", "CHEMICAL", 4, 6], ["\u2013OCH3", "CHEMICAL", 103, 108], ["1H", "SIMPLE_CHEMICAL", 4, 6], ["a sharp singlet", "PROBLEM", 42, 57]]], ["All of the complexes showed signals at a range of (6.90\u20137.26)\u2013(7.23\u20137.37) ppm corresponding to {m, 8H, (C6H4)2}.ResultsThe magnetic susceptibility of the Co(II) complex is 5.09 BM, which is nearer to the reported value for octahedral symmetry.21 The Ni(II) complex showed a magnetic moment of 2.94 BM, whereas the Cu(II) complex showed a magnetic moment of 1.98 BM, suggesting an octahedral geometry.", [["Co(II", "CHEMICAL", 154, 159], ["Ni", "CHEMICAL", 250, 252], ["Cu", "CHEMICAL", 314, 316], ["{m, 8H, (C6H4)2}", "CHEMICAL", 95, 111], ["Co(II)", "CHEMICAL", 154, 160], ["Ni(II)", "CHEMICAL", 250, 256], ["Cu(II)", "CHEMICAL", 314, 320], ["{m, 8H, (C6H4)2}", "SIMPLE_CHEMICAL", 95, 111], ["Co(II)", "SIMPLE_CHEMICAL", 154, 160], ["Co(II) complex", "PROTEIN", 154, 168], ["Ni(II) complex", "PROTEIN", 250, 264], ["Cu(II) complex", "PROTEIN", 314, 328], ["ppm", "TEST", 74, 77], ["an octahedral geometry", "PROBLEM", 377, 399], ["5.09 BM", "OBSERVATION", 172, 179], ["octahedral symmetry", "OBSERVATION", 223, 242], ["octahedral geometry", "OBSERVATION", 380, 399]]], ["Compounds 3a\u20133b act as bidentate ligands by coordinating to the transitional metal ions through their azo and enolic hydroxyl moiety.", [["azo", "CHEMICAL", 102, 105], ["enolic hydroxyl", "CHEMICAL", 110, 125], ["azo", "CHEMICAL", 102, 105], ["enolic hydroxyl", "CHEMICAL", 110, 125], ["3a\u20133b", "SIMPLE_CHEMICAL", 10, 15], ["transitional metal ions", "SIMPLE_CHEMICAL", 64, 87], ["azo", "SIMPLE_CHEMICAL", 102, 105], ["enolic hydroxyl moiety", "SIMPLE_CHEMICAL", 110, 132], ["the transitional metal ions", "TREATMENT", 60, 87], ["their azo", "TREATMENT", 96, 105], ["enolic hydroxyl moiety", "TREATMENT", 110, 132]]], ["Based upon the study of magnetic susceptibility values of the complexes, the probable structure is given in Scheme 1.ResultsThe predicted molecular weights of the synthesized compounds were confirmed by LC\u2013MS and the results are summarized in Table 1.", [["the study", "TEST", 11, 20], ["probable", "UNCERTAINTY", 77, 85], ["structure", "OBSERVATION", 86, 95]]], ["Compound 3a possesses a molecular ion peak at 301.2 m/z that strongly reveals the predicted molecular formula C15H9ClN2O3 that is reported in Figure 4.ResultsThe UV spectroscopic analyses of the synthesized ligands and complexes revealed that complexes 4a and 4e demonstrated a good bathochromic shift at 463 and 450 nm, whereas ligands 3a and 3b possessed a \u03bb max at 409 and 413 nm, respectively.", [["C15H9ClN2O3", "CHEMICAL", 110, 121], ["C15H9ClN2O3", "CHEMICAL", 110, 121], ["C15H9ClN2O3", "SIMPLE_CHEMICAL", 110, 121], ["complexes 4a and 4e", "PROTEIN", 243, 262], ["The UV spectroscopic analyses", "TEST", 158, 187], ["the synthesized ligands", "TEST", 191, 214], ["a good bathochromic shift", "PROBLEM", 276, 301], ["ligands", "TEST", 329, 336], ["good", "OBSERVATION_MODIFIER", 278, 282], ["bathochromic shift", "OBSERVATION", 283, 301]]], ["The solvent effect of the ligands and their respective complexes are spectrally presented in Figure 3.ResultsThe X-ray diffraction (XRD) technique provides the most definitive structural information.", [["The X-ray diffraction (XRD) technique", "TEST", 109, 146], ["solvent effect", "OBSERVATION", 4, 18]]], ["The study of the XRD pattern of the synthesized complexes was performed using a Cu K\u03b1 X-ray source and a step of 0.02 (2\u03b8) and run at 2\u03b8 = 2\u201380\u00b0 using a Shimadzu XRD 7000 instrument at a scanning speed of 2.000 (deg/min).", [["Cu", "CHEMICAL", 80, 82], ["Cu", "CHEMICAL", 80, 82], ["K", "CHEMICAL", 83, 84], ["The study", "TEST", 0, 9], ["the XRD pattern", "TEST", 13, 28], ["a Cu K\u03b1 X-ray", "TEST", 78, 91], ["a Shimadzu XRD", "TREATMENT", 151, 165], ["a scanning speed", "TEST", 185, 201]]], ["Using Origin data analysis software, the structures of the obtained complexes were interpreted.", [["Origin data analysis software", "TEST", 6, 35]]], ["The pattern and the number of reflections reported in Figure 5 clearly declared the structural difference of compounds 4e and 4f.ResultsThe results of the antimicrobial activity of the newly synthesized 3-aryl-azo-4-hydroxy coumarin analogues and their complexes compared with reference antibiotics (RA) ampicillin and fluconazole (as antibacterial and antifungal standard drugs, respectively) expressed in mean \u00b1 SD are reported in Table 2.", [["3-aryl-azo-4-hydroxy coumarin", "CHEMICAL", 203, 232], ["RA", "CHEMICAL", 300, 302], ["ampicillin", "CHEMICAL", 304, 314], ["fluconazole", "CHEMICAL", 319, 330], ["3-aryl-azo-4-hydroxy coumarin", "CHEMICAL", 203, 232], ["ampicillin", "CHEMICAL", 304, 314], ["fluconazole", "CHEMICAL", 319, 330], ["3-aryl-azo-4-hydroxy coumarin analogues", "SIMPLE_CHEMICAL", 203, 242], ["ampicillin", "SIMPLE_CHEMICAL", 304, 314], ["fluconazole", "SIMPLE_CHEMICAL", 319, 330], ["the antimicrobial activity", "TEST", 151, 177], ["azo", "TEST", 210, 213], ["hydroxy coumarin analogues", "TREATMENT", 216, 242], ["reference antibiotics (RA", "TREATMENT", 277, 302], ["ampicillin", "TREATMENT", 304, 314], ["fluconazole", "TREATMENT", 319, 330], ["antibacterial", "TREATMENT", 335, 348], ["antifungal standard drugs", "TREATMENT", 353, 378], ["pattern", "OBSERVATION_MODIFIER", 4, 11]]], ["The reported results revealed that compounds 4a and 4e showed significant antimicrobial activity in comparison to standard drugs (p < 0.05) against E. coli, K. pneumonia, S. aureus, C. albicans and C. neoformans.", [["compounds 4a and 4e", "CHEMICAL", 35, 54], ["K. pneumonia", "DISEASE", 157, 169], ["4e", "SIMPLE_CHEMICAL", 52, 54], ["E. coli", "ORGANISM", 148, 155], ["K. pneumonia", "ORGANISM", 157, 169], ["S. aureus", "ORGANISM", 171, 180], ["C. albicans", "ORGANISM", 182, 193], ["C. neoformans", "ORGANISM", 198, 211], ["E. coli", "SPECIES", 148, 155], ["K. pneumonia", "SPECIES", 157, 169], ["S. aureus", "SPECIES", 171, 180], ["C. albicans", "SPECIES", 182, 193], ["C. neoformans", "SPECIES", 198, 211], ["E. coli", "SPECIES", 148, 155], ["K. pneumonia", "SPECIES", 157, 169], ["S. aureus", "SPECIES", 171, 180], ["C. albicans", "SPECIES", 182, 193], ["C. neoformans", "SPECIES", 198, 211], ["significant antimicrobial activity", "PROBLEM", 62, 96], ["standard drugs", "TREATMENT", 114, 128], ["E. coli", "PROBLEM", 148, 155], ["pneumonia", "PROBLEM", 160, 169], ["S. aureus", "PROBLEM", 171, 180], ["C. albicans", "PROBLEM", 182, 193], ["C. neoformans", "PROBLEM", 198, 211], ["significant", "OBSERVATION_MODIFIER", 62, 73], ["antimicrobial activity", "OBSERVATION", 74, 96], ["pneumonia", "OBSERVATION", 160, 169], ["aureus", "OBSERVATION", 174, 180], ["neoformans", "OBSERVATION", 201, 211]]], ["All compounds except for 4d and 4h showed significant antibacterial activity against S. aureus.", [["S. aureus", "ORGANISM", 85, 94], ["S. aureus", "SPECIES", 85, 94], ["S. aureus", "SPECIES", 85, 94], ["significant antibacterial activity", "PROBLEM", 42, 76], ["S. aureus", "PROBLEM", 85, 94], ["significant", "OBSERVATION_MODIFIER", 42, 53], ["antibacterial activity", "OBSERVATION", 54, 76], ["aureus", "OBSERVATION", 88, 94]]], ["However, complex 4a showed highest mean zone of inhibition (mm) against K. pneumonia and C. neoformans, 19 \u00b1 1.1 and 27.5 \u00b1 1.64, respectively.", [["pneumonia", "DISEASE", 75, 84], ["C. neoformans", "ORGANISM", 89, 102], ["complex 4a", "PROTEIN", 9, 19], ["C. neoformans", "SPECIES", 89, 102], ["K. pneumonia", "SPECIES", 72, 84], ["C. neoformans", "SPECIES", 89, 102], ["K. pneumonia", "PROBLEM", 72, 84], ["C. neoformans", "TEST", 89, 102], ["pneumonia", "OBSERVATION", 75, 84], ["neoformans", "OBSERVATION_MODIFIER", 92, 102]]], ["The largest mean zones of inhibition exhibited by complex 4e against S. aureus and C. neoformans was 23 \u00b1 2.28 and 28.17 \u00b1 1.72, respectively.", [["S. aureus", "ORGANISM", 69, 78], ["C. neoformans", "ORGANISM", 83, 96], ["S. aureus", "SPECIES", 69, 78], ["C. neoformans", "SPECIES", 83, 96], ["S. aureus", "SPECIES", 69, 78], ["C. neoformans", "SPECIES", 83, 96], ["S. aureus", "PROBLEM", 69, 78], ["C. neoformans", "TEST", 83, 96], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["mean", "OBSERVATION_MODIFIER", 12, 16], ["zones", "OBSERVATION_MODIFIER", 17, 22], ["aureus", "OBSERVATION", 72, 78], ["neoformans", "OBSERVATION_MODIFIER", 86, 96]]], ["The anti-biogram pattern of compound 3a, 3b and their complexes against different fungal strains are illustrated in Figure 6.", [["3b", "GENE_OR_GENE_PRODUCT", 41, 43], ["The anti-biogram pattern", "TEST", 0, 24], ["different fungal strains", "PROBLEM", 72, 96], ["compound 3a", "OBSERVATION", 28, 39], ["fungal strains", "OBSERVATION", 82, 96]]], ["The graphical representation of complexes 4a and 4e is illustrated in Figure 7.ResultsThe inhibitory property of the compounds was determined in terms of MIC (\u03bcg mL\u22121).", [["complexes 4a and 4e", "PROTEIN", 32, 51]]], ["The Co++ complexes of both the ligands showed the antimicrobial activity against all the selected strains at MIC level 31.25 \u03bcg mL\u22121.", [["Co", "CHEMICAL", 4, 6], ["Co++", "CHEMICAL", 4, 8], ["Co++", "SIMPLE_CHEMICAL", 4, 8], ["Co++ complexes", "PROTEIN", 4, 18], ["The Co", "TEST", 0, 6], ["MIC level", "TEST", 109, 118], ["antimicrobial activity", "OBSERVATION", 50, 72]]], ["All compounds except for 4d and 4h showed a zone of inhibition at the MIC level 31.25 \u03bcg mL\u22121 against C. albicans (Table 3).ResultsNo mortality was found for all of the test compounds per the results of the toxicity study.", [["toxicity", "DISEASE", 207, 215], ["C. albicans", "ORGANISM", 102, 113], ["C. albicans", "SPECIES", 102, 113], ["C. albicans", "SPECIES", 102, 113], ["a zone of inhibition", "PROBLEM", 42, 62], ["mortality", "PROBLEM", 134, 143], ["the test compounds", "TEST", 165, 183], ["the toxicity study", "TEST", 203, 221]]], ["The synthesized compounds were safe up to 2000 mg/kg body weight.", [["body", "ANATOMY", 53, 57], ["body", "ORGANISM_SUBDIVISION", 53, 57], ["The synthesized compounds", "TREATMENT", 0, 25]]], ["No significant change in the body weight of the animals was observed.", [["body", "ANATOMY", 29, 33], ["body", "ORGANISM_SUBDIVISION", 29, 33], ["significant change", "PROBLEM", 3, 21], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["change", "OBSERVATION", 15, 21], ["body weight", "ANATOMY_MODIFIER", 29, 40]]], ["No toxic symptoms and gross behavioural changes were observed in the animals.DiscussionThe FT/IR spectra of synthesized ligands 3a and 3b showed vibrations at 1619\u20131603 cm\u22121, 1726\u20131745 cm\u22121, 1298\u20131246 cm\u22121 and 1529\u20131505 cm\u22121 corresponding to CC str., CO str., C\u2014O str. and NN str., respectively, which were also observed in the synthesized complexes (4a\u20134h).", [["CC", "CHEMICAL", 242, 244], ["CO", "CHEMICAL", 251, 253], ["O", "CHEMICAL", 262, 263], ["C\u2014O str", "GENE_OR_GENE_PRODUCT", 260, 267], ["toxic symptoms", "PROBLEM", 3, 17], ["gross behavioural changes", "PROBLEM", 22, 47], ["vibrations", "TEST", 145, 155], ["CC str.", "TEST", 242, 249], ["CO str.", "TEST", 251, 258], ["str", "PROBLEM", 264, 267], ["toxic", "OBSERVATION_MODIFIER", 3, 8], ["symptoms", "OBSERVATION", 9, 17], ["gross", "OBSERVATION_MODIFIER", 22, 27], ["behavioural", "OBSERVATION", 28, 39]]], ["The only exception is the bands due to OH str. at 3479\u20133445 cm\u22121 exhibited in the ligands that are not observable in the complexes.", [["OH str", "CHEMICAL", 39, 45], ["OH", "CHEMICAL", 39, 41], ["OH str", "GENE_OR_GENE_PRODUCT", 39, 45], ["the bands", "PROBLEM", 22, 31], ["OH str", "PROBLEM", 39, 45], ["not observable", "UNCERTAINTY", 99, 113]]], ["In metal Cu(II), Ni(II) Co(II) and Zn(II) complexes of 3a and 3b, the FT/IR absorption band due to the hydroxyl group at 4-HC has been diminished and indicates the metal co-ordination of the OH group via deprotonation due to liberation of hydrochloric acid.", [["Cu", "CHEMICAL", 9, 11], ["Ni", "CHEMICAL", 17, 19], ["Co(II", "CHEMICAL", 24, 29], ["Zn", "CHEMICAL", 35, 37], ["hydroxyl", "CHEMICAL", 103, 111], ["4-HC", "CHEMICAL", 121, 125], ["OH", "CHEMICAL", 191, 193], ["hydrochloric acid", "CHEMICAL", 239, 256], ["Cu(II)", "CHEMICAL", 9, 15], ["Ni(II) Co(II)", "CHEMICAL", 17, 30], ["Zn(II)", "CHEMICAL", 35, 41], ["hydroxyl", "CHEMICAL", 103, 111], ["4-HC", "CHEMICAL", 121, 125], ["OH", "CHEMICAL", 191, 193], ["hydrochloric acid", "CHEMICAL", 239, 256], ["metal Cu(II)", "SIMPLE_CHEMICAL", 3, 15], ["Ni(II) Co(II)", "SIMPLE_CHEMICAL", 17, 30], ["Zn(II)", "SIMPLE_CHEMICAL", 35, 41], ["hydroxyl", "SIMPLE_CHEMICAL", 103, 111], ["4-HC", "SIMPLE_CHEMICAL", 121, 125], ["OH", "SIMPLE_CHEMICAL", 191, 193], ["hydrochloric acid", "SIMPLE_CHEMICAL", 239, 256], ["Zn(II) complexes", "PROTEIN", 35, 51], ["Zn(II) complexes", "TEST", 35, 51], ["the FT/IR absorption band", "TREATMENT", 66, 91], ["the hydroxyl group", "TEST", 99, 117], ["diminished", "PROBLEM", 135, 145], ["deprotonation", "TREATMENT", 204, 217], ["hydrochloric acid", "TREATMENT", 239, 256], ["metal Cu", "OBSERVATION_MODIFIER", 3, 11], ["diminished", "OBSERVATION", 135, 145], ["hydrochloric acid", "OBSERVATION", 239, 256]]], ["In addition to these FT/IR spectral data, stretching of the M\u2212N and M\u2212O bonds of the complexes, which appear in the higher frequency wavenumber region in the range 451\u2013441 and 538\u2013531 cm\u22121, also indicates that complexation occurred through nitrogen and oxygen atoms from the azo-enolic ligands.22, 23 The 1H NMR spectra of ligands 3a and 3b showed the enolic OH peak at 16.81 and 16.86 ppm.", [["nitrogen", "CHEMICAL", 240, 248], ["oxygen", "CHEMICAL", 253, 259], ["OH", "CHEMICAL", 359, 361], ["\u2212N", "CHEMICAL", 61, 63], ["M\u2212O", "CHEMICAL", 68, 71], ["nitrogen", "CHEMICAL", 240, 248], ["oxygen", "CHEMICAL", 253, 259], ["azo-enolic", "CHEMICAL", 275, 285], ["1H", "CHEMICAL", 305, 307], ["OH", "CHEMICAL", 359, 361], ["M\u2212N", "SIMPLE_CHEMICAL", 60, 63], ["M\u2212O bonds", "SIMPLE_CHEMICAL", 68, 77], ["nitrogen", "SIMPLE_CHEMICAL", 240, 248], ["oxygen atoms", "SIMPLE_CHEMICAL", 253, 265], ["azo-enolic ligands", "SIMPLE_CHEMICAL", 275, 293], ["enolic OH", "SIMPLE_CHEMICAL", 352, 361], ["these FT/IR spectral data", "TEST", 15, 40], ["the M\u2212N", "TEST", 56, 63], ["nitrogen and oxygen atoms", "TREATMENT", 240, 265], ["ligands", "TEST", 323, 330], ["the enolic OH peak", "TEST", 348, 366], ["complexes", "ANATOMY_MODIFIER", 85, 94], ["higher", "OBSERVATION_MODIFIER", 116, 122], ["range", "OBSERVATION_MODIFIER", 158, 163], ["complexation", "OBSERVATION", 210, 222], ["oxygen atoms", "OBSERVATION", 253, 265]]], ["The disappearance of the enolic OH group in all the complexes (4a\u20134h) may be due to the interaction of metal chlorides with the hydroxyl group of the ligands resulting in deprotonation and complexation of the ligands to the metal ions.", [["enolic OH", "CHEMICAL", 25, 34], ["metal chlorides", "CHEMICAL", 103, 118], ["hydroxyl", "CHEMICAL", 128, 136], ["enolic OH", "CHEMICAL", 25, 34], ["metal chlorides", "CHEMICAL", 103, 118], ["hydroxyl", "CHEMICAL", 128, 136], ["enolic OH", "SIMPLE_CHEMICAL", 25, 34], ["metal chlorides", "SIMPLE_CHEMICAL", 103, 118], ["hydroxyl", "SIMPLE_CHEMICAL", 128, 136], ["metal ions", "SIMPLE_CHEMICAL", 224, 234], ["metal chlorides", "TREATMENT", 103, 118], ["deprotonation", "PROBLEM", 171, 184], ["disappearance", "OBSERVATION_MODIFIER", 4, 17], ["enolic", "OBSERVATION_MODIFIER", 25, 31], ["OH", "OBSERVATION_MODIFIER", 32, 34], ["may be due to", "UNCERTAINTY", 70, 83], ["ligands", "ANATOMY", 150, 157], ["deprotonation", "OBSERVATION", 171, 184], ["metal ions", "OBSERVATION", 224, 234]]], ["Ligand 3b shows three identical, similar-environment protons at 3.83 ppm, which indicates the presence of an \u2013OCH3 functional group.", [["\u2013OCH3", "CHEMICAL", 109, 114], ["Ligand 3b", "GENE_OR_GENE_PRODUCT", 0, 9], ["protons", "SIMPLE_CHEMICAL", 53, 60], ["\u2013OCH3", "SIMPLE_CHEMICAL", 109, 114]]], ["The good bathochromic shift at 463 and 450 nm exhibited by complexes 4a and 4e may be due to the attachment of transition metal ion Co++ to the respective ligands 3a and 3b.", [["Co", "CHEMICAL", 132, 134], ["transition metal", "CHEMICAL", 111, 127], ["Co++", "CHEMICAL", 132, 136], ["Co++", "SIMPLE_CHEMICAL", 132, 136], ["good", "OBSERVATION_MODIFIER", 4, 8], ["bathochromic shift", "OBSERVATION", 9, 27]]], ["Most of the compounds showed good antimicrobial activity in comparison to ampicillin.", [["ampicillin", "CHEMICAL", 74, 84], ["ampicillin", "CHEMICAL", 74, 84], ["ampicillin", "SIMPLE_CHEMICAL", 74, 84], ["ampicillin", "TREATMENT", 74, 84], ["good", "OBSERVATION_MODIFIER", 29, 33], ["antimicrobial activity", "OBSERVATION", 34, 56]]], ["The enhanced antimicrobial activity exhibited by complexes 4a, 4b, 4e and 4f relative to their ligands against E. coli may be due to coordination of Co++ and Ni++ ions to the respective ligands 3a and 3b.", [["complexes 4a, 4b, 4e and 4f", "CHEMICAL", 49, 76], ["Co", "CHEMICAL", 149, 151], ["Ni", "CHEMICAL", 158, 160], ["Co++", "CHEMICAL", 149, 153], ["Ni++", "CHEMICAL", 158, 162], ["E. coli", "ORGANISM", 111, 118], ["Co++", "SIMPLE_CHEMICAL", 149, 153], ["Ni++ ions", "SIMPLE_CHEMICAL", 158, 167], ["complexes 4a, 4b, 4e and 4f", "PROTEIN", 49, 76], ["E. coli", "SPECIES", 111, 118], ["E. coli", "SPECIES", 111, 118], ["E. coli", "PROBLEM", 111, 118], ["Co", "TEST", 149, 151], ["Ni", "TEST", 158, 160], ["antimicrobial activity", "OBSERVATION", 13, 35], ["coli", "OBSERVATION", 114, 118]]], ["However, complexes 4a and 4e showed considerably enhanced antimicrobial activity against most of the pathogenic strains relative to their ligands.", [["complexes 4a and 4e", "CHEMICAL", 9, 28], ["considerably enhanced antimicrobial activity", "PROBLEM", 36, 80], ["the pathogenic strains", "PROBLEM", 97, 119], ["considerably", "OBSERVATION_MODIFIER", 36, 48], ["enhanced", "OBSERVATION_MODIFIER", 49, 57], ["antimicrobial activity", "OBSERVATION", 58, 80]]], ["Complexation reduces the polarity of the metal ion by coordinating with ligands and increases the lipophilicity of the metals.24 Thus, it facilitates the penetration of the novel synthesized complexes into the lipoid cell membrane of microorganisms and inhibits their growth.DiscussionThe limitations of our study include only the investigation of antimicrobial activity of the novel synthesized complexes against a few bacterial and fungal strains.", [["lipoid cell membrane", "ANATOMY", 210, 230], ["metal ion", "SIMPLE_CHEMICAL", 41, 50], ["metals", "SIMPLE_CHEMICAL", 119, 125], ["lipoid cell membrane", "CELLULAR_COMPONENT", 210, 230], ["our study", "TEST", 304, 313], ["antimicrobial activity", "TREATMENT", 348, 370], ["a few bacterial and fungal strains", "PROBLEM", 414, 448], ["polarity", "OBSERVATION_MODIFIER", 25, 33], ["lipophilicity", "OBSERVATION_MODIFIER", 98, 111], ["lipoid cell membrane", "OBSERVATION", 210, 230], ["growth", "OBSERVATION_MODIFIER", 268, 274], ["few", "OBSERVATION_MODIFIER", 416, 419], ["bacterial", "OBSERVATION_MODIFIER", 420, 429], ["fungal strains", "OBSERVATION", 434, 448]]], ["Furthermore, it is necessary to investigate the antimicrobial activities of the novel complexes against multidrug-resistant microorganisms.", [["multidrug-resistant microorganisms", "PROBLEM", 104, 138]]], ["A literature survey revealed that the metal complexes serve as vehicles for activation of the ligands as principal cytotoxic species.", [["A literature survey", "TEST", 0, 19], ["the metal complexes", "TREATMENT", 34, 53], ["principal cytotoxic species", "PROBLEM", 105, 132], ["principal", "OBSERVATION_MODIFIER", 105, 114], ["cytotoxic species", "OBSERVATION", 115, 132]]], ["Therefore, these complexes may be implemented for the investigation of cytotoxic activity against different cancer cell lines.ConclusionsIn the present work, metal complexes from 3-aryl-azo-4-hydroxy coumarin analogues were synthesized.", [["cancer cell lines", "ANATOMY", 108, 125], ["cancer", "DISEASE", 108, 114], ["3-aryl-azo-4-hydroxy coumarin", "CHEMICAL", 179, 208], ["3-aryl-azo-4-hydroxy coumarin", "CHEMICAL", 179, 208], ["cancer cell lines", "CELL", 108, 125], ["metal complexes", "SIMPLE_CHEMICAL", 158, 173], ["3-aryl-azo-4-hydroxy coumarin analogues", "SIMPLE_CHEMICAL", 179, 218], ["cancer cell lines", "CELL_LINE", 108, 125], ["cytotoxic activity", "PROBLEM", 71, 89], ["different cancer cell lines", "PROBLEM", 98, 125], ["metal complexes", "TEST", 158, 173], ["azo", "TEST", 186, 189], ["hydroxy coumarin analogues", "TREATMENT", 192, 218], ["cancer cell lines", "OBSERVATION", 108, 125]]], ["The spectral characterization of the complexes confirmed their structural environment.", [["The spectral characterization", "TEST", 0, 29], ["structural environment", "OBSERVATION", 63, 85]]], ["It is suggested that the pronounced antimicrobial activity executed by the complexes (4a and 4e) relative to their ligands permits their recommendation as a new chemical class of antimicrobial agents.Conflict of interestThe authors have no conflict of interest to declare.Authors' contributionThe conceptualization of this research work was designed by SKP.", [["the pronounced antimicrobial activity", "PROBLEM", 21, 58], ["antimicrobial agents", "TREATMENT", 179, 199], ["pronounced", "OBSERVATION_MODIFIER", 25, 35], ["antimicrobial activity", "OBSERVATION", 36, 58]]], ["The experimental work, interpretation of the data and drafting of the manuscript were performed by JS.", [["the data", "TEST", 41, 49]]]], "503e1f3f46f9ab6c560d68ff75a56ec5c779c7f1": [["The COVID-19 pandemic, which has exhausted the momentum in China, is still in the exponential phase in the rest of the world, without even reaching the peak.", [["The COVID", "TEST", 0, 9], ["pandemic", "PROBLEM", 13, 21], ["19 pandemic", "OBSERVATION_MODIFIER", 10, 21], ["momentum", "OBSERVATION_MODIFIER", 47, 55]]]], "e27a956f6dd15a93f81b5c4ce947fb64907eb1b2": [["IntroductionCoronaviruses (CoV) are the enveloped RNA viruses that can cause enzootic fatal infections primarily in birds and mammals.", [["infections", "DISEASE", 92, 102], ["IntroductionCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoV", "ORGANISM", 27, 30], ["CoV", "SPECIES", 27, 30], ["the enveloped RNA viruses", "PROBLEM", 36, 61], ["enzootic fatal infections", "PROBLEM", 77, 102], ["RNA viruses", "OBSERVATION", 50, 61], ["enzootic", "OBSERVATION_MODIFIER", 77, 85], ["fatal", "OBSERVATION_MODIFIER", 86, 91], ["infections", "OBSERVATION", 92, 102]]], ["[1] [2] [3] [4] Moreover, CoV has the ability to infect humankind.", [["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 0, 15], ["CoV", "ORGANISM", 26, 29]]], ["[5] [6] [7] The presenting symptoms and signs of the infection could be chills, night sweats, persistent cough, diarrhea, and fever.", [["infection", "DISEASE", 53, 62], ["chills", "DISEASE", 72, 78], ["night sweats", "DISEASE", 80, 92], ["cough", "DISEASE", 105, 110], ["diarrhea", "DISEASE", 112, 120], ["fever", "DISEASE", 126, 131], ["The presenting symptoms", "PROBLEM", 12, 35], ["the infection", "PROBLEM", 49, 62], ["chills", "PROBLEM", 72, 78], ["night sweats", "PROBLEM", 80, 92], ["persistent cough", "PROBLEM", 94, 110], ["diarrhea", "PROBLEM", 112, 120], ["fever", "PROBLEM", 126, 131], ["infection", "OBSERVATION", 53, 62], ["persistent", "OBSERVATION_MODIFIER", 94, 104], ["cough", "OBSERVATION", 105, 110], ["diarrhea", "OBSERVATION", 112, 120], ["fever", "OBSERVATION", 126, 131]]], ["However, the viral infection could cause a wide variety of clinical presentations, ranging from upper respiratory infections (URI) to lower respiratory infections (LRI), including bronchitis, pneumonia, and severe acute respiratory syndrome (SARS).", [["respiratory", "ANATOMY", 102, 113], ["respiratory", "ANATOMY", 140, 151], ["viral infection", "DISEASE", 13, 28], ["upper respiratory infections", "DISEASE", 96, 124], ["URI", "DISEASE", 126, 129], ["lower respiratory infections", "DISEASE", 134, 162], ["LRI", "DISEASE", 164, 167], ["bronchitis", "DISEASE", 180, 190], ["pneumonia", "DISEASE", 192, 201], ["acute respiratory syndrome", "DISEASE", 214, 240], ["SARS", "DISEASE", 242, 246], ["upper respiratory", "ORGANISM_SUBDIVISION", 96, 113], ["the viral infection", "PROBLEM", 9, 28], ["upper respiratory infections", "PROBLEM", 96, 124], ["URI", "PROBLEM", 126, 129], ["lower respiratory infections", "PROBLEM", 134, 162], ["bronchitis", "PROBLEM", 180, 190], ["pneumonia", "PROBLEM", 192, 201], ["severe acute respiratory syndrome", "PROBLEM", 207, 240], ["viral", "OBSERVATION_MODIFIER", 13, 18], ["infection", "OBSERVATION", 19, 28], ["wide", "OBSERVATION_MODIFIER", 43, 47], ["variety", "OBSERVATION_MODIFIER", 48, 55], ["upper", "ANATOMY_MODIFIER", 96, 101], ["respiratory", "ANATOMY", 102, 113], ["infections", "OBSERVATION", 114, 124], ["lower", "ANATOMY_MODIFIER", 134, 139], ["respiratory", "ANATOMY", 140, 151], ["infections", "OBSERVATION", 152, 162], ["bronchitis", "OBSERVATION", 180, 190], ["pneumonia", "OBSERVATION", 192, 201], ["severe", "OBSERVATION_MODIFIER", 207, 213], ["acute", "OBSERVATION_MODIFIER", 214, 219], ["respiratory syndrome", "OBSERVATION", 220, 240]]], ["CoV affects the respiratory system and specifically the lungs.", [["respiratory system", "ANATOMY", 16, 34], ["lungs", "ANATOMY", 56, 61], ["CoV", "ORGANISM", 0, 3], ["lungs", "ORGAN", 56, 61], ["CoV", "SPECIES", 0, 3], ["respiratory system", "ANATOMY", 16, 34], ["lungs", "ANATOMY", 56, 61]]], ["5, 8, 9 Furthermore, the viral infection can also affect the gastrointestinal tract, as well as the neurological and hepatic systems.", [["gastrointestinal tract", "ANATOMY", 61, 83], ["neurological", "ANATOMY", 100, 112], ["hepatic systems", "ANATOMY", 117, 132], ["viral infection", "DISEASE", 25, 40], ["neurological and hepatic systems", "DISEASE", 100, 132], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 61, 83], ["hepatic systems", "MULTI-TISSUE_STRUCTURE", 117, 132], ["the viral infection", "PROBLEM", 21, 40], ["viral", "OBSERVATION_MODIFIER", 25, 30], ["infection", "OBSERVATION", 31, 40], ["gastrointestinal tract", "ANATOMY", 61, 83], ["hepatic", "ANATOMY", 117, 124]]], ["10 The severe acute respiratory syndrome (SARS) epidemic in 2003 and the Middle East respiratory syndrome (MERS) in 2012 revealed that CoV can be fatal when they cross the species barrier and infect humans.", [["acute respiratory syndrome", "DISEASE", 14, 40], ["SARS", "DISEASE", 42, 46], ["Middle East respiratory syndrome", "DISEASE", 73, 105], ["CoV", "ORGANISM", 135, 138], ["humans", "ORGANISM", 199, 205], ["humans", "SPECIES", 199, 205], ["CoV", "SPECIES", 135, 138], ["humans", "SPECIES", 199, 205], ["The severe acute respiratory syndrome", "PROBLEM", 3, 40], ["SARS", "PROBLEM", 42, 46], ["epidemic", "PROBLEM", 48, 56], ["the Middle East respiratory syndrome", "PROBLEM", 69, 105], ["CoV", "PROBLEM", 135, 138], ["severe", "OBSERVATION_MODIFIER", 7, 13], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["respiratory syndrome", "OBSERVATION", 20, 40], ["Middle", "ANATOMY_MODIFIER", 73, 79], ["respiratory syndrome", "OBSERVATION", 85, 105]]], ["6 A newly identified CoV called SARS-CoV-2 (formerly entitled nCoV) appeared within the last month of 2019 in the city of Wuhan, China.", [["CoV", "ORGANISM", 21, 24], ["SARS-CoV-2", "ORGANISM", 32, 42], ["SARS-CoV", "SPECIES", 32, 40], ["CoV", "TEST", 37, 40], ["CoV", "OBSERVATION", 21, 24]]], ["11 Very early findings suggested that the virus passed from a specific animal species to humans.", [["humans", "ORGANISM", 89, 95], ["humans", "SPECIES", 89, 95], ["humans", "SPECIES", 89, 95], ["the virus", "PROBLEM", 38, 47], ["virus", "OBSERVATION", 42, 47]]], ["However, some studies then revealed that SARS-CoV-2 could also be passed from person to person, leading to serious respiratory diseases such as acute respiratory distress syndrome similar to that seen in the SARS-CoV infection.", [["respiratory", "ANATOMY", 115, 126], ["respiratory", "ANATOMY", 150, 161], ["SARS", "DISEASE", 41, 45], ["respiratory diseases", "DISEASE", 115, 135], ["acute respiratory distress syndrome", "DISEASE", 144, 179], ["SARS-CoV infection", "DISEASE", 208, 226], ["SARS-CoV-2", "ORGANISM", 41, 51], ["SARS-CoV", "ORGANISM", 208, 216], ["person", "SPECIES", 78, 84], ["person", "SPECIES", 88, 94], ["SARS-CoV", "SPECIES", 41, 49], ["SARS-CoV", "SPECIES", 208, 216], ["some studies", "TEST", 9, 21], ["SARS", "PROBLEM", 41, 45], ["serious respiratory diseases", "PROBLEM", 107, 135], ["acute respiratory distress syndrome", "PROBLEM", 144, 179], ["the SARS", "PROBLEM", 204, 212], ["CoV infection", "PROBLEM", 213, 226], ["serious", "OBSERVATION_MODIFIER", 107, 114], ["respiratory diseases", "OBSERVATION", 115, 135], ["acute", "OBSERVATION_MODIFIER", 144, 149], ["respiratory distress", "OBSERVATION", 150, 170], ["CoV", "OBSERVATION_MODIFIER", 213, 216], ["infection", "OBSERVATION", 217, 226]]], ["12, 13 SARS-CoV-2 is an enveloped, singlestranded, positive-sense RNA (beta-) CoV.", [["enveloped, singlestranded, positive-sense RNA (beta-) CoV.", "DNA", 24, 82], ["CoV", "TEST", 12, 15]]], ["The same as SARS-CoV and MERS-CoV, the SARS-CoV-2 genome can encode structural proteins such as the spike glycoprotein, non-structural proteins, and accessory proteins.", [["SARS-CoV", "ORGANISM", 12, 20], ["MERS-CoV", "ORGANISM", 25, 33], ["SARS-CoV-2", "ORGANISM", 39, 49], ["SARS-CoV and MERS-CoV", "DNA", 12, 33], ["SARS-CoV-2 genome", "DNA", 39, 56], ["structural proteins", "PROTEIN", 68, 87], ["spike glycoprotein", "PROTEIN", 100, 118], ["non-structural proteins", "PROTEIN", 120, 143], ["accessory proteins", "PROTEIN", 149, 167], ["SARS-CoV", "SPECIES", 12, 20], ["MERS-CoV", "SPECIES", 25, 33], ["SARS-CoV", "SPECIES", 39, 47], ["SARS", "TEST", 12, 16], ["the SARS", "TEST", 35, 43], ["structural proteins", "PROBLEM", 68, 87], ["the spike glycoprotein", "TEST", 96, 118], ["non-structural proteins", "TEST", 120, 143], ["accessory proteins", "PROBLEM", 149, 167]]], ["The spike glycoprotein, in which this virus has encoding functions, plays an important role in the interactions of the virus and the cell receptor during viral entry.", [["cell", "ANATOMY", 133, 137], ["cell", "CELL", 133, 137], ["spike glycoprotein", "PROTEIN", 4, 22], ["The spike glycoprotein", "PROBLEM", 0, 22], ["this virus", "PROBLEM", 33, 43], ["the virus", "TREATMENT", 115, 124], ["the cell receptor", "TREATMENT", 129, 146], ["spike glycoprotein", "OBSERVATION_MODIFIER", 4, 22]]], ["6 More specifically, a spike protein that is associated with the envelope of SARS-CoV-2 binds first to the host receptor and then mediates the entry of the CoV into the host cells by fusing viral and host membranes.", [["cells", "ANATOMY", 174, 179], ["membranes", "ANATOMY", 205, 214], ["SARS", "DISEASE", 77, 81], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 77, 87], ["CoV", "GENE_OR_GENE_PRODUCT", 156, 159], ["cells", "CELL", 174, 179], ["host membranes", "CELLULAR_COMPONENT", 200, 214], ["spike protein", "PROTEIN", 23, 36], ["host cells", "CELL_TYPE", 169, 179], ["SARS-CoV", "SPECIES", 77, 85], ["a spike protein", "PROBLEM", 21, 36], ["fusing viral and host membranes", "PROBLEM", 183, 214], ["host cells", "OBSERVATION", 169, 179], ["host membranes", "OBSERVATION", 200, 214]]], ["[14] [15] [16] Once the fusion has taken place, the RNA virus begins to replicate its genome in the cell and makes new virions that will be secreted to infect other cells.", [["cell", "ANATOMY", 100, 104], ["virions", "ANATOMY", 119, 126], ["cells", "ANATOMY", 165, 170], ["[14] [15] [16", "SIMPLE_CHEMICAL", 0, 13], ["cell", "CELL", 100, 104], ["cells", "CELL", 165, 170], ["the fusion", "TREATMENT", 20, 30], ["the RNA virus", "PROBLEM", 48, 61], ["new virions", "PROBLEM", 115, 126], ["cell", "ANATOMY", 100, 104]]], ["[17] [18] [19] There is a clear pathobiological association between CoV and the renin-angiotensin system (RAS).", [["angiotensin", "CHEMICAL", 86, 97], ["CoV", "GENE_OR_GENE_PRODUCT", 68, 71], ["renin-angiotensin system", "GENE_OR_GENE_PRODUCT", 80, 104], ["RAS", "GENE_OR_GENE_PRODUCT", 106, 109], ["renin", "PROTEIN", 80, 85], ["CoV", "TEST", 68, 71], ["the renin", "TEST", 76, 85]]], ["SARS-CoV (a member of the CoV family that emerged in 2002), which is very similar to SARS-CoV-2, and angiotensin converting enzyme 2 (ACE2) interactions have been extensively studied.", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 85, 89], ["angiotensin", "CHEMICAL", 101, 112], ["SARS-CoV", "ORGANISM", 0, 8], ["CoV", "ORGANISM", 26, 29], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 85, 95], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 101, 132], ["ACE2", "GENE_OR_GENE_PRODUCT", 134, 138], ["CoV family", "PROTEIN", 26, 36], ["angiotensin converting enzyme 2", "PROTEIN", 101, 132], ["ACE2", "PROTEIN", 134, 138], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 85, 93], ["CoV", "TEST", 90, 93], ["angiotensin converting enzyme", "TEST", 101, 130]]], ["13, 16 There is a fundamental atomic interaction between the spike protein receptor binding domain of the virus and the host receptor of ACE2.", [["ACE2", "GENE_OR_GENE_PRODUCT", 137, 141], ["spike protein receptor binding domain", "PROTEIN", 61, 98], ["ACE2", "PROTEIN", 137, 141], ["a fundamental atomic interaction", "PROBLEM", 16, 48], ["the virus", "TREATMENT", 102, 111], ["fundamental", "OBSERVATION_MODIFIER", 18, 29], ["atomic interaction", "OBSERVATION", 30, 48]]], ["SARS-CoV infections lead to ACE2 down-regulation by the binding of the SARS-CoV spike protein to ACE2.", [["SARS", "DISEASE", 0, 4], ["infections", "DISEASE", 9, 19], ["SARS-CoV", "ORGANISM", 0, 8], ["ACE2", "GENE_OR_GENE_PRODUCT", 28, 32], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 71, 79], ["ACE2", "GENE_OR_GENE_PRODUCT", 97, 101], ["ACE2", "PROTEIN", 28, 32], ["SARS-CoV spike protein", "PROTEIN", 71, 93], ["ACE2", "PROTEIN", 97, 101], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 71, 79], ["SARS", "PROBLEM", 0, 4], ["CoV infections", "PROBLEM", 5, 19], ["ACE2", "TEST", 28, 32], ["the SARS", "PROBLEM", 67, 75], ["CoV spike protein", "PROBLEM", 76, 93], ["ACE2", "TEST", 97, 101], ["CoV", "OBSERVATION_MODIFIER", 5, 8], ["infections", "OBSERVATION", 9, 19]]], ["20 Thus, the SARS-CoV family, including SARS-CoV-2, utilizes ACE2 as a critical receptor to enter target host cells.", [["cells", "ANATOMY", 110, 115], ["SARS", "DISEASE", 13, 17], ["SARS-CoV", "ORGANISM", 13, 21], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 40, 50], ["ACE2", "GENE_OR_GENE_PRODUCT", 61, 65], ["host cells", "CELL", 105, 115], ["SARS-CoV family", "PROTEIN", 13, 28], ["ACE2", "PROTEIN", 61, 65], ["target host cells", "CELL_TYPE", 98, 115], ["SARS-CoV", "SPECIES", 13, 21], ["SARS-CoV", "SPECIES", 40, 48], ["ACE2", "TREATMENT", 61, 65], ["a critical receptor", "TREATMENT", 69, 88], ["host cells", "OBSERVATION", 105, 115]]], ["13, 16 The main task of ACE2 is to hydrolyze angiotensin II (Ang II) to form angiotensin (1-7) (Ang-(1-7)) that binds to the G-coupled protein receptor MAS to antagonize Ang II-mediated cellular effects.", [["cellular", "ANATOMY", 186, 194], ["angiotensin II", "CHEMICAL", 45, 59], ["Ang II", "CHEMICAL", 61, 67], ["angiotensin (1-7)", "CHEMICAL", 77, 94], ["Ang-(1-7)", "CHEMICAL", 96, 105], ["Ang II", "CHEMICAL", 170, 176], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 45, 59], ["Ang II", "GENE_OR_GENE_PRODUCT", 61, 67], ["angiotensin (1-7", "GENE_OR_GENE_PRODUCT", 77, 93], ["Ang-(1-7)", "SIMPLE_CHEMICAL", 96, 105], ["G-coupled protein receptor MAS", "GENE_OR_GENE_PRODUCT", 125, 155], ["Ang II", "GENE_OR_GENE_PRODUCT", 170, 176], ["cellular", "CELL", 186, 194], ["ACE2", "PROTEIN", 24, 28], ["Ang II", "PROTEIN", 61, 67], ["G-coupled protein receptor", "PROTEIN", 125, 151], ["Ang II", "PROTEIN", 170, 176], ["hydrolyze angiotensin II (Ang II)", "TREATMENT", 35, 68], ["angiotensin", "TEST", 77, 88], ["Ang", "TEST", 96, 99], ["the G-coupled protein receptor MAS", "TREATMENT", 121, 155], ["Ang II-mediated cellular effects", "PROBLEM", 170, 202], ["main", "OBSERVATION_MODIFIER", 11, 15], ["cellular effects", "OBSERVATION", 186, 202]]], ["This function is very important since the increased Ang II levels are estimated to cause increased ACE2 activity.", [["Ang II", "CHEMICAL", 52, 58], ["Ang II", "GENE_OR_GENE_PRODUCT", 52, 58], ["ACE2", "GENE_OR_GENE_PRODUCT", 99, 103], ["Ang II", "PROTEIN", 52, 58], ["ACE2", "PROTEIN", 99, 103], ["the increased Ang II levels", "PROBLEM", 38, 65], ["increased ACE2 activity", "PROBLEM", 89, 112], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["ACE2 activity", "OBSERVATION", 99, 112]]], ["ACE2 is one of the central RAS enzymes that regulate blood pressure, fluid/electrolyte balance, and systemic vascular resistance in the tissue RAS.", [["blood", "ANATOMY", 53, 58], ["fluid", "ANATOMY", 69, 74], ["vascular", "ANATOMY", 109, 117], ["tissue", "ANATOMY", 136, 142], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["RAS", "GENE_OR_GENE_PRODUCT", 27, 30], ["blood", "ORGANISM_SUBSTANCE", 53, 58], ["fluid", "ORGANISM_SUBSTANCE", 69, 74], ["vascular", "MULTI-TISSUE_STRUCTURE", 109, 117], ["tissue", "TISSUE", 136, 142], ["RAS", "GENE_OR_GENE_PRODUCT", 143, 146], ["ACE2", "PROTEIN", 0, 4], ["central RAS enzymes", "PROTEIN", 19, 38], ["the central RAS enzymes", "TEST", 15, 38], ["blood pressure", "TEST", 53, 67], ["fluid/electrolyte balance", "TEST", 69, 94], ["systemic vascular resistance in the tissue RAS", "PROBLEM", 100, 146], ["electrolyte balance", "OBSERVATION", 75, 94], ["systemic", "ANATOMY_MODIFIER", 100, 108], ["vascular", "ANATOMY", 109, 117], ["resistance", "OBSERVATION", 118, 128], ["tissue", "ANATOMY", 136, 142]]], ["ACE2 is also critical for the RAS, which functions for the regulation of cell growth/proliferation, inflammation/cytokine production, blood pressure, and as a homeostatic regulator of vascular function.", [["cell", "ANATOMY", 73, 77], ["blood", "ANATOMY", 134, 139], ["vascular", "ANATOMY", 184, 192], ["inflammation", "DISEASE", 100, 112], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["RAS", "GENE_OR_GENE_PRODUCT", 30, 33], ["cell", "CELL", 73, 77], ["blood", "ORGANISM_SUBSTANCE", 134, 139], ["vascular", "MULTI-TISSUE_STRUCTURE", 184, 192], ["ACE2", "PROTEIN", 0, 4], ["RAS", "PROTEIN", 30, 33], ["cytokine", "PROTEIN", 113, 121], ["the RAS", "PROBLEM", 26, 33], ["cell growth", "PROBLEM", 73, 84], ["proliferation", "PROBLEM", 85, 98], ["inflammation", "PROBLEM", 100, 112], ["cytokine production", "PROBLEM", 113, 132], ["blood pressure", "TEST", 134, 148], ["vascular", "ANATOMY", 184, 192]]], ["The RAS is highly active within the lungs where SARS-CoV-2 is estimated to be the primary target organ.", [["lungs", "ANATOMY", 36, 41], ["organ", "ANATOMY", 97, 102], ["RAS", "GENE_OR_GENE_PRODUCT", 4, 7], ["lungs", "ORGAN", 36, 41], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 48, 58], ["organ", "ORGAN", 97, 102], ["RAS", "PROTEIN", 4, 7], ["SARS", "TEST", 48, 52], ["CoV", "TEST", 53, 56], ["RAS", "OBSERVATION", 4, 7], ["highly", "OBSERVATION_MODIFIER", 11, 17], ["active", "OBSERVATION_MODIFIER", 18, 24], ["lungs", "ANATOMY", 36, 41]]], ["Ang II can cause pulmonary vasoconstriction in response to hypoxia, which is important in patients with pneumonia or lung injury.", [["pulmonary", "ANATOMY", 17, 26], ["lung", "ANATOMY", 117, 121], ["Ang II", "CHEMICAL", 0, 6], ["hypoxia", "DISEASE", 59, 66], ["pneumonia", "DISEASE", 104, 113], ["lung injury", "DISEASE", 117, 128], ["Ang II", "GENE_OR_GENE_PRODUCT", 0, 6], ["pulmonary", "ORGAN", 17, 26], ["patients", "ORGANISM", 90, 98], ["lung", "ORGAN", 117, 121], ["Ang II", "PROTEIN", 0, 6], ["patients", "SPECIES", 90, 98], ["pulmonary vasoconstriction", "PROBLEM", 17, 43], ["hypoxia", "PROBLEM", 59, 66], ["pneumonia", "PROBLEM", 104, 113], ["lung injury", "PROBLEM", 117, 128], ["pulmonary", "ANATOMY", 17, 26], ["vasoconstriction", "OBSERVATION", 27, 43], ["hypoxia", "OBSERVATION", 59, 66], ["pneumonia", "OBSERVATION", 104, 113], ["lung", "ANATOMY", 117, 121], ["injury", "OBSERVATION", 122, 128]]], ["Locally increased Ang II production increases vascular permeability, which facilitates pulmonary edema.", [["vascular", "ANATOMY", 46, 54], ["pulmonary", "ANATOMY", 87, 96], ["Ang II", "CHEMICAL", 18, 24], ["pulmonary edema", "DISEASE", 87, 102], ["Ang II", "GENE_OR_GENE_PRODUCT", 18, 24], ["vascular", "MULTI-TISSUE_STRUCTURE", 46, 54], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 87, 102], ["Ang II", "PROTEIN", 18, 24], ["Locally increased Ang II production", "PROBLEM", 0, 35], ["vascular permeability", "PROBLEM", 46, 67], ["pulmonary edema", "PROBLEM", 87, 102], ["increased", "OBSERVATION_MODIFIER", 8, 17], ["Ang", "OBSERVATION", 18, 21], ["II", "OBSERVATION_MODIFIER", 22, 24], ["production", "OBSERVATION_MODIFIER", 25, 35], ["increases", "OBSERVATION_MODIFIER", 36, 45], ["vascular", "ANATOMY", 46, 54], ["permeability", "OBSERVATION_MODIFIER", 55, 67], ["pulmonary", "ANATOMY", 87, 96], ["edema", "OBSERVATION", 97, 102]]], ["ACE2, which plays a role in regulating the Ang II as well as Ang-(1-7) levels, may be important for those pathobiological lung events.", [["lung", "ANATOMY", 122, 126], ["Ang II", "CHEMICAL", 43, 49], ["Ang-(1-7)", "CHEMICAL", 61, 70], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ang II", "GENE_OR_GENE_PRODUCT", 43, 49], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 61, 69], ["lung", "ORGAN", 122, 126], ["ACE2", "PROTEIN", 0, 4], ["Ang II", "PROTEIN", 43, 49], ["ACE2", "TREATMENT", 0, 4], ["the Ang II", "TREATMENT", 39, 49], ["those pathobiological lung events", "PROBLEM", 100, 133], ["lung", "ANATOMY", 122, 126]]], ["13, 21, 22 ACE2 is an important negative directing factor for the severity of lung injury, and SARS-CoV spike protein-associated ACE2 inhibition has been shown to contribute to the severity of lung pathologies.", [["lung", "ANATOMY", 78, 82], ["lung", "ANATOMY", 193, 197], ["lung injury", "DISEASE", 78, 89], ["SARS", "DISEASE", 95, 99], ["lung pathologies", "DISEASE", 193, 209], ["ACE2", "GENE_OR_GENE_PRODUCT", 11, 15], ["lung", "ORGAN", 78, 82], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 95, 103], ["ACE2", "GENE_OR_GENE_PRODUCT", 129, 133], ["lung", "ORGAN", 193, 197], ["13, 21, 22 ACE2", "PROTEIN", 0, 15], ["SARS-CoV spike protein", "PROTEIN", 95, 117], ["ACE2", "PROTEIN", 129, 133], ["SARS-CoV", "SPECIES", 95, 103], ["lung injury", "PROBLEM", 78, 89], ["SARS", "TEST", 95, 99], ["CoV spike protein", "TEST", 100, 117], ["ACE2 inhibition", "PROBLEM", 129, 144], ["lung pathologies", "PROBLEM", 193, 209], ["lung", "ANATOMY", 78, 82], ["injury", "OBSERVATION", 83, 89], ["lung", "ANATOMY", 193, 197], ["pathologies", "OBSERVATION", 198, 209]]], ["20 In addition, numerous genes are involved within the interactions of ACE2, the RAS, and the pulmonary microenvironment.IntroductionThe activation of the local pulmonary RAS can affect the genesis of lung damage through multiple mechanisms, such as increments in vascular permeability and alterations in alveolar epithelial cells.", [["pulmonary", "ANATOMY", 94, 103], ["pulmonary", "ANATOMY", 161, 170], ["lung", "ANATOMY", 201, 205], ["vascular", "ANATOMY", 264, 272], ["alveolar epithelial cells", "ANATOMY", 305, 330], ["lung damage", "DISEASE", 201, 212], ["ACE2", "GENE_OR_GENE_PRODUCT", 71, 75], ["RAS", "GENE_OR_GENE_PRODUCT", 81, 84], ["pulmonary", "ORGAN", 94, 103], ["pulmonary", "ORGAN", 161, 170], ["RAS", "GENE_OR_GENE_PRODUCT", 171, 174], ["lung", "ORGAN", 201, 205], ["vascular", "MULTI-TISSUE_STRUCTURE", 264, 272], ["alveolar epithelial cells", "CELL", 305, 330], ["ACE2", "PROTEIN", 71, 75], ["RAS", "PROTEIN", 81, 84], ["pulmonary RAS", "PROTEIN", 161, 174], ["alveolar epithelial cells", "CELL_TYPE", 305, 330], ["the local pulmonary RAS", "TREATMENT", 151, 174], ["lung damage", "PROBLEM", 201, 212], ["vascular permeability", "TEST", 264, 285], ["alterations in alveolar epithelial cells", "PROBLEM", 290, 330], ["pulmonary", "ANATOMY", 94, 103], ["pulmonary", "ANATOMY", 161, 170], ["lung", "ANATOMY", 201, 205], ["damage", "OBSERVATION", 206, 212], ["multiple", "OBSERVATION_MODIFIER", 221, 229], ["vascular", "ANATOMY", 264, 272], ["permeability", "OBSERVATION", 273, 285], ["alveolar epithelial cells", "OBSERVATION", 305, 330]]], ["The pathogenesis of the CoV is a rather complicated process, which may also include local tissue RAS.", [["tissue", "ANATOMY", 90, 96], ["CoV", "ORGANISM", 24, 27], ["tissue", "TISSUE", 90, 96], ["RAS", "GENE_OR_GENE_PRODUCT", 97, 100], ["RAS", "PROTEIN", 97, 100], ["the CoV", "PROBLEM", 20, 27], ["local tissue RAS", "PROBLEM", 84, 100], ["CoV", "OBSERVATION", 24, 27], ["complicated", "OBSERVATION_MODIFIER", 40, 51], ["process", "OBSERVATION", 52, 59], ["may also include", "UNCERTAINTY", 67, 83], ["local tissue", "OBSERVATION", 84, 96]]], ["13, 21 The main purpose of this present in silico genomic study was to assess how the expressions of the RAS gene family changes after cellular infection with SARS-CoV in the lung epithelial cell culture.", [["cellular", "ANATOMY", 135, 143], ["lung epithelial cell culture", "ANATOMY", 175, 203], ["infection", "DISEASE", 144, 153], ["RAS", "GENE_OR_GENE_PRODUCT", 105, 108], ["cellular", "CELL", 135, 143], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 159, 167], ["lung epithelial cell culture", "CELL", 175, 203], ["RAS gene family", "DNA", 105, 120], ["lung epithelial cell culture", "CELL_LINE", 175, 203], ["SARS-CoV", "SPECIES", 159, 167], ["silico genomic study", "TEST", 43, 63], ["cellular infection", "PROBLEM", 135, 153], ["SARS", "PROBLEM", 159, 163], ["CoV in the lung epithelial cell culture", "TEST", 164, 203], ["main", "OBSERVATION_MODIFIER", 11, 15], ["infection", "OBSERVATION", 144, 153], ["lung", "ANATOMY", 175, 179], ["epithelial cell", "OBSERVATION", 180, 195]]], ["We hypothesized that CoV could affect pulmonary tissues via integration with the critical immune genes of the affected cellular microenvironment after their interaction with RAS elements.", [["pulmonary tissues", "ANATOMY", 38, 55], ["cellular", "ANATOMY", 119, 127], ["CoV", "ORGANISM", 21, 24], ["pulmonary tissues", "TISSUE", 38, 55], ["cellular", "CELL", 119, 127], ["RAS", "GENE_OR_GENE_PRODUCT", 174, 177], ["immune genes", "DNA", 90, 102], ["RAS elements", "DNA", 174, 186], ["CoV", "PROBLEM", 21, 24], ["pulmonary tissues", "PROBLEM", 38, 55], ["CoV", "OBSERVATION", 21, 24], ["pulmonary tissues", "ANATOMY", 38, 55]]], ["We also aimed to figure out whether these genomic alterations are related to the exposure time of the virus.", [["these genomic alterations", "PROBLEM", 36, 61], ["the virus", "PROBLEM", 98, 107]]], ["In order to understand the pathobiology of SARS-CoV and SARS-CoV-2 infection better, since they share similarities within many aspects we examined the gene expression changes of other gene families as well.", [["SARS", "DISEASE", 43, 47], ["SARS-CoV-2 infection", "DISEASE", 56, 76], ["SARS-CoV", "ORGANISM", 43, 51], ["SARS-CoV-2", "ORGANISM", 56, 66], ["SARS-CoV", "SPECIES", 43, 51], ["SARS-CoV-2", "SPECIES", 56, 66], ["SARS", "PROBLEM", 43, 47], ["CoV", "PROBLEM", 48, 51], ["SARS", "PROBLEM", 56, 60], ["infection", "PROBLEM", 67, 76]]], ["Elucidation of the interactions between SARS-CoV-2 and RAS genes and the description of the related genomic mechanisms are very important in the fight against this fatal viral global infection.Obtaining and normalizing whole-genome expression data of human bronchial epithelial cells infected with SARS-CoVGene expression data of human bronchial epithelial cells treated with SARS-CoV for 12, 24, and 48 hours were obtained from Array Express (GSE17400).", [["bronchial epithelial cells", "ANATOMY", 257, 283], ["bronchial epithelial cells", "ANATOMY", 336, 362], ["viral global infection", "DISEASE", 170, 192], ["GSE17400", "CHEMICAL", 444, 452], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 40, 50], ["RAS", "GENE_OR_GENE_PRODUCT", 55, 58], ["human", "ORGANISM", 251, 256], ["bronchial epithelial cells", "CELL", 257, 283], ["SARS-CoVGene", "GENE_OR_GENE_PRODUCT", 298, 310], ["human", "ORGANISM", 330, 335], ["bronchial epithelial cells", "CELL", 336, 362], ["SARS-CoV", "ORGANISM", 376, 384], ["SARS-CoV-2 and RAS genes", "DNA", 40, 64], ["human bronchial epithelial cells", "CELL_TYPE", 251, 283], ["human bronchial epithelial cells", "CELL_TYPE", 330, 362], ["human", "SPECIES", 251, 256], ["human", "SPECIES", 330, 335], ["human", "SPECIES", 251, 256], ["human", "SPECIES", 330, 335], ["SARS-CoV", "SPECIES", 376, 384], ["SARS", "TEST", 40, 44], ["CoV", "TEST", 45, 48], ["this fatal viral global infection", "PROBLEM", 159, 192], ["human bronchial epithelial cells", "PROBLEM", 251, 283], ["SARS", "PROBLEM", 298, 302], ["human bronchial epithelial cells", "PROBLEM", 330, 362], ["infection", "OBSERVATION", 183, 192], ["bronchial", "ANATOMY", 257, 266], ["epithelial cells", "OBSERVATION", 267, 283], ["bronchial", "ANATOMY", 336, 345], ["epithelial cells", "OBSERVATION", 346, 362]]], ["23 These data were generated by Yoshikawa et al. to characterize the dynamic, spatial, and temporal changes of the gene expression induced by SARS-CoV using microarray technology.Obtaining and normalizing whole-genome expression data of human bronchial epithelial cells infected with SARS-CoVIn order to use the obtained data in other targeted analyses, the raw data were normalized by robust multisequence analysis in accordance with the procedure in the Affy package in R. These data consist of 23,344 genes (54,675 probe sets).", [["bronchial epithelial cells", "ANATOMY", 243, 269], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 142, 150], ["human", "ORGANISM", 237, 242], ["bronchial epithelial cells", "CELL", 243, 269], ["human bronchial epithelial cells", "CELL_TYPE", 237, 269], ["23,344 genes", "DNA", 497, 509], ["54,675 probe sets", "DNA", 511, 528], ["human", "SPECIES", 237, 242], ["SARS-CoV", "SPECIES", 142, 150], ["human", "SPECIES", 237, 242], ["These data", "TEST", 3, 13], ["microarray technology", "TREATMENT", 157, 178], ["human bronchial epithelial cells", "PROBLEM", 237, 269], ["robust multisequence analysis", "TEST", 386, 415], ["the procedure", "TREATMENT", 435, 448], ["bronchial", "ANATOMY", 243, 252], ["epithelial cells", "OBSERVATION", 253, 269]]], ["In addition, each gene has three repeated expression data values for 12, 24, and 48 hours, respectively.Comparison of RAS gene transcripts in 12-, 24-and 48-hour SARS-CoV-infected groupsThe whole normalized gene expression data of lung epithelial cells infected with SARS-CoV for 12, 24, and 48 hours were compared between different groups in order to determine significantly and differentially expressed RAS family genes.", [["lung epithelial cells", "ANATOMY", 231, 252], ["SARS-CoV-infected", "DISEASE", 162, 179], ["RAS", "GENE_OR_GENE_PRODUCT", 118, 121], ["SARS-CoV", "ORGANISM", 162, 170], ["lung epithelial cells", "CELL", 231, 252], ["SARS-CoV", "ORGANISM", 267, 275], ["RAS", "GENE_OR_GENE_PRODUCT", 405, 408], ["RAS gene transcripts", "RNA", 118, 138], ["lung epithelial cells", "CELL_TYPE", 231, 252], ["RAS family genes", "DNA", 405, 421], ["SARS-CoV", "SPECIES", 162, 170], ["SARS-CoV", "SPECIES", 267, 275], ["RAS gene transcripts", "TEST", 118, 138], ["lung epithelial cells", "PROBLEM", 231, 252], ["SARS-CoV", "TEST", 267, 275], ["infected", "OBSERVATION", 171, 179], ["lung", "ANATOMY", 231, 235], ["epithelial cells", "OBSERVATION", 236, 252]]], ["The mean value of RAS gene transcripts was determined for each group infected with SARS-CoV for 12, 24, and 48 hours.", [["SARS", "DISEASE", 83, 87], ["RAS", "GENE_OR_GENE_PRODUCT", 18, 21], ["SARS-CoV", "ORGANISM", 83, 91], ["RAS gene transcripts", "RNA", 18, 38], ["SARS-CoV", "SPECIES", 83, 91], ["The mean value", "TEST", 0, 14], ["RAS gene transcripts", "TREATMENT", 18, 38]]], ["The comparison was made between the 12-and 24-hour groups as well as between the 12-and 48-hour groups, based on the RAS gene transcripts. p-Values were calculated for each gene using the t-test.", [["RAS", "GENE_OR_GENE_PRODUCT", 117, 120], ["RAS gene transcripts", "RNA", 117, 137], ["p-Values", "TEST", 139, 147], ["the t-test", "TEST", 184, 194]]], ["The genes belonging to the RAS family with a statistically significant difference among the groups were determined (p\u2a7d0.05).Linear regression analysis of the genes (other than the RAS genes) with the highest variance among the groupsIn order to determine the genes whose expression is highly correlated with the exposure time to the virus, we performed linear regression analysis.", [["RAS", "GENE_OR_GENE_PRODUCT", 27, 30], ["RAS", "GENE_OR_GENE_PRODUCT", 180, 183], ["RAS family", "PROTEIN", 27, 37], ["RAS genes", "DNA", 180, 189], ["Linear regression analysis", "TEST", 124, 150], ["linear regression analysis", "TEST", 353, 379], ["regression", "OBSERVATION", 131, 141], ["genes", "OBSERVATION_MODIFIER", 158, 163]]], ["Genes with a standard deviation >0.9 were identified between the groups using Microsoft Excel (2016).", [["a standard deviation", "PROBLEM", 11, 31]]], ["Genes with a Pearson's r >0.95 were selected for use in the subsequent analyses.Hierarchical clustering, pathway analysis, and network analysisIn order to determine whether the identified genes could distinguish between the virus and infected groups, to identify the network connections between these genes and to demonstrate the pathways in which these genes were involved, we performed hierarchical clustering, pathway analysis, and network analysis.Hierarchical clustering, pathway analysis, and network analysisGenes with the highest variation and Pearson's r-value between groups were hierarchically clustered using the similarity metric parameter and the Euclidean distance Gene Cluster v3.0 program as a full link.", [["a Pearson's r", "TEST", 11, 24], ["pathway analysis", "TEST", 105, 121], ["network analysis", "TEST", 127, 143], ["the virus and infected groups", "PROBLEM", 220, 249], ["pathway analysis", "TEST", 413, 429], ["network analysis", "TEST", 435, 451], ["pathway analysis", "TEST", 477, 493], ["network analysis", "TEST", 499, 515], ["the highest variation", "PROBLEM", 526, 547]]], ["24 Using the DAVID online tool, the pathways related to the genes were determined to elaborate on the pathway data resulting from the analysis further.", [["the analysis", "TEST", 130, 142]]], ["25, 26 In addition, the GeneMANIA application in Cytoscape was used to indicate the network and pathway relationship between the selected genes and other genes.", [["GeneMANIA", "DNA", 24, 33], ["the GeneMANIA application", "TREATMENT", 20, 45]]], ["27,28ResultsAmong the three groups of human bronchial epithelial cells with different exposure times to SARS-CoV (12-, 24-and 48-hour groups), we identified the changes in expression of the RAS gene transcripts as well as the trend in expression of the most differentially expressed genes among groups other than the RAS family.ResultsA total of seven RAS signaling pathway genes (nine probe sets; alanyl aminopeptidase (ANPEP), ACE2, angiotensin converting enzyme (ACE), insulinlike growth factor 2 receptor (IGF2R), angiotensinogen (AGT), epidermal growth factor receptor (EGFR) and membrane metalloendopeptidase (MME)) showed significantly different expression values between the 12-hour group and the 24-hour group.", [["bronchial epithelial cells", "ANATOMY", 44, 70], ["membrane", "ANATOMY", 585, 593], ["SARS", "DISEASE", 104, 108], ["angiotensin", "CHEMICAL", 435, 446], ["alanyl", "CHEMICAL", 398, 404], ["human", "ORGANISM", 38, 43], ["bronchial epithelial cells", "CELL", 44, 70], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 104, 112], ["RAS", "GENE_OR_GENE_PRODUCT", 190, 193], ["RAS", "GENE_OR_GENE_PRODUCT", 317, 320], ["RAS", "GENE_OR_GENE_PRODUCT", 352, 355], ["alanyl aminopeptidase", "GENE_OR_GENE_PRODUCT", 398, 419], ["ANPEP", "GENE_OR_GENE_PRODUCT", 421, 426], ["ACE2", "GENE_OR_GENE_PRODUCT", 429, 433], ["angiotensin converting enzyme", "GENE_OR_GENE_PRODUCT", 435, 464], ["ACE", "GENE_OR_GENE_PRODUCT", 466, 469], ["insulinlike growth factor 2 receptor", "GENE_OR_GENE_PRODUCT", 472, 508], ["IGF2R", "GENE_OR_GENE_PRODUCT", 510, 515], ["angiotensinogen", "GENE_OR_GENE_PRODUCT", 518, 533], ["AGT", "GENE_OR_GENE_PRODUCT", 535, 538], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 541, 573], ["EGFR", "GENE_OR_GENE_PRODUCT", 575, 579], ["membrane metalloendopeptidase", "GENE_OR_GENE_PRODUCT", 585, 614], ["MME", "GENE_OR_GENE_PRODUCT", 616, 619], ["human bronchial epithelial cells", "CELL_TYPE", 38, 70], ["RAS gene transcripts", "RNA", 190, 210], ["RAS family", "PROTEIN", 317, 327], ["RAS signaling pathway genes", "DNA", 352, 379], ["alanyl aminopeptidase", "PROTEIN", 398, 419], ["ANPEP", "PROTEIN", 421, 426], ["ACE2", "PROTEIN", 429, 433], ["angiotensin converting enzyme", "PROTEIN", 435, 464], ["ACE", "PROTEIN", 466, 469], ["insulinlike growth factor 2 receptor", "PROTEIN", 472, 508], ["IGF2R", "PROTEIN", 510, 515], ["angiotensinogen", "PROTEIN", 518, 533], ["AGT", "PROTEIN", 535, 538], ["epidermal growth factor receptor", "PROTEIN", 541, 573], ["EGFR", "PROTEIN", 575, 579], ["membrane metalloendopeptidase", "PROTEIN", 585, 614], ["MME", "PROTEIN", 616, 619], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["SARS-CoV", "SPECIES", 104, 112], ["human bronchial epithelial cells", "PROBLEM", 38, 70], ["SARS", "TEST", 104, 108], ["CoV", "TEST", 109, 112], ["alanyl aminopeptidase (ANPEP)", "TREATMENT", 398, 427], ["ACE2", "TEST", 429, 433], ["angiotensin", "TREATMENT", 435, 446], ["enzyme", "TEST", 458, 464], ["ACE", "TEST", 466, 469], ["insulinlike growth factor", "TEST", 472, 497], ["IGF2R", "TEST", 510, 515], ["angiotensinogen (AGT)", "TEST", 518, 539], ["epidermal growth factor receptor", "TEST", 541, 573], ["EGFR", "TEST", 575, 579], ["membrane metalloendopeptidase (MME)", "TEST", 585, 620], ["significantly different expression values", "PROBLEM", 629, 670], ["bronchial", "ANATOMY", 44, 53], ["epithelial cells", "OBSERVATION", 54, 70]]], ["Comparing the 12-hour and 48-hour groups, eight genes (nine probe sets; arginyl aminopeptidase (RNPEP), epidermal growth factor receptor (EGFR), ANPEP, neurolysin (NLN), ACE2, IGF2R, leucyl and cysteinyl aminopeptidase (LNPEP) and cathepsin D (CTSD)) were statistically significantly expressed (Table 1) .", [["cysteinyl", "CHEMICAL", 194, 203], ["arginyl", "CHEMICAL", 72, 79], ["leucyl", "CHEMICAL", 183, 189], ["cysteinyl", "CHEMICAL", 194, 203], ["arginyl aminopeptidase", "GENE_OR_GENE_PRODUCT", 72, 94], ["RNPEP", "GENE_OR_GENE_PRODUCT", 96, 101], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 104, 136], ["EGFR", "GENE_OR_GENE_PRODUCT", 138, 142], ["ANPEP", "GENE_OR_GENE_PRODUCT", 145, 150], ["neurolysin", "GENE_OR_GENE_PRODUCT", 152, 162], ["NLN", "GENE_OR_GENE_PRODUCT", 164, 167], ["ACE2", "GENE_OR_GENE_PRODUCT", 170, 174], ["IGF2R", "GENE_OR_GENE_PRODUCT", 176, 181], ["leucyl", "GENE_OR_GENE_PRODUCT", 183, 189], ["cysteinyl aminopeptidase", "GENE_OR_GENE_PRODUCT", 194, 218], ["LNPEP", "GENE_OR_GENE_PRODUCT", 220, 225], ["cathepsin D", "GENE_OR_GENE_PRODUCT", 231, 242], ["CTSD", "GENE_OR_GENE_PRODUCT", 244, 248], ["arginyl aminopeptidase", "PROTEIN", 72, 94], ["RNPEP", "PROTEIN", 96, 101], ["epidermal growth factor receptor", "PROTEIN", 104, 136], ["EGFR", "PROTEIN", 138, 142], ["ANPEP", "PROTEIN", 145, 150], ["neurolysin", "PROTEIN", 152, 162], ["NLN", "PROTEIN", 164, 167], ["ACE2", "PROTEIN", 170, 174], ["IGF2R", "PROTEIN", 176, 181], ["leucyl", "PROTEIN", 183, 189], ["cysteinyl aminopeptidase", "PROTEIN", 194, 218], ["LNPEP", "PROTEIN", 220, 225], ["cathepsin D", "PROTEIN", 231, 242], ["CTSD", "PROTEIN", 244, 248], ["arginyl aminopeptidase (RNPEP)", "TREATMENT", 72, 102], ["epidermal growth factor receptor", "PROBLEM", 104, 136], ["EGFR", "TEST", 138, 142], ["ANPEP", "TREATMENT", 145, 150], ["neurolysin (NLN", "TREATMENT", 152, 167], ["ACE2", "TEST", 170, 174], ["IGF2R", "TREATMENT", 176, 181], ["leucyl", "TREATMENT", 183, 189], ["cysteinyl aminopeptidase (LNPEP)", "TREATMENT", 194, 226], ["cathepsin D (CTSD)", "TREATMENT", 231, 249]]], ["Four common genes (IGF2R, ANPEP, ACE2, and EGFR) in these two separate groups were identified (Figure 1 ).", [["IGF2R", "GENE_OR_GENE_PRODUCT", 19, 24], ["ANPEP", "GENE_OR_GENE_PRODUCT", 26, 31], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["EGFR", "GENE_OR_GENE_PRODUCT", 43, 47], ["IGF2R", "DNA", 19, 24], ["ANPEP", "DNA", 26, 31], ["ACE2", "DNA", 33, 37], ["EGFR", "DNA", 43, 47], ["ANPEP", "TEST", 26, 31], ["ACE2", "TEST", 33, 37], ["EGFR", "TEST", 43, 47], ["common genes", "ANATOMY", 5, 17]]], ["The list of the RAS family genes whose expression shows a significant difference between 12-hour vs 24-hour (A) and 12-hour vs 48-hour (B) is depicted.", [["RAS", "GENE_OR_GENE_PRODUCT", 16, 19], ["RAS family genes", "DNA", 16, 32]]], ["Seven of the RAS signaling pathway genes showed different expression values in 12-hour vs 24-hour group, while 8 of the genes found significantly expressed in the 12-hour vs 48-hour group.", [["RAS", "GENE_OR_GENE_PRODUCT", 13, 16], ["RAS signaling pathway genes", "DNA", 13, 40], ["different expression values", "PROBLEM", 48, 75], ["different", "OBSERVATION_MODIFIER", 48, 57], ["expression", "OBSERVATION_MODIFIER", 58, 68]]], ["As mentioned, these genes consistently showed statistically meaningful expression differences according to exposure time to the virus. four common members of RAS genes found in the two groups ( Figure 2 ).", [["RAS", "GENE_OR_GENE_PRODUCT", 158, 161], ["RAS genes", "DNA", 158, 167], ["RAS genes", "PROBLEM", 158, 167]]], ["In order to figure out the role of the non-RAS genes, we determined the most variant genes among these three groups.", [["RAS", "GENE_OR_GENE_PRODUCT", 43, 46], ["RAS genes", "DNA", 43, 52]]], ["The standard deviation values of 29 genes (36 probe sets) were found to be >0.9.", [["29 genes", "DNA", 33, 41], ["The standard deviation values", "TEST", 0, 29], ["probe sets", "TEST", 46, 56]]], ["Linear regression analysis revealed that all these genes had a Pearson's r >0.95 and were highly correlated with the exposure time to the virus (Table 2) .ResultsLikewise, all of these genes showed a positive correlation with exposure time to the virus.", [["Linear regression analysis", "TEST", 0, 26], ["a Pearson's r", "TEST", 61, 74]]], ["The correlation figure for each gene that was found to be highly correlated to virus infection exposure time is presented in the Supplemental Material.ResultsIn addition, as shown in Figure 3 , these genes were able to be clustered for the 12-, 24-and 48-hour groups separately.", [["infection", "DISEASE", 85, 94], ["virus infection exposure", "PROBLEM", 79, 103]]], ["Table 3 shows the pathway analysis of all the significant genes.", [["the pathway analysis", "TEST", 14, 34], ["significant genes", "OBSERVATION", 46, 63]]], ["With the aim of discovering the relationship of these genes with each other and with other genes, a network analysis was performed ( Figure 4 ).DiscussionSARS-CoV-2 was found to be mostly similar to the SARS-CoV at the amino-acid level, despite some differences.", [["SARS", "DISEASE", 203, 207], ["amino-acid", "CHEMICAL", 219, 229], ["amino-acid", "CHEMICAL", 219, 229], ["DiscussionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 144, 164], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 203, 211], ["amino-acid", "AMINO_ACID", 219, 229], ["SARS-CoV", "SPECIES", 203, 211], ["a network analysis", "TEST", 98, 116], ["DiscussionSARS", "TEST", 144, 158], ["CoV", "TEST", 159, 162], ["the SARS", "TEST", 199, 207], ["the amino-acid level", "TEST", 215, 235]]], ["Based on the phylogenetic analysis on all genomes of various viruses, SARS-CoV-2 is in the same beta-CoV clone as SARS-CoV, SARS-like bat CoV, and MERS-CoV.", [["SARS", "DISEASE", 70, 74], ["SARS-CoV-2", "ORGANISM", 70, 80], ["beta-CoV", "GENE_OR_GENE_PRODUCT", 96, 104], ["SARS-CoV", "ORGANISM", 114, 122], ["SARS-like bat CoV", "ORGANISM", 124, 141], ["MERS-CoV", "ORGANISM", 147, 155], ["SARS-CoV-2", "DNA", 70, 80], ["beta-CoV clone", "DNA", 96, 110], ["SARS-CoV", "SPECIES", 70, 78], ["SARS-CoV", "SPECIES", 114, 122], ["bat CoV", "SPECIES", 134, 141], ["MERS-CoV", "SPECIES", 147, 155], ["the phylogenetic analysis", "TEST", 9, 34], ["various viruses", "PROBLEM", 53, 68], ["SARS", "TEST", 70, 74], ["CoV", "TEST", 75, 78], ["SARS", "TEST", 114, 118], ["CoV", "TEST", 119, 122], ["SARS", "TEST", 124, 128], ["bat CoV", "TEST", 134, 141], ["viruses", "OBSERVATION", 61, 68]]], ["SARS-CoV-2 has the highest similarity with SARS-like bat CoV and is less associated with MERS-CoV.", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 43, 47], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-like bat CoV", "ORGANISM", 43, 60], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 89, 97], ["SARS-CoV", "SPECIES", 0, 8], ["bat CoV", "SPECIES", 53, 60], ["MERS-CoV", "SPECIES", 89, 97], ["SARS", "PROBLEM", 43, 47], ["bat CoV", "PROBLEM", 53, 60], ["SARS", "OBSERVATION", 43, 47]]], ["29 The mechanism of SARS-CoV and its association with the renin-angiotensin pathway had been defined in previous studies.", [["SARS", "DISEASE", 20, 24], ["angiotensin", "CHEMICAL", 64, 75], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 20, 28], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 58, 75], ["renin", "PROTEIN", 58, 63], ["SARS-CoV", "SPECIES", 20, 28], ["SARS", "PROBLEM", 20, 24], ["CoV", "PROBLEM", 25, 28], ["the renin-angiotensin pathway", "TREATMENT", 54, 83], ["previous studies", "TEST", 104, 120], ["SARS", "OBSERVATION", 20, 24]]], ["The first genetic proof of the ACE2 and SARS-CoV receptor relationship was reported by Kuba et al. 20 Our results showed that in lung epithelial cells, ACE2 gene expression increased between 12 and 24 hours and remained at the same level between 24 .", [["lung epithelial cells", "ANATOMY", 129, 150], ["ACE2", "GENE_OR_GENE_PRODUCT", 31, 35], ["SARS-CoV receptor", "GENE_OR_GENE_PRODUCT", 40, 57], ["lung epithelial cells", "CELL", 129, 150], ["ACE2", "GENE_OR_GENE_PRODUCT", 152, 156], ["ACE2", "PROTEIN", 31, 35], ["SARS-CoV receptor", "PROTEIN", 40, 57], ["lung epithelial cells", "CELL_TYPE", 129, 150], ["ACE2", "PROTEIN", 152, 156], ["the ACE2", "TEST", 27, 35], ["lung epithelial cells", "PROBLEM", 129, 150], ["ACE2 gene expression", "TEST", 152, 172], ["lung", "ANATOMY", 129, 133], ["epithelial cells", "OBSERVATION", 134, 150], ["expression", "OBSERVATION_MODIFIER", 162, 172], ["increased", "OBSERVATION_MODIFIER", 173, 182]]], ["Hierarchical cluster of most variant genes between three groups.", [["cluster", "OBSERVATION_MODIFIER", 13, 20], ["most variant", "OBSERVATION_MODIFIER", 24, 36], ["genes", "OBSERVATION", 37, 42]]], ["In the 12-hour group, these genes show low expression, while in the 48-hour group, they all show high expression.", [["low expression", "OBSERVATION_MODIFIER", 39, 53], ["high expression", "OBSERVATION", 97, 112]]], ["Pathways related to non-RAS differentially expressed genes.", [["RAS", "GENE_OR_GENE_PRODUCT", 24, 27], ["RAS differentially expressed genes", "DNA", 24, 58]]], ["Most of non-RAS differentially expressed genes were found to be related immune the system and pathways which could be involved during the course of the viral infectious disease.DiscussionOAS2 2\u2032-5\u2032-oligoadenylate synthetase 2 (OAS2) Related genes Homo sapiens KEGG_PATHWAY hepatitis C, measles, influenza A, herpes simplex infection CXCL10 C-X-C motif chemokine ligand 10 (CXCL10) Related genes Homo sapiens KEGG_PATHWAY cytokine-cytokine receptor interaction, chemokine signaling pathway, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, cytosolic DNA-sensing pathway, TNF signaling pathway, influenza A CXCL11 C-X-C motif chemokine ligand 11 ACE2 protein level in the lungs of SARS-CoV-infected mice on day 2.", [["cytosolic", "ANATOMY", 567, 576], ["lungs", "ANATOMY", 698, 703], ["viral infectious disease", "DISEASE", 152, 176], ["DiscussionOAS2 2\u2032-5\u2032-oligoadenylate", "CHEMICAL", 177, 212], ["hepatitis C", "DISEASE", 273, 284], ["measles", "DISEASE", 286, 293], ["influenza A", "DISEASE", 295, 306], ["herpes simplex infection", "DISEASE", 308, 332], ["SARS-CoV-infected", "DISEASE", 707, 724], ["DiscussionOAS2 2\u2032-5\u2032-oligoadenylate", "CHEMICAL", 177, 212], ["RAS", "GENE_OR_GENE_PRODUCT", 12, 15], ["2\u2032-5\u2032-oligoadenylate synthetase 2", "GENE_OR_GENE_PRODUCT", 192, 225], ["OAS2", "GENE_OR_GENE_PRODUCT", 227, 231], ["Homo sapiens", "ORGANISM", 247, 259], ["KEGG_PATHWAY hepatitis C", "ORGANISM", 260, 284], ["measles", "ORGANISM", 286, 293], ["influenza A", "ORGANISM", 295, 306], ["herpes simplex", "ORGANISM", 308, 322], ["CXCL10 C-X-C motif chemokine ligand 10", "GENE_OR_GENE_PRODUCT", 333, 371], ["CXCL10", "GENE_OR_GENE_PRODUCT", 373, 379], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 490, 508], ["RIG-I-like receptor", "GENE_OR_GENE_PRODUCT", 528, 547], ["DNA", "CELLULAR_COMPONENT", 577, 580], ["TNF", "GENE_OR_GENE_PRODUCT", 598, 601], ["C-X-C motif chemokine ligand 11 ACE2", "GENE_OR_GENE_PRODUCT", 640, 676], ["lungs", "ORGAN", 698, 703], ["SARS-CoV", "ORGANISM", 707, 715], ["mice", "ORGANISM", 725, 729], ["RAS differentially expressed genes", "DNA", 12, 46], ["DiscussionOAS2 2\u2032-5\u2032-oligoadenylate synthetase 2 (OAS2) Related genes", "DNA", 177, 246], ["herpes simplex infection CXCL10 C-X-C motif chemokine ligand 10", "DNA", 308, 371], ["CXCL10", "PROTEIN", 373, 379], ["cytokine", "PROTEIN", 421, 429], ["cytokine receptor", "PROTEIN", 430, 447], ["chemokine", "PROTEIN", 461, 470], ["TNF", "PROTEIN", 598, 601], ["CXCL11", "PROTEIN", 633, 639], ["ACE2", "PROTEIN", 672, 676], ["Homo sapiens", "SPECIES", 247, 259], ["herpes simplex", "SPECIES", 308, 322], ["Homo sapiens", "SPECIES", 395, 407], ["mice", "SPECIES", 725, 729], ["Homo sapiens", "SPECIES", 247, 259], ["Homo sapiens", "SPECIES", 395, 407], ["SARS-CoV", "SPECIES", 707, 715], ["mice", "SPECIES", 725, 729], ["the viral infectious disease", "PROBLEM", 148, 176], ["DiscussionOAS2", "TEST", 177, 191], ["oligoadenylate synthetase", "TREATMENT", 198, 223], ["Homo sapiens", "TEST", 247, 259], ["hepatitis C", "PROBLEM", 273, 284], ["measles", "PROBLEM", 286, 293], ["influenza A", "PROBLEM", 295, 306], ["herpes simplex infection", "PROBLEM", 308, 332], ["CXCL10 C", "TEST", 333, 341], ["C motif chemokine ligand", "TREATMENT", 344, 368], ["CXCL10)", "TREATMENT", 373, 380], ["Homo sapiens", "TREATMENT", 395, 407], ["cytokine-cytokine receptor interaction", "TREATMENT", 421, 459], ["chemokine signaling pathway", "TREATMENT", 461, 488], ["receptor signaling pathway", "TREATMENT", 500, 526], ["receptor signaling pathway", "TREATMENT", 539, 565], ["cytosolic DNA", "TEST", 567, 580], ["TNF signaling pathway", "TEST", 598, 619], ["influenza", "TEST", 621, 630], ["A CXCL11 C", "TEST", 631, 641], ["motif chemokine ligand", "TEST", 646, 668], ["ACE2 protein level", "TEST", 672, 690], ["SARS", "PROBLEM", 707, 711], ["viral", "OBSERVATION_MODIFIER", 152, 157], ["infectious", "OBSERVATION", 158, 168], ["lungs", "ANATOMY", 698, 703], ["SARS", "OBSERVATION", 707, 711]]], ["They also reported that the addition of SARS-CoV spike into mice exacerbates acute lung failure in vivo that can be reduced by inhibiting the renin-angiotensin pathway.", [["lung", "ANATOMY", 83, 87], ["SARS", "DISEASE", 40, 44], ["acute lung failure", "DISEASE", 77, 95], ["angiotensin", "CHEMICAL", 148, 159], ["SARS-CoV", "ORGANISM", 40, 48], ["mice", "ORGANISM", 60, 64], ["lung", "ORGAN", 83, 87], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 142, 159], ["renin", "PROTEIN", 142, 147], ["mice", "SPECIES", 60, 64], ["SARS-CoV", "SPECIES", 40, 48], ["mice", "SPECIES", 60, 64], ["SARS", "PROBLEM", 40, 44], ["CoV spike", "PROBLEM", 45, 54], ["acute lung failure", "PROBLEM", 77, 95], ["the renin-angiotensin pathway", "TREATMENT", 138, 167], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["lung", "ANATOMY", 83, 87], ["failure", "OBSERVATION", 88, 95]]], ["20 Moreover, SARS-CoV-2 uses a similar mechanism as SARS-CoV.", [["SARS", "DISEASE", 13, 17], ["SARS", "DISEASE", 52, 56], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 52, 60], ["SARS-CoV", "SPECIES", 13, 21], ["SARS-CoV", "SPECIES", 52, 60], ["SARS", "TEST", 13, 17]]], ["The structural analyses showed that like SARS-CoV, SARS-CoV-2 also utilizes ACE2 as the host receptor.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 41, 49], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 51, 61], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["ACE2", "PROTEIN", 76, 80], ["SARS-CoV", "SPECIES", 41, 49], ["The structural analyses", "TEST", 0, 23], ["like SARS", "PROBLEM", 36, 45], ["SARS", "PROBLEM", 51, 55], ["ACE2", "TREATMENT", 76, 80]]], ["16 Based on the evidence with regard to the similarity between SARS-CoV and SARS-CoV-2, we used data from Yoshikawa et al. In their study, all the genome expression data of the confluent 2B4 cells which were infected with SARS-CoV and grown in T-75 flasks for 12, 24 and 48 hours were used to characterize the dynamic, spatial and temporal changes of the gene expressions caused by SARS-CoV.", [["2B4 cells", "ANATOMY", 187, 196], ["SARS", "DISEASE", 63, 67], ["SARS-CoV", "ORGANISM", 63, 71], ["SARS-CoV-2", "ORGANISM", 76, 86], ["2B4 cells", "CELL", 187, 196], ["SARS-CoV", "ORGANISM", 222, 230], ["T-75 flasks", "CELL", 244, 255], ["SARS-CoV", "ORGANISM", 382, 390], ["confluent 2B4 cells", "CELL_LINE", 177, 196], ["SARS-CoV", "SPECIES", 63, 71], ["SARS-CoV", "SPECIES", 76, 84], ["SARS-CoV", "SPECIES", 222, 230], ["T-75", "SPECIES", 244, 248], ["SARS-CoV", "SPECIES", 382, 390], ["SARS", "TEST", 63, 67], ["SARS", "PROBLEM", 76, 80], ["CoV", "TEST", 81, 84], ["their study", "TEST", 126, 137], ["the confluent 2B4 cells", "PROBLEM", 173, 196], ["SARS", "PROBLEM", 222, 226], ["CoV", "TEST", 227, 230], ["the gene expressions", "PROBLEM", 351, 371], ["confluent", "OBSERVATION_MODIFIER", 177, 186], ["2B4 cells", "OBSERVATION", 187, 196], ["infected", "OBSERVATION_MODIFIER", 208, 216]]], ["The study was performed three times at each time point in order to meet the minimum number required for the application of statistical algorithms, and a total of nine arrays were given for SARS-CoV.", [["SARS", "DISEASE", 189, 193], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 189, 197], ["SARS-CoV", "SPECIES", 189, 197], ["The study", "TEST", 0, 9], ["statistical algorithms", "TEST", 123, 145], ["a total of nine arrays", "TREATMENT", 151, 173], ["SARS", "PROBLEM", 189, 193]]], ["23 Our current study was carried out to understand the biological mechanism of SARS-CoV-2 infection better by focusing on the similarity of SARS-CoV-2 and SARS-CoV in terms of structure, biological function, and the pathology of the infection.", [["SARS", "DISEASE", 79, 83], ["SARS", "DISEASE", 140, 144], ["infection", "DISEASE", 233, 242], ["SARS-CoV-2", "ORGANISM", 79, 89], ["SARS-CoV-2", "ORGANISM", 140, 150], ["SARS-CoV", "ORGANISM", 155, 163], ["SARS-CoV-2", "SPECIES", 79, 89], ["SARS-CoV", "SPECIES", 140, 148], ["SARS-CoV", "SPECIES", 155, 163], ["Our current study", "TEST", 3, 20], ["SARS", "PROBLEM", 79, 83], ["CoV-2 infection", "PROBLEM", 84, 99], ["SARS", "TEST", 140, 144], ["CoV", "TEST", 145, 148], ["SARS", "PROBLEM", 155, 159], ["the infection", "PROBLEM", 229, 242], ["infection", "OBSERVATION", 233, 242]]], ["We proposed a hypothesis based on the genomic results obtained in the present study under three key headings ( Figure 5 ).Initial phaseAccording to the results of the analysis, there was a significant up-regulation of ACE2 and ANPEP genes in human bronchial epithelial cells within 12 and 24 hours of infection.", [["bronchial epithelial cells", "ANATOMY", 248, 274], ["infection", "DISEASE", 301, 310], ["ACE2", "GENE_OR_GENE_PRODUCT", 218, 222], ["ANPEP", "GENE_OR_GENE_PRODUCT", 227, 232], ["human", "ORGANISM", 242, 247], ["bronchial epithelial cells", "CELL", 248, 274], ["ACE2", "PROTEIN", 218, 222], ["ANPEP genes", "DNA", 227, 238], ["human bronchial epithelial cells", "CELL_TYPE", 242, 274], ["human", "SPECIES", 242, 247], ["human", "SPECIES", 242, 247], ["a hypothesis", "PROBLEM", 12, 24], ["the present study", "TEST", 66, 83], ["the analysis", "TEST", 163, 175], ["ACE2", "PROBLEM", 218, 222], ["ANPEP genes in human bronchial epithelial cells", "PROBLEM", 227, 274], ["infection", "PROBLEM", 301, 310], ["human", "ANATOMY_MODIFIER", 242, 247], ["bronchial", "ANATOMY", 248, 257], ["epithelial cells", "OBSERVATION", 258, 274], ["infection", "OBSERVATION", 301, 310]]], ["Many previous studies indicated that SARS-CoV also uses ACE2 as a receptor to enter host cells, as in SARS-CoV-2.", [["cells", "ANATOMY", 89, 94], ["SARS", "DISEASE", 37, 41], ["SARS-CoV", "ORGANISM", 37, 45], ["ACE2", "GENE_OR_GENE_PRODUCT", 56, 60], ["host cells", "CELL", 84, 94], ["SARS-CoV-2", "ORGANISM", 102, 112], ["ACE2", "PROTEIN", 56, 60], ["host cells", "CELL_TYPE", 84, 94], ["SARS-CoV", "SPECIES", 37, 45], ["SARS-CoV", "SPECIES", 102, 110], ["Many previous studies", "TEST", 0, 21], ["SARS", "PROBLEM", 37, 41], ["ACE2", "TREATMENT", 56, 60], ["a receptor", "TREATMENT", 64, 74], ["SARS", "OBSERVATION", 37, 41]]], ["30 The results of our present study showed the additional possible function of ANPEP ( Figure 5 ).Initial phaseThe ANPEP gene acts as a receptor, especially for HCoV-229E, another member of the CoV family.", [["ANPEP", "GENE_OR_GENE_PRODUCT", 79, 84], ["ANPEP", "GENE_OR_GENE_PRODUCT", 115, 120], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 161, 170], ["CoV", "GENE_OR_GENE_PRODUCT", 194, 197], ["ANPEP", "PROTEIN", 79, 84], ["ANPEP gene", "DNA", 115, 125], ["HCoV", "PROTEIN", 161, 165], ["229E", "PROTEIN", 166, 170], ["CoV family", "PROTEIN", 194, 204], ["HCoV-229E", "SPECIES", 161, 170], ["our present study", "TEST", 18, 35]]], ["This virus is predicted to induce the infection by triggering conformational changes in the spike glycoprotein, which interacts with the host ANPEP receptor and activates membrane fusion.", [["membrane", "ANATOMY", 171, 179], ["infection", "DISEASE", 38, 47], ["ANPEP receptor", "GENE_OR_GENE_PRODUCT", 142, 156], ["membrane", "CELLULAR_COMPONENT", 171, 179], ["spike glycoprotein", "PROTEIN", 92, 110], ["ANPEP receptor", "PROTEIN", 142, 156], ["This virus", "PROBLEM", 0, 10], ["the infection", "PROBLEM", 34, 47], ["triggering conformational changes", "PROBLEM", 51, 84], ["the spike glycoprotein", "PROBLEM", 88, 110], ["the host ANPEP receptor", "TREATMENT", 133, 156], ["activates membrane fusion", "TREATMENT", 161, 186], ["virus", "OBSERVATION", 5, 10], ["infection", "OBSERVATION", 38, 47], ["membrane fusion", "OBSERVATION", 171, 186]]], ["31 Moreover, ANPEP (CD13) can act as a receptor in SARS-CoV and induce growth inhibition and apoptosis by infecting hematopoietic stem/progenitor cells.", [["hematopoietic stem/progenitor cells", "ANATOMY", 116, 151], ["SARS", "DISEASE", 51, 55], ["ANPEP", "GENE_OR_GENE_PRODUCT", 13, 18], ["CD13", "GENE_OR_GENE_PRODUCT", 20, 24], ["SARS-CoV", "ORGANISM", 51, 59], ["hematopoietic stem/progenitor cells", "CELL", 116, 151], ["ANPEP", "PROTEIN", 13, 18], ["CD13", "PROTEIN", 20, 24], ["hematopoietic stem/progenitor cells", "CELL_TYPE", 116, 151], ["SARS-CoV", "SPECIES", 51, 59], ["SARS", "PROBLEM", 51, 55], ["CoV", "PROBLEM", 56, 59], ["induce growth inhibition", "PROBLEM", 64, 88], ["apoptosis", "PROBLEM", 93, 102], ["infecting hematopoietic stem", "OBSERVATION", 106, 134], ["progenitor cells", "OBSERVATION", 135, 151]]], ["32 These findings are in concordance with our results demonstrating the up-regulation in the ACE2 and ANPEP as exposure time to the virus increased.Initial phaseAs suggested in many previous studies, ACE2 forms Ang-(1-7) from Ang II and binds to the MAS receptor, the specific receptor of Ang- (1-7) , and then inhibits inflammatory, vascular and cellular growth mechanisms.", [["vascular", "ANATOMY", 334, 342], ["cellular", "ANATOMY", 347, 355], ["Ang-(1-7)", "CHEMICAL", 211, 220], ["Ang II", "CHEMICAL", 226, 232], ["Ang- (1-7", "CHEMICAL", 289, 298], ["ACE2", "GENE_OR_GENE_PRODUCT", 93, 97], ["ANPEP", "GENE_OR_GENE_PRODUCT", 102, 107], ["ACE2", "GENE_OR_GENE_PRODUCT", 200, 204], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 211, 219], ["Ang II", "GENE_OR_GENE_PRODUCT", 226, 232], ["MAS receptor", "GENE_OR_GENE_PRODUCT", 250, 262], ["Ang- (1-7", "GENE_OR_GENE_PRODUCT", 289, 298], ["vascular", "MULTI-TISSUE_STRUCTURE", 334, 342], ["cellular", "CELL", 347, 355], ["ACE2", "PROTEIN", 93, 97], ["ANPEP", "PROTEIN", 102, 107], ["ACE2", "PROTEIN", 200, 204], ["Ang II", "PROTEIN", 226, 232], ["MAS receptor", "PROTEIN", 250, 262], ["the ACE2", "TREATMENT", 89, 97], ["ANPEP", "TREATMENT", 102, 107], ["the virus", "PROBLEM", 128, 137], ["ACE2", "TEST", 200, 204], ["Ang", "TEST", 211, 214], ["Ang", "TEST", 289, 292], ["inflammatory, vascular and cellular growth mechanisms", "PROBLEM", 320, 373], ["virus", "OBSERVATION", 132, 137], ["inflammatory", "OBSERVATION", 320, 332], ["vascular", "ANATOMY", 334, 342], ["cellular growth", "OBSERVATION", 347, 362]]], ["33 In this case, it may be useful to use the agonistic peptides of Ang-(1-7) to change the functioning of ACE2 in favor of the infected host in the initial phase of infection.Propagating phaseBased on our results, in this phase, as the exposure time to SARS-CoV increases, EGFR and IGF2R, two receptors with key roles in the RAS signaling pathway, were significantly down-regulated in the infected human bronchial epithelial cells.Propagating phaseHabib et al. proposed that apoptosis occurs in various cell types that require an active tyrosine kinase but do not require EGFR autophosphorylation sites by experimentally increasing the level of EGFR expression.", [["bronchial epithelial cells", "ANATOMY", 404, 430], ["cell", "ANATOMY", 503, 507], ["Ang-(1-7", "CHEMICAL", 67, 75], ["infection", "DISEASE", 165, 174], ["SARS", "DISEASE", 253, 257], ["tyrosine", "CHEMICAL", 537, 545], ["tyrosine", "CHEMICAL", 537, 545], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 67, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 106, 110], ["EGFR", "GENE_OR_GENE_PRODUCT", 273, 277], ["IGF2R", "GENE_OR_GENE_PRODUCT", 282, 287], ["RAS", "GENE_OR_GENE_PRODUCT", 325, 328], ["human", "ORGANISM", 398, 403], ["bronchial epithelial cells", "CELL", 404, 430], ["cell", "CELL", 503, 507], ["EGFR", "GENE_OR_GENE_PRODUCT", 572, 576], ["EGFR", "GENE_OR_GENE_PRODUCT", 645, 649], ["ACE2", "PROTEIN", 106, 110], ["EGFR", "PROTEIN", 273, 277], ["IGF2R", "PROTEIN", 282, 287], ["RAS", "PROTEIN", 325, 328], ["infected human bronchial epithelial cells", "CELL_TYPE", 389, 430], ["tyrosine kinase", "PROTEIN", 537, 552], ["EGFR", "PROTEIN", 572, 576], ["EGFR", "PROTEIN", 645, 649], ["human", "SPECIES", 398, 403], ["SARS-CoV", "SPECIES", 253, 261], ["human", "SPECIES", 398, 403], ["the agonistic peptides", "TREATMENT", 41, 63], ["Ang", "TEST", 67, 70], ["ACE2", "TREATMENT", 106, 110], ["the infected host", "TREATMENT", 123, 140], ["infection", "PROBLEM", 165, 174], ["SARS", "PROBLEM", 253, 257], ["CoV increases", "PROBLEM", 258, 271], ["EGFR", "TEST", 273, 277], ["the infected human bronchial epithelial cells", "PROBLEM", 385, 430], ["apoptosis", "PROBLEM", 475, 484], ["an active tyrosine kinase", "TREATMENT", 527, 552], ["EGFR autophosphorylation sites", "TREATMENT", 572, 602], ["infected", "OBSERVATION", 127, 135], ["infection", "OBSERVATION", 165, 174], ["infected", "OBSERVATION", 389, 397], ["human", "ANATOMY_MODIFIER", 398, 403], ["bronchial", "ANATOMY", 404, 413], ["epithelial cells", "OBSERVATION", 414, 430], ["apoptosis", "OBSERVATION", 475, 484], ["various cell types", "OBSERVATION", 495, 513], ["active", "OBSERVATION_MODIFIER", 530, 536], ["tyrosine kinase", "OBSERVATION", 537, 552]]], ["The expression of a predominant negative RAS mutant in cells that over-express the EGFR leads to significantly enhanced EGFR-induced apoptosis.", [["cells", "ANATOMY", 55, 60], ["RAS", "GENE_OR_GENE_PRODUCT", 41, 44], ["cells", "CELL", 55, 60], ["EGFR", "GENE_OR_GENE_PRODUCT", 83, 87], ["EGFR", "GENE_OR_GENE_PRODUCT", 120, 124], ["predominant negative RAS mutant", "PROTEIN", 20, 51], ["EGFR", "PROTEIN", 83, 87], ["EGFR", "PROTEIN", 120, 124], ["a predominant negative RAS mutant in cells", "PROBLEM", 18, 60], ["the EGFR", "TEST", 79, 87], ["significantly enhanced EGFR", "PROBLEM", 97, 124], ["induced apoptosis", "PROBLEM", 125, 142], ["apoptosis", "OBSERVATION", 133, 142]]], ["34 On the other hand, IGF2R, acting as a G-coupled protein receptor, could lead to the activation of the mitochondria-mediated apoptosis pathway, when insulin-like growth factor-II (IGF2) binds to this receptor.", [["mitochondria", "ANATOMY", 105, 117], ["IGF2R", "GENE_OR_GENE_PRODUCT", 22, 27], ["G-coupled protein receptor", "GENE_OR_GENE_PRODUCT", 41, 67], ["mitochondria", "CELLULAR_COMPONENT", 105, 117], ["insulin-like growth factor-II", "GENE_OR_GENE_PRODUCT", 151, 180], ["IGF2", "GENE_OR_GENE_PRODUCT", 182, 186], ["IGF2R", "PROTEIN", 22, 27], ["G-coupled protein receptor", "PROTEIN", 41, 67], ["insulin-like growth factor-II", "PROTEIN", 151, 180], ["IGF2", "PROTEIN", 182, 186], ["a G-coupled protein receptor", "TREATMENT", 39, 67], ["insulin", "TREATMENT", 151, 158]]], ["35 Thus, those two receptors, which are associated with cellular apoptosis, are expected to be downregulated as the infection time of virus-infected cells progresses.", [["cellular", "ANATOMY", 56, 64], ["cells", "ANATOMY", 149, 154], ["infection", "DISEASE", 116, 125], ["cellular", "CELL", 56, 64], ["cells", "CELL", 149, 154], ["virus-infected cells", "CELL_TYPE", 134, 154], ["cellular apoptosis", "PROBLEM", 56, 74], ["the infection time of virus", "PROBLEM", 112, 139], ["infected cells", "PROBLEM", 140, 154], ["associated with", "UNCERTAINTY", 40, 55], ["cellular apoptosis", "OBSERVATION", 56, 74], ["infection", "OBSERVATION", 116, 125], ["infected cells", "OBSERVATION", 140, 154]]], ["This event could give the chance for the virus to have sufficient time to continue replication and increase its copy number.", [["the virus", "PROBLEM", 37, 46], ["replication", "TREATMENT", 83, 94]]], ["This phase of the viral infection might be important, particularly for hypertensive subjects.Complicating phaseIn this in silico genomic study, 29 genes (36 probe sets) were detected which showed noteworthy up-regulation in 24-versus 48-hour groups.", [["viral infection", "DISEASE", 18, 33], ["hypertensive", "DISEASE", 71, 83], ["29 genes", "DNA", 144, 152], ["the viral infection", "PROBLEM", 14, 33], ["hypertensive subjects", "PROBLEM", 71, 92], ["silico genomic study", "TEST", 122, 142], ["probe sets", "TEST", 157, 167], ["viral", "OBSERVATION_MODIFIER", 18, 23], ["infection", "OBSERVATION", 24, 33]]], ["Almost all of these are genes associated with the immune system, innate immune response, and adaptive immune response.Complicating phaseThe relevant biological analyzers of these genes whose expressions are concordant with cell exposure time to the virus were explored via the pathway analyzers of the 29 genes.", [["immune system", "ANATOMY", 50, 63], ["cell", "ANATOMY", 223, 227], ["cell", "CELL", 223, 227], ["29 genes", "DNA", 302, 310], ["phase", "OBSERVATION_MODIFIER", 131, 136]]], ["The genes involved in specific pathways related to the critical pathological events of CoV infection, including SARS-CoV and SARS-CoV-2, such as the Toll-like receptor (TLR) signaling pathway.Complicating phaseTLRs are essential sensor molecules of the host innate immune system.", [["CoV infection", "DISEASE", 87, 100], ["CoV", "ORGANISM", 87, 90], ["SARS-CoV", "ORGANISM", 112, 120], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 125, 135], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 149, 167], ["TLR", "GENE_OR_GENE_PRODUCT", 169, 172], ["phaseTLRs", "GENE_OR_GENE_PRODUCT", 205, 214], ["immune system", "ANATOMICAL_SYSTEM", 265, 278], ["Toll-like receptor", "PROTEIN", 149, 167], ["TLR", "PROTEIN", 169, 172], ["phaseTLRs", "PROTEIN", 205, 214], ["SARS-CoV", "SPECIES", 112, 120], ["SARS-CoV", "SPECIES", 125, 133], ["CoV infection", "PROBLEM", 87, 100], ["SARS", "PROBLEM", 112, 116], ["SARS", "PROBLEM", 125, 129], ["Complicating phaseTLRs", "PROBLEM", 192, 214], ["CoV", "OBSERVATION_MODIFIER", 87, 90], ["infection", "OBSERVATION", 91, 100], ["sensor molecules", "OBSERVATION", 229, 245]]], ["Various TLRs are involved in early interactions of invasive viruses and host cells, which affect viral pathogenesis and regulate viral replication as well as host responses.", [["cells", "ANATOMY", 77, 82], ["TLRs", "GENE_OR_GENE_PRODUCT", 8, 12], ["host cells", "CELL", 72, 82], ["TLRs", "PROTEIN", 8, 12], ["host cells", "CELL_TYPE", 72, 82], ["invasive viruses", "PROBLEM", 51, 67], ["host cells", "PROBLEM", 72, 82], ["viral pathogenesis", "PROBLEM", 97, 115], ["viral replication", "TREATMENT", 129, 146], ["host cells", "OBSERVATION", 72, 82], ["viral replication", "OBSERVATION", 129, 146]]], ["Initiation of antiviral immune responses with TLR agonists has been shown to provide protection from many different viruses, including hepatitis B virus, influenza virus, some HIV strains, and CoV.", [["hepatitis B", "DISEASE", 135, 146], ["influenza virus", "DISEASE", 154, 169], ["TLR", "GENE_OR_GENE_PRODUCT", 46, 49], ["hepatitis B virus", "ORGANISM", 135, 152], ["influenza virus", "ORGANISM", 154, 169], ["HIV", "ORGANISM", 176, 179], ["TLR", "PROTEIN", 46, 49], ["hepatitis B virus", "SPECIES", 135, 152], ["influenza virus", "SPECIES", 154, 169], ["HIV", "SPECIES", 176, 179], ["hepatitis B virus", "SPECIES", 135, 152], ["HIV", "SPECIES", 176, 179], ["CoV.", "SPECIES", 193, 197], ["antiviral immune responses", "TREATMENT", 14, 40], ["TLR agonists", "TREATMENT", 46, 58], ["many different viruses", "PROBLEM", 101, 123], ["hepatitis B virus", "PROBLEM", 135, 152], ["influenza virus", "PROBLEM", 154, 169], ["some HIV strains", "PROBLEM", 171, 187], ["viruses", "OBSERVATION", 116, 123], ["HIV strains", "OBSERVATION", 176, 187]]], ["Furthermore, non-structural protein 3 of the SARS-CoV interacts with IRF3 through the papain-like protease domain.", [["non-structural protein 3", "GENE_OR_GENE_PRODUCT", 13, 37], ["SARS-CoV", "ORGANISM", 45, 53], ["IRF3", "GENE_OR_GENE_PRODUCT", 69, 73], ["papain", "GENE_OR_GENE_PRODUCT", 86, 92], ["non-structural protein 3", "PROTEIN", 13, 37], ["SARS-CoV", "PROTEIN", 45, 53], ["IRF3", "PROTEIN", 69, 73], ["papain-like protease domain", "PROTEIN", 86, 113], ["SARS-CoV", "SPECIES", 45, 53], ["non-structural protein", "TEST", 13, 35], ["the SARS", "PROBLEM", 41, 49], ["IRF3", "TREATMENT", 69, 73], ["the papain", "TREATMENT", 82, 92], ["non-structural protein", "OBSERVATION", 13, 35]]], ["After that, the associations of the TLR and RLR pathways occur, and this binding prevents the nuclear translocation as well as the phosphorylation of IRF3.", [["nuclear", "ANATOMY", 94, 101], ["TLR", "GENE_OR_GENE_PRODUCT", 36, 39], ["RLR", "GENE_OR_GENE_PRODUCT", 44, 47], ["nuclear", "CELLULAR_COMPONENT", 94, 101], ["IRF3", "GENE_OR_GENE_PRODUCT", 150, 154], ["TLR", "PROTEIN", 36, 39], ["RLR", "PROTEIN", 44, 47], ["IRF3", "PROTEIN", 150, 154], ["this binding", "PROBLEM", 68, 80], ["the nuclear translocation", "PROBLEM", 90, 115], ["the phosphorylation of IRF3", "TREATMENT", 127, 154]]], ["36 It has previously been observed that he TLR signal through the TRIF adapter protein protects mice from lethal SARS-CoV.", [["SARS", "DISEASE", 113, 117], ["TLR", "GENE_OR_GENE_PRODUCT", 43, 46], ["TRIF", "GENE_OR_GENE_PRODUCT", 66, 70], ["mice", "ORGANISM", 96, 100], ["SARS-CoV", "ORGANISM", 113, 121], ["TLR", "PROTEIN", 43, 46], ["TRIF adapter protein", "PROTEIN", 66, 86], ["mice", "SPECIES", 96, 100], ["mice", "SPECIES", 96, 100], ["SARS-CoV", "SPECIES", 113, 121], ["the TRIF adapter protein", "TREATMENT", 62, 86]]], ["Thus, a balanced immune response that works both in TRIF and MyD88-guided pathways provides the most effective host-cell intrinsic antiviral defense responses against severe SARS-CoV, and the absence of any branch of TLR signaling leads to SARS-CoV being fatal.", [["cell", "ANATOMY", 116, 120], ["SARS-CoV", "DISEASE", 174, 182], ["SARS-CoV", "DISEASE", 240, 248], ["TRIF", "GENE_OR_GENE_PRODUCT", 52, 56], ["MyD88", "GENE_OR_GENE_PRODUCT", 61, 66], ["host-cell", "CELL", 111, 120], ["SARS-CoV", "ORGANISM", 174, 182], ["TLR", "GENE_OR_GENE_PRODUCT", 217, 220], ["SARS-CoV", "ORGANISM", 240, 248], ["TRIF", "PROTEIN", 52, 56], ["MyD88", "PROTEIN", 61, 66], ["TLR", "PROTEIN", 217, 220], ["SARS-CoV", "SPECIES", 174, 182], ["SARS-CoV", "SPECIES", 240, 248], ["MyD88-guided pathways", "TREATMENT", 61, 82], ["severe SARS-CoV", "PROBLEM", 167, 182], ["SARS", "PROBLEM", 240, 244], ["antiviral defense", "OBSERVATION", 131, 148], ["branch", "ANATOMY_MODIFIER", 207, 213]]], ["37 Another important pathway is associated with the interferon beta 1 (IFNB1) gene identified as a result of pathway analysis is the natural killer (NK) cell-mediated cytotoxicity pathway.", [["natural killer (NK) cell", "ANATOMY", 133, 157], ["interferon beta 1", "GENE_OR_GENE_PRODUCT", 52, 69], ["IFNB1", "GENE_OR_GENE_PRODUCT", 71, 76], ["natural killer", "CELL", 133, 147], ["NK) cell", "CELL", 149, 157], ["interferon beta 1 (IFNB1) gene", "DNA", 52, 82], ["natural killer (NK) cell", "CELL_TYPE", 133, 157], ["the interferon beta 1 (IFNB1)", "TREATMENT", 48, 77], ["pathway analysis", "TEST", 109, 125], ["cell-mediated cytotoxicity pathway", "TREATMENT", 153, 187]]], ["Interferons are considered as the screams of the affected cells during the active virus attack.", [["cells", "ANATOMY", 58, 63], ["cells", "CELL", 58, 63], ["Interferons", "PROTEIN", 0, 11], ["Interferons", "TREATMENT", 0, 11], ["the affected cells", "PROBLEM", 45, 63], ["the active virus attack", "PROBLEM", 71, 94], ["active", "OBSERVATION_MODIFIER", 75, 81], ["virus", "OBSERVATION", 82, 87]]], ["IFNB1 deficiency results in partial suppression of the sterol pathway in macrophages during viral infections, thereby associating the regulation of the lipid metabolism pathway with interferon antiviral defense responses.", [["macrophages", "ANATOMY", 73, 84], ["viral infections", "DISEASE", 92, 108], ["sterol", "CHEMICAL", 55, 61], ["IFNB1", "GENE_OR_GENE_PRODUCT", 0, 5], ["sterol", "SIMPLE_CHEMICAL", 55, 61], ["macrophages", "CELL", 73, 84], ["lipid", "SIMPLE_CHEMICAL", 152, 157], ["IFNB1", "PROTEIN", 0, 5], ["macrophages", "CELL_TYPE", 73, 84], ["interferon", "PROTEIN", 182, 192], ["IFNB1 deficiency", "PROBLEM", 0, 16], ["partial suppression of the sterol pathway", "PROBLEM", 28, 69], ["macrophages", "PROBLEM", 73, 84], ["viral infections", "PROBLEM", 92, 108], ["the lipid metabolism pathway", "TREATMENT", 148, 176], ["interferon antiviral defense responses", "TREATMENT", 182, 220], ["partial suppression", "OBSERVATION", 28, 47], ["macrophages", "ANATOMY", 73, 84], ["viral infections", "OBSERVATION", 92, 108]]], ["38 Furthermore, NK cells are important in immune defense against virus infections.", [["NK cells", "ANATOMY", 16, 24], ["infections", "DISEASE", 71, 81], ["NK cells", "CELL", 16, 24], ["NK cells", "CELL_TYPE", 16, 24], ["NK cells", "PROBLEM", 16, 24], ["virus infections", "PROBLEM", 65, 81], ["NK cells", "OBSERVATION", 16, 24]]], ["Enlarged virus replication and more serious diseases during encephalomyocarditis virus, Coxsackie virus, and Theiler's murine encephalitis virus infections are linked with the reduction of NK cells or low levels of NK cell cytolytic function.", [["NK cells", "ANATOMY", 189, 197], ["NK cell", "ANATOMY", 215, 222], ["encephalomyocarditis virus", "DISEASE", 60, 86], ["Coxsackie virus", "DISEASE", 88, 103], ["Theiler's murine encephalitis", "DISEASE", 109, 138], ["infections", "DISEASE", 145, 155], ["encephalomyocarditis virus", "ORGANISM", 60, 86], ["Coxsackie virus", "ORGANISM", 88, 103], ["Theiler's murine encephalitis virus", "ORGANISM", 109, 144], ["NK cells", "CELL", 189, 197], ["NK cell", "CELL", 215, 222], ["NK cells", "CELL_TYPE", 189, 197], ["encephalomyocarditis virus", "SPECIES", 60, 86], ["Coxsackie virus", "SPECIES", 88, 103], ["Theiler", "SPECIES", 109, 116], ["murine", "SPECIES", 119, 125], ["encephalitis virus", "SPECIES", 126, 144], ["encephalomyocarditis virus", "SPECIES", 60, 86], ["Coxsackie virus", "SPECIES", 88, 103], ["Theiler's murine encephalitis virus", "SPECIES", 109, 144], ["Enlarged virus replication", "PROBLEM", 0, 26], ["more serious diseases during encephalomyocarditis virus", "PROBLEM", 31, 86], ["Coxsackie virus", "PROBLEM", 88, 103], ["Theiler's murine encephalitis virus infections", "PROBLEM", 109, 155], ["NK cells", "PROBLEM", 189, 197], ["low levels of NK cell cytolytic function", "PROBLEM", 201, 241], ["virus replication", "OBSERVATION", 9, 26], ["more", "OBSERVATION_MODIFIER", 31, 35], ["serious", "OBSERVATION_MODIFIER", 36, 43], ["encephalomyocarditis virus", "OBSERVATION", 60, 86], ["Coxsackie virus", "OBSERVATION", 88, 103], ["NK cells", "OBSERVATION", 189, 197], ["low levels", "OBSERVATION_MODIFIER", 201, 211], ["NK cell cytolytic function", "OBSERVATION", 215, 241]]], ["NK cells are correspondingly associated with direct inhibition of virus replication and stimulation of liver damage during mouse hepatitis virus (MHV) infection.", [["NK cells", "ANATOMY", 0, 8], ["liver", "ANATOMY", 103, 108], ["liver damage", "DISEASE", 103, 115], ["mouse hepatitis virus (MHV) infection", "DISEASE", 123, 160], ["NK cells", "CELL", 0, 8], ["liver", "ORGAN", 103, 108], ["mouse hepatitis virus (MHV)", "ORGANISM", 123, 150], ["NK cells", "CELL_TYPE", 0, 8], ["mouse", "SPECIES", 123, 128], ["hepatitis virus", "SPECIES", 129, 144], ["mouse hepatitis virus", "SPECIES", 123, 144], ["MHV", "SPECIES", 146, 149], ["NK cells", "PROBLEM", 0, 8], ["virus replication", "TREATMENT", 66, 83], ["liver damage", "PROBLEM", 103, 115], ["mouse hepatitis virus (MHV) infection", "PROBLEM", 123, 160], ["liver", "ANATOMY", 103, 108], ["infection", "OBSERVATION", 151, 160]]], ["It is not known whether NK cells play a direct antiviral role in human infections with picornaviruses or CoV such as SARS.", [["NK cells", "ANATOMY", 24, 32], ["infections", "DISEASE", 71, 81], ["SARS", "DISEASE", 117, 121], ["NK cells", "CELL", 24, 32], ["human", "ORGANISM", 65, 70], ["CoV", "ORGANISM", 105, 108], ["NK cells", "CELL_TYPE", 24, 32], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["NK cells", "PROBLEM", 24, 32], ["human infections", "PROBLEM", 65, 81], ["picornaviruses", "PROBLEM", 87, 101], ["SARS", "PROBLEM", 117, 121], ["not known", "UNCERTAINTY", 6, 15]]], ["39 Lysosome, which has an important path in CoV infection, is another pathway related to the pathway analysis performed.", [["CoV infection", "DISEASE", 44, 57], ["Lysosome", "GENE_OR_GENE_PRODUCT", 3, 11], ["CoV", "ORGANISM", 44, 47], ["CoV infection", "PROBLEM", 44, 57], ["the pathway analysis", "TEST", 89, 109], ["Lysosome", "OBSERVATION", 3, 11], ["CoV", "OBSERVATION_MODIFIER", 44, 47], ["infection", "OBSERVATION", 48, 57]]], ["Enveloped viruses must fuse with a host-cell membrane so as to transport their genomes to the host cell.", [["cell membrane", "ANATOMY", 40, 53], ["cell", "ANATOMY", 99, 103], ["cell membrane", "CELLULAR_COMPONENT", 40, 53], ["host cell", "CELL", 94, 103], ["host cell", "CELL_TYPE", 94, 103], ["Enveloped viruses", "PROBLEM", 0, 17], ["a host-cell membrane", "TREATMENT", 33, 53], ["viruses", "OBSERVATION", 10, 17], ["host cell", "OBSERVATION", 94, 103]]], ["Although some viruses fuse with the plasma membrane, many viral infections are associated with endocytosis before fusion.", [["plasma membrane", "ANATOMY", 36, 51], ["viral infections", "DISEASE", 58, 74], ["plasma membrane", "CELLULAR_COMPONENT", 36, 51], ["some viruses fuse", "PROBLEM", 9, 26], ["the plasma membrane", "PROBLEM", 32, 51], ["many viral infections", "PROBLEM", 53, 74], ["endocytosis before fusion", "PROBLEM", 95, 120], ["viruses", "OBSERVATION", 14, 21], ["viral infections", "OBSERVATION", 58, 74]]], ["In the endosomal microenvironment, a particular marker induces conformational changes in viral fusion proteins, leading to viral and host membrane fusion.", [["endosomal", "ANATOMY", 7, 16], ["membrane", "ANATOMY", 138, 146], ["endosomal", "CELLULAR_COMPONENT", 7, 16], ["membrane", "CELLULAR_COMPONENT", 138, 146], ["viral fusion proteins", "PROTEIN", 89, 110], ["conformational changes in viral fusion proteins", "PROBLEM", 63, 110], ["viral", "PROBLEM", 123, 128], ["host membrane fusion", "TREATMENT", 133, 153], ["endosomal microenvironment", "OBSERVATION", 7, 33], ["viral fusion", "OBSERVATION", 89, 101], ["viral", "OBSERVATION_MODIFIER", 123, 128], ["host membrane fusion", "OBSERVATION", 133, 153]]], ["40 According to the De Haan et al. study, the proteins known to be important for late endosomal maturation and endosome-lysosome fusion deeply promoted infection of cells with mouse hepatitis CoV (MHV).", [["endosomal", "ANATOMY", 86, 95], ["endosome", "ANATOMY", 111, 119], ["lysosome", "ANATOMY", 120, 128], ["cells", "ANATOMY", 165, 170], ["infection", "DISEASE", 152, 161], ["hepatitis CoV", "DISEASE", 182, 195], ["late endosomal", "CELLULAR_COMPONENT", 81, 95], ["endosome", "CELLULAR_COMPONENT", 111, 119], ["lysosome", "CELLULAR_COMPONENT", 120, 128], ["cells", "CELL", 165, 170], ["mouse hepatitis CoV", "ORGANISM", 176, 195], ["MHV", "ORGANISM", 197, 200], ["mouse", "SPECIES", 176, 181], ["hepatitis CoV", "SPECIES", 182, 195], ["mouse hepatitis CoV", "SPECIES", 176, 195], ["MHV", "SPECIES", 197, 200], ["study", "TEST", 35, 40], ["late endosomal maturation", "PROBLEM", 81, 106], ["endosome-lysosome fusion", "TREATMENT", 111, 135], ["infection of cells", "PROBLEM", 152, 170], ["mouse hepatitis CoV", "PROBLEM", 176, 195], ["endosomal maturation", "OBSERVATION", 86, 106], ["lysosome fusion", "OBSERVATION", 120, 135], ["infection", "OBSERVATION", 152, 161]]], ["41 In another study of SARS-CoV, SARS-CoV accessory protein open reading frames (SARS 3a) were oligomerized by dynamically inserting them into late endosomal, lysosomal and trans-Golgi network membranes.", [["endosomal", "ANATOMY", 148, 157], ["lysosomal", "ANATOMY", 159, 168], ["Golgi network membranes", "ANATOMY", 179, 202], ["SARS", "DISEASE", 23, 27], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 23, 31], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 33, 41], ["endosomal", "CELLULAR_COMPONENT", 148, 157], ["lysosomal", "CELLULAR_COMPONENT", 159, 168], ["Golgi network membranes", "CELLULAR_COMPONENT", 179, 202], ["SARS-CoV accessory protein open reading frames", "DNA", 33, 79], ["SARS-CoV", "SPECIES", 23, 31], ["SARS-CoV", "SPECIES", 33, 41], ["another study", "TEST", 6, 19], ["SARS", "PROBLEM", 23, 27], ["CoV", "PROBLEM", 28, 31], ["SARS", "PROBLEM", 33, 37], ["CoV accessory protein", "TREATMENT", 38, 59], ["network membranes", "OBSERVATION", 185, 202]]], ["42 Furthermore, the chemotactic cytokines are engaged in a great deal of biological processes.", [["chemotactic cytokines", "PROTEIN", 20, 41], ["the chemotactic cytokines", "TEST", 16, 41]]], ["Besides microbial infection, the infected cells have strong chemokine signals.", [["cells", "ANATOMY", 42, 47], ["microbial infection", "DISEASE", 8, 27], ["cells", "CELL", 42, 47], ["infected cells", "CELL_TYPE", 33, 47], ["chemokine", "PROTEIN", 60, 69], ["microbial infection", "PROBLEM", 8, 27], ["the infected cells", "PROBLEM", 29, 47], ["microbial", "OBSERVATION_MODIFIER", 8, 17], ["infection", "OBSERVATION", 18, 27], ["infected cells", "OBSERVATION", 33, 47], ["strong", "OBSERVATION_MODIFIER", 53, 59], ["chemokine signals", "OBSERVATION", 60, 77]]], ["Those signals could play significant roles in both innate and adaptive immune responses that control the growth of the invading pathogen.", [["adaptive immune responses", "TREATMENT", 62, 87], ["the invading pathogen", "PROBLEM", 115, 136], ["invading", "OBSERVATION_MODIFIER", 119, 127]]], ["43 Therefore, the presence of chemokine signaling pathways parallels the other results obtained.", [["chemokine", "PROTEIN", 30, 39]]], ["The main limitation of this study is the lack of uninfected control data, which is subject to further experimental studies.ConclusionIn conclusion, if the results obtained in the current study are validated by in vitro experiments and clinical samples, it can be suggested that the disruption of RAS genes may be important for the initial management of the CoV infections, particularly SARS-CoV-2.", [["samples", "ANATOMY", 244, 251], ["CoV infections", "DISEASE", 357, 371], ["SARS", "DISEASE", 386, 390], ["RAS", "GENE_OR_GENE_PRODUCT", 296, 299], ["CoV", "ORGANISM", 357, 360], ["SARS-CoV-2", "ORGANISM", 386, 396], ["RAS genes", "DNA", 296, 305], ["SARS-CoV", "SPECIES", 386, 394], ["this study", "TEST", 23, 33], ["further experimental studies", "TEST", 94, 122], ["the current study", "TEST", 175, 192], ["clinical samples", "TEST", 235, 251], ["the disruption of RAS genes", "PROBLEM", 278, 305], ["the initial management", "TREATMENT", 327, 349], ["the CoV infections", "PROBLEM", 353, 371], ["main", "OBSERVATION_MODIFIER", 4, 8], ["limitation", "OBSERVATION_MODIFIER", 9, 19], ["CoV", "ANATOMY", 357, 360], ["infections", "OBSERVATION", 361, 371]]], ["The results of the current study help us to understand better the pathobiology of SARS-CoV and other similar CoV family members such as SARS-CoV-2.", [["SARS", "DISEASE", 82, 86], ["SARS-CoV", "ORGANISM", 82, 90], ["CoV", "ORGANISM", 109, 112], ["SARS-CoV-2", "ORGANISM", 136, 146], ["SARS-CoV", "SPECIES", 82, 90], ["SARS-CoV", "SPECIES", 136, 144], ["the current study", "TEST", 15, 32]]], ["Based on our results, the interactions between the SARS-CoV-2 and RAS genes, resulting in immune-related genomic disruption, lead to acquired immune deficiency states.", [["immune deficiency", "DISEASE", 142, 159], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 51, 61], ["RAS", "GENE_OR_GENE_PRODUCT", 66, 69], ["SARS-CoV-2 and RAS genes", "DNA", 51, 75], ["the SARS", "TEST", 47, 55], ["CoV", "TEST", 56, 59], ["immune-related genomic disruption", "PROBLEM", 90, 123], ["acquired immune deficiency states", "PROBLEM", 133, 166], ["genomic disruption", "OBSERVATION", 105, 123], ["immune deficiency", "OBSERVATION", 142, 159]]], ["It is hoped that critical local RAS-affecting drugs such as MAS agonists, soluble ACE2 and Ang-(1-7) will be used for the modulation of SARS-CoV-2 and RAS pathological interactions for the improvement of immune genomic states in patients infected with SARS-CoV-2 in future trials.Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.FundingThe author(s) received no financial support for the research, authorship, and/or publication of this article.Supplemental materialSupplemental material for this article is available online.ORCID iDsSeyhan Turk https://orcid.org/0000-0003-3843-4173ORCID iDsElif Sena Temirci https://orcid.org/0000-0001-5944-6718ORCID iDsUmit Yavuz Malkan https://orcid.org/0000-0001-5444-4895", [["Ang", "CHEMICAL", 91, 94], ["SARS", "DISEASE", 252, 256], ["iDsElif", "CHEMICAL", 711, 718], ["iDsUmit", "CHEMICAL", 775, 782], ["iDsElif", "CHEMICAL", 711, 718], ["RAS", "GENE_OR_GENE_PRODUCT", 32, 35], ["ACE2", "GENE_OR_GENE_PRODUCT", 82, 86], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 91, 99], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 136, 146], ["RAS", "GENE_OR_GENE_PRODUCT", 151, 154], ["patients", "ORGANISM", 229, 237], ["SARS-CoV-2", "ORGANISM", 252, 262], ["ACE2", "PROTEIN", 82, 86], ["patients", "SPECIES", 229, 237], ["SARS-CoV", "SPECIES", 252, 260], ["Yavuz Malkan", "SPECIES", 783, 795], ["critical local RAS", "PROBLEM", 17, 35], ["drugs", "TREATMENT", 46, 51], ["MAS agonists", "TREATMENT", 60, 72], ["soluble ACE2", "TREATMENT", 74, 86], ["Ang", "TEST", 91, 94], ["SARS", "TEST", 136, 140], ["CoV", "TEST", 141, 144], ["RAS pathological interactions", "PROBLEM", 151, 180], ["immune genomic states", "PROBLEM", 204, 225], ["SARS", "PROBLEM", 252, 256], ["CoV", "TEST", 257, 260], ["financial support", "TREATMENT", 484, 501], ["Supplemental material", "TREATMENT", 567, 588], ["Supplemental material", "TREATMENT", 588, 609]]]], "PMC7253984": [["Fundingnone.Conflicts of interest/competing interestsnothing to declare.Ethics approvalnot applicable.", [["Fundingnone", "CHEMICAL", 0, 11]]]], "PMC7298497": [["FundingNo funding was required for the letter.Availability of data and materialsNot applicable.Authors\u2019 contributionsAll authors wrote, proofread, participated in the care of the patient and approved the final manuscript.Consent for publicationInformed written consent was obtained from patient for publication of this case.", [["patient", "ORGANISM", 179, 186], ["patient", "ORGANISM", 287, 294], ["patient", "SPECIES", 179, 186], ["patient", "SPECIES", 287, 294], ["No", "UNCERTAINTY", 7, 9], ["funding", "OBSERVATION", 10, 17]]], ["Schvartsman reports grants and personal fees from Bristol-Myers Squibb, personal fees from Novartis, personal fees from Roche, personal fees from MSD, personal fees from Amgen, personal fees from Sanofi, personal fees from AstraZeneca, outside the submitted work.", [["AstraZeneca", "CHEMICAL", 223, 234]]]], "1eab38d2cf808ff238e32172416e47e0f7262d0e": [["F2, and GRM5.", [["F2", "CELL", 0, 2], ["GRM5", "GENE_OR_GENE_PRODUCT", 8, 12], ["GRM5", "PROTEIN", 8, 12]]], ["The pathways revealed that the possible targets of LJF involved in the regulation 29 of the IL-17 signalling pathway.", [["LJF", "CHEMICAL", 51, 54], ["LJF", "GENE_OR_GENE_PRODUCT", 51, 54], ["IL-17", "GENE_OR_GENE_PRODUCT", 92, 97], ["LJF", "PROTEIN", 51, 54], ["IL", "PROTEIN", 92, 94], ["the IL", "TREATMENT", 88, 94]]], ["Then, in vivo experiments indicated that LJF decreased the levels 30 of proinflammatory cytokines (TNF-, IL-1 , and IL-6) in serum and bronchoalveolar lavage 31 fluid, decreased the levels of oxidative stress factors (MDA and MPO) and increased the activities 32 obtain the aqueous extract, which was kept at -20 \u2103 until use.", [["serum", "ANATOMY", 125, 130], ["bronchoalveolar lavage 31 fluid", "ANATOMY", 135, 166], ["aqueous extract", "ANATOMY", 274, 289], ["LJF", "CHEMICAL", 41, 44], ["LJF", "CHEMICAL", 41, 44], ["MDA", "CHEMICAL", 218, 221], ["LJF", "SIMPLE_CHEMICAL", 41, 44], ["TNF", "GENE_OR_GENE_PRODUCT", 99, 102], ["IL-1", "GENE_OR_GENE_PRODUCT", 105, 109], ["IL-6", "GENE_OR_GENE_PRODUCT", 116, 120], ["serum", "ORGANISM_SUBSTANCE", 125, 130], ["bronchoalveolar lavage 31 fluid", "ORGANISM_SUBSTANCE", 135, 166], ["MDA", "SIMPLE_CHEMICAL", 218, 221], ["MPO", "SIMPLE_CHEMICAL", 226, 229], ["aqueous extract", "ORGANISM_SUBSTANCE", 274, 289], ["proinflammatory cytokines", "PROTEIN", 72, 97], ["TNF", "PROTEIN", 99, 102], ["IL-6", "PROTEIN", 116, 120], ["oxidative stress factors", "PROTEIN", 192, 216], ["MDA", "PROTEIN", 218, 221], ["MPO", "PROTEIN", 226, 229], ["proinflammatory cytokines", "TEST", 72, 97], ["TNF", "TEST", 99, 102], ["IL", "TEST", 105, 107], ["IL", "TEST", 116, 118], ["serum", "TEST", 125, 130], ["bronchoalveolar lavage", "TEST", 135, 157], ["oxidative stress factors", "PROBLEM", 192, 216], ["MPO", "TEST", 226, 229], ["the aqueous extract", "TREATMENT", 270, 289], ["bronchoalveolar", "ANATOMY", 135, 150]]], ["Prior to HPLC analysis, the 116 solution was filtered through a 0.45 \u03bcm membrane.", [["membrane", "ANATOMY", 72, 80], ["membrane", "CELLULAR_COMPONENT", 72, 80], ["HPLC analysis", "TEST", 9, 22], ["a 0.45 \u03bcm membrane", "TREATMENT", 62, 80]]], ["The chromatographic fingerprinting of LJF 117 showed 14 main peaks, which were identified as 2 (neochlorogenic acid), 5 (chlorogenic acid), 6 118 (chlorogenic acid), 10 (secoxyloganin), 11 (isochlorogenic acid B), 12 (isochlorogenic acid A), 119 and 14 (isochlorogenic acid).", [["LJF 117", "CHEMICAL", 38, 45], ["neochlorogenic acid), 5 (chlorogenic acid", "CHEMICAL", 96, 137], ["6 118 (chlorogenic acid", "CHEMICAL", 140, 163], ["secoxyloganin", "CHEMICAL", 170, 183], ["isochlorogenic acid B", "CHEMICAL", 190, 211], ["isochlorogenic acid A), 119 and 14 (isochlorogenic acid", "CHEMICAL", 218, 273], ["neochlorogenic acid", "CHEMICAL", 96, 115], ["chlorogenic acid", "CHEMICAL", 121, 137], ["chlorogenic acid", "CHEMICAL", 147, 163], ["secoxyloganin", "CHEMICAL", 170, 183], ["isochlorogenic acid B", "CHEMICAL", 190, 211], ["isochlorogenic acid A", "CHEMICAL", 218, 239], ["isochlorogenic acid", "CHEMICAL", 254, 273], ["LJF 117", "SIMPLE_CHEMICAL", 38, 45], ["neochlorogenic acid", "SIMPLE_CHEMICAL", 96, 115], ["chlorogenic acid", "SIMPLE_CHEMICAL", 121, 137], ["chlorogenic acid", "SIMPLE_CHEMICAL", 147, 163], ["secoxyloganin", "SIMPLE_CHEMICAL", 170, 183], ["isochlorogenic acid B", "SIMPLE_CHEMICAL", 190, 211], ["isochlorogenic acid A", "SIMPLE_CHEMICAL", 218, 239], ["isochlorogenic acid", "SIMPLE_CHEMICAL", 254, 273], ["The chromatographic fingerprinting of LJF", "TEST", 0, 41], ["neochlorogenic acid", "TEST", 96, 115], ["chlorogenic acid", "TEST", 121, 137], ["chlorogenic acid", "TEST", 147, 163], ["secoxyloganin", "TEST", 170, 183], ["isochlorogenic acid B", "TEST", 190, 211], ["isochlorogenic acid A", "TEST", 218, 239], ["isochlorogenic acid", "TEST", 254, 273]]], ["The method could be used to identify the characteristics of LJF (Fig. 120 S1 ).", [["LJF", "PROTEIN", 60, 63], ["The method", "TREATMENT", 0, 10]]], ["121 For further analyses, the bronchoalveolar lavage fluid (BALF), lung tissue and blood were 136 collected and stored at \u221280 \u00b0C. 137ELISA analysis 138After treatment, the levels of IL-1\u03b2, IL-6, and TNF-\u03b1 in the serum and BALF were 139 determined with an enzyme-linked immunosorbent assay (ELISA) kit, and an ELISA kit was used 140 to determine the levels of GSH-Px, MPO, MDA, and SOD in the lung tissue.", [["bronchoalveolar lavage fluid", "ANATOMY", 30, 58], ["BALF", "ANATOMY", 60, 64], ["lung tissue", "ANATOMY", 67, 78], ["blood", "ANATOMY", 83, 88], ["serum", "ANATOMY", 212, 217], ["BALF", "ANATOMY", 222, 226], ["lung tissue", "ANATOMY", 392, 403], ["GSH", "CHEMICAL", 359, 362], ["GSH", "CHEMICAL", 359, 362], ["MDA", "CHEMICAL", 372, 375], ["bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 30, 58], ["BALF", "ORGANISM_SUBSTANCE", 60, 64], ["lung tissue", "TISSUE", 67, 78], ["blood", "ORGANISM_SUBSTANCE", 83, 88], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 182, 187], ["IL-6", "GENE_OR_GENE_PRODUCT", 189, 193], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 199, 204], ["serum", "ORGANISM_SUBSTANCE", 212, 217], ["BALF", "ORGANISM_SUBSTANCE", 222, 226], ["GSH-Px", "SIMPLE_CHEMICAL", 359, 365], ["MPO", "SIMPLE_CHEMICAL", 367, 370], ["MDA", "SIMPLE_CHEMICAL", 372, 375], ["SOD", "SIMPLE_CHEMICAL", 381, 384], ["lung tissue", "TISSUE", 392, 403], ["IL", "PROTEIN", 182, 184], ["IL-6", "PROTEIN", 189, 193], ["TNF-\u03b1", "PROTEIN", 199, 204], ["MPO", "PROTEIN", 367, 370], ["SOD", "PROTEIN", 381, 384], ["further analyses", "TEST", 8, 24], ["the bronchoalveolar lavage fluid (BALF)", "TEST", 26, 65], ["lung tissue", "TEST", 67, 78], ["blood", "TEST", 83, 88], ["analysis", "TEST", 139, 147], ["treatment", "TREATMENT", 157, 166], ["the levels", "TEST", 168, 178], ["IL", "TEST", 182, 184], ["IL", "TEST", 189, 191], ["TNF", "TEST", 199, 202], ["the serum", "TEST", 208, 217], ["BALF", "TEST", 222, 226], ["an enzyme", "TEST", 252, 261], ["immunosorbent assay", "TEST", 269, 288], ["an ELISA kit", "TEST", 306, 318], ["GSH", "TEST", 359, 362], ["Px", "TEST", 363, 365], ["MPO", "TEST", 367, 370], ["MDA", "TEST", 372, 375], ["SOD in the lung tissue", "PROBLEM", 381, 403], ["bronchoalveolar", "ANATOMY", 30, 45], ["lung tissue", "ANATOMY", 67, 78], ["blood", "ANATOMY", 83, 88], ["lung tissue", "ANATOMY", 392, 403]]], ["All data are 141 presented as the mean \u00b1 SD.", [["All data", "TEST", 0, 8]]], ["GraphPad Prism 6 software was employed for one-way ANOVA, and 142 a P-value \u2264 0.05 was confirmed to be statistically significant.", [["a P-value", "TEST", 66, 75]]], ["143Histologic examination 144The rat lung tissues were fixed in 4% formaldehyde, embedded in paraffin and cut into 5 \u03bcm 145 sections.", [["lung tissues", "ANATOMY", 37, 49], ["sections", "ANATOMY", 124, 132], ["formaldehyde", "CHEMICAL", 67, 79], ["formaldehyde", "CHEMICAL", 67, 79], ["paraffin", "CHEMICAL", 93, 101], ["rat", "ORGANISM", 33, 36], ["lung tissues", "TISSUE", 37, 49], ["formaldehyde", "SIMPLE_CHEMICAL", 67, 79], ["rat", "SPECIES", 33, 36], ["rat", "SPECIES", 33, 36], ["143Histologic examination", "TEST", 0, 25], ["lung tissues", "ANATOMY", 37, 49], ["fixed", "OBSERVATION_MODIFIER", 55, 60]]], ["Then, the sections underwent haematoxylin-eosin (H&E) staining.", [["sections", "ANATOMY", 10, 18], ["haematoxylin-eosin", "CHEMICAL", 29, 47], ["haematoxylin", "CHEMICAL", 29, 41], ["eosin", "CHEMICAL", 42, 47], ["haematoxylin-eosin", "SIMPLE_CHEMICAL", 29, 47], ["H&E", "SIMPLE_CHEMICAL", 49, 52]]], ["The changes in 146 pulmonary histopathology were visualized under a microscope, and the pathological scores were 147 obtained.", [["pulmonary", "ANATOMY", 19, 28], ["pulmonary", "ORGAN", 19, 28], ["The changes in 146 pulmonary histopathology", "PROBLEM", 0, 43], ["a microscope", "TEST", 66, 78], ["the pathological scores", "TEST", 84, 107], ["pulmonary", "ANATOMY", 19, 28], ["histopathology", "OBSERVATION", 29, 43]]], ["The degree of pulmonary injury was evaluated according to a previous report (Liu et al., 148 2018) .", [["pulmonary", "ANATOMY", 14, 23], ["pulmonary injury", "DISEASE", 14, 30], ["pulmonary", "ORGAN", 14, 23], ["pulmonary injury", "PROBLEM", 14, 30], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["pulmonary", "ANATOMY", 14, 23], ["injury", "OBSERVATION", 24, 30]]], ["149RNA-Seq analysis 150Total RNA was extracted with TRIzol reagent (TIANGEN, China) and detected on a 1% 151 agarose gel.", [["agarose", "SIMPLE_CHEMICAL", 109, 116], ["150Total RNA", "RNA", 20, 32], ["RNA", "TEST", 29, 32], ["TRIzol reagent", "TREATMENT", 52, 66], ["a 1% 151 agarose gel", "TREATMENT", 100, 120]]], ["The purity, concentration, and integrity of the total RNA samples were assessed prior 152 to further analysis.", [["samples", "ANATOMY", 58, 65], ["the total RNA samples", "TEST", 44, 65], ["further analysis", "TEST", 93, 109], ["concentration", "OBSERVATION_MODIFIER", 12, 25]]], ["After cluster generation, the library preparations were sequenced on the 153 Illumina HiSeqTM 4000 platform by Biomarker Technologies (Beijing, China), and the raw reads 154 were generated.", [["the library preparations", "TEST", 26, 50]]], ["Then, the raw reads were filtered by removing adapter and poly-N sequences and 155 inferior quality reads from the raw reads.", [["adapter and poly-N sequences", "DNA", 46, 74], ["poly-N sequences", "TEST", 58, 74]]], ["The clean reads were mapped to the Rattus norvegicus 156 (Rnor_6.0) reference genome sequence by the HISAT2 tools.", [["Rattus norvegicus", "ORGANISM", 35, 52], ["Rattus norvegicus 156 (Rnor_6.0) reference genome sequence", "DNA", 35, 93], ["Rattus norvegicus", "SPECIES", 35, 52], ["Rattus norvegicus", "SPECIES", 35, 52], ["clean", "OBSERVATION", 4, 9]]], ["Gene expression analysis of the different groups was performed by DESeq2.", [["DESeq2", "PROTEIN", 66, 72], ["Gene expression analysis", "TEST", 0, 24]]], ["159RNA-Seq analysis 150Genes with a P-value < 0.05 were defined as differentially expressed genes (DEGs).", [["differentially expressed genes", "DNA", 67, 97], ["DEGs", "DNA", 99, 103], ["a P-value", "TEST", 34, 43]]], ["Then, we 160 used the KOBAS3.0 platform to perform the enrichment analysis of the DEGs (Xie et al., 2011) .", [["the enrichment analysis", "TEST", 51, 74]]], ["161RNA-Seq analysis 150The volcano plot and heatmap were generated with the OmicShare online tools 162 The mRNA expression of 170 BCL2A1, CXCL1, CXCL2, CXCL6, DNAJC5, FADD, KIT, IFNG, IL1R1, IL6, IL17A, IL17F, 171 IL17C, ITGA5, MMP9, NFKBIA, NPLOC4, PPP1R15A, THBS1, TNFAIP3, TRADD, and 172 GAPDH were detected by qRT-PCR in the lung tissues.", [["lung tissues", "ANATOMY", 329, 341], ["BCL2A1", "GENE_OR_GENE_PRODUCT", 130, 136], ["CXCL1", "GENE_OR_GENE_PRODUCT", 138, 143], ["CXCL2", "GENE_OR_GENE_PRODUCT", 145, 150], ["CXCL6", "GENE_OR_GENE_PRODUCT", 152, 157], ["DNAJC5", "GENE_OR_GENE_PRODUCT", 159, 165], ["FADD", "GENE_OR_GENE_PRODUCT", 167, 171], ["KIT", "GENE_OR_GENE_PRODUCT", 173, 176], ["IFNG", "GENE_OR_GENE_PRODUCT", 178, 182], ["IL1R1", "GENE_OR_GENE_PRODUCT", 184, 189], ["IL6", "GENE_OR_GENE_PRODUCT", 191, 194], ["IL17A", "GENE_OR_GENE_PRODUCT", 196, 201], ["IL17F", "GENE_OR_GENE_PRODUCT", 203, 208], ["IL17C", "GENE_OR_GENE_PRODUCT", 214, 219], ["ITGA5", "GENE_OR_GENE_PRODUCT", 221, 226], ["MMP9", "GENE_OR_GENE_PRODUCT", 228, 232], ["NFKBIA", "GENE_OR_GENE_PRODUCT", 234, 240], ["NPLOC4", "GENE_OR_GENE_PRODUCT", 242, 248], ["PPP1R15A", "GENE_OR_GENE_PRODUCT", 250, 258], ["THBS1", "GENE_OR_GENE_PRODUCT", 260, 265], ["TNFAIP3", "GENE_OR_GENE_PRODUCT", 267, 274], ["TRADD", "GENE_OR_GENE_PRODUCT", 276, 281], ["GAPDH", "GENE_OR_GENE_PRODUCT", 291, 296], ["lung tissues", "TISSUE", 329, 341], ["BCL2A1", "PROTEIN", 130, 136], ["CXCL1", "PROTEIN", 138, 143], ["CXCL2", "PROTEIN", 145, 150], ["CXCL6", "PROTEIN", 152, 157], ["DNAJC5", "PROTEIN", 159, 165], ["FADD", "PROTEIN", 167, 171], ["KIT", "PROTEIN", 173, 176], ["IFNG", "PROTEIN", 178, 182], ["IL1R1", "PROTEIN", 184, 189], ["IL6", "PROTEIN", 191, 194], ["IL17A", "PROTEIN", 196, 201], ["IL17F", "PROTEIN", 203, 208], ["IL17C", "PROTEIN", 214, 219], ["ITGA5", "PROTEIN", 221, 226], ["MMP9", "PROTEIN", 228, 232], ["NFKBIA", "PROTEIN", 234, 240], ["NPLOC4", "PROTEIN", 242, 248], ["PPP1R15A", "PROTEIN", 250, 258], ["THBS1", "PROTEIN", 260, 265], ["TNFAIP3", "PROTEIN", 267, 274], ["TRADD", "PROTEIN", 276, 281], ["172 GAPDH", "PROTEIN", 287, 296], ["The volcano plot", "TEST", 23, 39], ["The mRNA expression", "TEST", 103, 122], ["BCL2A1", "TEST", 130, 136], ["CXCL1", "TEST", 138, 143], ["CXCL2", "TEST", 145, 150], ["CXCL6", "TEST", 152, 157], ["DNAJC5", "TEST", 159, 165], ["FADD", "TEST", 167, 171], ["KIT", "TEST", 173, 176], ["IFNG", "TEST", 178, 182], ["IL1R1", "TEST", 184, 189], ["IL6", "TEST", 191, 194], ["IL17A", "TEST", 196, 201], ["IL17F", "TEST", 203, 208], ["IL17C", "TEST", 214, 219], ["ITGA5", "TEST", 221, 226], ["MMP9", "TEST", 228, 232], ["NFKBIA", "TEST", 234, 240], ["NPLOC4", "TEST", 242, 248], ["PPP1R15A", "TEST", 250, 258], ["THBS1", "TEST", 260, 265], ["TNFAIP3", "TEST", 267, 274], ["TRADD", "TEST", 276, 281], ["GAPDH", "TEST", 291, 296], ["qRT", "TEST", 314, 317], ["PCR", "TEST", 318, 321], ["lung tissues", "ANATOMY", 329, 341]]], ["The genes primer sequences (Table S9 ) 173 J o u r n a l P r e -p r o o f for qRT-PCR were designed the primer3 platform (http://frodo.wi.mit.edu/primer3/).", [["genes primer sequences", "DNA", 4, 26], ["P r e", "DNA", 57, 62], ["-p", "DNA", 63, 65], ["qRT", "DNA", 78, 81], ["primer3 platform", "DNA", 104, 120], ["The genes primer sequences", "TEST", 0, 26], ["a l P r e -p r o o f", "TEST", 53, 73], ["qRT", "TEST", 78, 81], ["PCR", "TEST", 82, 85]]], ["All 174 qRT-PCR was repeated three times, the expression levels of candidate genes were determined 175 using the 2 -\u0394\u0394CT method.", [["candidate genes", "DNA", 67, 82], ["PCR", "TEST", 12, 15], ["the 2 -\u0394\u0394CT method", "TREATMENT", 109, 127]]], ["Expression levels were normalized against the reference gene GAPDH.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 61, 66], ["reference gene GAPDH", "DNA", 46, 66], ["Expression levels", "TEST", 0, 17]]], ["176RNA-Seq analysis 150Data are represented as mean values \u00b1 SD, and GraphPad Prism 6 software was employed for 177 one-way ANOVA, *P<0.05, ** P<0.01.", [["SD", "TEST", 61, 63], ["P", "TEST", 132, 133]]], ["178Active compounds and target screening 180In total, 23 ingredients in LJF fulfilled the two criteria simultaneously (DL \u2265 0.18 and OB \u2265 181 30%).", [["target screening", "TEST", 24, 40], ["DL", "TEST", 119, 121], ["OB", "TEST", 133, 135]]], ["However, five ingredients (scolymoside, hederagenol, heriguard, hyperin, and 182 luteolin-7-o-glucoside) did not meet the criteria of OB \u2265 30%, but they were also presented as 183 candidates.", [["scolymoside", "CHEMICAL", 27, 38], ["hederagenol", "CHEMICAL", 40, 51], ["heriguard", "CHEMICAL", 53, 62], ["hyperin", "CHEMICAL", 64, 71], ["182 luteolin-7-o-glucoside", "CHEMICAL", 77, 103], ["scolymoside", "CHEMICAL", 27, 38], ["hederagenol", "CHEMICAL", 40, 51], ["heriguard", "CHEMICAL", 53, 62], ["hyperin", "CHEMICAL", 64, 71], ["luteolin-7-o-glucoside", "CHEMICAL", 81, 103], ["scolymoside", "SIMPLE_CHEMICAL", 27, 38], ["hederagenol", "SIMPLE_CHEMICAL", 40, 51], ["heriguard", "SIMPLE_CHEMICAL", 53, 62], ["hyperin", "SIMPLE_CHEMICAL", 64, 71], ["182 luteolin-7-o-glucoside", "SIMPLE_CHEMICAL", 77, 103], ["hyperin", "TEST", 64, 71], ["luteolin", "TEST", 81, 89]]], ["Hence, 28 main ingredients were obtained as potentially active constituents in LJF, 184 including flavonoids and organic acids (Table S1 ).", [["LJF", "CHEMICAL", 79, 82], ["organic acids", "CHEMICAL", 113, 126], ["flavonoids", "CHEMICAL", 98, 108], ["LJF", "SIMPLE_CHEMICAL", 79, 82], ["flavonoids", "SIMPLE_CHEMICAL", 98, 108], ["organic acids", "SIMPLE_CHEMICAL", 113, 126], ["flavonoids", "TREATMENT", 98, 108], ["organic acids", "TEST", 113, 126], ["active", "OBSERVATION_MODIFIER", 56, 62], ["constituents", "OBSERVATION_MODIFIER", 63, 75]]], ["These 28 active components were used to 185 identify the targets in SwissTargetPrediction and SEA.", [["SEA", "PROTEIN", 94, 97]]], ["The ALI-related genes were collected from the GeneCards 187 database, and 1047 ALI-related genes were identified (Table S3 ).", [["ALI", "DISEASE", 4, 7], ["ALI", "DISEASE", 79, 82], ["ALI-related genes", "DNA", 4, 21], ["GeneCards 187 database", "DNA", 46, 68], ["ALI-related genes", "PROBLEM", 79, 96], ["ALI", "OBSERVATION", 4, 7]]], ["The shared targets of the 28 188 active compounds and ALI-related genes were identified by generating Venn diagrams.", [["ALI", "DISEASE", 54, 57], ["ALI-related genes", "DNA", 54, 71], ["Venn diagrams", "DNA", 102, 115], ["ALI-related genes", "PROBLEM", 54, 71]]], ["Ultimately, 189 94 genes were identified as both the targets of active ingredients and ALI-related genes.", [["ALI", "DISEASE", 87, 90], ["ALI-related genes", "DNA", 87, 104], ["active ingredients", "PROBLEM", 64, 82], ["ALI", "PROBLEM", 87, 90], ["active", "OBSERVATION_MODIFIER", 64, 70], ["ingredients", "OBSERVATION", 71, 82]]], ["190Compound-target network construction and analysis 191The 94 identified genes were used to construct the compound-target network with Cytoscape 192 3.7.1 software.", [["analysis", "TEST", 44, 52], ["Cytoscape", "TEST", 136, 145]]], ["Among the active compounds in LJF, eight active compounds demonstrated a 193 higher number of connections and were connected with more than 20 targets, including 194 ethyl-linolenate, hederagenol, chrysoeriol, kaempferol, luteolin, mandenol, quercetin and 195 ZINC03978781.", [["LJF", "CHEMICAL", 30, 33], ["194 ethyl-linolenate", "CHEMICAL", 162, 182], ["hederagenol", "CHEMICAL", 184, 195], ["chrysoeriol", "CHEMICAL", 197, 208], ["kaempferol", "CHEMICAL", 210, 220], ["luteolin", "CHEMICAL", 222, 230], ["mandenol", "CHEMICAL", 232, 240], ["quercetin", "CHEMICAL", 242, 251], ["ZINC03978781", "CHEMICAL", 260, 272], ["ethyl-linolenate", "CHEMICAL", 166, 182], ["hederagenol", "CHEMICAL", 184, 195], ["chrysoeriol", "CHEMICAL", 197, 208], ["kaempferol", "CHEMICAL", 210, 220], ["luteolin", "CHEMICAL", 222, 230], ["mandenol", "CHEMICAL", 232, 240], ["quercetin", "CHEMICAL", 242, 251], ["ZINC03978781", "CHEMICAL", 260, 272], ["LJF", "SIMPLE_CHEMICAL", 30, 33], ["ethyl-linolenate", "SIMPLE_CHEMICAL", 166, 182], ["hederagenol", "SIMPLE_CHEMICAL", 184, 195], ["chrysoeriol", "SIMPLE_CHEMICAL", 197, 208], ["kaempferol", "SIMPLE_CHEMICAL", 210, 220], ["luteolin", "SIMPLE_CHEMICAL", 222, 230], ["mandenol", "SIMPLE_CHEMICAL", 232, 240], ["quercetin", "SIMPLE_CHEMICAL", 242, 251], ["195 ZINC03978781", "SIMPLE_CHEMICAL", 256, 272], ["ethyl-linolenate", "TREATMENT", 166, 182], ["hederagenol", "TREATMENT", 184, 195], ["chrysoeriol", "TREATMENT", 197, 208], ["kaempferol", "TREATMENT", 210, 220], ["luteolin", "TREATMENT", 222, 230], ["mandenol", "TREATMENT", 232, 240], ["quercetin", "TREATMENT", 242, 251], ["active", "OBSERVATION_MODIFIER", 10, 16], ["compounds", "OBSERVATION_MODIFIER", 17, 26]]], ["The network analysis showed that one compound in the herbs can be linked with 196 more than one target.", [["The network analysis", "TEST", 0, 20]]], ["In the compound-target network, ALOX5 (arachidonate 5-lipoxygenase) 197 was simultaneously targeted by 11 active ingredients, AKR1B1 (aldo-keto reductase family 1 198 member B1) was targeted by 10 active ingredients, and PTGS2 (prostaglandin G/H synthase 2) 199 was targeted by 10 active ingredients (Fig.1.) .", [["arachidonate 5-lipoxygenase", "CHEMICAL", 39, 66], ["aldo-keto", "CHEMICAL", 134, 143], ["prostaglandin G/H synthase 2) 199", "CHEMICAL", 228, 261], ["arachidonate", "CHEMICAL", 39, 51], ["prostaglandin G", "CHEMICAL", 228, 243], ["H", "CHEMICAL", 244, 245], ["ALOX5", "SIMPLE_CHEMICAL", 32, 37], ["arachidonate 5-lipoxygenase) 197", "SIMPLE_CHEMICAL", 39, 71], ["AKR1B1", "SIMPLE_CHEMICAL", 126, 132], ["aldo-keto reductase family 1 198 member B1", "GENE_OR_GENE_PRODUCT", 134, 176], ["PTGS2", "GENE_OR_GENE_PRODUCT", 221, 226], ["prostaglandin G/H synthase 2", "GENE_OR_GENE_PRODUCT", 228, 256], ["aldo-keto reductase family 1 198 member B1", "PROTEIN", 134, 176], ["PTGS2", "PROTEIN", 221, 226], ["prostaglandin G/H synthase 2", "PROTEIN", 228, 256], ["ALOX5 (arachidonate 5-lipoxygenase)", "TREATMENT", 32, 67], ["AKR1B1 (aldo-keto reductase family", "TREATMENT", 126, 160], ["PTGS2 (prostaglandin G/H synthase", "TREATMENT", 221, 254]]], ["In the PPI network, eleven targets were linked 200 PTGS2 might be identified as hub genes.", [["PTGS2", "GENE_OR_GENE_PRODUCT", 51, 56], ["PTGS2", "PROTEIN", 51, 56], ["hub genes", "DNA", 80, 89]]], ["204Target-pathway network 205The 94 potential target proteins were subjected to enrichment analysis by Kobas3.0.", [["enrichment analysis", "TEST", 80, 99], ["Kobas", "TEST", 103, 108]]], ["As a 206 result, 84 significant pathways related to LJF were identified by Kobas3.0 (Table S4) .", [["LJF", "DISEASE", 52, 55], ["LJF", "CANCER", 52, 55], ["LJF", "DNA", 52, 55], ["significant pathways", "PROBLEM", 20, 40], ["Kobas", "TEST", 75, 80]]], ["Then, the 207 target-pathway network was constructed (Fig.S2 ), containing 86 targets and 84 corresponding 208 pathways.", [["Fig.S2", "DNA", 54, 60]]], ["It was obvious that the targets for LJF were mainly interlinked in three pathways, 209 including metabolic pathways (degree = 25), neuroactive ligand-receptor interaction pathways 210 (degree = 23), and pathways involved in cancer (degree = 19).", [["cancer", "ANATOMY", 224, 230], ["cancer", "DISEASE", 224, 230], ["LJF", "GENE_OR_GENE_PRODUCT", 36, 39], ["cancer", "CANCER", 224, 230], ["LJF", "PROTEIN", 36, 39], ["LJF", "TEST", 36, 39], ["metabolic pathways", "TEST", 97, 115], ["neuroactive ligand", "TEST", 131, 149], ["cancer", "OBSERVATION", 224, 230]]], ["Moreover, we identified the 211 calcium signalling pathway (degree = 12) and NOD-like receptor signalling pathway (degree = 212 10).", [["calcium", "CHEMICAL", 32, 39], ["calcium", "CHEMICAL", 32, 39], ["calcium", "SIMPLE_CHEMICAL", 32, 39], ["NOD-like receptor", "GENE_OR_GENE_PRODUCT", 77, 94], ["NOD-like receptor", "PROTEIN", 77, 94], ["calcium signalling pathway", "TEST", 32, 58], ["degree", "TEST", 60, 66], ["NOD", "TEST", 77, 80]]], ["Fortunately, we also observed that these targets participated in pathways linked to immune 213 and inflammatory signalling pathways, including human cytomegalovirus infection-associated 214 pathways, the IL-17 signalling pathway, the PPAR signalling pathway, the PI3K-Akt signalling 215 pathway, human T-cell leukaemia virus 1 infection-associated pathways, pathways involved in 216 inflammatory mediator regulation of TRP channels, the Jak-STAT signalling pathway, natural 217 killer cell-mediated cytotoxicity-associated pathways, T cell receptor signalling pathway, 218 NF-kappa B signalling pathway, TNF signalling pathway and the Toll-like receptor signalling 219 pathway.", [["natural 217 killer cell", "ANATOMY", 466, 489], ["T cell", "ANATOMY", 533, 539], ["cytomegalovirus infection", "DISEASE", 149, 174], ["infection", "DISEASE", 327, 336], ["immune 213", "GENE_OR_GENE_PRODUCT", 84, 94], ["human", "ORGANISM", 143, 148], ["cytomegalovirus", "ORGANISM", 149, 164], ["IL-17", "GENE_OR_GENE_PRODUCT", 204, 209], ["PPAR", "GENE_OR_GENE_PRODUCT", 234, 238], ["PI3K", "GENE_OR_GENE_PRODUCT", 263, 267], ["Akt", "GENE_OR_GENE_PRODUCT", 268, 271], ["215", "GENE_OR_GENE_PRODUCT", 283, 286], ["human T-cell leukaemia virus 1", "ORGANISM", 296, 326], ["TRP", "GENE_OR_GENE_PRODUCT", 419, 422], ["Jak-", "GENE_OR_GENE_PRODUCT", 437, 441], ["STAT", "GENE_OR_GENE_PRODUCT", 441, 445], ["natural 217 killer cell", "CELL", 466, 489], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 533, 548], ["NF-kappa B", "GENE_OR_GENE_PRODUCT", 573, 583], ["TNF", "GENE_OR_GENE_PRODUCT", 604, 607], ["Toll-like receptor signalling 219", "GENE_OR_GENE_PRODUCT", 635, 668], ["PPAR", "PROTEIN", 234, 238], ["PI3K", "PROTEIN", 263, 267], ["Akt", "PROTEIN", 268, 271], ["TRP channels", "PROTEIN", 419, 431], ["STAT", "PROTEIN", 441, 445], ["T cell receptor", "PROTEIN", 533, 548], ["TNF", "PROTEIN", 604, 607], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 296, 301], ["leukaemia virus 1", "SPECIES", 309, 326], ["human cytomegalovirus", "SPECIES", 143, 164], ["human", "SPECIES", 296, 301], ["inflammatory signalling pathways", "PROBLEM", 99, 131], ["human cytomegalovirus infection", "PROBLEM", 143, 174], ["the IL", "TEST", 200, 206], ["the PPAR signalling pathway", "TEST", 230, 257], ["the PI3K", "TEST", 259, 267], ["Akt signalling", "TEST", 268, 282], ["human T-cell leukaemia virus 1 infection", "PROBLEM", 296, 336], ["cytotoxicity", "TEST", 499, 511], ["cytomegalovirus infection", "OBSERVATION", 149, 174]]], ["220LJF inhibits the expression of IL-6, TNF-\u03b1, and IL-1\u03b2 in LPS-induced ALI rats 221To detect the anti-inflammatory effects of LJF, we examined the levels of IL-6, TNF-\u03b1, and 222 IL-1\u03b2 in serum and BALF after treatment with LPS, LJF and DXSM.", [["serum", "ANATOMY", 188, 193], ["BALF", "ANATOMY", 198, 202], ["220LJF", "CHEMICAL", 0, 6], ["LPS", "CHEMICAL", 60, 63], ["ALI", "DISEASE", 72, 75], ["LPS", "CHEMICAL", 224, 227], ["DXSM", "CHEMICAL", 237, 241], ["220LJF", "SIMPLE_CHEMICAL", 0, 6], ["IL-6", "GENE_OR_GENE_PRODUCT", 34, 38], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 40, 45], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 51, 56], ["LPS", "SIMPLE_CHEMICAL", 60, 63], ["rats", "ORGANISM", 76, 80], ["221To", "SIMPLE_CHEMICAL", 81, 86], ["LJF", "SIMPLE_CHEMICAL", 127, 130], ["IL-6", "GENE_OR_GENE_PRODUCT", 158, 162], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 164, 169], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 179, 184], ["serum", "ORGANISM_SUBSTANCE", 188, 193], ["BALF", "ORGANISM_SUBSTANCE", 198, 202], ["LPS", "SIMPLE_CHEMICAL", 224, 227], ["LJF", "SIMPLE_CHEMICAL", 229, 232], ["DXSM", "SIMPLE_CHEMICAL", 237, 241], ["IL-6", "PROTEIN", 34, 38], ["TNF", "PROTEIN", 40, 43], ["IL-1\u03b2", "PROTEIN", 51, 56], ["IL-6", "PROTEIN", 158, 162], ["TNF", "PROTEIN", 164, 167], ["222 IL-1\u03b2", "PROTEIN", 175, 184], ["BALF", "CELL_TYPE", 198, 202], ["rats", "SPECIES", 76, 80], ["IL", "TEST", 34, 36], ["TNF", "TEST", 40, 43], ["IL", "TEST", 51, 53], ["LPS", "TEST", 60, 63], ["ALI rats", "TEST", 72, 80], ["the levels", "TEST", 144, 154], ["IL", "TEST", 158, 160], ["TNF", "TEST", 164, 167], ["IL", "TEST", 179, 181], ["serum", "TEST", 188, 193], ["treatment", "TREATMENT", 209, 218], ["LPS", "TREATMENT", 224, 227], ["LJF", "TREATMENT", 229, 232], ["DXSM", "TEST", 237, 241]]], ["The results showed that 223 exposure of serum and BALF to LPS increased the production of these inflammatory cytokines 224 (P<0.05).", [["serum", "ANATOMY", 40, 45], ["BALF", "ANATOMY", 50, 54], ["LPS", "CHEMICAL", 58, 61], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["BALF", "ORGANISM_SUBSTANCE", 50, 54], ["LPS", "SIMPLE_CHEMICAL", 58, 61], ["BALF", "CELL_TYPE", 50, 54], ["inflammatory cytokines", "PROTEIN", 96, 118], ["serum", "TEST", 40, 45], ["BALF", "TEST", 50, 54], ["LPS", "TEST", 58, 61], ["these inflammatory cytokines", "TEST", 90, 118], ["P", "TEST", 124, 125], ["inflammatory", "OBSERVATION_MODIFIER", 96, 108]]], ["However, production of these inflammatory cytokines (IL-6, TNF-\u03b1, and IL-1\u03b2) were 225 significantly inhibited by LJF and DXSM (P<0.05) ( Fig.3A and 3B) .", [["IL-6", "GENE_OR_GENE_PRODUCT", 53, 57], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 59, 64], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 70, 75], ["LJF", "SIMPLE_CHEMICAL", 113, 116], ["DXSM", "SIMPLE_CHEMICAL", 121, 125], ["inflammatory cytokines", "PROTEIN", 29, 51], ["IL-6", "PROTEIN", 53, 57], ["TNF", "PROTEIN", 59, 62], ["\u03b1", "PROTEIN", 63, 64], ["IL-1\u03b2", "PROTEIN", 70, 75], ["these inflammatory cytokines", "TEST", 23, 51], ["IL", "TEST", 53, 55], ["TNF", "TEST", 59, 62], ["IL", "TEST", 70, 72], ["DXSM", "TEST", 121, 125], ["inflammatory", "OBSERVATION_MODIFIER", 29, 41]]], ["Then, the level of oxidative 226 stress was measured, and LPS-induced ALI could increase the levels of MDA and MPO and 227 decrease the activities of SOD and GSH-Px in the lung tissue (P<0.05) (Fig.3C) .", [["lung tissue", "ANATOMY", 172, 183], ["LPS", "CHEMICAL", 58, 61], ["ALI", "DISEASE", 70, 73], ["MDA", "CHEMICAL", 103, 106], ["GSH", "CHEMICAL", 158, 161], ["MDA", "CHEMICAL", 103, 106], ["GSH", "CHEMICAL", 158, 161], ["LPS", "SIMPLE_CHEMICAL", 58, 61], ["MDA", "SIMPLE_CHEMICAL", 103, 106], ["MPO", "SIMPLE_CHEMICAL", 111, 114], ["SOD", "SIMPLE_CHEMICAL", 150, 153], ["GSH-Px", "GENE_OR_GENE_PRODUCT", 158, 164], ["lung tissue", "TISSUE", 172, 183], ["MPO", "PROTEIN", 111, 114], ["SOD", "PROTEIN", 150, 153], ["LPS", "TEST", 58, 61], ["ALI", "PROBLEM", 70, 73], ["MDA", "TEST", 103, 106], ["MPO", "TEST", 111, 114], ["SOD", "TEST", 150, 153], ["GSH", "TEST", 158, 161], ["lung", "ANATOMY", 172, 176], ["tissue", "ANATOMY_MODIFIER", 177, 183]]], ["Interestingly, the 228 levels of SOD and GSH-Px were significantly enhanced by LJF and DXSM (P<0.05).", [["GSH", "CHEMICAL", 41, 44], ["GSH", "CHEMICAL", 41, 44], ["SOD", "GENE_OR_GENE_PRODUCT", 33, 36], ["GSH-Px", "GENE_OR_GENE_PRODUCT", 41, 47], ["LJF", "SIMPLE_CHEMICAL", 79, 82], ["SOD", "PROTEIN", 33, 36], ["SOD", "TEST", 33, 36], ["GSH", "TEST", 41, 44], ["DXSM", "TEST", 87, 91]]], ["229LJF alleviated pulmonary morphological damage in LPS-induced ALI rats 230H&E staining was used to detect the pathological changes in the lungs.", [["pulmonary", "ANATOMY", 18, 27], ["lungs", "ANATOMY", 140, 145], ["229LJF", "CHEMICAL", 0, 6], ["LPS", "CHEMICAL", 52, 55], ["ALI", "DISEASE", 64, 67], ["229LJF", "SIMPLE_CHEMICAL", 0, 6], ["pulmonary", "ORGAN", 18, 27], ["LPS", "SIMPLE_CHEMICAL", 52, 55], ["rats", "ORGANISM", 68, 72], ["lungs", "ORGAN", 140, 145], ["rats", "SPECIES", 68, 72], ["alleviated pulmonary morphological damage in LPS", "PROBLEM", 7, 55], ["the pathological changes in the lungs", "PROBLEM", 108, 145], ["alleviated", "OBSERVATION_MODIFIER", 7, 17], ["pulmonary", "ANATOMY", 18, 27], ["morphological", "OBSERVATION_MODIFIER", 28, 41], ["damage", "OBSERVATION", 42, 48], ["LPS", "OBSERVATION_MODIFIER", 52, 55], ["pathological", "OBSERVATION", 112, 124], ["lungs", "ANATOMY", 140, 145]]], ["After treatment with 231 LPS, the rat lung tissue showed increases in inflammatory cell infiltrates and alveolar histological 232 structure damage compared with the lung tissue in the Ctrl group.", [["lung tissue", "ANATOMY", 38, 49], ["inflammatory cell", "ANATOMY", 70, 87], ["alveolar", "ANATOMY", 104, 112], ["lung tissue", "ANATOMY", 165, 176], ["LPS", "CHEMICAL", 25, 28], ["LPS", "SIMPLE_CHEMICAL", 25, 28], ["rat", "ORGANISM", 34, 37], ["lung tissue", "TISSUE", 38, 49], ["inflammatory cell", "CELL", 70, 87], ["alveolar", "TISSUE", 104, 112], ["lung tissue", "TISSUE", 165, 176], ["rat", "SPECIES", 34, 37], ["rat", "SPECIES", 34, 37], ["treatment", "TREATMENT", 6, 15], ["LPS", "TREATMENT", 25, 28], ["the rat lung tissue", "TEST", 30, 49], ["inflammatory cell infiltrates", "PROBLEM", 70, 99], ["alveolar histological 232 structure damage", "PROBLEM", 104, 146], ["lung", "ANATOMY", 38, 42], ["increases", "OBSERVATION_MODIFIER", 57, 66], ["inflammatory cell infiltrates", "OBSERVATION", 70, 99], ["alveolar", "ANATOMY_MODIFIER", 104, 112], ["histological", "OBSERVATION_MODIFIER", 113, 125], ["232 structure", "OBSERVATION", 126, 139], ["lung", "ANATOMY", 165, 169], ["tissue", "OBSERVATION", 170, 176], ["Ctrl", "ANATOMY", 184, 188]]], ["In our study, the ALI group 233 showed severe alveolar oedema fluid accumulation, alveolar capillary congestion and bronchial 234 epithelial detachment (Fig.4B) .", [["alveolar", "ANATOMY", 46, 54], ["alveolar capillary", "ANATOMY", 82, 100], ["bronchial 234 epithelial", "ANATOMY", 116, 140], ["ALI", "DISEASE", 18, 21], ["alveolar oedema", "DISEASE", 46, 61], ["alveolar", "TISSUE", 46, 54], ["alveolar capillary", "TISSUE", 82, 100], ["epithelial", "TISSUE", 130, 140], ["our study", "TEST", 3, 12], ["the ALI group", "TEST", 14, 27], ["severe alveolar oedema fluid accumulation", "PROBLEM", 39, 80], ["alveolar capillary congestion", "PROBLEM", 82, 111], ["bronchial 234 epithelial detachment", "PROBLEM", 116, 151], ["ALI", "ANATOMY", 18, 21], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["alveolar", "ANATOMY_MODIFIER", 46, 54], ["oedema", "OBSERVATION", 55, 61], ["fluid accumulation", "OBSERVATION", 62, 80], ["alveolar", "ANATOMY_MODIFIER", 82, 90], ["capillary", "ANATOMY", 91, 100], ["congestion", "OBSERVATION", 101, 111], ["bronchial", "ANATOMY", 116, 125], ["234 epithelial detachment", "OBSERVATION", 126, 151]]], ["LJF was superior to DXSM in alleviating LPS-induced ALI ( (Table S5) .", [["LJF", "CHEMICAL", 0, 3], ["DXSM", "CHEMICAL", 20, 24], ["LPS", "CHEMICAL", 40, 43], ["ALI", "DISEASE", 52, 55], ["LJF", "CHEMICAL", 0, 3], ["LJF", "SIMPLE_CHEMICAL", 0, 3], ["DXSM", "SIMPLE_CHEMICAL", 20, 24], ["LPS", "SIMPLE_CHEMICAL", 40, 43], ["alleviating LPS", "PROBLEM", 28, 43], ["ALI", "PROBLEM", 52, 55], ["ALI", "ANATOMY", 52, 55]]], ["To determine the differentially 246 expressed genes (DEGs), a P-value < 0.05 was used as the cut-off value for gene expression in the 247 Ctrl, ALI, ALI-LJF, and ALI-DXMS groups, which was detected by pairwise comparisons 248 between the ALI group and the Ctrl, ALI-LJF, and ALI-DXMS groups.", [["ALI", "DISEASE", 144, 147], ["ALI", "DISEASE", 149, 152], ["ALI", "DISEASE", 162, 165], ["ALI", "DISEASE", 238, 241], ["ALI", "DISEASE", 262, 265], ["ALI", "DISEASE", 275, 278], ["differentially 246 expressed genes", "DNA", 17, 51], ["DEGs", "DNA", 53, 57], ["a P-value", "TEST", 60, 69], ["gene expression", "TEST", 111, 126], ["ALI", "TEST", 144, 147], ["ALI", "TEST", 149, 152], ["the Ctrl", "TEST", 252, 260], ["ALI", "TEST", 262, 265], ["ALI", "ANATOMY", 144, 147], ["ALI", "ANATOMY", 149, 152], ["ALI", "ANATOMY", 162, 165], ["Ctrl", "ANATOMY", 256, 260], ["ALI", "ANATOMY", 262, 265], ["ALI", "ANATOMY", 275, 278]]], ["As a result, 7,811 DEGs 249 in rat lung were identified after LPS stimulation, whereas 775 and 3,654 DEGs were identified in 250 rat lung tissue treated with LJF and DXSM, respectively.", [["lung", "ANATOMY", 35, 39], ["lung tissue", "ANATOMY", 133, 144], ["LPS", "CHEMICAL", 62, 65], ["rat", "ORGANISM", 31, 34], ["lung", "ORGAN", 35, 39], ["LPS", "SIMPLE_CHEMICAL", 62, 65], ["rat", "ORGANISM", 129, 132], ["lung tissue", "TISSUE", 133, 144], ["LJF", "SIMPLE_CHEMICAL", 158, 161], ["rat", "SPECIES", 31, 34], ["rat", "SPECIES", 129, 132], ["rat", "SPECIES", 31, 34], ["rat", "SPECIES", 129, 132], ["DEGs", "TEST", 19, 23], ["LPS stimulation", "TEST", 62, 77], ["DEGs", "TEST", 101, 105], ["LJF and DXSM", "TREATMENT", 158, 170], ["lung", "ANATOMY", 35, 39], ["lung tissue", "ANATOMY", 133, 144]]], ["Overall, 1,688 upregulated and 1,966 251 downregulated DEGs were identified in the ALI vs. ALI-DXSM groups, and 340 upregulated and 252 435 downregulated DEGs were identified in the ALI vs. ALI-LJF groups ( Fig.5A-C) .", [["ALI", "DISEASE", 83, 86], ["ALI", "DISEASE", 91, 94], ["ALI", "DISEASE", 182, 185], ["ALI", "DISEASE", 190, 193], ["downregulated DEGs", "TEST", 41, 59], ["downregulated DEGs", "TEST", 140, 158], ["ALI", "TEST", 190, 193], ["ALI", "ANATOMY", 83, 86], ["ALI", "ANATOMY", 182, 185]]], ["In brief, 253 after removing the duplicate genes, 509 DEG genes were associated with the ALI group that were 254 also affected in the Ctrl, ALI and ALI-LJF groups; 2,546 genes were associated with the Ctrl, ALI 255 and ALI-DXSM groups; and only 298 key DEG genes were associated with the Ctrl, ALI, 256 ALI-LJF and ALI-DXSM groups (Fig.5D) .", [["ALI", "DISEASE", 89, 92], ["ALI", "DISEASE", 140, 143], ["ALI", "DISEASE", 148, 151], ["ALI", "DISEASE", 294, 297], ["ALI", "DISEASE", 303, 306], ["ALI", "DISEASE", 315, 318], ["DEG", "GENE_OR_GENE_PRODUCT", 54, 57], ["DEG", "GENE_OR_GENE_PRODUCT", 253, 256], ["DEG genes", "DNA", 54, 63], ["Ctrl, ALI and ALI-LJF groups", "DNA", 134, 162], ["DEG genes", "DNA", 253, 262], ["509 DEG genes", "PROBLEM", 50, 63], ["ALI", "TEST", 207, 210], ["ALI", "TEST", 219, 222], ["ALI", "TEST", 303, 306], ["ALI", "PROBLEM", 315, 318], ["Ctrl", "ANATOMY", 134, 138], ["ALI", "ANATOMY", 140, 143], ["ALI", "ANATOMY", 148, 151], ["ALI", "ANATOMY", 294, 297], ["ALI", "ANATOMY", 315, 318]]], ["257LJF alleviated pulmonary morphological damage in LPS-induced ALI rats 230To characterize these differentially expressed genes, trend analysis was applied to determine 258 the expression patterns of the 509 DEGs in the Ctrl, ALI and ALI-LJF groups (Table S6 ).", [["pulmonary", "ANATOMY", 18, 27], ["257LJF", "CHEMICAL", 0, 6], ["pulmonary morphological damage", "DISEASE", 18, 48], ["LPS", "CHEMICAL", 52, 55], ["ALI", "DISEASE", 64, 67], ["ALI", "DISEASE", 227, 230], ["257LJF", "SIMPLE_CHEMICAL", 0, 6], ["pulmonary", "ORGAN", 18, 27], ["LPS", "SIMPLE_CHEMICAL", 52, 55], ["rats", "ORGANISM", 68, 72], ["rats", "SPECIES", 68, 72], ["alleviated pulmonary morphological damage in LPS", "PROBLEM", 7, 55], ["ALI rats", "TEST", 64, 72], ["trend analysis", "TEST", 130, 144], ["pulmonary", "ANATOMY", 18, 27], ["morphological damage", "OBSERVATION", 28, 48], ["ALI", "ANATOMY", 227, 230], ["ALI", "ANATOMY", 235, 238]]], ["In the 259 J o u r n a l P r e -p r o o f ALI vs. Ctrl groups, the expression of 255 genes displayed an initial increase, but there was a 260 decrease in the ALI vs ALI-LJF groups; however, the expression of 217 genes exhibited a 261 reduction in the ALI vs. ALI-LJF groups, but there was a subsequent increase in the ALI vs. 262 ALI-LJF groups (Fig.6) .", [["ALI", "DISEASE", 42, 45], ["ALI", "DISEASE", 158, 161], ["ALI", "DISEASE", 165, 168], ["ALI", "DISEASE", 251, 254], ["ALI", "DISEASE", 259, 262], ["ALI", "DISEASE", 318, 321], ["ALI", "DISEASE", 330, 333], ["255 genes", "DNA", 81, 90], ["217 genes", "DNA", 208, 217], ["ALI vs", "TEST", 42, 48], ["the ALI", "PROBLEM", 314, 321], ["ALI", "ANATOMY", 42, 45], ["increase", "OBSERVATION_MODIFIER", 112, 120], ["decrease", "OBSERVATION_MODIFIER", 142, 150], ["ALI", "ANATOMY", 158, 161], ["ALI", "ANATOMY", 251, 254], ["increase", "OBSERVATION_MODIFIER", 302, 310], ["ALI", "ANATOMY", 318, 321]]], ["Specifically, eight genes (DYRK1A, CA4, IL6, PTAFR, ARG1, MGLL, 263 LTB4R, and TYMP) among the DEGs of the ALI-LJF group were predicted as targets of active 264 ingredients of LJF.", [["ALI", "DISEASE", 107, 110], ["DYRK1A", "GENE_OR_GENE_PRODUCT", 27, 33], ["CA4", "GENE_OR_GENE_PRODUCT", 35, 38], ["IL6", "GENE_OR_GENE_PRODUCT", 40, 43], ["PTAFR", "GENE_OR_GENE_PRODUCT", 45, 50], ["ARG1", "GENE_OR_GENE_PRODUCT", 52, 56], ["MGLL, 263 LTB4R", "GENE_OR_GENE_PRODUCT", 58, 73], ["TYMP", "GENE_OR_GENE_PRODUCT", 79, 83], ["LJF", "SIMPLE_CHEMICAL", 176, 179], ["DYRK1A", "DNA", 27, 33], ["CA4", "DNA", 35, 38], ["IL6", "DNA", 40, 43], ["PTAFR", "DNA", 45, 50], ["ARG1", "DNA", 52, 56], ["MGLL", "DNA", 58, 62], ["263 LTB4R", "DNA", 64, 73], ["TYMP", "DNA", 79, 83], ["DEGs", "DNA", 95, 99], ["ALI-LJF group", "DNA", 107, 120], ["DYRK1A", "TEST", 27, 33], ["CA4", "TEST", 35, 38], ["IL6", "TEST", 40, 43], ["PTAFR", "TEST", 45, 50], ["ARG1", "TEST", 52, 56], ["MGLL", "TEST", 58, 62], ["LTB4R", "TEST", 68, 73], ["ALI", "ANATOMY", 107, 110]]], ["265Verification of RNA-Seq Results by qRT-PCR 266To verify the reliability of the gene expression data obtained by RNA-Seq, eight genes 267 (IL1R1, DNAJC5, THBS1, NPLOC4, BCL2A1, PPP1R15A, KIT, and ITGA5) were randomly 268 selected for qRT-PCR detection.", [["IL1R1", "GENE_OR_GENE_PRODUCT", 141, 146], ["DNAJC5", "GENE_OR_GENE_PRODUCT", 148, 154], ["THBS1", "GENE_OR_GENE_PRODUCT", 156, 161], ["NPLOC4", "GENE_OR_GENE_PRODUCT", 163, 169], ["BCL2A1", "GENE_OR_GENE_PRODUCT", 171, 177], ["PPP1R15A", "GENE_OR_GENE_PRODUCT", 179, 187], ["KIT", "GENE_OR_GENE_PRODUCT", 189, 192], ["ITGA5", "GENE_OR_GENE_PRODUCT", 198, 203], ["qRT-PCR 266To", "DNA", 38, 51], ["genes 267", "DNA", 130, 139], ["IL1R1", "DNA", 141, 146], ["DNAJC5", "DNA", 148, 154], ["THBS1", "DNA", 156, 161], ["NPLOC4", "DNA", 163, 169], ["BCL2A1", "DNA", 171, 177], ["PPP1R15A", "DNA", 179, 187], ["KIT", "DNA", 189, 192], ["ITGA5", "DNA", 198, 203], ["qRT", "DNA", 236, 239], ["RNA", "TEST", 19, 22], ["qRT", "TEST", 38, 41], ["PCR", "TEST", 42, 45], ["the gene expression data", "TEST", 78, 102], ["RNA", "TEST", 115, 118], ["IL1R1", "TEST", 141, 146], ["THBS1", "TEST", 156, 161], ["NPLOC4", "TEST", 163, 169], ["BCL2A1", "TEST", 171, 177], ["PPP1R15A", "TEST", 179, 187], ["KIT", "TEST", 189, 192], ["qRT", "TEST", 236, 239], ["PCR detection", "TEST", 240, 253]]], ["The qRT-PCR results showed that the tendency of gene 269 expression was consistent with the RNA-Seq results.", [["The qRT-PCR", "TEST", 0, 11], ["consistent with", "UNCERTAINTY", 72, 87]]], ["For each gene, the qRT-PCR expression 270 results showed a similar tendency to the RNA-Seq results (Fig.S3) .", [["qRT", "DNA", 19, 22], ["the qRT", "TEST", 15, 22], ["PCR expression", "TEST", 23, 37]]], ["The results showed that the 271 RNA-Seq results were credible in this study.", [["this study", "TEST", 65, 75]]], ["272Pathway enrichment analysis 273To thoroughly investigate the potential pathways involved in the immune and inflammatory 274 responses, the Kobas3.0 platform was employed for KEGG pathway analysis of these DEGs.", [["enrichment analysis", "TEST", 11, 30], ["the Kobas", "TEST", 138, 147], ["KEGG pathway analysis", "TEST", 177, 198]]], ["The 275 KEGG analysis showed that 40 KEGG pathways were significantly enriched for these DEGs 276 (Table S7; signalling pathway (Fig.7) .", [["Table S7", "GENE_OR_GENE_PRODUCT", 99, 107], ["DEGs 276", "DNA", 89, 97], ["Fig.7", "DNA", 129, 134], ["The 275 KEGG analysis", "TEST", 0, 21], ["KEGG pathways", "TEST", 37, 50], ["these DEGs", "TEST", 83, 93], ["Table S7", "TEST", 99, 107], ["signalling pathway", "TEST", 109, 127]]], ["Within the four classic immune pathways (rno04657, rno04668, 283 rno04064, and rno04630), we identified 24 candidate genes associated with ALI: CXCL2, CXCL1, 284 CXCL6, IL10, LIF, IL12RB2, IL22, NFKBIA, IFNG, IL12A, IL6, BIRC2, IL17A, IL17C, IL17F, 285 CXCL12, IL1R1, TRADD, MMP9, CCND1, IL19 , FADD, BCL2A1, and TNFAIP3.", [["ALI", "DISEASE", 139, 142], ["rno04657", "GENE_OR_GENE_PRODUCT", 41, 49], ["rno04668", "GENE_OR_GENE_PRODUCT", 51, 59], ["rno04064", "GENE_OR_GENE_PRODUCT", 65, 73], ["rno04630", "GENE_OR_GENE_PRODUCT", 79, 87], ["CXCL2", "GENE_OR_GENE_PRODUCT", 144, 149], ["CXCL1", "GENE_OR_GENE_PRODUCT", 151, 156], ["CXCL6", "GENE_OR_GENE_PRODUCT", 162, 167], ["IL10", "GENE_OR_GENE_PRODUCT", 169, 173], ["LIF", "GENE_OR_GENE_PRODUCT", 175, 178], ["IL12RB2", "GENE_OR_GENE_PRODUCT", 180, 187], ["IL22", "GENE_OR_GENE_PRODUCT", 189, 193], ["NFKBIA", "GENE_OR_GENE_PRODUCT", 195, 201], ["IFNG", "GENE_OR_GENE_PRODUCT", 203, 207], ["IL12A", "GENE_OR_GENE_PRODUCT", 209, 214], ["IL6", "GENE_OR_GENE_PRODUCT", 216, 219], ["BIRC2", "GENE_OR_GENE_PRODUCT", 221, 226], ["IL17A", "GENE_OR_GENE_PRODUCT", 228, 233], ["IL17C", "GENE_OR_GENE_PRODUCT", 235, 240], ["IL17F", "GENE_OR_GENE_PRODUCT", 242, 247], ["CXCL12", "GENE_OR_GENE_PRODUCT", 253, 259], ["IL1R1", "GENE_OR_GENE_PRODUCT", 261, 266], ["TRADD", "GENE_OR_GENE_PRODUCT", 268, 273], ["MMP9", "GENE_OR_GENE_PRODUCT", 275, 279], ["CCND1", "GENE_OR_GENE_PRODUCT", 281, 286], ["IL19", "GENE_OR_GENE_PRODUCT", 288, 292], ["FADD", "GENE_OR_GENE_PRODUCT", 295, 299], ["BCL2A1", "GENE_OR_GENE_PRODUCT", 301, 307], ["TNFAIP3", "GENE_OR_GENE_PRODUCT", 313, 320], ["CXCL2", "PROTEIN", 144, 149], ["CXCL1", "PROTEIN", 151, 156], ["IL10", "DNA", 169, 173], ["LIF", "PROTEIN", 175, 178], ["IL12RB2", "DNA", 180, 187], ["IL22", "DNA", 189, 193], ["NFKBIA", "DNA", 195, 201], ["IFNG", "DNA", 203, 207], ["IL12A", "DNA", 209, 214], ["IL6", "DNA", 216, 219], ["BIRC2", "DNA", 221, 226], ["IL17A", "DNA", 228, 233], ["IL17C", "DNA", 235, 240], ["IL17F", "DNA", 242, 247], ["CXCL12", "DNA", 253, 259], ["IL1R1", "DNA", 261, 266], ["TRADD", "DNA", 268, 273], ["MMP9", "DNA", 275, 279], ["CCND1", "DNA", 281, 286], ["IL19", "DNA", 288, 292], ["FADD", "DNA", 295, 299], ["BCL2A1", "DNA", 301, 307], ["TNFAIP3", "DNA", 313, 320], ["CXCL2", "TEST", 144, 149], ["CXCL1", "TEST", 151, 156], ["CXCL6", "TEST", 162, 167], ["IL10", "TEST", 169, 173], ["LIF", "TEST", 175, 178], ["IL12RB2", "TEST", 180, 187], ["IL22", "TEST", 189, 193], ["NFKBIA", "TEST", 195, 201], ["IFNG", "TEST", 203, 207], ["IL12A", "TEST", 209, 214], ["IL6", "TEST", 216, 219], ["BIRC2", "TEST", 221, 226], ["IL17A", "TEST", 228, 233], ["IL17C", "TEST", 235, 240], ["IL17F", "TEST", 242, 247], ["CXCL12", "TEST", 253, 259], ["IL1R1", "TEST", 261, 266], ["TRADD", "TEST", 268, 273], ["MMP9", "TEST", 275, 279], ["CCND1", "TEST", 281, 286], ["IL19", "TEST", 288, 292], ["FADD", "TEST", 295, 299], ["BCL2A1", "TEST", 301, 307], ["TNFAIP3", "TEST", 313, 320]]], ["286LJF treatment activated the IL-17 signalling pathway 287In this study, IL-17 signalling pathway involved in thirteen DEGs, including CXCL2, 288 CXCL1, CXCL6, NFKBIA, IFNG, IL6, IL17A, IL17F, IL17C, MMP9, TNFAIP3, FADD and 289 TRADD.", [["286LJF", "CHEMICAL", 0, 6], ["286LJF", "SIMPLE_CHEMICAL", 0, 6], ["IL-17", "GENE_OR_GENE_PRODUCT", 31, 36], ["IL-17", "GENE_OR_GENE_PRODUCT", 74, 79], ["CXCL2", "GENE_OR_GENE_PRODUCT", 136, 141], ["CXCL1", "GENE_OR_GENE_PRODUCT", 147, 152], ["CXCL6", "GENE_OR_GENE_PRODUCT", 154, 159], ["NFKBIA", "GENE_OR_GENE_PRODUCT", 161, 167], ["IFNG", "GENE_OR_GENE_PRODUCT", 169, 173], ["IL6", "GENE_OR_GENE_PRODUCT", 175, 178], ["IL17A", "GENE_OR_GENE_PRODUCT", 180, 185], ["IL17F", "GENE_OR_GENE_PRODUCT", 187, 192], ["IL17C", "GENE_OR_GENE_PRODUCT", 194, 199], ["MMP9", "GENE_OR_GENE_PRODUCT", 201, 205], ["TNFAIP3", "GENE_OR_GENE_PRODUCT", 207, 214], ["FADD", "GENE_OR_GENE_PRODUCT", 216, 220], ["TRADD", "GENE_OR_GENE_PRODUCT", 229, 234], ["CXCL2", "PROTEIN", 136, 141], ["CXCL1", "PROTEIN", 147, 152], ["CXCL6", "PROTEIN", 154, 159], ["NFKBIA", "PROTEIN", 161, 167], ["IFNG", "PROTEIN", 169, 173], ["IL6", "PROTEIN", 175, 178], ["IL17A", "PROTEIN", 180, 185], ["IL17F", "PROTEIN", 187, 192], ["IL17C", "DNA", 194, 199], ["MMP9", "DNA", 201, 205], ["TNFAIP3", "PROTEIN", 207, 214], ["FADD", "PROTEIN", 216, 220], ["289 TRADD", "PROTEIN", 225, 234], ["the IL", "TREATMENT", 27, 33], ["this study", "TEST", 62, 72], ["IL", "TEST", 74, 76], ["CXCL2", "TEST", 136, 141], ["CXCL1", "TEST", 147, 152], ["CXCL6", "TEST", 154, 159], ["NFKBIA", "TEST", 161, 167], ["IFNG", "TEST", 169, 173], ["IL6", "TEST", 175, 178], ["IL17A", "TEST", 180, 185], ["IL17F", "TEST", 187, 192], ["IL17C", "TEST", 194, 199], ["MMP9", "TEST", 201, 205], ["TNFAIP3", "TEST", 207, 214], ["FADD", "TEST", 216, 220]]], ["LJF significantly inhibited CXCL2, CXCL1, CXCL6, NFKBIA, IFNG, IL6, IL17A, 290 IL17F, IL17C, MMP9, and TNFAIP3 mRNA expression in lung tissue homogenates according to 291 RNA-Seq, which indicates that the IL-17 signalling pathway is critical for treatment of 292 LPS-induced ALI with LJF (Fig.S4) .", [["lung tissue homogenates", "ANATOMY", 130, 153], ["LJF", "CHEMICAL", 0, 3], ["LPS", "CHEMICAL", 263, 266], ["ALI", "DISEASE", 275, 278], ["LJF", "CHEMICAL", 0, 3], ["LJF", "SIMPLE_CHEMICAL", 0, 3], ["CXCL2", "GENE_OR_GENE_PRODUCT", 28, 33], ["CXCL1", "GENE_OR_GENE_PRODUCT", 35, 40], ["CXCL6", "GENE_OR_GENE_PRODUCT", 42, 47], ["NFKBIA", "GENE_OR_GENE_PRODUCT", 49, 55], ["IFNG", "GENE_OR_GENE_PRODUCT", 57, 61], ["IL6", "GENE_OR_GENE_PRODUCT", 63, 66], ["IL17A", "GENE_OR_GENE_PRODUCT", 68, 73], ["IL17F", "GENE_OR_GENE_PRODUCT", 79, 84], ["IL17C", "GENE_OR_GENE_PRODUCT", 86, 91], ["MMP9", "GENE_OR_GENE_PRODUCT", 93, 97], ["TNFAIP3", "GENE_OR_GENE_PRODUCT", 103, 110], ["lung tissue homogenates", "TISSUE", 130, 153], ["IL-17", "GENE_OR_GENE_PRODUCT", 205, 210], ["LPS", "SIMPLE_CHEMICAL", 263, 266], ["LJF", "SIMPLE_CHEMICAL", 284, 287], ["CXCL2", "PROTEIN", 28, 33], ["CXCL1", "PROTEIN", 35, 40], ["IL", "PROTEIN", 205, 207], ["LJF", "TEST", 0, 3], ["CXCL2", "TEST", 28, 33], ["CXCL1", "TEST", 35, 40], ["CXCL6", "TEST", 42, 47], ["NFKBIA", "TEST", 49, 55], ["IFNG", "TEST", 57, 61], ["IL6", "TEST", 63, 66], ["IL17A", "TEST", 68, 73], ["IL17F", "TEST", 79, 84], ["IL17C", "TEST", 86, 91], ["MMP9", "TEST", 93, 97], ["TNFAIP3 mRNA expression in lung tissue homogenates", "PROBLEM", 103, 153], ["the IL", "TEST", 201, 207], ["treatment", "TREATMENT", 246, 255], ["LPS", "TEST", 263, 266], ["ALI", "PROBLEM", 275, 278], ["significantly", "OBSERVATION_MODIFIER", 4, 17], ["inhibited", "OBSERVATION_MODIFIER", 18, 27], ["CXCL2", "OBSERVATION", 28, 33], ["CXCL1", "ANATOMY_MODIFIER", 35, 40], ["lung", "ANATOMY", 130, 134]]], ["Interestingly, the involved IL-17 family members, including 293 IL-17A, IL-17C and IL-17F, played a significant role in the acute inflammatory responses 294 (Fig.S4) .", [["IL-17", "GENE_OR_GENE_PRODUCT", 28, 33], ["IL-17A", "GENE_OR_GENE_PRODUCT", 64, 70], ["IL-17C", "GENE_OR_GENE_PRODUCT", 72, 78], ["IL-17F", "GENE_OR_GENE_PRODUCT", 83, 89], ["IL-17 family members", "PROTEIN", 28, 48], ["IL", "PROTEIN", 83, 85], ["the acute inflammatory responses", "PROBLEM", 120, 152], ["acute", "OBSERVATION_MODIFIER", 124, 129], ["inflammatory", "OBSERVATION", 130, 142]]], ["Consistent with the RNA-Seq data, the expression of CXCL2, CXCL1, CXCL6, 295 NFKBIA, IFNG, IL6, IL17A, IL17F, IL17C, MMP9 and TNFAIP3 in lung tissue was 296 significantly decreased compared with that in the ALI and LJF groups according to the qRT-PCR 297 analyses (P<0.05) (Fig.8) .", [["lung tissue", "ANATOMY", 137, 148], ["ALI", "DISEASE", 207, 210], ["CXCL2", "GENE_OR_GENE_PRODUCT", 52, 57], ["CXCL1", "GENE_OR_GENE_PRODUCT", 59, 64], ["CXCL6", "GENE_OR_GENE_PRODUCT", 66, 71], ["NFKBIA", "GENE_OR_GENE_PRODUCT", 77, 83], ["IFNG", "GENE_OR_GENE_PRODUCT", 85, 89], ["IL6", "GENE_OR_GENE_PRODUCT", 91, 94], ["IL17A", "GENE_OR_GENE_PRODUCT", 96, 101], ["IL17F", "GENE_OR_GENE_PRODUCT", 103, 108], ["IL17C", "GENE_OR_GENE_PRODUCT", 110, 115], ["MMP9", "GENE_OR_GENE_PRODUCT", 117, 121], ["TNFAIP3", "GENE_OR_GENE_PRODUCT", 126, 133], ["lung tissue", "TISSUE", 137, 148], ["LJF", "CANCER", 215, 218], ["CXCL2", "PROTEIN", 52, 57], ["CXCL1", "PROTEIN", 59, 64], ["CXCL6", "PROTEIN", 66, 71], ["NFKBIA", "PROTEIN", 77, 83], ["IFNG", "PROTEIN", 85, 89], ["IL6", "PROTEIN", 91, 94], ["IL17A", "PROTEIN", 96, 101], ["IL17F", "PROTEIN", 103, 108], ["IL17C", "PROTEIN", 110, 115], ["MMP9", "PROTEIN", 117, 121], ["TNFAIP3", "PROTEIN", 126, 133], ["the RNA", "TEST", 16, 23], ["CXCL2", "TEST", 52, 57], ["CXCL1", "TEST", 59, 64], ["CXCL6", "TEST", 66, 71], ["NFKBIA", "TEST", 77, 83], ["IFNG", "TEST", 85, 89], ["IL6", "TEST", 91, 94], ["IL17A", "TEST", 96, 101], ["IL17F", "TEST", 103, 108], ["IL17C", "TEST", 110, 115], ["MMP9", "TEST", 117, 121], ["TNFAIP3 in lung tissue", "TEST", 126, 148], ["the qRT", "TEST", 239, 246], ["PCR", "TEST", 247, 250], ["P", "TEST", 265, 266], ["CXCL2", "ANATOMY", 52, 57], ["TNFAIP3", "OBSERVATION", 126, 133], ["lung", "ANATOMY", 137, 141], ["significantly", "OBSERVATION_MODIFIER", 157, 170], ["decreased", "OBSERVATION_MODIFIER", 171, 180]]], ["The expression of TRADD and FADD was increased compared with 298 that in the ALI and LJF groups by the qRT-PCR analyses (Fig.8) , and associated with apoptosis in 299 the IL-17 signalling pathway (Fig.S4) .", [["ALI", "DISEASE", 77, 80], ["TRADD", "GENE_OR_GENE_PRODUCT", 18, 23], ["FADD", "GENE_OR_GENE_PRODUCT", 28, 32], ["LJF", "CANCER", 85, 88], ["IL-17", "GENE_OR_GENE_PRODUCT", 171, 176], ["TRADD", "PROTEIN", 18, 23], ["FADD", "PROTEIN", 28, 32], ["TRADD and FADD", "PROBLEM", 18, 32], ["the qRT-PCR analyses", "TEST", 99, 119], ["apoptosis", "TEST", 150, 159], ["the IL", "TEST", 167, 173], ["TRADD", "OBSERVATION", 18, 23], ["increased", "OBSERVATION_MODIFIER", 37, 46]]], ["300Discussion 301We employed network pharmacology to determine the potential active ingredients and targets 302 of LJF.", [["LJF", "GENE_OR_GENE_PRODUCT", 115, 118]]], ["Then, we performed compound-target and target-pathway network analyses to explore the 303 mechanisms of LJF.", [["LJF", "DISEASE", 104, 107], ["LJF", "GENE_OR_GENE_PRODUCT", 104, 107]]], ["Furthermore, an LPS-induced rat model was constructed to evaluate the 304 effect of LJF in the treatment of ALI.", [["LPS", "CHEMICAL", 16, 19], ["LJF", "CHEMICAL", 84, 87], ["ALI", "DISEASE", 108, 111], ["LJF", "CHEMICAL", 84, 87], ["LPS", "SIMPLE_CHEMICAL", 16, 19], ["rat", "ORGANISM", 28, 31], ["LJF", "SIMPLE_CHEMICAL", 84, 87], ["rat", "SPECIES", 28, 31], ["an LPS", "TEST", 13, 19], ["LJF", "TREATMENT", 84, 87], ["ALI", "PROBLEM", 108, 111], ["ALI", "OBSERVATION", 108, 111]]], ["According to the degree of the nodes in the compound-target 305 network, we identified eight compounds as potential active ingredients that might participate in 306 the regulatory processes of LJF in ALI.", [["LJF", "CHEMICAL", 193, 196], ["ALI", "DISEASE", 200, 203], ["305 network", "MULTI-TISSUE_STRUCTURE", 60, 71], ["LJF", "GENE_OR_GENE_PRODUCT", 193, 196], ["potential active ingredients", "PROBLEM", 106, 134], ["nodes", "OBSERVATION", 31, 36], ["active", "OBSERVATION_MODIFIER", 116, 122], ["ingredients", "OBSERVATION", 123, 134], ["ALI", "ANATOMY", 200, 203]]], ["Obviously, the active ingredients chrysoeriol (Wei et qRT-PCR analysis showed that the trends for eight genes (IL1R1, DNAJC5, THBS1, NPLOC4, 340 BCL2A1, PPP1R15A, KIT, and ITGA5) were consistent with the RNA-Seq results.", [["chrysoeriol", "CHEMICAL", 34, 45], ["chrysoeriol", "CHEMICAL", 34, 45], ["chrysoeriol", "SIMPLE_CHEMICAL", 34, 45], ["IL1R1", "GENE_OR_GENE_PRODUCT", 111, 116], ["DNAJC5", "GENE_OR_GENE_PRODUCT", 118, 124], ["THBS1", "GENE_OR_GENE_PRODUCT", 126, 131], ["NPLOC4", "GENE_OR_GENE_PRODUCT", 133, 139], ["BCL2A1", "GENE_OR_GENE_PRODUCT", 145, 151], ["PPP1R15A", "GENE_OR_GENE_PRODUCT", 153, 161], ["KIT", "GENE_OR_GENE_PRODUCT", 163, 166], ["ITGA5", "GENE_OR_GENE_PRODUCT", 172, 177], ["IL1R1", "DNA", 111, 116], ["DNAJC5", "DNA", 118, 124], ["THBS1", "DNA", 126, 131], ["NPLOC4", "DNA", 133, 139], ["BCL2A1", "DNA", 145, 151], ["PPP1R15A", "DNA", 153, 161], ["KIT", "DNA", 163, 166], ["ITGA5", "DNA", 172, 177], ["Wei et qRT", "TEST", 47, 57], ["PCR analysis", "TEST", 58, 70], ["IL1R1", "TEST", 111, 116], ["DNAJC5", "TEST", 118, 124], ["THBS1", "TEST", 126, 131], ["NPLOC4", "TEST", 133, 139], ["BCL2A1", "TEST", 145, 151], ["PPP1R15A", "TEST", 153, 161], ["KIT", "TEST", 163, 166], ["active", "OBSERVATION_MODIFIER", 15, 21], ["consistent with", "UNCERTAINTY", 184, 199]]], ["These 341 findings indicated that the RNA-Seq results were credible.", [["the RNA", "TEST", 34, 41]]], ["By comparative analysis, we found that 342 there were more differentially expressed genes in the ALI, ALI-LJF and ALI-DXSM groups.", [["ALI", "DISEASE", 97, 100], ["ALI", "DISEASE", 102, 105], ["ALI", "DISEASE", 114, 117], ["comparative analysis", "TEST", 3, 23], ["ALI", "TEST", 102, 105], ["ALI", "PROBLEM", 114, 117], ["ALI", "ANATOMY", 97, 100], ["ALI", "ANATOMY", 102, 105], ["ALI", "ANATOMY", 114, 117]]], ["In all, 343Discussion 301192 DEGs were unique to the ALI-LJF group, and 298 DEGs were shared among the three groups.", [["ALI", "DISEASE", 53, 56], ["ALI-LJF", "CANCER", 53, 60], ["343Discussion 301192 DEGs", "DNA", 8, 33], ["ALI-LJF group", "DNA", 53, 66]]], ["344Discussion 301Through KEGG enrichment analysis, we found that the IL-17 signalling pathway was 345 significantly enriched in the ALI-LJF group.", [["344Discussion 301", "CHEMICAL", 0, 17], ["ALI", "DISEASE", 132, 135], ["IL-17", "GENE_OR_GENE_PRODUCT", 69, 74], ["IL", "PROTEIN", 69, 71], ["344Discussion 301", "SPECIES", 0, 17], ["KEGG enrichment analysis", "TEST", 25, 49], ["the IL", "TEST", 65, 71], ["ALI", "ANATOMY", 132, 135]]], ["Thirteen genes were found, such as CXCL2, CXCL1, 346 CXCL6, NFKBIA, IFNG, IL6, IL17A, IL17F, IL17C, TRADD, MMP9,", [["CXCL2", "GENE_OR_GENE_PRODUCT", 35, 40], ["CXCL1", "GENE_OR_GENE_PRODUCT", 42, 47], ["CXCL6", "GENE_OR_GENE_PRODUCT", 53, 58], ["NFKBIA", "GENE_OR_GENE_PRODUCT", 60, 66], ["IFNG", "GENE_OR_GENE_PRODUCT", 68, 72], ["IL6", "GENE_OR_GENE_PRODUCT", 74, 77], ["IL17A", "GENE_OR_GENE_PRODUCT", 79, 84], ["IL17F", "GENE_OR_GENE_PRODUCT", 86, 91], ["IL17C", "GENE_OR_GENE_PRODUCT", 93, 98], ["TRADD", "GENE_OR_GENE_PRODUCT", 100, 105], ["MMP9", "GENE_OR_GENE_PRODUCT", 107, 111], ["CXCL2", "PROTEIN", 35, 40], ["CXCL1", "PROTEIN", 42, 47], ["346 CXCL6", "PROTEIN", 49, 58], ["NFKBIA", "PROTEIN", 60, 66], ["IFNG", "DNA", 68, 72], ["IL6", "DNA", 74, 77], ["IL17A", "DNA", 79, 84], ["IL17F", "DNA", 86, 91], ["IL17C", "DNA", 93, 98], ["TRADD", "DNA", 100, 105], ["MMP9", "DNA", 107, 111], ["CXCL2", "TEST", 35, 40], ["CXCL1", "TEST", 42, 47], ["CXCL6", "TEST", 53, 58], ["NFKBIA", "TEST", 60, 66], ["IFNG", "TEST", 68, 72], ["IL6", "TEST", 74, 77], ["IL17A", "TEST", 79, 84]]]], "2ff42b4a06fa64efff82df4f04ea1647eedfa8e3": [["ABSTR AC T Background and study aims Gastrointestinal endoscopy, being an aerosol-generating procedure, has the potential to transmit Severe Acute Respiratory Distress Syndrome Corona Virus-2 (SARS-CoV-2) during the current pandemic.", [["Respiratory Distress Syndrome", "DISEASE", 147, 176], ["Corona Virus-2", "ORGANISM", 177, 191], ["SARS-CoV-2", "ORGANISM", 193, 203], ["Severe Acute Respiratory Distress Syndrome Corona Virus-2 (SARS-CoV-2", "SPECIES", 134, 203], ["Gastrointestinal endoscopy", "TEST", 37, 63], ["an aerosol-generating procedure", "TREATMENT", 71, 102], ["Severe Acute Respiratory Distress Syndrome", "PROBLEM", 134, 176], ["Corona Virus", "TEST", 177, 189], ["SARS-CoV", "TEST", 193, 201], ["Gastrointestinal", "ANATOMY", 37, 53], ["Severe", "OBSERVATION_MODIFIER", 134, 140], ["Acute", "OBSERVATION_MODIFIER", 141, 146], ["Respiratory Distress", "OBSERVATION", 147, 167]]], ["A survey, perhaps the first, was conducted among Indian endoscopists to assess the impact of Coronavirus Disease (COVID)-19 on gastroinestinal endoscopy practice in the country.", [["Coronavirus Disease", "DISEASE", 93, 112], ["A survey", "TEST", 0, 8], ["Coronavirus Disease", "PROBLEM", 93, 112], ["gastroinestinal endoscopy", "TREATMENT", 127, 152], ["Coronavirus Disease", "OBSERVATION", 93, 112]]]], "be1c11f12d6cdbcf706c2a722477168b5bc1dfad": [["Mycoplasma pneumoniaeEncefalomielitis diseminada aguda suggestive of a demyelinating disease.", [["Mycoplasma pneumoniae", "DISEASE", 0, 21], ["Encefalomielitis", "CHEMICAL", 21, 37], ["demyelinating disease", "DISEASE", 71, 92], ["Mycoplasma pneumoniae", "ORGANISM", 0, 21], ["Mycoplasma pneumoniae", "SPECIES", 0, 21], ["Mycoplasma pneumoniae", "SPECIES", 0, 21], ["Encefalomielitis diseminada aguda", "SPECIES", 21, 54], ["Mycoplasma pneumoniae", "PROBLEM", 0, 21], ["a demyelinating disease", "PROBLEM", 69, 92], ["pneumoniae", "OBSERVATION", 11, 21], ["suggestive of", "UNCERTAINTY", 55, 68], ["demyelinating disease", "OBSERVATION", 71, 92]]], ["One month later, the neuro-ophthalmological symptoms resolved, with normal follow-up magnetic resonance imagings.", [["the neuro-ophthalmological symptoms", "PROBLEM", 17, 52], ["magnetic resonance imagings", "TEST", 85, 112]]], ["The diagnosis was acute disseminated encephalitis secondary to M. pneumoniae.", [["encephalitis", "DISEASE", 37, 49], ["M. pneumoniae", "ORGANISM", 63, 76], ["M. pneumoniae", "SPECIES", 63, 76], ["M. pneumoniae", "SPECIES", 63, 76], ["acute disseminated encephalitis", "PROBLEM", 18, 49], ["M. pneumoniae", "PROBLEM", 63, 76], ["acute", "OBSERVATION_MODIFIER", 18, 23], ["disseminated", "OBSERVATION_MODIFIER", 24, 36], ["encephalitis", "OBSERVATION", 37, 49], ["M. pneumoniae", "OBSERVATION", 63, 76]]], ["The diagnosis was made using PCR (gold standard) and/or IgM in serology.", [["IgM", "GENE_OR_GENE_PRODUCT", 56, 59], ["IgM", "PROTEIN", 56, 59], ["PCR", "TEST", 29, 32], ["IgM in serology", "PROBLEM", 56, 71]]], ["It is important to think about this possible aetiology in cases of suggestive demyelinating disease.", [["demyelinating disease", "DISEASE", 78, 99], ["demyelinating disease", "PROBLEM", 78, 99], ["suggestive", "UNCERTAINTY", 67, 77], ["demyelinating disease", "OBSERVATION", 78, 99]]], ["There is controversy about the role of antibiotics and on whether corticosteroids are contemplated.", [["corticosteroids", "CHEMICAL", 66, 81], ["corticosteroids", "SIMPLE_CHEMICAL", 66, 81], ["antibiotics", "TREATMENT", 39, 50], ["corticosteroids", "TREATMENT", 66, 81]]], ["In conclusion, M. pneumoniae must be a differential diagnosis in acute neuro-ophthalmological disorders in children.Neuro-ophthalmological manifestations as complication of an infection with Mycoplasma pneumoniae and subsequent development of disseminated acute encephalitis\u00a9 2020 Sociedad Espa\u00f1ola de Oftalmolog\u00eda.", [["acute neuro-ophthalmological disorders", "DISEASE", 65, 103], ["infection", "DISEASE", 176, 185], ["Mycoplasma pneumoniae", "DISEASE", 191, 212], ["acute encephalitis", "DISEASE", 256, 274], ["M. pneumoniae", "ORGANISM", 15, 28], ["children", "ORGANISM", 107, 115], ["Mycoplasma pneumoniae", "ORGANISM", 191, 212], ["M. pneumoniae", "SPECIES", 15, 28], ["children", "SPECIES", 107, 115], ["Mycoplasma pneumoniae", "SPECIES", 191, 212], ["M. pneumoniae", "SPECIES", 15, 28], ["Mycoplasma pneumoniae", "SPECIES", 191, 212], ["M. pneumoniae", "PROBLEM", 15, 28], ["acute neuro-ophthalmological disorders", "PROBLEM", 65, 103], ["Neuro-ophthalmological manifestations", "PROBLEM", 116, 153], ["an infection", "PROBLEM", 173, 185], ["Mycoplasma pneumoniae", "PROBLEM", 191, 212], ["disseminated acute encephalitis", "PROBLEM", 243, 274], ["pneumoniae", "OBSERVATION", 18, 28], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["neuro-ophthalmological disorders", "OBSERVATION", 71, 103], ["infection", "OBSERVATION", 176, 185], ["Mycoplasma pneumoniae", "OBSERVATION", 191, 212], ["disseminated", "OBSERVATION_MODIFIER", 243, 255], ["acute", "OBSERVATION_MODIFIER", 256, 261], ["encephalitis", "OBSERVATION", 262, 274]]], ["Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.Introducci\u00f3nLa encefalomielitis diseminada aguda (ADEM) es una de las causas m\u00e1s frecuentes de afectaci\u00f3n de la sustancia blanca en los ni\u00f1os en edad escolar y en los adultos j\u00f3venes.", [["ADEM", "DISEASE", 107, 111]]], ["Se estima una incidencia de aproximadamente 0,2-0,64 casos/ 100000 habitantes a\u00f1o 1,2 .Introducci\u00f3nLa ADEM se considera una enfermedad inflamatoriadesmielinizante inmunomediada, cuya cl\u00ednica neurol\u00f3gica se manifiesta generalmente tras una infecci\u00f3n o vacunaci\u00f3n, pudiendo ser el inicio agudo o subagudo 3 .", [["ADEM", "DISEASE", 102, 106], ["Se", "CHEMICAL", 0, 2], ["vacunaci\u00f3n", "TEST", 251, 261]]], ["Los microorganismos m\u00e1s frecuentes son varicela z\u00f3ster, sarampi\u00f3n y rubeola 1 En la patogenia se considera una respuesta autoinmune a un ant\u00edgeno com\u00fan presente en la mielina y en el agente infeccioso.", [["Los microorganismos", "TEST", 0, 19]]], ["Se ha descrito una participaci\u00f3n de los linfocitos B a trav\u00e9s de los anticuerpos antigangl\u00f3sidos (GM1) y de los linfocitos T ante diversos ant\u00edgenos de la mielina como la prote\u00edna proteolip\u00eddica, la glicoprote\u00edna de la mielina del oligodendrocito o la prote\u00edna b\u00e1sica de la mielina (PBM) entre otros 3 .Introducci\u00f3nEn cuanto a las manifestaciones cl\u00ednicas, se ha descrito primero una fase prodr\u00f3mica similar a un cuadro pseudogripal con fiebre y malestar general, desarrollando tras 3 a 6 semanas del contacto con el agente desencadenante, la sintomatolog\u00eda cl\u00ednica m\u00e1s florida, de predominio neurol\u00f3gico y neuroftalmol\u00f3gico.", [["la prote\u00edna b\u00e1sica de la mielina (PBM", "TREATMENT", 249, 286]]], ["Se han descrito meningitis as\u00e9pticas, polirradiculitis, hemiparesias, neuropat\u00edas craneales, oftalmoparesia, neuritis \u00f3ptica, convulsiones, afectaci\u00f3n de v\u00edas largas con espasticidad o hiperreflexia y ataxia cerebelosa, entre otras 2,4 .Introducci\u00f3nSe han descrito complicaciones secundarias a este cuadro cl\u00ednico que incluyen lesiones mucocut\u00e1neas, artritis, anemia hemol\u00edtica, hemorragias, pericarditis y alteraciones neurol\u00f3gicas graves como mielitis, meningoencefalitis o incluso el coma 5 .Introducci\u00f3nLa prueba de imagen de elecci\u00f3n es la resonancia magn\u00e9tica nuclear (MRI) en la que aparecen realzadas en T2 lesiones reversibles, bien definidas e hiperintensas en sustancia blanca, que suelen afectar al t\u00e1lamo y ganglios basales, as\u00ed como a la m\u00e9dula espinal en ocasiones, pudiendo encontrarse tambi\u00e9n en sustancia gris.", [["Se", "CHEMICAL", 0, 2], ["meningitis as\u00e9pticas", "DISEASE", 16, 36], ["neuritis \u00f3ptica", "DISEASE", 109, 124], ["ataxia cerebelosa", "DISEASE", 201, 218], ["artritis", "DISEASE", 350, 358], ["anemia hemol\u00edtica", "DISEASE", 360, 377], ["hemorragias", "DISEASE", 379, 390], ["pericarditis", "DISEASE", 392, 404], ["como mielitis", "DISEASE", 440, 453], ["coma", "DISEASE", 487, 491], ["Se han descrito meningitis as\u00e9pticas", "PROBLEM", 0, 36], ["polirradiculitis", "PROBLEM", 38, 54], ["hemiparesias", "PROBLEM", 56, 68], ["neuropat\u00edas craneales", "PROBLEM", 70, 91], ["oftalmoparesia", "PROBLEM", 93, 107], ["neuritis", "PROBLEM", 109, 117], ["convulsiones", "PROBLEM", 126, 138], ["y ataxia cerebelosa", "PROBLEM", 199, 218], ["artritis", "PROBLEM", 350, 358], ["anemia hemol\u00edtica", "PROBLEM", 360, 377], ["hemorragias", "PROBLEM", 379, 390], ["pericarditis", "PROBLEM", 392, 404], ["graves como mielitis", "PROBLEM", 433, 453], ["MRI", "TEST", 575, 578], ["meningitis", "OBSERVATION", 16, 26], ["neuritis", "OBSERVATION", 109, 117], ["anemia hemol\u00edtica", "OBSERVATION", 360, 377], ["pericarditis", "OBSERVATION", 392, 404]]], ["Aun as\u00ed, unas im\u00e1genes aisladas en MRI no son diagn\u00f3sticas de ADEM 5 .", [["ADEM", "DISEASE", 62, 66], ["MRI", "TEST", 35, 38]]], ["M. pneumoniae es una bacteria de vida libre sin pared celular.", [["M. pneumoniae", "ORGANISM", 0, 13], ["M. pneumoniae", "SPECIES", 0, 13], ["M. pneumoniae", "SPECIES", 0, 13], ["M. pneumoniae", "PROBLEM", 0, 13], ["una bacteria", "TEST", 17, 29], ["pneumoniae", "OBSERVATION", 3, 13]]], ["Es un agente causal de neumon\u00eda adquirida de la comunidad, aunque raramente causa alteraci\u00f3n el sistema nervioso central (0,1%) 2,3 (tabla 1).Tabla 1 -Resumen comparativo de los casos cl\u00ednicosNuestros objetivos son describir dos cuadros cl\u00ednicos neuroftalmol\u00f3gicos en ni\u00f1os por una infecci\u00f3n sist\u00e9mica por M. pneumoniae y llamar la atenci\u00f3n sobre esta etiolog\u00eda y la importancia pron\u00f3stica para que nos haga pensar en ella.Casos cl\u00ednicosSe presentan los casos cl\u00ednicos de dos ni\u00f1as de 14 y 12 a\u00f1os que acudieron a urgencias por dos cuadros distintos de s\u00edntomas oftalmol\u00f3gicos y neurol\u00f3gicos.Casos cl\u00ednicosLa primera presentaba un cuadro de oftalmoplej\u00eda internuclear bilateral con diplop\u00eda y limitaci\u00f3n en aducci\u00f3n mayor en ojo izquierdo (OI).", [["pneumoniae", "PROBLEM", 309, 319], ["Casos", "TEST", 592, 597], ["bilateral", "ANATOMY_MODIFIER", 668, 677]]], ["Convergencia normal Figura 1 -Se muestran las pruebas complementarias de la paciente 1 (CPG) A) Im\u00e1genes de angio-MRI sin alteraciones.", [["Convergencia", "TEST", 0, 12]]], ["B) MRI con gadolinio de la columna cervical sin alteraciones.", [["MRI", "TEST", 3, 6], ["con gadolinio", "TEST", 7, 20], ["cervical", "ANATOMY", 35, 43]]], ["C) Imagen de axial de MRI en secuencia FLAIR con gadolinio donde se observan lesiones hiperintensas en regi\u00f3n capsulotal\u00e1mica sugerentes de enfermedad desmielinizante.", [["Imagen de axial de MRI", "TEST", 3, 25]]], ["D) MRI realizada 6 meses tras la primera en la que no se observan lesiones.", [["MRI", "TEST", 3, 6], ["realizada", "TEST", 7, 16]]], ["E) Campimetr\u00eda Humphrey 24-2 dentro de la normalidad en ambos ojos (m\u00ednimo defecto paracentral OI).Casos cl\u00ednicoscon punto de rotura a menos de 5 cm.", [["la normalidad en ambos ojos", "TREATMENT", 39, 66]]], ["En la exploraci\u00f3n neurol\u00f3gica no presentaba disdiadococinesia, ni ataxia, ni alteraciones de los reflejos ni de la fuerza muscular con test de fatigabilidad negativos.", [["ni ataxia", "DISEASE", 63, 72], ["ni ataxia", "PROBLEM", 63, 72], ["ni de la fuerza muscular con test", "TEST", 106, 139]]], ["Como antecedente personal a destacar, present\u00f3 un cuadro de hipertensi\u00f3n intracraneal idiop\u00e1tica 7 a\u00f1os antes que se resolvi\u00f3 con acetazolamida y corticosteroides.Casos cl\u00ednicosSe realizaron m\u00faltiples pruebas de imagen ( fig. 1 ), resultando la angiorresonancia magn\u00e9tica nuclear normal, la columna cervical y dorsolumbar no presentaron lesiones de tipo desmielinizante, pero en T2 de la MRI cerebral (marzo de 2018) se aprecian m\u00faltiples lesiones de aspecto hiperintenso sugerentes de lesiones de tipo desmielinizante, que tras 5 meses se resolvieron.Casos cl\u00ednicosEntre otras pruebas complementarias se realiz\u00f3 una tomograf\u00eda de coherencia \u00f3ptica de dominio espectral (SD-OCT) en la que se observ\u00f3 un defecto en capa de fibras nerviosas de la retina en el cuadrante temporal, as\u00ed como una alteraci\u00f3n de capa de c\u00e9lulas ganglionares, que pudieran ser secuela de la hipertensi\u00f3n intracraneal previa.", [["SD", "DISEASE", 671, 673], ["intracraneal previa", "DISEASE", 879, 898], ["Casos cl\u00ednicos", "SPECIES", 552, 566], ["acetazolamida y corticosteroides", "TREATMENT", 130, 162], ["Casos", "TREATMENT", 163, 168], ["presentaron lesiones", "PROBLEM", 325, 345], ["Entre otras", "TEST", 566, 577], ["previa", "PROBLEM", 892, 898], ["normal", "OBSERVATION", 280, 286], ["cervical", "ANATOMY", 299, 307], ["cerebral", "ANATOMY", 392, 400], ["previa", "OBSERVATION", 892, 898]]], ["La campimetr\u00eda Humphrey 24-2 result\u00f3 normal en ambos ojos.", [["La campimetr\u00eda Humphrey", "TEST", 0, 23]]], ["Mediante punci\u00f3n lumbar, se analiz\u00f3 el l\u00edquido cefalorraqu\u00eddeo (LCR), resultando negativo para bandas oligoclonales.", [["lumbar", "ANATOMY", 17, 23]]], ["Se realizaron anal\u00edticas completas con perfil metab\u00f3lico normal, an\u00e1lisis de t\u00f3xicos negativo, hemograma normal, PCR elevada y serolog\u00edas negativas para virus de inmunodeficiencia humana, virus de hepatitis B y C, virus de Epstein Barr, citomegalovirus, virus herpes simplex, virus varicela z\u00f3ster y rubeola.", [["inmunodeficiencia humana", "DISEASE", 162, 186], ["hepatitis B", "DISEASE", 197, 208], ["herpes simplex", "DISEASE", 260, 274], ["Epstein Barr", "ORGANISM", 223, 235], ["citomegalovirus, virus", "ORGANISM", 237, 259], ["herpes simplex", "ORGANISM", 260, 274], ["virus herpes simplex", "SPECIES", 254, 274], ["Se realizaron anal\u00edticas", "TEST", 0, 24], ["hemograma", "TEST", 95, 104], ["PCR", "TEST", 113, 116], ["para virus", "PROBLEM", 148, 158], ["citomegalovirus", "PROBLEM", 237, 252], ["virus herpes simplex", "PROBLEM", 254, 274], ["Epstein Barr", "OBSERVATION", 223, 235]]], ["Result\u00f3 positiva la serolog\u00eda para M. pneumoniae tanto IgM como IgG, por lo que se pudo identificar el agente etiol\u00f3gico del cuadro.", [["M. pneumoniae", "SPECIES", 35, 48], ["Result\u00f3", "TEST", 0, 7], ["pneumoniae", "TEST", 38, 48], ["IgM", "TEST", 55, 58]]], ["El resultado de PCR de M. pneumoniae fue positivo.", [["M. pneumoniae", "SPECIES", 23, 36], ["M. pneumoniae", "SPECIES", 23, 36]]], ["La serolog\u00eda en nuestro centro se realiza en pacientes con sospecha de ADEM para descartar esta etiolog\u00eda a ra\u00edz de una serie de casos que tuvieron lugar en 2018 y 2019.", [["ADEM", "DISEASE", 71, 75]]], ["Entre otras pruebas complementarias se realizaron potenciales evocados (PEV) con velocidad y amplitud de conducci\u00f3n normal y PEV auditivos normales.", [["Entre otras", "TEST", 0, 11]]], ["El electromiograma suger\u00eda m\u00ednima radiculitis probablemente en fase de resoluci\u00f3n, el test de Ishihara fue normal y la paciente no presentaba defecto pupilar aferente (DPAR).Casos cl\u00ednicosEl diagn\u00f3stico final fue oftalmoplej\u00eda internuclear bilateral (Wall Eyed Bilateral InterNuclear Ophthalmoplegia [WEBINO]) por encefalomielitis aguda diseminada (ADEM) relacionada con infecci\u00f3n por M. pneumoniae.Casos cl\u00ednicosEl tratamiento que se paut\u00f3 fue un ciclo de metilprednisolona intravenosa a dosis altas 10 mg/kg/d\u00eda durante 3 d\u00edas y una pauta oral de prednisona 1 mg/kg/d\u00eda 20 d\u00edas, as\u00ed como cotrimoxazol para la profilaxis ante Pneumocystis jiroveci.", [["ADEM", "DISEASE", 349, 353], ["Pneumocystis jiroveci", "DISEASE", 627, 648], ["M. pneumoniae", "ORGANISM", 385, 398], ["oral", "ORGANISM_SUBDIVISION", 541, 545], ["M. pneumoniae", "SPECIES", 385, 398], ["Pneumocystis jiroveci", "SPECIES", 627, 648], ["M. pneumoniae", "SPECIES", 385, 398], ["Casos cl\u00ednicosEl tratamiento que se paut\u00f3 fue un ciclo de metilprednisolona intravenosa a dosis altas 10 mg/kg/d\u00eda durante 3 d\u00edas y una pauta oral de prednisona 1 mg/kg/d\u00eda 20 d\u00edas", "SPECIES", 399, 579], ["Pneumocystis jiroveci", "SPECIES", 627, 648], ["El electromiograma", "TEST", 0, 18], ["radiculitis", "PROBLEM", 34, 45], ["Casos", "TEST", 174, 179], ["internuclear bilateral (Wall Eyed Bilateral InterNuclear Ophthalmoplegia", "PROBLEM", 227, 299], ["por encefalomielitis aguda diseminada", "PROBLEM", 310, 347], ["relacionada con infecci\u00f3n", "PROBLEM", 355, 380], ["pneumoniae", "PROBLEM", 388, 398], ["Casos cl\u00ednicosEl tratamiento que se paut\u00f3 fue un ciclo de metilprednisolona intravenosa a dosis altas", "TREATMENT", 399, 500], ["una pauta oral de prednisona", "TREATMENT", 531, 559], ["ante Pneumocystis jiroveci", "PROBLEM", 622, 648], ["radiculitis", "OBSERVATION", 34, 45], ["bilateral", "ANATOMY_MODIFIER", 240, 249], ["Wall", "ANATOMY_MODIFIER", 251, 255], ["Bilateral", "ANATOMY_MODIFIER", 261, 270], ["InterNuclear Ophthalmoplegia", "OBSERVATION", 271, 299], ["pneumoniae", "OBSERVATION", 388, 398], ["Pneumocystis jiroveci", "OBSERVATION", 627, 648]]], ["La evoluci\u00f3n fue favorable.", [["fue favorable", "OBSERVATION", 13, 26]]], ["La paciente no ha presentado nuevas incidencias y sigue asintom\u00e1tica un a\u00f1o despu\u00e9s del episodio.Casos cl\u00ednicosLa segunda paciente acudi\u00f3 al servicio de Urgencias por p\u00e9rdida de visi\u00f3n de 2 horas de evoluci\u00f3n (AV: OD percepci\u00f3n de luz y OI cuenta dedos a menos de 1 metro) acompa\u00f1ada de cefalea holocraneal opresiva en \u00abcasco\u00bb de 2 h de evoluci\u00f3n.", [["Casos cl\u00ednicos", "SPECIES", 97, 111], ["ha", "PROBLEM", 15, 17], ["acompa\u00f1ada de cefalea holocraneal opresiva", "TREATMENT", 273, 315]]], ["DPAR OD menor, DPAR OI.", [["OI", "DISEASE", 20, 22]]], ["Como antecedente personal a destacar, present\u00f3 una migra\u00f1a, con aura visual at\u00edpica, un mes antes que se trat\u00f3 con magnesio.", [["con aura visual at\u00edpica", "DISEASE", 60, 83]]], ["La MRI con contraste mostr\u00f3 lesiones hiperintensas en T2, sugerentes de enfermedad desmielinizante ( fig. 2) .", [["La MRI con contraste", "TEST", 0, 20]]], ["Tras dos meses despu\u00e9s del episodio, en la MRI con contraste se observaba disminuci\u00f3n de tama\u00f1o y mejor\u00eda de las lesiones.", [["del episodio", "PROBLEM", 23, 35], ["en la MRI", "TEST", 37, 46]]], ["La OCT de la capa de fibras nerviosas de la retina (RNFL) fue normal, as\u00ed como la campimetr\u00eda Humphrey 24-2.", [["retina", "MULTI-TISSUE_STRUCTURE", 44, 50], ["La OCT", "TEST", 0, 6], ["la retina", "ANATOMY", 41, 50]]], ["Las anal\u00edticas de perfil metab\u00f3lico y hemograma fueron normales, el an\u00e1lisis de t\u00f3xicos negativo y, como en el otro caso, PCR tambi\u00e9n elevada.", [["PCR tambi\u00e9n elevada", "TREATMENT", 122, 141]]], ["Las serolog\u00edas fueron negativas para el virus de inmunodeficiencia humana, virus deFigura 2 -Se muestran las pruebas complementarias de la paciente 2 (AOJ) A) Imag\u00e9nes sagitales y axial de MRI y secuencia FLAIR con gadolinio donde se observan las lesiones hiperintensas en sustancia blanca yuxtacortical sugerentes de enfermedad desmielinizante.", [["inmunodeficiencia humana", "DISEASE", 49, 73], ["Las serolog\u00edas", "TEST", 0, 14], ["para el virus", "TEST", 32, 45], ["humana", "TEST", 67, 73], ["virus deFigura", "TEST", 75, 89], ["axial de MRI y secuencia", "TEST", 180, 204], ["FLAIR", "TEST", 205, 210], ["gadolinio", "TEST", 215, 224]]], ["B) Imagen de MRI con gadolinio en T2 donde se observa la disminuci\u00f3n y/o desaparici\u00f3n de algunas de las lesiones hiperintensas, a los 3 meses.", [["Imagen de MRI", "TEST", 3, 16], ["gadolinio", "TEST", 21, 30], ["desaparici\u00f3n", "PROBLEM", 73, 85]]], ["C) Im\u00e1genes de angio-MRI sin alteraciones.", [["Im\u00e1genes de angio", "TEST", 3, 20]]], ["D) OCT-SD de la capa de fibras nerviosas de la retina sin alteraciones.hepatitis B, virus de hepatitis C, virus Espstein Barr, citomegalovirus, virus herpes simplex, virus varicela z\u00f3ster y rubeola y positivas (IgM e IgG) para M. pneumoniae.", [["hepatitis B", "DISEASE", 71, 82], ["hepatitis C", "DISEASE", 93, 104], ["herpes simplex", "DISEASE", 150, 164], ["hepatitis B, virus de hepatitis C", "ORGANISM", 71, 104], ["virus Espstein Barr", "ORGANISM", 106, 125], ["citomegalovirus, virus herpes simplex", "ORGANISM", 127, 164], ["virus varicela z\u00f3ster y rubeola y positivas", "ORGANISM", 166, 209], ["IgM e IgG", "GENE_OR_GENE_PRODUCT", 211, 220], ["M. pneumoniae", "ORGANISM", 227, 240], ["IgM", "PROTEIN", 211, 214], ["virus herpes simplex", "SPECIES", 144, 164], ["virus varicela z\u00f3ster", "SPECIES", 166, 187], ["rubeola y positivas", "SPECIES", 190, 209], ["M. pneumoniae", "SPECIES", 227, 240], ["varicela z\u00f3ster y rubeola y positivas", "SPECIES", 172, 209], ["M. pneumoniae", "SPECIES", 227, 240], ["OCT", "TEST", 3, 6], ["SD de la capa", "PROBLEM", 7, 20], ["hepatitis B", "PROBLEM", 71, 82], ["virus de hepatitis C", "PROBLEM", 84, 104], ["virus", "PROBLEM", 106, 111], ["citomegalovirus", "PROBLEM", 127, 142], ["virus herpes simplex", "PROBLEM", 144, 164], ["virus varicela", "TEST", 166, 180], ["IgM e IgG", "TEST", 211, 220], ["para M. pneumoniae", "PROBLEM", 222, 240], ["pneumoniae", "OBSERVATION", 230, 240]]], ["El resto de pruebas complementarias como electroencefalograma fue normal (con actividad de fondo en vigilia dentro de lo normal y sin actividad epileptiforme, ni asimetr\u00edas ni otras anomal\u00edas significativas) y los PEV sin alteraciones significativas en todo el trayecto de la v\u00eda visual.", [["PEV sin alteraciones", "TREATMENT", 214, 234]]], ["El diagn\u00f3stico final fue ADEM relacionada con infecci\u00f3n por M. pneumoniae con neuritis retrobulbar.Figura 2 -Se muestran las pruebas complementarias de la paciente 2 (AOJ) A) Imag\u00e9nes sagitales y axial de MRI y secuencia FLAIR con gadolinio donde se observan las lesiones hiperintensas en sustancia blanca yuxtacortical sugerentes de enfermedad desmielinizante.", [["ADEM", "DISEASE", 25, 29], ["neuritis", "DISEASE", 78, 86], ["Figura 2 -Se", "CHEMICAL", 99, 111], ["M. pneumoniae", "SPECIES", 60, 73], ["M. pneumoniae", "SPECIES", 60, 73], ["pneumoniae con neuritis retrobulbar", "PROBLEM", 63, 98], ["Figura", "TEST", 99, 105], ["axial de MRI y secuencia", "TEST", 196, 220], ["FLAIR", "TEST", 221, 226], ["gadolinio", "TEST", 231, 240], ["pneumoniae", "OBSERVATION", 63, 73], ["retrobulbar", "ANATOMY", 87, 98]]], ["B) Imagen de MRI con gadolinio en T2 donde se observa la disminuci\u00f3n y/o desaparici\u00f3n de algunas de las lesiones hiperintensas, a los 3 meses.", [["Imagen de MRI", "TEST", 3, 16], ["gadolinio", "TEST", 21, 30], ["desaparici\u00f3n", "PROBLEM", 73, 85]]], ["C) Im\u00e1genes de angio-MRI sin alteraciones.", [["Im\u00e1genes de angio", "TEST", 3, 20]]], ["D) OCT-SD de la capa de fibras nerviosas de la retina sin alteraciones.El tratamiento que recibi\u00f3 la paciente fue metilprednisolona intravenosa durante 3 d\u00edas y prednisona v\u00eda oral a dosis altas 1 mg/kg/d\u00eda.Figura 2 -Se muestran las pruebas complementarias de la paciente 2 (AOJ) A) Imag\u00e9nes sagitales y axial de MRI y secuencia FLAIR con gadolinio donde se observan las lesiones hiperintensas en sustancia blanca yuxtacortical sugerentes de enfermedad desmielinizante.", [["Figura 2 -Se", "CHEMICAL", 207, 219], ["oral", "ORGANISM_SUBDIVISION", 176, 180], ["dosis altas 1 mg/kg/d\u00eda", "SPECIES", 183, 206], ["OCT", "TEST", 3, 6], ["SD de la capa", "PROBLEM", 7, 20], ["El tratamiento que recibi\u00f3 la paciente fue metilprednisolona intravenosa durante", "TREATMENT", 71, 151], ["oral a dosis altas", "TREATMENT", 176, 194], ["Figura", "TEST", 207, 213], ["axial de MRI y secuencia", "TEST", 304, 328], ["FLAIR", "TEST", 329, 334], ["gadolinio", "TEST", 339, 348]]], ["B) Imagen de MRI con gadolinio en T2 donde se observa la disminuci\u00f3n y/o desaparici\u00f3n de algunas de las lesiones hiperintensas, a los 3 meses.", [["Imagen de MRI", "TEST", 3, 16], ["gadolinio", "TEST", 21, 30], ["desaparici\u00f3n", "PROBLEM", 73, 85]]], ["C) Im\u00e1genes de angio-MRI sin alteraciones.", [["Im\u00e1genes de angio", "TEST", 3, 20]]], ["D) OCT-SD de la capa de fibras nerviosas de la retina sin alteraciones.A pesar de ser una sospecha de infecci\u00f3n por M. pneumoniae con IgM positivo, no se trata con antibi\u00f3ticos, porque es debatido el tratamiento antibi\u00f3tico y s\u00ed se ha mostrado m\u00e1s efectivo el tratamiento inmunosupresor.Figura 2 -Se muestran las pruebas complementarias de la paciente 2 (AOJ) A) Imag\u00e9nes sagitales y axial de MRI y secuencia FLAIR con gadolinio donde se observan las lesiones hiperintensas en sustancia blanca yuxtacortical sugerentes de enfermedad desmielinizante.", [["Figura 2 -Se", "CHEMICAL", 287, 299], ["OCT", "TEST", 3, 6], ["SD de la capa", "PROBLEM", 7, 20], ["pneumoniae", "PROBLEM", 119, 129], ["Figura", "TEST", 287, 293], ["axial de MRI y secuencia", "TEST", 384, 408], ["FLAIR", "TEST", 409, 414], ["gadolinio", "TEST", 419, 428]]], ["B) Imagen de MRI con gadolinio en T2 donde se observa la disminuci\u00f3n y/o desaparici\u00f3n de algunas de las lesiones hiperintensas, a los 3 meses.", [["Imagen de MRI", "TEST", 3, 16], ["gadolinio", "TEST", 21, 30], ["desaparici\u00f3n", "PROBLEM", 73, 85]]], ["C) Im\u00e1genes de angio-MRI sin alteraciones.", [["Im\u00e1genes de angio", "TEST", 3, 20]]], ["D) OCT-SD de la capa de fibras nerviosas de la retina sin alteraciones.Ninguna de las pacientes present\u00f3 otra focalidad neurol\u00f3gica ni lesi\u00f3n medular.", [["OCT", "TEST", 3, 6], ["SD de la capa", "PROBLEM", 7, 20]]], ["A los tres y seis de evoluci\u00f3n, respectivamente, los s\u00edntomas neuroftalmol\u00f3gicos se resolvieron en ambos casos y las MRI de control resultaron sorprendentemente normales.Discusi\u00f3nM. pneumoniae causa el 5-10% de infecciones del sistema nervioso central seg\u00fan algunas fuentes, si bien es cierto que las principales causas de ADEM son sarampi\u00f3n, rubeola y varicela z\u00f3ster 1,2 .Discusi\u00f3nLa exposici\u00f3n a M. pneumoniae produce ocasionalmente un estado de portador asintom\u00e1tico.", [["ADEM", "DISEASE", 323, 327], ["pneumoniae", "SPECIES", 182, 192], ["M. pneumoniae", "SPECIES", 399, 412], ["pneumoniae", "PROBLEM", 182, 192], ["rubeola y varicela z\u00f3ster", "TREATMENT", 343, 368], ["a M. pneumoniae", "PROBLEM", 397, 412]]], ["La ADEM por esta infecci\u00f3n se asocia en un 75% de los casos a un cuadro prodr\u00f3mico leve de 2 a 30 d\u00edas antes de la aparici\u00f3n de la sintomatolog\u00eda neurol\u00f3gica 2,6 .Discusi\u00f3nEl m\u00e9todo gold standard para el diagn\u00f3stico de M. pneumoniae es la PCR en sangre y LCR, aunque generalmente se realiza por serolog\u00eda (IgM e IgG), a pesar de baja sensibilidad para IgM descrita en algunos estudios (32-77%) 6 .Discusi\u00f3nEl diagn\u00f3stico diferencial principal de ADEM son otras causas infecciosas (virus de la inmunodeficiencia humana, virus de la hepatitis B, virus de la hepatitis C, virus de Epstein Barr, citomegalovirus, virus herpes simplex, virus varicela z\u00f3ster, ruebola, viriasis respiratorias y gastrointestinales) y las enfermedades desmielinizantes 2, 4, 7 .", [["ADEM", "DISEASE", 3, 7], ["ADEM", "DISEASE", 446, 450], ["hepatitis B", "DISEASE", 531, 542], ["hepatitis C", "DISEASE", 556, 567], ["herpes simplex", "DISEASE", 615, 629], ["virus herpes", "SPECIES", 609, 621], ["pneumoniae", "PROBLEM", 222, 232], ["la PCR", "TEST", 236, 242], ["IgM e IgG", "TEST", 306, 315], ["para IgM", "TEST", 347, 355], ["estudios", "TEST", 376, 384], ["infecciosas (virus de la inmunodeficiencia humana", "PROBLEM", 468, 517], ["virus de la hepatitis B", "PROBLEM", 519, 542], ["virus de la hepatitis C", "PROBLEM", 544, 567], ["virus", "PROBLEM", 569, 574], ["citomegalovirus", "PROBLEM", 592, 607], ["virus herpes simplex", "PROBLEM", 609, 629], ["virus varicela z\u00f3ster", "PROBLEM", 631, 652], ["ruebola", "PROBLEM", 654, 661]]], ["Seg\u00fan los criterios del International Pediatric Multiple Sclerosis Study Group (IPMSSG) de 2013 el diagn\u00f3stico de esclerosis m\u00faltiple (EM) quedar\u00eda definido en MRI como 1) nueve o m\u00e1s lesiones en sustancia blanca o una realzada con gadolinio; 2) tres o m\u00e1s lesiones periventriculares; 3) una lesi\u00f3n yuxtacortical; 4) una lesi\u00f3n infratentorial.", [["Multiple Sclerosis", "DISEASE", 48, 66], ["infratentorial", "DISEASE", 328, 342], ["m\u00e1s", "TEST", 180, 183], ["lesiones", "TEST", 184, 192], ["una realzada con gadolinio", "TEST", 215, 241], ["periventriculares", "PROBLEM", 266, 283], ["una lesi\u00f3n yuxtacortical", "TEST", 288, 312], ["una lesi\u00f3n infratentorial", "PROBLEM", 317, 342], ["Sclerosis", "OBSERVATION", 57, 66], ["infratentorial", "ANATOMY_MODIFIER", 328, 342]]], ["El LCR debe presentar bandas oligoclonales o elevaci\u00f3n del \u00edndice de IgG.", [["IgG", "ORGANISM_SUBSTANCE", 69, 72], ["LCR", "DNA", 3, 6], ["IgG", "PROTEIN", 69, 72], ["El LCR", "TEST", 0, 6]]], ["La combinaci\u00f3n de LCR alterado y dos lesiones en MRI (de las cuales una debe ser en el cerebro) pueden significar un criterio de diseminaci\u00f3n en el espacio de la clasificaci\u00f3n de McDonald 8 .Discusi\u00f3nEn los ni\u00f1os, dos eventos desmielinizantes distintos separados en tiempo y espacio hacen criterio de EM, a diferencia de una recurrencia de ADEM, en la que no aparecer\u00edan lesiones nuevas sino que aumentar\u00edan las preexistentes 8 .Discusi\u00f3nEn este estudio de Dale et al. se compar\u00f3 la presentaci\u00f3n de los cuadros cl\u00ednicos de la ADEM y la EM.", [["ADEM", "DISEASE", 340, 344], ["ADEM", "DISEASE", 526, 530], ["en MRI", "TEST", 46, 52], ["una", "TEST", 68, 71], ["ADEM", "PROBLEM", 340, 344]]], ["Obtuvieron como enfermedad infecciosa predesmielinizante (74 vs. 38%, P< 0,05), presentaci\u00f3n polisintom\u00e1tica (91 vs. 38%, P< 0,002), signos piramidales (71 vs. 23%, P< 0,01), encefalopat\u00eda (69 vs. 15%, P< 0,002) y neuritis \u00f3ptica bilateral (23 vs. 8%, no estad\u00edsticamente significativo) y unilateral solo en casos de EM 7 .Discusi\u00f3nLa importancia de los anticuerpos anti-MOG en las ADEM en ni\u00f1os, sobre todo en las causadas por Mycoplasma, se describe en el trabajo de Mol et al. realizado en Pa\u00edses Bajos.", [["presentaci\u00f3n polisintom\u00e1tica", "DISEASE", 80, 108], ["signos piramidales", "DISEASE", 133, 151], ["encefalopat\u00eda", "DISEASE", 175, 188], ["neuritis", "DISEASE", 214, 222], ["ADEM", "DISEASE", 382, 386], ["predesmielinizante", "TEST", 38, 56], ["P", "TEST", 70, 71], ["presentaci\u00f3n polisintom\u00e1tica", "TEST", 80, 108], ["P", "TEST", 122, 123], ["signos piramidales", "TEST", 133, 151], ["P", "TEST", 165, 166], ["encefalopat\u00eda", "TEST", 175, 188], ["P", "TEST", 202, 203], ["y neuritis \u00f3ptica bilateral", "PROBLEM", 212, 239], ["Mycoplasma", "PROBLEM", 428, 438], ["bilateral", "ANATOMY_MODIFIER", 230, 239]]], ["Se observ\u00f3 que en los pacientes con anti-MOG positivos, el fenotipo m\u00e1s frecuente de presentaci\u00f3n hab\u00eda sido ADEM (56%) en ni\u00f1os y neuritis \u00f3ptica (44%) en adultos.", [["ADEM", "DISEASE", 109, 113], ["neuritis \u00f3ptica", "DISEASE", 131, 146], ["ADEM", "PROBLEM", 109, 113], ["\u00f3ptica", "TEST", 140, 146]]], ["Mostraron tambi\u00e9n que la mayor\u00eda de los pacientes anti-MOG negativos no presentaron recidivas (89%) 9 .Discusi\u00f3nExiste controversia sobre el papel de los antibi\u00f3ticos como parte del tratamiento de la ADEM.", [["ADEM", "DISEASE", 200, 204]]], ["No ha sido demostrado que un tratamiento antibi\u00f3tico espec\u00edfico solucione el cuadro.Discusi\u00f3nLos que se utilizan para tratar infecciones por M. pneumoniae son azitromicina, eritromicina, tetraciclinas (doxiciclina) y las fluoroquinolonas de \u00faltima generaci\u00f3n, aunque estas \u00faltimas se suelen emplear en adultos 6 .Discusi\u00f3nEs cierto que no hay ensayos cl\u00ednicos que gu\u00eden el tratamiento de este cuadro y que el manejo se basa en la experiencia y el juicio cl\u00ednico, as\u00ed como en casos cl\u00ednicos de la literatura.Discusi\u00f3nAl tratarse de una enfermedad de probable origen inmunomediado, se emplean f\u00e1rmacos con efecto inmunomodulador.", [["ha", "PROBLEM", 3, 5], ["pneumoniae", "PROBLEM", 144, 154], ["eritromicina", "TREATMENT", 173, 185], ["tetraciclinas (doxiciclina)", "TREATMENT", 187, 214], ["origen inmunomediado", "TREATMENT", 558, 578]]], ["El primer escal\u00f3n terap\u00e9utico propuesto ser\u00edan los corticosteroides intravenosos como la metilprednisolona (20-30 mg/kg/d\u00eda, m\u00e1ximo 1gm/d\u00eda) durante 3-5 d\u00edas, seguido de corticosteroides v\u00eda oral durante 4-6 semanas (evidencia 2 C).", [["corticosteroides intravenosos como la metilprednisolona", "TREATMENT", 51, 106], ["m\u00e1ximo", "TREATMENT", 125, 131], ["durante", "TREATMENT", 141, 148], ["seguido de corticosteroides", "TREATMENT", 159, 186], ["oral durante", "TREATMENT", 191, 203]]], ["Si los corticoides fracasan o la respuesta a estos es insuficiente, se iniciar\u00eda el tratamiento con inmunoglobulinas intravenosas (evidencia 2 C) y si con ello no se consiguiera mejor\u00eda, se realizar\u00eda plasmaf\u00e9resis (evidencia 2 C) 10 .Discusi\u00f3nRespecto al pron\u00f3stico, se ha correlacionado en algunos trabajos la ADEM con una posible presentaci\u00f3n previa a la EM.", [["ADEM", "DISEASE", 312, 316], ["Si", "CHEMICAL", 0, 2]]], ["Un reciente estudio de Papetti L et al. de 91 pacientes, ha reportado la evoluci\u00f3n a EM del 21,2% de los pacientes con ADEM, en seguimiento medio de 5,6 \u00b1 2,3 a\u00f1os.", [["ADEM", "DISEASE", 119, 123], ["ADEM", "PROBLEM", 119, 123]]], ["Apuntan como factores predictores (tras un an\u00e1lisis multivariante) la presencia de bandas oligoclonales en LCR (p< 0,001), infecci\u00f3n previa por virus de Epstein Barr (p< 0,001), lesiones periventriculares (p< 0,001), lesiones hipointensas en T1 (p< 0,001) y lesiones en el cuerpo calloso (p< 0,001).", [["infecci\u00f3n previa", "PROBLEM", 123, 139], ["lesiones periventriculares", "PROBLEM", 178, 204], ["lesiones hipointensas en T1", "PROBLEM", 217, 244], ["y lesiones", "TEST", 256, 266]]], ["Aun as\u00ed, el grupo IPMSSG advierte que un episodio con las caracter\u00edsticas cl\u00ednicas de ADEM no puede ser considerado como el primer evento de EM, a menos que el curso de la enfermedad cl\u00ednica cumpla los criterios descritos en el consenso 7 .Conclusi\u00f3nM. pneumoniae existe en nuestro medio, y aunque es poco frecuente, debe formar parte del enfoque diagn\u00f3stico en afectaciones neuroftalmol\u00f3gicas agudas o subagudas en ni\u00f1os.", [["ADEM", "DISEASE", 86, 90], ["pneumoniae", "SPECIES", 253, 263], ["pneumoniae", "PROBLEM", 253, 263]]], ["La ADEM entra en el diagn\u00f3stico diferencial de las enfermedades desmielinizantes incluso pudiendo ser precursora de estas en algunos casos.Conflicto de interesesLos autores declaran no tener ning\u00fan conflicto de intereses. b i b l i o g r a f \u00ed a", [["ADEM", "DISEASE", 3, 7]]]]}